WO2007075598A2 - N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase - Google Patents
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase Download PDFInfo
- Publication number
- WO2007075598A2 WO2007075598A2 PCT/US2006/048290 US2006048290W WO2007075598A2 WO 2007075598 A2 WO2007075598 A2 WO 2007075598A2 US 2006048290 W US2006048290 W US 2006048290W WO 2007075598 A2 WO2007075598 A2 WO 2007075598A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- chloro
- hydroxy
- alkyl
- fluorophenyl
- Prior art date
Links
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 title claims abstract description 72
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 title claims abstract description 72
- -1 N-hydroxyamidino compounds Chemical class 0.000 claims abstract description 183
- 238000000034 method Methods 0.000 claims abstract description 76
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 43
- 201000011510 cancer Diseases 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 214
- 150000001875 compounds Chemical class 0.000 claims description 202
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 185
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 156
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 149
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 146
- 125000003118 aryl group Chemical group 0.000 claims description 134
- 125000001072 heteroaryl group Chemical group 0.000 claims description 130
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 127
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 125
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 119
- 125000001188 haloalkyl group Chemical group 0.000 claims description 106
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 94
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 91
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 90
- 125000001424 substituent group Chemical group 0.000 claims description 79
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 73
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 72
- 150000003839 salts Chemical class 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 67
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 42
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 41
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 38
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 37
- 229910052701 rubidium Inorganic materials 0.000 claims description 37
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 35
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 35
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 35
- 125000000304 alkynyl group Chemical group 0.000 claims description 31
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 claims description 28
- 125000005311 halosulfanyl group Chemical group 0.000 claims description 28
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 229910052720 vanadium Inorganic materials 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 11
- 239000000651 prodrug Substances 0.000 claims description 11
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 10
- 230000001506 immunosuppresive effect Effects 0.000 claims description 10
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 206010062016 Immunosuppression Diseases 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 6
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 5
- 229910052721 tungsten Inorganic materials 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 229910052770 Uranium Inorganic materials 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 229910052702 rhenium Inorganic materials 0.000 claims description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 229960004854 viral vaccine Drugs 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 38
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- PCJZJCYRQCYPNQ-UHFFFAOYSA-N 1-[[4-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]methyl]-3-phenylurea Chemical compound N=1ON=C(CNC(=O)NC=2C=CC=CC=2)C=1C(=NO)NC1=CC=C(F)C(Cl)=C1 PCJZJCYRQCYPNQ-UHFFFAOYSA-N 0.000 claims 1
- GAFWXKBVTLRUGT-UHFFFAOYSA-N 1-tert-butyl-3-[[4-[N'-(3-chloro-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]methyl]urea Chemical compound CC(C)(C)NC(=O)NCC1=NON=C1C(=NO)NC1=CC=C(F)C(Cl)=C1 GAFWXKBVTLRUGT-UHFFFAOYSA-N 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- UDLWYEBIUZWFRZ-UHFFFAOYSA-N 4-(benzenesulfonamidomethyl)-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide Chemical compound N=1ON=C(CNS(=O)(=O)C=2C=CC=CC=2)C=1C(=NO)NC1=CC=C(F)C(Cl)=C1 UDLWYEBIUZWFRZ-UHFFFAOYSA-N 0.000 claims 1
- JLGNYCBOGGRKIK-UHFFFAOYSA-N 4-[(6-aminohexylamino)methyl]-N'-(3-chloro-4-fluorophenyl)-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide Chemical compound NCCCCCCNCC1=NON=C1C(=NO)NC1=CC=C(F)C(Cl)=C1 JLGNYCBOGGRKIK-UHFFFAOYSA-N 0.000 claims 1
- QWGKQRLIDNSODX-UHFFFAOYSA-N 4-oxo-1,2,5-oxadiazole-3-carboximidamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC(=N)C1=NONC1=O QWGKQRLIDNSODX-UHFFFAOYSA-N 0.000 claims 1
- XVEVWOAHSYZRQE-UHFFFAOYSA-N Brunfelsamidine Chemical compound NC(=N)C=1C=CNC=1 XVEVWOAHSYZRQE-UHFFFAOYSA-N 0.000 claims 1
- ZJZNHFNJWXCNOO-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-4-[(4-sulfamoylphenoxy)methyl]-1,2,5-oxadiazole-3-carboximidamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1OCC1=NON=C1C(=NO)NC1=CC=C(F)C(Cl)=C1 ZJZNHFNJWXCNOO-UHFFFAOYSA-N 0.000 claims 1
- FGUJJELACMYHCQ-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-4-[(pyridin-2-ylmethylamino)methyl]-1,2,5-oxadiazole-3-carboximidamide Chemical compound N=1ON=C(CNCC=2N=CC=CC=2)C=1C(=NO)NC1=CC=C(F)C(Cl)=C1 FGUJJELACMYHCQ-UHFFFAOYSA-N 0.000 claims 1
- POQLUHFRKHIJBN-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethyl]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCC1=NON=C1C(=NO)NC1=CC=C(F)C(Cl)=C1 POQLUHFRKHIJBN-UHFFFAOYSA-N 0.000 claims 1
- AWKKMWRRTHEWNY-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-4-[[2-(2-methylpiperidin-1-yl)ethylamino]methyl]-1,2,5-oxadiazole-3-carboximidamide Chemical compound CC1CCCCN1CCNCC1=NON=C1C(=NO)NC1=CC=C(F)C(Cl)=C1 AWKKMWRRTHEWNY-UHFFFAOYSA-N 0.000 claims 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- OJEYDZBIAYMFFD-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1C[CH]CC1 OJEYDZBIAYMFFD-UHFFFAOYSA-N 0.000 claims 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 1
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 claims 1
- LROADTYWQQTGIK-INIZCTEOSA-N n-(3-chloro-4-fluorophenyl)-n-hydroxy-4-[[[(1r)-2-hydroxy-1-phenylethyl]amino]methyl]-1,2,5-oxadiazole-3-carboximidamide Chemical compound N([C@@H](CO)C=1C=CC=CC=1)CC1=NON=C1C(=N)N(O)C1=CC=C(F)C(Cl)=C1 LROADTYWQQTGIK-INIZCTEOSA-N 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 44
- 201000010099 disease Diseases 0.000 abstract description 31
- 238000011282 treatment Methods 0.000 abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 157
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 141
- 238000006243 chemical reaction Methods 0.000 description 136
- 239000000243 solution Substances 0.000 description 128
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 112
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 99
- 239000000047 product Substances 0.000 description 86
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- 125000005843 halogen group Chemical group 0.000 description 70
- 229910001868 water Inorganic materials 0.000 description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 40
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 28
- 239000003112 inhibitor Substances 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 23
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 21
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 229960004799 tryptophan Drugs 0.000 description 19
- 239000007787 solid Substances 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000020477 pH reduction Effects 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 229940127084 other anti-cancer agent Drugs 0.000 description 7
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- CWNKMHIETKEBCA-UHFFFAOYSA-N alpha-Ethylaminohexanophenone Chemical compound CCCCC(NCC)C(=O)C1=CC=CC=C1 CWNKMHIETKEBCA-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical compound O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- SMXMELMJCICPJG-UHFFFAOYSA-N piperidine-4-sulfonamide Chemical compound NS(=O)(=O)C1CCNCC1 SMXMELMJCICPJG-UHFFFAOYSA-N 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 3
- 0 *C(*)(*)C1[U]=CCC=NC1C(N(*)*)=N Chemical compound *C(*)(*)C1[U]=CCC=NC1C(N(*)*)=N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- SLIKWVTWIGHFJE-UHFFFAOYSA-N diphenoxymethylidenecyanamide Chemical compound C=1C=CC=CC=1OC(=NC#N)OC1=CC=CC=C1 SLIKWVTWIGHFJE-UHFFFAOYSA-N 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- DKORSYDQYFVQNS-UHFFFAOYSA-N propyl methanesulfonate Chemical compound CCCOS(C)(=O)=O DKORSYDQYFVQNS-UHFFFAOYSA-N 0.000 description 3
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 3
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- NIDRYBLTWYFCFV-FMTVUPSXSA-N (+)-calanolide A Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-FMTVUPSXSA-N 0.000 description 2
- VJVZPTPOYCJFNI-UHFFFAOYSA-M (2-ethoxy-2-oxoethyl)-triphenylphosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC(=O)OCC)C1=CC=CC=C1 VJVZPTPOYCJFNI-UHFFFAOYSA-M 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 2
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 description 2
- BWPGCNBJSRYYLD-UHFFFAOYSA-N 2-diazonio-1,4-dimethoxy-3-oxobut-1-en-1-olate Chemical compound COCC(=O)C(=[N+]=[N-])C(=O)OC BWPGCNBJSRYYLD-UHFFFAOYSA-N 0.000 description 2
- ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 description 2
- VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 description 2
- YJOPKSOGULJASY-UHFFFAOYSA-N 4-(2h-tetrazol-5-ylmethyl)morpholine Chemical compound N1=NNN=C1CN1CCOCC1 YJOPKSOGULJASY-UHFFFAOYSA-N 0.000 description 2
- NHHQOYLPBUYHQU-UHFFFAOYSA-N 4-methylthiadiazole-5-carboxylic acid Chemical compound CC=1N=NSC=1C(O)=O NHHQOYLPBUYHQU-UHFFFAOYSA-N 0.000 description 2
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 2
- 229910017912 NH2OH Inorganic materials 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- 229960004748 abacavir Drugs 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 229950010030 dl-alanine Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 238000010575 fractional recrystallization Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000006028 immune-suppresssive effect Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- KBEMFSMODRNJHE-JFWOZONXSA-N lodenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@@H]1F KBEMFSMODRNJHE-JFWOZONXSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- XHFGWHUWQXTGAT-UHFFFAOYSA-N n-methylpropan-2-amine Chemical compound CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
- 229960005235 piperonyl butoxide Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- AWLWPSSHYJQPCH-VIFPVBQESA-N (2s)-2-amino-3-(6-nitro-1h-indol-3-yl)propanoic acid Chemical compound [O-][N+](=O)C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 AWLWPSSHYJQPCH-VIFPVBQESA-N 0.000 description 1
- HMRUCLPSAJCCAH-JGJYBARTSA-N (3Z,4Z)-3,4-bis(hydroxyimino)oxolan-2-one Chemical compound O\N=C\1/COC(=O)/C/1=N\O HMRUCLPSAJCCAH-JGJYBARTSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- HINZVVDZPLARRP-YSVIXOAZSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 HINZVVDZPLARRP-YSVIXOAZSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004507 1,2,5-oxadiazol-3-yl group Chemical group O1N=C(C=N1)* 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- ZADWXFSZEAPBJS-JTQLQIEISA-N 1-methyl-L-tryptophan Chemical compound C1=CC=C2N(C)C=C(C[C@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-JTQLQIEISA-N 0.000 description 1
- IDCPFAYURAQKDZ-UHFFFAOYSA-N 1-nitroguanidine Chemical compound NC(=N)N[N+]([O-])=O IDCPFAYURAQKDZ-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- ASOMNDIOOKDVDC-UHFFFAOYSA-N 1h-indol-2-yl-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl]methanone Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=CC=C3C=2)CC1 ASOMNDIOOKDVDC-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- BRYYGUAHLMGILG-UHFFFAOYSA-N 2-[2-[(2-chloro-6-fluorophenyl)methyl]-4,7-dimethyl-1,3-dioxopurino[7,8-a]imidazol-6-yl]acetic acid Chemical compound OC(=O)CN1C(C)=CN(C=2C3=O)C1=NC=2N(C)C(=O)N3CC1=C(F)C=CC=C1Cl BRYYGUAHLMGILG-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- NBNQOWVYEXFQJC-UHFFFAOYSA-N 2-sulfanyl-3h-thiadiazole Chemical compound SN1NC=CS1 NBNQOWVYEXFQJC-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- SSPJJNVAHYBCTR-UHFFFAOYSA-N 3-[4-(3-aminopropyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCCCC1=NON=C1C1=NOC(=O)N1C1=CC=C(F)C(Cl)=C1 SSPJJNVAHYBCTR-UHFFFAOYSA-N 0.000 description 1
- NXRVIAVFXFJYBG-UHFFFAOYSA-N 3-[4-[(3-chloro-4-fluorophenyl)carbamoyl]-1,2,5-oxadiazol-3-yl]propyl methanesulfonate Chemical compound CS(=O)(=O)OCCCC1=NON=C1C(=O)NC1=CC=C(F)C(Cl)=C1 NXRVIAVFXFJYBG-UHFFFAOYSA-N 0.000 description 1
- HVTQMEXMYFDLGM-UHFFFAOYSA-N 3-[[1-[(2-chloro-4-fluorophenyl)methyl]-5-methylpyrazol-3-yl]carbamoyl]pyrazine-2-carboxylic acid Chemical compound N=1N(CC=2C(=CC(F)=CC=2)Cl)C(C)=CC=1NC(=O)C1=NC=CN=C1C(O)=O HVTQMEXMYFDLGM-UHFFFAOYSA-N 0.000 description 1
- NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- MLRAJZNPKPVUDQ-UHFFFAOYSA-N 3-sulfanyl-1,2-dihydrotriazole Chemical compound SN1NNC=C1 MLRAJZNPKPVUDQ-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- AGWSISOYPHROLN-UHFFFAOYSA-N 5-(chloromethyl)-2h-tetrazole Chemical compound ClCC=1N=NNN=1 AGWSISOYPHROLN-UHFFFAOYSA-N 0.000 description 1
- PXJBYULSJLWXNJ-UHFFFAOYSA-N 5-[(2-chloro-6-fluorophenyl)methyl]-n-(2-hydroxyethyl)-1,3,4-oxadiazole-2-carboxamide Chemical compound O1C(C(=O)NCCO)=NN=C1CC1=C(F)C=CC=C1Cl PXJBYULSJLWXNJ-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- ATCRIOJPQXDFNY-ZETCQYMHSA-N 6-chloro-2-(1-furo[2,3-c]pyridin-5-yl-ethylsulfanyl)-pyrimidin-4-ylamine Chemical compound S([C@@H](C)C=1N=CC=2OC=CC=2C=1)C1=NC(N)=CC(Cl)=N1 ATCRIOJPQXDFNY-ZETCQYMHSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- DJRYWDUXVVMZNE-UHFFFAOYSA-N CC(C)N(C)CCc1n[o]nc1C(Nc(cc1Cl)ccc1F)=N Chemical compound CC(C)N(C)CCc1n[o]nc1C(Nc(cc1Cl)ccc1F)=N DJRYWDUXVVMZNE-UHFFFAOYSA-N 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- OWHIVDUCQOYGSV-UHFFFAOYSA-N COCc1c(C(OC)=O)nn[s]1 Chemical compound COCc1c(C(OC)=O)nn[s]1 OWHIVDUCQOYGSV-UHFFFAOYSA-N 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000287497 Calypte Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 1
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
- 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- HOASGSMFBCDSCX-UHFFFAOYSA-N N'-(3-chloro-4-fluorophenyl)-N-hydroxy-4-[(3-morpholin-4-ylpropylsulfonylamino)methyl]-1,2,5-oxadiazole-3-carboximidamide 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.ClC=1C=C(C=CC1F)NC(=NO)C1=NON=C1CNS(=O)(=O)CCCN1CCOCC1 HOASGSMFBCDSCX-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 125000004633 N-oxo-pyridyl group Chemical group 0.000 description 1
- LRXYRGILEMKZQH-UHFFFAOYSA-N NCCc1n[o]nc1C(N1c(cc2Cl)ccc2F)=NOC1=O Chemical compound NCCc1n[o]nc1C(N1c(cc2Cl)ccc2F)=NOC1=O LRXYRGILEMKZQH-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- CEZZFCAJQWQFFE-UHFFFAOYSA-N NS(NCc1n[o]nc1/C(/Nc(cc1Cl)ccc1F)=N/O)(=O)=O Chemical compound NS(NCc1n[o]nc1/C(/Nc(cc1Cl)ccc1F)=N/O)(=O)=O CEZZFCAJQWQFFE-UHFFFAOYSA-N 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- VVTXYMQTLAGPPH-UHFFFAOYSA-N O=C(c1ccccc1)NCc1n[o]nc1/C(/Nc(cc1Cl)ccc1F)=N/C1OC1 Chemical compound O=C(c1ccccc1)NCc1n[o]nc1/C(/Nc(cc1Cl)ccc1F)=N/C1OC1 VVTXYMQTLAGPPH-UHFFFAOYSA-N 0.000 description 1
- VZFDYUWYRUGALD-UHFFFAOYSA-N OCCCc1n[o]nc1C(Nc(cc1Cl)ccc1F)=O Chemical compound OCCCc1n[o]nc1C(Nc(cc1Cl)ccc1F)=O VZFDYUWYRUGALD-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 102100024078 Plasma serine protease inhibitor Human genes 0.000 description 1
- 101710183733 Plasma serine protease inhibitor Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 229910006024 SO2Cl2 Inorganic materials 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002022 anti-cellular effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- HEGCWAOVTPVFBJ-UHFFFAOYSA-N benzyl 4-chlorosulfonylpiperidine-1-carboxylate Chemical compound C1CC(S(=O)(=O)Cl)CCN1C(=O)OCC1=CC=CC=C1 HEGCWAOVTPVFBJ-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NIDRYBLTWYFCFV-UHFFFAOYSA-N calanolide F Natural products C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZJULYDCRWUEPTK-UHFFFAOYSA-N dichloromethyl Chemical compound Cl[CH]Cl ZJULYDCRWUEPTK-UHFFFAOYSA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 108010007811 human immunodeficiency virus p17 gag peptide Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000003259 immunoinhibitory effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000003046 intermediate neglect of differential overlap Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229950004697 lasinavir Drugs 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229950005339 lobucavir Drugs 0.000 description 1
- 229950003557 lodenosine Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 1
- QGBPKJFJAVDUNC-UHFFFAOYSA-N methyl 4-methoxy-3-oxobutanoate Chemical compound COCC(=O)CC(=O)OC QGBPKJFJAVDUNC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- WXDMRYGQJJBLTD-PJQLUOCWSA-N n-[(e)-(2-chloro-6-fluorophenyl)methylideneamino]-2-(3,5-dioxo-2h-1,2,4-triazin-6-yl)acetamide Chemical compound FC1=CC=CC(Cl)=C1\C=N\NC(=O)CC1=NNC(=O)NC1=O WXDMRYGQJJBLTD-PJQLUOCWSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005893 naphthalimidyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000005482 norpinyl group Chemical group 0.000 description 1
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 238000007280 thionation reaction Methods 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- NDLIRBZKZSDGSO-UHFFFAOYSA-N tosyl azide Chemical compound CC1=CC=C(S(=O)(=O)[N-][N+]#N)C=C1 NDLIRBZKZSDGSO-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- LHJCZOXMCGQVDQ-UHFFFAOYSA-N tri(propan-2-yl)silyl trifluoromethanesulfonate Chemical compound CC(C)[Si](C(C)C)(C(C)C)OS(=O)(=O)C(F)(F)F LHJCZOXMCGQVDQ-UHFFFAOYSA-N 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- N-HYDROXYAMTOINOHETEROCYCLES AS MODULATORS OF ⁇ NDOLEAMINE 2,3-DIOXYGENASE
- the present invention is directed to modulators of indoleamine 2,3-dioxygenase (EDO), as well as compositions and pharmaceutical methods thereof.
- EEO indoleamine 2,3-dioxygenase
- Tryptophan is an essential amino acid required for the biosynthesis of proteins, niacin and the neurotransmitter 5-hydroxytryptamine (serotonin).
- the enzyme indoleamine 2,3-dioxygenase also known as INDO or IDO
- IFN-7 gamma interferon
- EFN-7 stimulation induces activation of EDO, which leads to a depletion of Trp, thereby arresting the growth of Trp-dependent intracellular pathogens such as Toxoplasma gondii and Chlamydia trachomatis.
- EDO activity also has an antiproliferative effect on many tumor cells, and EDO induction has been observed in vivo during rejection of allogeneic tumors, indicating a possible role for this enzyme in the tumor rejection process (Daubener, et al, 1999, Adv. Exp. Med. Biol., 467: 517-24; Taylor, et at., 1991, FASEB J., 5: 2516-22).
- HeLa cells co-cultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of EDO activity.
- a reduction in PBL proliferation upon treatment with interleukin-2 (IL2) was believed to result from EDO released by the tumor cells in response to IFNG secretion by the PBLs.
- IL2 interleukin-2
- IMT 1 - methyl -tryptophan
- IDO immunodeficiency virus
- EDO inhibition can enhance the levels of virus-specific T cells and, concomitantly, reduce the number of virally-infected macrophages in a mouse model of HIV (Portula et al, 2005, Blood, 106:2382-90). IDO is believed to play a role in the immunosuppressive processes that prevent fetal rejection in utero. More than 40 years ago, it was observed that, during pregnancy, the genetically disparate mammalian conceptus survives in spite of what would be predicted by tissue transplantation immunology (Medawar, 1953, Symp. Soc. Exp. Biol. 7: 320-38).
- the mammalian conceptus appears to suppresses T-cell activity and defends itself against rejection, and blocking tryptophan catabolism during murine pregnancy allows maternal T cells to provoke fetal allograft rejection (Munn, et al., 1998, Science 281 : 1191-3).
- EDO inhibitor 1-MT
- chemotherapeutic agents can synergize with chemotherapeutic agents to reduce tumor growth in mice, suggesting that EDO inhibition may also enhance the anti-tumor activity of conventional cytotoxic therapies (Muller et al, 2005, Nature Med., 11:312-9).
- One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs.
- APCs human EDO-expressing antigen- presenting cells (APCs) that coexpressed CDl 23 (EL3RA) and CCR6 and inhibited T-cell proliferation have also been described.
- TDLNs mouse tumor-draining lymph nodes
- pDCs plasmacytoid dendritic cells
- EDO degrades the indole moiety of tryptophan, serotonin and melatonin, and initiates the production of neuroactive and immunoregulatory metabolites, collectively known as kynurenines.
- kynurenines neuroactive and immunoregulatory metabolites
- IDO expressed by dendritic cells can greatly affect T-cell proliferation and survival. IDO induction in DCs could be a common mechanism of deletional tolerance driven by regulatory T cells.
- tryptophan metabolism and kynurenine production might represent a crucial interface between the immune and nervous systems (Grohmarra, et al., 2003, Trends Immunol., 24: 242-8).
- availability of free serum Trp is diminished and, as a consequence of reduced serotonin production, serotonergic functions may also be affected (Wirleitner, et al., 2003, Curr. Med. Chem., 10: 1581-91).
- interferon- ⁇ has been observed to induce neuropsychiatric side effects, such as depressive symptoms and changes in cognitive function. Direct influence on serotonergic neurotransmission may contribute to these side effects.
- IDO activation leads to reduced levels of tryptophan, the precursor of serotonin (5-HT)
- IDO may play a role in these neuropsychiatric side effects by reducing central 5-HT synthesis.
- kynurenine metabolites such as 3-hydroxy-kynurenine (3 -OH-KYN) and quinolinic acid (QUIN) have toxic effects on brain function.
- 3-OH-KYN is able to produce oxidative stress by increasing the production of reactive oxygen species (ROS), and QUIN may produce overstimulation of hippocampal N-methyl-D-aspartate (NMDA) receptors, which leads to apoptosis and hippocampal atrophy.
- ROS reactive oxygen species
- NMDA hippocampal N-methyl-D-aspartate
- Both ROS overproduction and hippocampal atrophy caused by NMDA overstimulation have been associated with depression (Wichers and Maes, 2004, J. Psychiatry Neurosci., 29: 11—17).
- IDO activity may play a role in depression.
- Small molecule inhibitors of EDO are being developed to treat or prevent IDO-related diseases such as those described above.
- PCT Publication WO 99/29310 reports methods for altering T cell-mediated immunity comprising altering local extracellular concentrations of tryptophan and tryptophan metabolites, using an inhibitor of IDO such as 1 -methyl-DL-tryptophan, p-(3- benzofuranyl)-DL- alanine, p-[3 -benzo(b)thienyl] -DL-alanine, and 6-nitro-L-tryptophan) (Munn, 1999).
- IDO in immunosuppression, tumor resistance and/or rejection, chronic infections, HTV-infection, AIDS (including its manifestations such as cachexia, dementia and diarrhea), autoimmune diseases or disorders (such as rheumatoid arthritis), and immunologic tolerance and prevention of fetal rejection in utero
- therapeutic agents aimed at suppression of tryptophan degradation by inhibiting IDO activity are desirable.
- Inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HTV. Inhibition of IDO may also be an important treatment strategy for patients with neurological or neuropsychiatric diseases or disorders such as depression.
- the compounds, compositions and methods herein help meet the current need for EDO modulators.
- the present invention provides, inter alia, compounds of Formula Ia:
- the present invention further provides compositions comprising a compound of Formula Ia, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
- the present invention further provides methods of modulating enzyme activity of IDO comprising contacting a compound of Formula Ia, or pharmaceutically acceptable salt thereof, with IDO.
- the present invention further provides methods of treating EDO-associated diseases, including cancer, viral infection and depression, comprising administering to a patient a therapeutically effective amount of a compound of Formula Ia, or pharmaceutically acceptable salt thereof.
- the present invention further provides methods of altering extracellular tryptophan levels in a mammal comprising administering to the mammal an effective amount of a compound of Formula Ia, or pharmaceutically acceptable salt thereof.
- the present invention further provides methods of inhibiting immunosuppression, such as EDO-mediated immunosuppression, in a patient comprising administering to the patient an effective amount of a compound of Formula Ia, or pharmaceutically acceptable salt thereof.
- the present invention further provides the compounds of Formula Ia for use in therapy.
- the present invention further provides the compounds of Formula Ia for use in the preparation of a medicament for use in therapy.
- U is N, O, S, CR , or NR " ;
- V, and W are each, independently, N, O, S, CR 2 , or NR 3 , wherein the five-membered ring containing U, V, and W is an aromatic heterocycle;
- A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C].
- R 0 is H, Ci -6 alkyl, C 2-6 alkenyl, C 2 . 6 alkynyl, Ci -6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci. 6 alkyl, C 2-6 alkenyl, C 2 .
- 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2 -6 alkynyl, C 1-6 haloalkyl, Ci -6 hydroxyalkyl, C 1-6 cyanoalkyl, halosulfanyl, Cy, -(C 1-4 alkyl)-Cy, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR 02 R" 2 , C(O)OR" 2 , OC(O)R b2 , OC(O)NR 02 R" 2 , NR 02 R" 2 , NR 02 C(O)R b2
- Cy, Cy 1 , and Cy 2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1 , 2, 3, 4 or 5 substituents independently selected from halo, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, halosulfanyl, CN, NO 2 , OR" 3 , SR a ⁇ C(O)R W , C(O)NR 03 R" 3 , C(O)OR 33 , OC(O)R b ⁇ OC(O)NR 0 V 3 , NR c3 R d3 , NR o3 C(0)R b3
- R 2 is H, halo, C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, CN, NO 2 , OH, C 1-4 alkoxy, amino, C 1-4 alkylamino, or C 2-8 dialkylamino;
- R 3 is H, C 1 ⁇ alkyl, C 2-4 alkenyl, or C 2-4 alkynyl;
- R 4 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C(O)-R 4a , SO 2 -R 4 ", aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, Ci
- R 5 and R 6 are independently selected from H, Cj -8 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, each optionally substituted by one or more substituents independently selected from halo, CN, NO 2 , OH, C ]-4 haloalkoxy, amino, C L4 alkylamino, C 2-8 dialkylamino, Ci -6 alkyl, C 2-6 alkenyl, and C 2-
- R 6a and R 6b are independently selected from H, Ci -8 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, each optionally substituted by one or more substituents independently selected from halo, CN, NO 2 , OH,
- R a , R aI , R a3 , R a4 , and R a5 are independently selected from H, Ci -6 alkyl, C,. 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci -6 alkyl, C] -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci -6 alkyl, aryl, arylalkyl, hetero
- R b , R bl , R", R M , and R bs are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2 . 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci -6 alkyl, Cj -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci_ 6 alkyl, C ]-6 haloalkyl, aryl, ary
- R b2 is H, Cj -6 alkyl, Cj -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, Cy 2 , or wherein said C L6 alkyl, C )-6 haloalkyl, C 2-6 alkenyl, C 2 . 6 alkynyl, or aryl is optionally substituted with
- substituents independently selected from halo, Ci. 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, C 1-6 hydroxyalkyl, C -6 cyanoalkyl, halosulfanyl, Cy 2 , CN, NO 2 , OR aS , SR a5 , C(O)R bS ,
- R c and R d are independently selected from H, Ci -I0 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci -I0 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci -6 alkyl, C ]-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalky
- R cl and R dl are independently selected from H, Ci -I0 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C M0 alkyl, C L6 haloalkyl, C 2 .
- 6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci -6 alkyl, C ]-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or R cl and R dl together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
- R c2 and R *12 are independently selected from H, Ci, )0 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, Cy 2 and Cy ⁇ (C] -6 alkyl)-, wherein said C M o alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl, is optionally substituted with 1, 2, or 3, substitutents independently selected from halo, Cj -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, halosulfanyl, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR 03 R" 3 , C(O)OR 33 , OC(O)R" 3 , OC(O)NR 03 R" 3 , NR 03 R" 3 , NR c3 C(
- R° 3 and R d3 are independently selected from H, Ci -I0 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci -I0 alkyl, C L6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci -6 alkyl, Ci -6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalky
- R c4 and R d4 are independently selected from H, Ci -I0 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-I 0 alkyl, C L6 haloalkyl, C 2 -S alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C ]-6 alkyl, Ci -6 haloalkyl, aryl, arylalkyl, heteroaryl, hetero
- R c5 and R d5 are independently selected from H, Ci -I0 alkyl, Ci_ 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-I 0 alkyl, C ]-6 haloalkyl, C 2 .
- 6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocyclo- alkylalkyl is optionally substituted with OH, amino, halo, Ci. 6 alkyi, C ]-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or R oS and R d5 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
- R e , R el , R e2 , R e3 , R e4 , and R e5 are independently selected from H, C 1-6 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, (Ci -6 alkoxy)-Ci -6 alkyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocycloalkylalkyl;
- R f , R ⁇ ,R G , R°, R f4 , and R ⁇ are independently selected from H, C, -6 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl;
- R 1 is H, CN, C(O)NH 2 , or NO 2 ;
- R' is H, halo, C 1-10 alkyl, C 2-6 alkenyl, C 2 . 6 alkynyl, Cy, Cy-(C 1-6 alkyl)-, CN, NO 2 , OR a ⁇ SR a3 ,
- NR c3 C( NR i )NR c3 R d3 , P(R D ) 2 , P(OR o3 ) 2 , P(O)R 03 R 0 , P(O)OR 03 OR 0 , S(O)R b3 , S(O)NR 03 R 113 , S(O) 2 R b3 , and S(O) 2 NR c3 R d3 ;
- R" is H, C,. ]0 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Cy, Cy-(C 1-6 alkyl)-, C(0)R b3 , C(O)NR c3 R d3 , C(O)OR" 3 , S(O)R b3 , S(O)NR 03 R 113 , S(O) 2 R b3 , or S(O) 2 NR c3 R d3 ; wherein said C 1-10 alkyl, C 2-6 alkenyl, or C 2 .
- V is O.
- U is N. In some embodiments, W is N. In some embodiments, U and W are both N. In some embodiments, U and W are both N and V is O. In some embodiments, at least one of U, V and W is N.
- U, V and W is N and another of U, V, and W is O or S.
- A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, C,.
- A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci -6 alkyl, C 2 . 6 alkenyl, C 2 .
- Ci -6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl is optionally substituted with 1, 2, or 3 substitutents independently selected from Cy 1 , CN, NO 2 , OR", SR", C(O)R", C(O)NR°R d , C(O)OR 8 , OC(O)R", OC(O)NR 0 R", NR c R d , NR 0 C(O)R", NR c C(O)NR c R d , NR 0 C(O)OR 3
- A is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2 - 6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, Ci -6 hydroxyalkyl, Ci -6 cyanoalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR 3 , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR'C ⁇ NR ⁇ , NR 0 C(O)OR 3 , S(O)R b , S(O)NR c R d , S(O) 2 R b
- A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C ]-6 haloalkyl, Ci -6 hydroxyalkyl, Ci -6 cyanoalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR°R d , C(O)OR 3 , OC(O)R b , OC(O)NR°R d , NR 0 R", NR c C(O)R b , NR 0 C(O)NR 0 R", NR 0 C(O)OR 8 , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR°S
- A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C] -6 alkyl, Ci -6 haloalkyl, Ci -6 hydroxyalkyl, Ci -6 cyanoalkyl, CN, NO 2 , OR a , SR 3 , C(O)R", C(O)NR 0 R", C(O)OR 2 , OC(O)R b , OC(O)NR c R d , NR°R d , NR 0 C(O)R", NR°C(O)NR c R d , NR 0 C(O)OR 3 , S(O)R", S(0)NR c R d , S(O) 2 R", NR 0 S(O) 2 R", and S(O) 2 NR°R d .
- A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C] -6 al
- Q is OR 0 , OC(O)R 0 , OC(O)NR 4 R 0 , NR 4 R 0 , NR 4 C(O)R 0 , NR 4 C(O)NR 4 R 0 , NR 4 C(O)OR 0 , NR 4 S(O)R 0 , NR 4 S(O) 2 R 0 , SR 0 , S(O)R 0 , S(O)NR 4 R 0 , S(O) 2 R 0 S(O) 2 NR 4 R 0 , C(O)R 0 , C(O)OR 0 , C(O)NR 4 R 0 , halo, cyano, azido, or nitro;
- Q is H, CN, OR 0 , OC(O)NR 4 R 0 , C(O)OR 0 , NR 4 R 0 NR 4 C(O)R 0 ,
- NR 4 C(O)NR 4 R 0 NR 4 C(O)OR 0 , NR 4 S(O) 2 R 0 , SR 0 , S(O) 2 R 0 , or OC(O)NR 4 R 0 .
- Q is H, CN, OR 0 , OC(O)NR 4 R 0 , C(O)OR 0 , NR 4 R 0 , NR 4 C(O)R 0 , NR 4 C(O)NR 4 R 0 , NR 4 C(O)OR 0 , NR 4 S(O) 2 R 0 , or OC(O)NR 4 R 0 .
- Q is OR 0 , OC(O)NR 4 R 0 , Or NR 4 R 0 . In some embodiments, Q is OR 0 .
- Q is SR 0 .
- Q is S(O) 2 R 0 . In some embodiments, Q is NR 4 R Q .
- Q is NR 4 R Q , and R 4 and R Q together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group or 5-20 membered heteroaryl group, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci -6 alkyl, C 2-6 alkenyl, C 2 .
- Q is NR 4 R Q and R 4 and R Q together with the N atom to which they are attached form a 5-20 membered heteroaryl group, optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C,.
- Q is NR 4 R Q and R 4 and R Q together with the N atom to which they are attached form a tetrazole group which is optionally substituted with halo, C 1-6 alkyl, Ci. 6 haloalkyl, or NR 02 R" 2 .
- Q is NR 4 R Q and R 4 and R Q together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 cyanoalkyl, Cy, -(C 1-4 alkyl)-Cy, CN, NO 2 , OR a2 , -(C 1-4 alkyl)-OR a2 , SR a2 , -(C M alkyl)-SR" 2 , C(O)R b2 , -(Cj -4 alkyl)-C(O)R b2 , C(O)NR 02 R 112 , -(C 1-4 alkyl)-C(O)NR c2 R d2 ,
- NR c2 C( NR i )NR c2 R d2 , P(R C ) 2 , P(OR c2 ) 2 , P(O)R c2 R G , P(O)OR c2 OR ⁇ , S(O)R b2 , -(C 1-4 alkyl)-S(O)R b2 , S(O)NR 02 R" 2 , S(O) 2 R b2 , -(C 1-4 alkyl)-S(O) 2 R b2 , NR c2 S(O) 2 R b2 ) -(C 1-4 alkyl)- NR 02 S(O) 2 R" 2 , S(O) 2 NR 62 R" 2 , and -(C 1-4 311CyI)-S(O) 2 NR 02 R" 2 .
- Q is NR 4 R 0 and R 4 and R Q together with the N atom to which they are attached form piperidinyl, morpholino, piperazinyl, 2,3-dihydro-lH-isoindolyl, or 1,2,3,4-tetrahydro- isoquinoline, each optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2 . 6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, Ci -6 hydroxyalkyl, Ci -6 cyanoalkyl, Cy, -(C,.
- Q is NR 4 R Q and R 4 and R Q together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 cyanoalkyl, Cy, -(Ci -4 alkyl)-Cy, CN 5 NO 2 , 0R a2 , SR 32 , C(O)R" 2 , C(O)NR 02 R" 2 , C(O)OR 32 , OC(O)R" 2 , OC(O)NR 02 R" 2 , NR 02 R" 2 , NR 02 C(O)R” 2 , NR 02 C(O)O” 2 , NR 02 C(O)
- Q is NR 4 R Q and R 4 and R Q together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, C] -6 hydroxyalkyl, C 1-6 cyanoalkyl, Cy, -(C M alkyl)-Cy, CN, NO 2 , OR a2 , SR a2 , C(O)R" 2 , C(O)NR c2 R d2 , C(O)OR 32 , OC(O)R" 2 , OC(O)NR 02 R" 2 , NR 02 R" 2 , NR o2 C(0)R b2 , NR 02 C(O)NR 02 R" 2 , NR 02 C(OJOR” 2 ,
- Q is NR 4 R Q and R 4 and R Q together with the N atom to which they are attached form piperidinyl, morpholino, piperazinyl, 2,3-dihydro-lH-isoindolyl, or 1,2,3,4-tetrahydro- isoquinoline, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C
- or Q is H, C 1-6 alkyl, C 2 . 6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-4 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C J-6 hydroxyalkyl, Ci -6 cyanoalkyl, Cy, -(C 1-4 alkyl)-Cy, CN, NO 2 , OR a2 , -(C 1-4 alkyl)-OR a2 , SR a2 , -(C 1-4 alkyl)-SR a2 , C(O)R" 2 , -(C,.
- R ⁇ is H, Cj. 6 alkyl, C 2-6 alkenyl, C 2- 6 alkynyl, C 1 . 6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or
- heterocycloalkylalkyl wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Cj -6 alkyl, C 2-6 alkenyl, C 2 .
- Ci -6 haloalkyl C 1-6 hydroxyalkyl, C 1-6 cyanoalkyl, Cy, -(C 1-4 alkyl)-Cy, CN, NO 2 , OR a2 , SR a2 , C(O)R" 2 , C(O)NR 02 R" 2 , C(O)OR 32 , OC(O)R b2 , OC(O)NR 02 R" 2 , NR 02 R" 2 , NR o2 C(0)R b2 ,
- R Q is H, Ci -6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci -6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclo-
- R Q is H, C] -6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said C L6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo,
- R Q is C 1-6
- R Q is C 1-6 alkyl optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6 haloalkyl, Ci -6 hydroxy- alkyl, C 1-6 cyanoalkyl, Cy, -(C 1-4 alkyl)-Cy, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR 52 R 112 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 5 NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , S(O)R b2 , S(O)OR a2
- R 4 and R Q together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group or 5-20 membered heteroaryl group, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Cj -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C -6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 cyanoalkyl, Cy, -(C 1-4 alkyl)-Cy, CN, NO 2 , OR 82 , - (C 1-4 alkyl)-OR a2 , SR a2 , -(C 1-4 alkyl) -SR a2 , C(O)R" 2 , -(C 1-4 alkyl)-C(O)R b2 , C(O)NR c2 R d2 , -(C 1-4 alkyl)- C(O)NR c
- R 4 and R Q together with the N atom to which they are attached form a
- R 4 is H, C 4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C(O)-R 48 , SO 2 -R 4 ⁇ aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C L6 haloalkyl, C 1-6 hydroxyalkyl,
- R 4 is H, Ci -4 alkyl, C(O)-R 4a , SO 2 -R 43 , aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci -4 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci.
- R 4 is H.
- R A and R B are independently selected from H, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocycloalkylalkyl, wherein said Ci -6 alkyl, C 2-6 alkenyl, C 2 .
- 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, Ci -4 haloalkyl, Cj -4 hydroxyalkyl, C].
- R A and R B are independently selected from H, F, and Ci. 6 alkyl. In some embodiments, R A and R B are, independently, H or Cj -6 alkyl. In some embodiments, R A and R B are both H.
- R A and R B together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7- membered cycloalkyl group or 3-, 4-, 5-, 6-, or 7- membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci_ 4 alkyl, C 2-4 alkenyl, C 2 . 4 alkynyl, C
- R a2 is H, alkyl, Cj. 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, Cy 2 , or Cy ⁇ (C 1-6 alkyl)-, wherein said Ci -6 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, or C 2-6 alkynyl, is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci -6 alkyl, C 2-6 alkenyl, C 2 - 6 alkynyl, C,. 6 haloalkyl, C,.
- R b2 is H, Ci -6 alkyl, C] -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, Cy 2 , or said Ci -6 alkyl, Cj -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, or aryl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C ]-6 alkyl, C 2- 6 alkenyl, C 2 .
- R° and R d are independently selected from H, C MO alkyl, C ]-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C MO alkyl, Ci. 6 haloalkyl, C 2-6 alkenyl, C 2 .
- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci -6 alkyl, Ci. 6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl.
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group.
- Cy is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR 03 R 113 , NR 03 R 113 , NR c3 C(O)R b3 , NR c3 C(O)OR a3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R" 3 , and S(O) 2 NR c3 R d3 .
- R 1 is H.
- R is H. In some embodiments, R 2 is H.
- R 3 is H.
- p is 1, 2, 3, 4 or 5.
- p is 1 or 2.
- p is 1.
- the compounds of the invention have Formula I:
- the compounds of the invention have Formula Ila:
- the compounds of the invention have Formula II:
- the compound has Formula III:
- the present invention provides compounds of Formula I:
- U, V, and W are independently selected from N, O, S, CR 2 , and NR 3 , wherein the frve- membered ring containing U, V, and W is an aromatic heterocycle;
- A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Cue alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci-S halo- alkyl, Cj. ⁇ hydroxyalkyl, Ci.6 cyanoalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR 0 , OC(O)R b , OC(O)NR c R d , NR c R
- Ci. ⁇ alkyl, C 2 . ⁇ alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocycloalkylalkyl wherein said Ci. ⁇ alkyl, C 2 . ⁇ alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Cj -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C ]-4 hydroxyalkyl, Ci -4 cyanoalkyl, CN, NO 2 , OR al
- R A and R B together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7- membered cycloalkyl group or 3-, 4-, 5-, 6-, or 7- membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, Ci -4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 cyanoalkyl, CN, NO 2 , OR al , SR al , C(O)R bl , C(O)NR cl R dl , C(O)OR" 1 , OC(O)R bl , OC(O)NR cl R dl , NR cl R dl , NR cI C(O)R bl , NR 0l C(O)NR 0l R dl
- Q is OR 0 , OC(O)R Q , OC(O)NR 4 R Q , NR 4 R Q , NR 4 C(O)R Q , NR 4 C(O)NR 4 R 0 , SR Q , S(O)R Q , S(O)NR 4 R 0 , S(O) 2 R 0 , or S(O) 2 NR 4 R 0 ;
- R° is H, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci -6 alkyl, C 2-6 alkenyl, C 2 .
- 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci -6 alkyl, C 2 .
- R 1 is H or C 1-4 alkyl
- R 2 is H, halo, C ]-4 alkyl, C -4 haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, CN, NO 2 , OH, C, -4 alkoxy, amino, C M alkylamino, or C 2-S dialkylamino;
- R 3 is H, Ci -4 alkyl, C 2 . 4 alkenyl, or C 2-4 alkynyl;
- R 4 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, or C(O)-(C 1-4 alkyl);
- R a , R al , R a2 , and R a3 are independently selected from H, C 1-6 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said C L6 alkyl, Ci.
- R" R bI , R" 2 , and R" 3 are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein
- R° and R d are independently selected from H, Ci -I0 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci -I0 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C 1-6 alkyl, Ci -6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycl
- R cl and R dI are independently selected from H, Ci.io alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Cj -10 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, hetero- aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci -6 alkyl, Ci -6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci -6 alkyl, C L6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or R 02 and R" 12 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; and
- R c3 and R d3 are independently selected from H, C M0 alkyl, C] -6 haloalkyl, C 2-6 alkenyl, C 2 . 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said Ci -]0 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl • is optionally substituted with OH, amino, halo, C J-6 alkyl, C i.
- stable refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent.
- alkyl is meant to refer to a saturated hydrocarbon group which is straight-chained or branched.
- Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n- propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like.
- An alkyl group can contain from 1 to about 20, from 2 to about 20, from 1 to about 10, from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms.
- alkenyl refers to an alkyl group having one or more double carbon-carbon bonds.
- Example alkenyl groups include ethenyl, propenyl, and the like.
- alkynyl refers to an alkyl group having one or more triple carbon-carbon bonds.
- Example alkynyl groups include ethynyl, propynyl, and the like.
- haloalkyl refers to an alkyl group having one or more halogen substituents.
- Example haloalkyl groups include CF 3 , C 2 F 5 , CHF 2 , CCl 3 , CHCl 2 , C 2 Cl 5 , and the like.
- halosulfanyl refers to a sulfur group having one or more halogen substituents.
- Example halosulfanyl groups include pentahalosulfanyl groups such as SF 5 .
- aryl refers to monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, aryl groups have from 6 to about 20 carbon atoms.
- cycloalkyl refers to non-aromatic carbocycles including cyclized alkyl, alkenyl, and alkynyl groups.
- Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems, including spirocycles.
- cycloalkyl groups can have from 3 to about 20 carbon atoms, 3 to about 14 carbon atoms, 3 to about 10 carbon atoms, or 3 to 7 carbon atoms.
- Cycloalkyl groups can further have 0, 1, 2, or 3 double bonds and/or 0, 1, or 2 triple bonds. Cycloalkyl groups can further be substituted by one or more oxo groups.
- cycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclopentene, cyclohexane, and the like.
- a cycloalkyl group having one or more fused aromatic rings can be attached though either the aromatic or non-aromatic portion.
- One or more ring-forming carbon atoms of a cycloalkyl group can be oxidized, for example, having an oxo or sulfido substituent.
- Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like.
- heteroaryl refers to an aromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.
- Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Any ring-forming N atom in a heteroaryl group can also be oxidized to form an N-oxo moiety.
- heteroaryl groups include without limitation, pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,3-thiadiazolyl, 1,2,4- thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, xanthene, and the like.
- the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms.
- heterocycloalkyl refers to a non-aromatic heterocycle where one or more of the ring-forming atoms is a heteroatom such as an O, N, or S atom.
- Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems as well as spirocycles. Any ring-forming C, N or S atom in a heterocycloalkyl group can be substituted by 1 or 2 oxo groups to form a carbonyl, N-oxo, sulfinyl, or sulfonyl moiety.
- heterocycloalkyl groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3- dihydrobenzofuryl, 1,3-benzodioxole, benzo-l,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like.
- heterocycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles such as indolene, isoindolene, tetrahydroquinoline, and tetrahydroisoquinoline groups.
- a heterocycloalkyl group having one or more fused aromatic rings can be attached though either the aromatic or non-aromatic portion.
- the heterocycloalkyl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms.
- the heterocycloalkyl group contains 3 to about 20, 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 triple bonds.
- halo or halogen includes fluoro, chloro, bromo, and iodo.
- hydroxyalkyl refers to an alkyl group substituted with a hydroxyl group.
- cyanoalkyl refers to an alkyl group substituted with a cyano group.
- alkoxy refers to an -O-alkyl group.
- Example alkoxy groups include methoxy, ethoxy, propoxy ⁇ e.g., n-propoxy and isopropoxy), t-butoxy, and the like.
- arylalkyl refers to alkyl substituted by aryl and "cycloalkylalkyl” refers to alkyl substituted by cycloalkyl.
- An example arylalkyl group is benzyl.
- heteroarylalkyl refers to alkyl substituted by heteroaryl and “heterocycloalkylalkyl” refers to alkyl substituted by heterocycloalkyl.
- amino refers to NH 2 .
- alkylamino refers to an amino group substituted by an alkyl group.
- dialkylamino refers to an amino group substituted by two alkyl groups.
- the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
- Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
- a bond in a structure diagram represented by a wavy line " WA/W/ ⁇ » j s intended to indicate that the structure represents the cis or the trans isomer, or a mixture of the cis and trans isomers in any proportion.
- Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
- Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
- Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam — lactim pairs, amide - imidic acid pairs, enamine — imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, IH- and 3H-imidazole, IH-, 2H- and 4H- 1 ,2,4-triazole, IH- and 2H- isoindole, and IH- and 2H-pyrazole.
- Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium.
- the compounds of the invention, and salts thereof are substantially isolated.
- substantially isolated is meant that the compound is at least partially or substantially separated from the environment, in which is was formed or detected. Partial separation can include, for example, a composition enriched in the compound of the invention.
- Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compound of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
- the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
- pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or ACN are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17 th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
- phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- prodrugs refer to any covalently bonded carriers which release the active parent drug when administered to a mammalian subject.
- Prodrugs can be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds.
- Prodrugs include compounds wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, sulfhydryl, or carboxyl group respectively.
- prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the invention. Preparation and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety.
- novel compounds of the present invention can be prepared in a variety of ways known to one skilled in the art of organic synthesis.
- the compounds of the present invention can be synthesized using the methods as hereinafter described below, together with synthetic methods known in the art of synthetic organic chemistry or variations thereon as appreciated by those skilled in the art.
- the compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. The processes described herein can be monitored according to any suitable method known in the art.
- product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C) infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
- spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C) infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry
- chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
- Preparation of compounds can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene, et al., Protective Groups in Organic Synthesis, 2
- the reactions of the processes described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, i.e., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.
- An example method includes fractional recrystallization using a "chiral resolving acid" which is an optically active, salt-forming organic acid.
- Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric • acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids.
- Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent ⁇ e.g., dinitrobenzoyl- phenylglycine).
- an optically active resolving agent e.g., dinitrobenzoyl- phenylglycine
- Suitable elution solvent composition can be determined by one skilled in the art.
- the protected compounds 1- 3 can be converted to the corresponding N-hydroxyamidines 1-4 by thionation with an appropriate reagent such as CS 2 or Lawesson's reagent followed by S-alkylation ⁇ e.g., S-methylation) with an appropriate reagent such as methyl iodide or methyltriflate followed by treatment with NH 2 OH.
- an appropriate reagent such as CS 2 or Lawesson's reagent followed by S-alkylation ⁇ e.g., S-methylation
- an appropriate reagent such as methyl iodide or methyltriflate followed by treatment with NH 2 OH.
- the N-hydroxyamidine group can be protected using, for example, phosgene, triphosgene, carbonyldiimidazole, etc., and the protected hydroxymethyl group can then be deprotected (such as by treatment with acid for alkylsilyl ethers) for further modification if desired.
- compounds of the invention can be prepared starting with the intermediate 2-1 (which can be prepared according to Scheme 1) which can be oxidized at the hydroxymethyl group according to standard procedures for conversion of an alcohol to an aldehyde to yield intermediates 2-2.
- the aldehydes (2-2) can be further reacted with appropriate nucleophiles to yield hydroxyl (2-5) or amino (2-4) intermediates with optional substitution (R A ) on the methylene.
- intermediates can be further modified by reaction of the hydroxyl groups with suitable electrophiles (e.g., alkylation, acylate, arylation) optionally in the presence of catalytic amounts of base or acid followed by deprotection to yield compounds of the invention 2-7 and 2-11.
- suitable electrophiles e.g., alkylation, acylate, arylation
- intermediate 2-5 can be oxidized to afford ketone 2-3 which can be further reacted with appropriate nucleophiles to yield hydroxyl (2-9) or amino (2-8) intermediates with optional substitution (R A and R B ) on the methylene.
- amines 2-4 and 2-8 can be directly deprotected to yield further compounds of the invention 2-6 and 2-10.
- Amino methyl compounds of the invention can be prepared according to the methods of
- Additional amino methyl compounds of the invention can be prepared according to the methods of Scheme 5 where the intermediate 4-2 is reacted with sodium azide followed by reduction (such as hydrogen over palladium or triphenylphosphine) to yield amino methyl compounds 4-6.
- the amino methyl compounds 4-6 can be further derivatized to make various compounds 4-7, such as amides, ureas, sulfonamides, carbamates and the like, by reaction of the amino moiety with R 0 C(O)- X, R Q S(O) 2 -X, R 0 OC(O)-X and the like (X is a leaving group).
- Alkoxy compounds 6-2 can be prepared, for example, according the route shown in Scheme 6.
- hydroxyalkyl or related compounds 6-1 are reacted with various electrophiles such as alkyl halides ("alkyl-X," where X is halo) followed by reaction with base such as hydroxide to form alkylated and similar compounds of formula 6-2.
- alkyl halides can be optionally substituted with other various functional groups.
- Compounds of the invention can modulate activity of the enzyme indoIeamine-2,3- dioxygenase (IDO).
- IDO indoIeamine-2,3- dioxygenase
- modulate is meant to refer to an ability to increase or decrease activity of an enzyme or receptor.
- compounds of the invention can be used in methods of modulating IDO by contacting the enzyme with any one or more of the compounds or compositions described herein.
- compounds of the present invention can act as inhibitors of IDO.
- the compounds of the invention can be used to modulate activity of EDO in cell or in an individual in need of modulation of the enzyme by administering a modulating (e.g., inhibiting) amount of a compound of the invention.
- the present invention further provides methods of inhibiting the degradation of tryptophan in a system containing cells expressing IDO such as a tissue, living organism, or cell culture.
- the present invention provides methods of altering (e.g., increasing) extracellular tryptophan levels in a mammal by administering an effective amount of a compound of composition provided herein. Methods of measuring tryptophan levels and tryptophan degradation are routine in the art.
- the present invention further provides methods of inhibiting immunosuppression such as IDO-mediated immunosuppression in a patient by administering to the patient an effective amount of a compound or composition recited herein.
- immunosuppression has been associated with, for example, cancers, tumor growth, metastasis, viral infection, viral replication, etc.
- the present invention further provides methods of treating diseases associated with activity or expression, including abnormal activity and/or overexpression, of DDO in an individual (e.g., patient) by administering to the individual in need of such treatment a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof.
- Example diseases can include any disease, disorder or condition that is directly or indirectly linked to expression or activity of the IDO enzyme, such as over expression or abnormal activity.
- An EDO-associated disease can also include any disease, disorder or condition that can be prevented, ameliorated, or cured by modulating enzyme activity.
- EDO-associated diseases include cancer, viral infection such as HIV infection, depression, neurodegenerative disorders such as Alzheimer's disease and Huntington's disease, trauma, age-related cataracts, organ transplantation (e.g., organ transplant rejection), and autoimmune diseases including asthma, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and systemic lupus erythematosusor.
- Example cancers treatable by the methods herein include cancer of the colon, pancreas, breast, prostate, lung, brain, ovary, cervix, testes, renal, head and neck, lymphoma, leukemia, melanoma, and the like.
- an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal.
- an in vitro cell can be a cell in a cell culture.
- an in vivo cell is a cell living in an organism such as a mammal.
- the term "contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system.
- "contacting" the EDO enzyme with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having EDO, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the IDO enzyme.
- terapéuticaally effective amount refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following:
- preventing the disease for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease;
- inhibiting the disease for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder;
- ameliorating the disease for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
- One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., JL2, GM- CSF, etc.), and/or tyrosine kinase inhibitors can be used in combination with the compounds of the present invention for treatment of EDO-associated diseases, disorders or conditions.
- the agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
- Suitable antiviral agents contemplated for use in combination with the compounds of the present invention can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.
- NRTIs nucleoside and nucleotide reverse transcriptase inhibitors
- NRTIs non-nucleoside reverse transcriptase inhibitors
- protease inhibitors and other antiviral drugs.
- Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L-FD4 (also called beta-L-D4C and named beta-L-2', 3'-dicleoxy-5-fiuoro-cytidene); DAPD, ((-)-beta-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA).
- ZT zidovudine
- ddl didanosine
- ddC zalcitabine
- stavudine d4T
- NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1- (ethoxy-methyl)-5-(l-methylethyl)-6-(phenylmethyl)-(2,4(lH,3H)- ⁇ yrimidinedione); and (+)- calanolide A (NSC-675451) and B.
- Suitable protease inhibitors include saquinavir (Ro 31- 8959); ritonavir (ABT-538); indinavir (MK-639); nelfiiavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-I 549.
- Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.l 1607.
- Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents
- uracil mustard including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes
- nitrogen mustards including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes
- uracil mustard such as uracil mustard, chlormethine, cyclophosphamide (Cytoxan M ), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethio- phosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
- suitable agents for use in combination with the compounds of the present invention include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen," which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide.
- DTIC dacarbazine
- BCNU carmustine
- cisplatin the "Dartmouth regimen” which consists of DTIC, BCNU, cisplatin and tamoxifen
- a combination of cisplatin, vinblastine, and DTIC or temozolomide.
- Compounds according to the invention may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in the treatment of melanoma.
- cytokines such as interferon alpha, inter
- Antimelanoma vaccines are, in some ways, similar to the anti-virus vaccines which are used to prevent diseases caused by viruses such as polio, measles, and mumps. Weakened melanoma cells or parts of melanoma cells called antigens may be injected into a patient to stimulate the body's immune system to destroy melanoma cells.
- Melanomas that are confined to the arms or legs may also be treated with a combination of agents including one or more compounds of the invention, using a hyperthermic isolated limb perfusion technique.
- This treatment protocol temporarily separates the circulation of the involved limb from the rest of the body and injects high doses of chemotherapy into the artery feeding the limb, thus providing high doses to the area of the tumor without exposing internal organs to these doses that might otherwise cause severe side effects.
- the fluid is warmed to 102° to 104° F.
- Melphalan is the drug most often used in this chemotherapy procedure. This can be given with another agent called tumor necrosis factor (TNF) (see section on cytokines).
- TNF tumor necrosis factor
- Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites
- folic acid antagonists including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors
- methotrexate 5-fluorouracil, floxuridine, cytarabine, 6- mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.
- Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactino- mycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (TAXOLTM), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide.
- certain natural products and their derivatives for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins
- vinblastine vincristine, vindesine
- bleomycin dactino- mycin, daunorubicin
- cytotoxic agents include navelbene, CPT-I l, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.
- cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis- platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.
- anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4- IBB and PD-I, or antibodies to cytokines (IL-10, TGF- ⁇ , etc.).
- trastuzumab Herceptin
- costimulatory molecules such as CTLA-4, 4- IBB and PD-I
- cytokines IL-10, TGF- ⁇ , etc.
- anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.
- anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.
- Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.
- compositions which is a combination of a compound of the invention and a pharmaceutically acceptable carrier.
- These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral.
- Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac.
- Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
- Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
- Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
- compositions which contain, as the active ingredient, one or more of the compounds of the invention above in combination with one or more pharmaceutically acceptable carriers.
- the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
- the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
- excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
- the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
- the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient.
- unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
- the active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
- the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
- a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
- the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.
- the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
- compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
- compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
- the pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
- the therapeutic dosage of the compounds of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
- the proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
- the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day.
- the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
- the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- the compounds of the invention can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like.
- Another aspect of the present invention relates to fluorescent dye, spin label, heavy metal or radio-labeled compounds of the invention that would be useful not only in imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the EDO enzyme in tissue samples, including human, and for identifying IDO enzyme ligands by inhibition binding of a labeled compound.
- the present invention includes IDO enzyme assays that contain such labeled compounds.
- the present invention further includes isotopically-labeled compounds of Formula I.
- An "isotopically” or “radio-labeled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
- Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 18 F, 35 S, 36 Cl, 82 Br 3 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I and 131 I.
- the radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound.
- a “radio-labeled” or “labeled compound” is a compound that has incorporated at least one radionuclide.
- the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1 , 35 S and 82 Br.
- Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art.
- a radio-labeled compound of the invention can be used in a screening assay to identify/evaluate compounds.
- a newly synthesized or identified compound i.e., test compound
- Kits The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of IDO-associated diseases or disorders, obesity, diabetes and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention.
- kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art.
- Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
- Step A 4H, 6H-Furo[3, 4-c][l, 2, 5]oxadiazol-4-one
- Step B N-(3-Chloro-4- ⁇ uorophenyl)-4-(hydroxymethyl)-l,2, 5-oxadiazoleS-carboxamide
- Step D N-(3-Chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-l, 2, 5-oxadiazole-3- carboth io amide
- Step E Methyl N- ⁇ -chloro ⁇ -fluorophenyO ⁇ -fCtriisopropylsilyQoxyJmethyl-l ⁇ . ⁇ -oxadiazole-S- carbimidoth ioate
- Step F N-fS-Chloro ⁇ -fluorophenyty-N'-hydroxy- ⁇ fftriisopropylsilylJoxyJmethyl-l ⁇ .S-oxadiazole-S- carboximidamide
- Methyl N-(3-chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-l,2,5-oxadiazole-3- carbimidothioate (3.0 g, 6.5 mmol) was dissolved in EtOH followed by addition of 4 mL hydroxylamine (99.9% in water solution) . The reaction was stirred at 75 0 C for 6 hrs and monitored by HPLC. The reaction was concentrated in vacuo to a yellow oil which was dissolved in chloroform and chromatographed on 120 g of silica gel eluting with (1: 4), EtOAc/hexane.
- Step G 4-(3-Chloro-4- ⁇ uorophenyl)-3-(4-[(triisopropylsilyl)oxy] methyl-1 ,2,5-oxadiazol-3-yl)-l ,2,4- oxadiazol-5(4H)-one
- N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(triisopropylsilyl)oxy]methyl-l,2,5-oxadiazole-3- carboximidamide (2.2 g, 5.0 mmol) was dissolved in anhydrous tetrahydrofuran (THF) (31 mL) followed by addition of iV.N-carbonyldiimidazole (980 mg, 6 mmol). The reaction was heated to 70
- Step H 4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-l, 2, 5-oxadiazol-3-yl]-l, 2, 4-oxadiazol- 5(4H)-one
- Step J N-(3-Chloro-4- ⁇ uoro-phenyl)-N'-hydroxy-4-hydroxymethyl-furazan-3-carboxamidine 4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-l,2,5-oxadiazol-3-yl]-l,2,4-oxadiazol-
- Step A 4-(3-Chloro-4-fluorophenyl)-3-[4-(phenoxymethyl)-l ,2,5-oxadiazol-3-yl] -1 ,2,4-oxadiazol- 5(4H)-one
- Step C N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(phenoxymethyl)-l,2,5-oxadiazole-3- carboximidamide
- 4-(3-chloro-4-fluorophenyl)-3-[4-(phenoxymethyl)-l,2,5-oxadiazol-3- yl]-l ,2,4-oxadiazol-5(4H)-one 9 mg, 23 mmol
- EtOH 0.5 mL
- 2.0 M of sodium hydroxide in water 35 ⁇ L
- Step A 4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylmethyl methanesulfonate
- Table 1 below (and Tables 2 and 3, infra) provide example compounds of the invention that show activity as IDO modulators according to one or more of the assays provided herein.
- the compounds were prepared according to synthetic procedure of the Example compound specified in the column marked "Prep. Ex.” and were purified by the method in the column marked “Pur. Meth.” In the "Pur.
- ACN refers to acetonitrile.
- DCM refers to dichloromethane.
- DMF refers to dimethylformamide.
- TFA refers to trifluoroacetic acid.
- TEA refers to tetraethylamine.
- DMAP refers to dimethylaminopyridine.
- DIPEA refers to N,N- diethylisopropylamine.
- Step A 4-(3-(Tri ⁇ uoromethyl)phenyl)-3-(4-[(2-morpholin-4-ylethyl)amino]methyl-l,2,5-oxadiazol-3- y I)-1, 2, 4-oxadiazol-5(4H)-one
- Step B 3-(4-[(2-Morpholin-4-ylethyl)amino]methyl-l,2,5-oxadiazol-3-yl)-4-[3-(trifluoromethyl)- phenyl] -1,2, 4-oxadiazol-5(4H)-one
- EtOH 200 ⁇ L
- 2 M of sodium hydroxide in water 60 ⁇ L
- Example 32 ⁇ (3-Chloro-4-fluorophenyI)- ⁇ r '-hydroxy-4-[(methylsulfonyI)(2-morpholin-4-yl- ethyl)amino]methyI-l,2,5-oxadiazole-3-carboximidamide
- Step A 4-(3-Chloro-4-fluorophenyl)-3-(4-[(2-morpholin-4-ylethyl)amino]methyl-l,2,5-oxadiazol-3- yl)-l,2, 4-oxadiazol-5(4H)-one
- Step B N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-[(methylsulfonyl)(2-morpholin-4- ylethyl)amino]methyl-l,2,5-oxadiazole-3-carboximidamide
- Step A 3-[4-(azidomethyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4- ⁇ uorophenyl)-l,2,4-oxadiazol-5(4H)- one
- Step B ⁇ - ⁇ -(Aminomethyiyi.l ⁇ -oxadiazol-i-ylJ ⁇ - ⁇ -chloro ⁇ -fluorophenyfyA ⁇ -oxadiazol- 5(4H)-one
- Step C 4-[(Benzylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2, 5-oxadiazole-3- carboximidamide Benzoic acid (4.3 mg, 0.035 mmol) and 3-[4-(aminomethyl)-l,2,5-oxadiazol-3-yl]-4-(3- chloro-4-fluorophenyl)-l,2,4-oxadiazol-5(4H)-one (10 mg, 0.032 mmol) was dissolved in ACN (0.2 mL) and DCM (0.2 mL).
- Example 36 Benzyl ( ⁇ 4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5- oxadiazol-3-yl ⁇ methyl)carbamate
- Step A N-(3-Cyanophenyl)-4-methyl-l,2, 5-oxadiazole-3-carboxamide
- Step B N-(3-Cyanophenyl)-N'-hydroxy-4-methyl-l ,2,5-oxadiazole-3-carboximidamide
- Example 38 iV-(3-Chloro-4-fluorophenyl)- ⁇ r '-hydroxy-4-methyl-l ,2,3-thiadiazole-5-carbox- imidamide
- Step A 4-Methyl-[l,2,3]thiadiazole-5-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide
- Step B N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-methyl-l,2, 3-thiadiazole-5-carboximidamide
- Examples 39 and 40 4-[(5-Amino-lH-tetrazoH-yl)methyl]-iV-(3-chIoro-4-fluorophenyl)-iV- hydroxy-l,2,5-oxadiazole-3-carboximidamide (39), and 4-[(5-Amino-2H-tetrazol-2-yl)methyl]- -/V-(3-chloro-4-fluorophenyl)- ⁇ -hydroxy-l,2,5-oxadiazole-3-carboximidamide (40)
- Step A ⁇ -(3-Chloro-4-fluorophenyl)-4-[(lH-tetrazol-5-ylamino)methyl]-l,2,5-oxadiazole-3- carboxamide
- Step B N- ⁇ -Chloro- ⁇ fluorophenyfy- ⁇ lfl-ft- ⁇ rimethylsilytyethoxyJmethyl-lH-tetrazol-S-yQamino]- methyl-l,2,5-oxadiazole-3-carboxamide, and N-(3-Chloro-4-fluorophenyl)-4-[(2-[2-(trimethyl- silyl)ethoxy]methyl-2H-tetrazol-5-yl)amino]methyl-l,2,5-oxadiazole-3-carboxamide
- Step C N- ⁇ -chloro ⁇ -fluorophenylJ-N'-hydroxy- ⁇ ttl-ft-ftrimethylsilytyethoxyJmethyl-lH-tetrazol- 5-yl)amino]methyl-l,2,5-oxadiazole-3-carboximidamide
- N-(3-Chloro-4-fluorophenyl)-4-[(l-[2-(trimethylsilyl)ethoxy]methyl-lH-tetrazol-5-yl)amino]- methyl-l,2,5-oxadiazole-3-carboxamide (96 mg, 0.20 mmol) was suspended in benzene (1.0 mL) and pyridine (0.5 mL) under an atmosphere of nitrogen. Phosphorus pentachloride (46.9 mg, 0.225 mmol) was added and the solution was heated at reflux for 2 hrs. The reaction was then stripped to dryness in vacuo.
- Step D N-fi-chloro ⁇ -fluorophenylJ-N'-hydroxy ⁇ -ftlH-tetrazol-S-ylaminoJmethylJ-l ⁇ .S-oxadiazole- 3-carboximidamide
- Example 139 Ethyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-l,2,5- oxadiazol-3-yl)propanoate
- reaction was quenched with a 1 ⁇ HCl solution, the aqueous solution was then extracted with ethyl acetate. The combined organic solutions were washed with brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified with flash chromatography (30% ethyl acetate/ hexane) to give the desired product as a white solid.
- Step 3 Ethyl 3-(4-[(3-chloro-4- ⁇ uorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)propanoate
- Step 4 Ethyl 3-4-[(Z)-[(3-chloro-4 ⁇ fluorophenyl)amino] (hydroxyimino)methyl] -1 ,2,5-oxadiazol ⁇ 3- ylpropanoate
- Ethyl 3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)-propanoate 27 mg, 0.079 mmol
- benzene (1 mL) under a nitrogen atmosphere
- phosphorus pentachloride (18.0 mg, 0.086 mmol
- Example 140 ⁇ '-(3-ChIoro-4-fluorophenyl)- ⁇ ' r -hydroxy-4-(3-morpholin-4-ylpropyl)-l ⁇ ,5- oxadiazoIe-3-carboxiniidamide
- Step 2 3-(4-[(3-Chloro-4-fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)propyl methanesulfonate
- N-(3-Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-l ,2,5-oxadiazole-3-carboxamide 60 mg, 0.20 mmol was dissolved in anhydrous DCM (2 mL), followed by addition of TEA (57 ⁇ L, 0.41 mmol). The reaction was stirred and cooled to 0 0 C, and then methanesulfonyl chloride (29 ⁇ L, 0.37 mmol) was added dropwise. The reaction was quenched with water and diluted with DCM.
- Step 3 N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyt)-l,2,5-oxadia ⁇ ole-3-carboxamide
- Step 4 N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(3-morpholin-4-ylpropyl)-l,2,5-oxadiazole-3- carboximidamide
- N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyl)-l,2,5-oxadiazole-3-carboxamide (10.0 mg, 27.1 ⁇ mol) was suspended in benzene (0.4 mL) under a nitrogen atmosphere and phosphorus pentachloride (6.2 mg, 29.8 ⁇ mol) was added and the solution was heated at reflux for 2.5 h. The reaction was then stripped to dryness in vacuo. The reaction was dissolved in EtOH (0.3 mL) and hydroxylamine (40 ⁇ L, 0.7 mmol) (50% solution in water) was added to the reaction.
- Example 141 5-[(5-Amino-lH-tetrazol-l-yl)methyl]-iV-(3-chIoro-4-fluorophenyI)-iV'-hydroxy- l,2,3-thiadiazole-4-carboxiniidamide
- Methyl 4-methoxy-3-oxobutanoate (4.28 g, 0.029 mol) was dissolved in ether (20 mL). The solution was cooled in an ice bath. To the solution was added p-toluenesulfonyl azide (5.78 g, 0.029 mol) followed by N-ethylethanamine (2.0 mL, 0.019 mol). The solution was stirred at 0 °C for 15 minutes, then at rt for 30 minutes. Upon evaporation, the tosyl amide bi-product solidified. This was filtered off and the filtrate was purified by flash chromatography to give the desired product (4.5 g, 89%) as a light oil.
- Step F N- (3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-l, 2, S-thiadiazole-4- carboxamide
- Step G N-(3-chloro-4- ⁇ uorophenyl)-5-[(triisopropy ⁇ silyl)oxy]methyl-l,2,3-thiadiazole-4- ca rboth ioam ide
- Step H Methyl N-(3-chloro-4-fluorophenyl)-5-[(triiso ⁇ ropylsilyl)oxy]methyl-l, 2, 3-thiadiazole-4- carbimidothioate
- Step I N-(3-ckloro-4-fluorophenyl)-N'-hydroxy-5-[(triisopropylsilyl)oxy] 'methyl-1 ,2,3-thiadiazole-4- carboximidamide
- Methyl N ⁇ -chloro ⁇ -fluorophenyO-S-t ⁇ triisopropylsily ⁇ oxyjmethyl-l ⁇ j S-thiadiazole ⁇ - carbimidothioate (90 mg, 0.0002 mol) was dissolved in EtOH (2 mL) followed by addition of hydroxylamine (116 ⁇ L, 0.00190 mol) (50% by wt, 99.9% in water solution) . The reaction was stirred at 60 0 C for 4 h and overnight at room temperature. The reaction was evaporated and purified by flash chromatography to give the desired product (85 mg, 98%).
- Step J 4-(3-Chloro-4-fluorophenyl)-3-(5-[(triisopropylsilyl)oxy]methyl-l,2,3-thiadiazol-4-yl)-l,2,4- oxadiazol-5(4H)-one
- Step K 4-(3-Chloro-4-fluorophenyl)-3-[5-(hydroxymethyl)-l ,2,3-thiadiazo ⁇ -4-yl] -1 ,2,4-oxadiazol- 5(4H)-one
- Step L 4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,3-thiadiazol-5- ylmeihyl methanesulfonate
- Step M 3-5-[(5-Amino-lH-tetrazol-l-yl)methyl]-l,2, 3-thiadiazol-4-yl-4-(3-chloro ⁇ 4-fluorophenyl)- 1,2, 4-oxadiazol-5(4H)-one trifluoroacetate
- Step N 5-[(5-Amino-lH-tetrazol-l-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2,3- th iadiazole-4-carboximidamide trifluoroacetate
- Example 142 iV-(3-Chloro-4-fluorophenyl)-iV'-hydroxy-5-(hydroxymethyl)-l,2,3-thiadiazole-4- carboximidamide
- Example 143 4-[(Aminosulfonyl)amino]methyl- ⁇ ' ' -(3-chloro-4-fluorophenyl)- ⁇ r -hydroxy-l,2,5- oxadiazole-3-carboximidamide trifluoroacetate
- Example 144 ⁇ -(3-Chloro-4-fluorophenyI)-4-([(E/Z)-(cyanoimino)(methylainino)methyl]- aniinomethyl)-7V'-hydroxy-l,2,5-oxadiazole-3-carboximidamide
- Example 145 iV-(3-Chloro-4-fluorophenyl)-iV'-hy droxy-4-( [(methyla mino)sulf onyl] amino- methyl)-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
- Example 146 4-[(Aminocarbonyl)amino]methyI-N-(3-chloro-4-fluorophenyI)-iV'-hydroxy-l,2,5- oxadiazoIe-3-carboxiniidamide trifluoroacetate
- Example 147 4-([(Tert-butyIamino)carbonyl] aminomethyl)-iV-(3-chloro-4-fluorophenyl)-iV'- hydroxy-l,2,5-oxadiazoIe-3-carboximidamide trifluoroacetate
- Example 148 ⁇ -(S-Chloro ⁇ -fluorophenyl ⁇ '-hydroxy ⁇ -CfCS-morpholin ⁇ -ylpropy ⁇ sulfonyl]- aminomethyl)-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
- Step A 3-Chloro-N-( ⁇ 4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl) '-1,2,5- oxadiaz ol-3-yl ⁇ methyl)propane-l -sulfonamide
- Step B N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-([(3-morpholin-4-ylpropyl)sulfonyl]aminomethyl)- 1,2, 5-oxadiazole-3-carboximidamide trifluoroacetate A solution of 3-chloro-N-(4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-
- Example 149 iV-(3-Chloro-4-fluorophenyl)--V'-hydroxy-4-[(piperidin-4-ylsuIfonyl)ainino]- niethy]-l,2,5-oxadiazoIe-3-carboximidaniide trifluoroacetate
- Step A N-(4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-J,2,4-oxadiazol-3-ylJ-l,2,5-oxadiazol- 3-ylme thyl)piperidine-4-sulfonamide trifluoroacetate
- Step B N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-[(piperidin-4-ylsulfonyl)amino]methyl-l ,2,5- oxadiazole-3-carboximidamide trifluoroacetate:
- Example 150 4-[(Il-(AminosuIfonyI)piperidin-4-yl]sulfonylamino)methyI]-iV-(3-chloro-4- fluorophenyl)-iV-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
- Example 151 4-([(l-Acetylpiperidin-4-yl)suIfonyl]aminomethyl)- ⁇ '-(3-chloro-4-fluorophenyI)- JV'-hydroxy-l,2,5-oxadiazoIe-3-carboximidainide trifluoroacetate
- Example 152 A ⁇ 3-ChIoro-4-fluorophenyl)rN r -hydroxy-4-[5-(morpholin-4-ylmethyI)-2H- tetrazol-2-yl]methyI-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
- Example 153 7V-(3-ChIoro-4-fluorophenyl)--V'-hydroxy-4-[5-(morpholin-4-ylmethyl)-lH- tetrazol-l-yl]methyI-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
- Step A 4-(lH-tetra ⁇ ol-5-ylmethyl)morpholine:
- Step B N-(3-chloro-4- ⁇ uorophenyl)-N'-hydroxy-4-[5-(morpholin-4-ylmethyl)-2H-tetrazol-2-yl]- methyl- 1, 2, 5-oxadiazole-3-carboximidamide trifluoroacetate and
- the reaction was then diluted with MeOH and purified by preparative LCMS to yield two isomers.
- the purified isomers were concentrated to dryness, redissolved in EtOH (1.0 mL) and a solution of sodium hydroxide in water (0.5 mL, 1 N) was added. The reactions were stirred for 20 minutes. Reactions were quenched with acetic acid, diluted with MeOH and purified by preparative LCMS to yield the two isomers (2.2 mg, 2.4%) and (3.2 mg, 3.5%).
- Example 152 1 H NMR (400 MHz, DMSO-rf tf ): ⁇ 11.5 (s, IH), 9.0 (s, IH), 7.2 (t, IH), 7.0 (d, IH), 6.75 (d, IH), 6.4 (s, 2H), 3.6 (bs, 8H).
- Example 154 4-[(5-Amino-l ,3,4-thiadiazol-2-yl)thio] methyl-iV-(3-chIoro-4-fluorophenyI)- ⁇ '- hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
- Example 155 4-[(5-Amino-4H-l,2,4-triazol-3-yl)thio]methyl- ⁇ r -(3-chIoro-4-fluorophenyI)-iV'- hydroxy-l,2,5-oxadiazoIe-3-carboximidamide trifluoroacetate
- Example 156 4-[(5-Amino-4H-l,2,4-triazol-3-yl)sulfonyl]methyI-iV-(3-chloro-4-fluorophenyl)- ⁇ -hydroxy-l ⁇ jS-oxadiazole-S-carboximidamide trifluoroacetate
- Example 157 iV-(3-Chloro-4-fluorophenyl)-4-[((E/Z)-(cyanoimino)[(4-methoxybenzyl)amino]- methylamino)methyl]-7V'-hydroxy-l,2,5-oxadiazole-3-carboximidamidc trifluoroacetate
- Example 158 4-
- N-(3-Chloro-4-fluorophenyl)-4-[((E/Z)-(cyanoimino)[(4-methoxybenzyl)amino]methyl- amino)methyl]-N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate (20 mg, 0.04 mmol) was dissolved in TFA (1.0 mL) and stirred for 1 hour at rt. Purification by preparative LCMS gave the' desired product (12 mg, 50%).
- Example 159 4-( ⁇ [(l£/Z)-Amino(iiitroiinino)methyl]ainino ⁇ methyl)-7V-(3-chloro-4-fluoro- phenyl)-N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
- Example 160 4-( ⁇ f Amino(imino)methyl]amino ⁇ methyl)-7Y-(3-chloro-4-fluorophenyl)-N'- hydroxy-l,2,5-oxadiazole-3-carboximidamide
- Example 161 ⁇ r -(3-Chloro-4-fluorophenyl)-iV'-hydroxy-4-(4H-l,2,4-triazoI-4-ylmethyl)-l,2,5- oxadiazole-3-carboximidamide trifluoroacetate
- Step A N-(3-Chloro-4-fluorophenyl)-4-[(E)-2-methoxyvinyl]-l, 2, 5-oxadiazole-3-carboxamide N-(3-chloro-4- ⁇ uorophenyl)-4 ⁇ [(Z)-2-methoxyvinyl]-l,2,5-oxadiazole-3-carboxamide
- Step B N-(3-Chloro ⁇ 4-fluorophenyl)-4-(2-methoxyethyl)-l,2,5-oxadiazole-3-carboxamide
- Step C N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(2-methoxyethyl)-l, 2, 5-oxadiazole-3- carboximidamide
- N-(3-Chloro-4-fluorophenyl)-4-(2-methoxyethyl)-l,2,5-oxadiazole-3-carboxamide (2.5 g, 8.3 mmol) was suspended in benzene (40 mL), pyridine (2.7 rtiL) and phosphorus pentachloride (3.5 g, 17 mmol) was added to the solution. The mixture was heated at 60 0 C for 2.5 h. The reaction was then concentrated to dryness in vacuo. The crude was dissolved in EtOH (50 mL) and cooled to 0 0 C and 50% hydroxylamine in water (10 mL) was added to the reaction flask until the pH reached 8.
- Step D 4-(3-Chloro-4-fluorophenyl)-3-[4-(2-methoxyethyl)-l,2, 5-oxadiazol-3-yl]-l ,2, 4-oxadiazol- 5(4H)-one
- Step E 4-(3-Chloro-4-fluorophenyl)-3-[4-(2-hydroxyethyl)-l,2,5-oxadiazol-3-yl]-l,2,4-oxadiazol- 5(4H)-one
- 4-(3-chloro-4-fluorophenyl)-3-[4-(2-methoxyethyl)-l,2,5-oxadiazol-3-yl]- l,2,4-oxadiazol-5(4H)-one (2.55 g, 0.00748 mol) in DCM (24 mL) was added 1.0 M of boron tribromide in DCM (22.4 mL) under an atmosphere of nitrogen at -78 0 C.
- Step F 2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylethyl methanesulfonate
- Step G 4-[2-(5-Amino-lH-tetra ⁇ ol-l-yl)ethyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2, 5- oxadiazole-3-carboximidamide 2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylethyl methanesulfonate (16.0 mg, 0.039 mmol) was dissolved in anhydrous ACN (0.6 mL), followed by addition of DIPEA (27.5 ⁇ L, 0.158 mmol) and 1 H-tetrazol-5 -amine (4.0 mg, 0.047 mmol).
- Example 163 4-[2-(5-Amino-2H-tetrazol-2-yl)ethyI]-iV-(3-chloro-4-fluorophenyl)-iV'-hydroxy- l,2,5-oxadiazole-3-carboximidamide
- the first eluting peak (isomer 1) was dissolved in MeOH (0.5 mL) and 2.0 N of sodium hydroxide in water (0.079 mL) was added. After stirring for 0.5 h, reaction solution was diluted with MeOH and few drops of acetic acid and purified by preparative LCMS to give the desired product as a white powder (3.8 mg, 26%).
- Example 164 ⁇ -(3-Chloro-4-fluorophenyl)-iV-hydroxy-4-[2-(lH-imidazol-l-yl)ethyI]-l,2,5- oxa diazole-3-carboximidamide
- Example 165 iV-(3-Chloro-4-fluorophenyl)-iV-hydroxy-4-(2-morpholin-4-ylethyl)-l,2,5- oxadiazole-3-carboximidamide
- Example 166 ⁇ r -(3-ChIoro-4-fluorophenyl)- ⁇ ' 1 -hydroxy-4-[2-(4-methy]piperazin-l-yl)ethyl]- l,2,5-oxadiazoIe-3-carboximidamide
- This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methanesulfonate and 1-methylpiperazine as the starting materials.
- MF Ci 6 H 20 ClFN 6 O 2 ; LCMS for
- Example 167 7V-(3-Chloro-4-fluorophenyl)-iV'-hydroxy-4-[2-(4H-l,2,4-triazol-4-yl)ethylJ-l,2,5- oxadiazole-3-carboximidaniide
- Example 168 ⁇ -(S-Chloro ⁇ -fluorophenyO-iV-hydroxy- ⁇ ll-ClH-l ⁇ -triazol-l-yOethyll-l ⁇ jS- oxadiazole-3-carboximidamide
- This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methane- sulfonate and lH-l,2,4-triazole as the starting materials.
- MF Ci 3 HnClFN 7 O 2 ; LCMS for
- Example 170 iV-(3-ChIoro-4-fluorophenyl)-iV-hydroxy-4-[2-(2H-tetrazol-2-yl)ethyll-l,2,5- oxadiazole-3-carboxiniidaniide
- Example 171 iV-(3-ChIoro-4-fluorophenyl)-7V -hydroxy ⁇ -vinyl-l ⁇ S-oxadiazoIe-S-carbox- imidamide ,
- Example 172 iV-(3-ChIoro-4-fluorophenyI)-4-[2-(dimethylamino)ethyl]-iV-liydroxy-l,2,5-oxa- diazoIe-3-carboximidamide
- Example 173 iV-(3-Chloro-4-fluorophenyl)--V-hydroxy-4-(2-thiomorpholin-4-ylethyl)-l,2,S- oxadiazole-3-carboximidamide
- Example 175 ⁇ r -(3-Chloro-4-fluorophenyl)-iV-liydroxy-4- ⁇ 2-[isopropyI(methyl)amino]ethyl ⁇ - l,2,5-oxadiazoIe-3-carboximidamide
- Example 176 iV-(3-ChIoro-4-fluorophenyl)-iV-hydroxy-4-2-[(methylsuIfonyl)amino]ethyl-l,2,5- oxadiazole-3-carboximidamide
- Step A 3-[4-(2-azidoethyl)-l r 2,5-oxadiazol-3-yl]-4-(3-chloro-4- ⁇ uorophenyl)-l,2,4-oxadiazol-5(4H)- one
- Step B 3-[4-(2-aminoethyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4-oxadiazol- 5(4H)-one trifluoroacetate
- Step C ⁇ -(3-chloro-4-fluorophenyl)-N'-hydroxy-4-2-[( ⁇ ethylsulfonyl)amino]ethyl-l,2,5-oxadiazole- 3-carboximidamide
- Example 178 Ethyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-l,2,5- oxadiazol-3-yl)propanoate
- Step 1 N-(3-Chloro-4-fluorophenyl)-4-formyl-l, 2, 5-oxadiazole-S-carboxamide
- Step 2 Ethyl (2E)-3-(4-[(3-chloro-4 ⁇ fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)acrylate
- the resulting solution was heated at 80 0 C for 3 h, then cooled to rt overnight.
- the reaction was quenched with a 1 N HCl solution, the aqueous solution was extracted with ethyl acetate.
- the combined organic solutions were washed with brine, dried over Na 2 SO 4 , filtered and concentrate under reduced pressure.
- the residue was purified with flash chromatography (30% ethyl acetate/ hexane) to give the desired product as a white solid (0.91 g, 89%).
- Step 3 Ethyl 3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)propanoate
- Step 4 Ethyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N'-h.ydroxycarbamimidoyl)-l,2,5-oxadia ⁇ ol-3- yl)propanoate
- Example 179 yV-(3-ChIoro-4-fluorophenyI)- ⁇ r '-hydroxy-4-(3-morphoIin-4-ylpropyI)-l,2,5- oxadiazole-3-carboximidamide Step 1: N ⁇ (3-Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-l, 2, 5-oxadiazole-3-carboxamide
- Step 2 3-(4-[(3-Chloro-4- ⁇ uorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)propyl methane- sulfonate
- N-(3 -Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-l ,2,5-oxadiazole-3 -carboxamide 60 mg, 0.20 mmol was dissolved in anhydrous DCM (2 mL), followed by addition of TEA (57 ⁇ L, 0.41 mmol). The reaction was stirred and cooled to 0 0 C, and methanesulfonyl chloride (29 ⁇ L, 0.37 mmol) was added drop-wise. The reaction was quenched with water and diluted with DCM.
- Step 3 N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyl)-l ,2,5-oxadiazole-3-carboxamide
- Step 4 N-(3-Chloro-4- ⁇ uorophenyl)-N'-hydroxy-4-(3-morpholin-4-ylpropyl)-l,2, 5-oxadiazole-S- carboximidamide
- N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyl)-l,2,5-oxadiazole-3-carboxamide (10.0 mg, 27 ⁇ mol) was suspended in benzene (0.4 mL) under an atmosphere of nitrogen and phosphorus pentachloride (6.2 mg, 29.8 ⁇ mol) was added. The solution was heated at reflux for 2.5 h. The volatiles were evaporated in vacuo. The reaction was dissolved in EtOH (0.3 mL) and hydroxylamine (40 ⁇ L, 0.7 mmol) (50% solution in water) was added to the reaction.
- Example 180 4- ⁇ 3-[(Aminosulfonyl)amino]propyI ⁇ -JV " -(3-chloro-4-fluorophenyl)- ⁇ ' ⁇ -hydroxy- l,2,5-oxadiazole-3-carboximidamide
- Stepl S-fe- ⁇ -Azidopropyty-l. ⁇ .S-oxadiazolS-ylJ ⁇ - ⁇ -chloro ⁇ -fluorophenyty-l ⁇ -oxadiazol- 5(4H)-one
- Step 2 S-ft- ⁇ -AminopropylJ-l ⁇ -oxadiazolS-ylJ- ⁇ -chloro-J-fluorophenyfy-I ⁇ -oxadiazol- 5(4H)-one tri ⁇ uoro acetate
- Example 182 iV-(3-Chloro-4-fluorophenyI)- ⁇ '-hydroxy-4-[3-(4H-l,2,4-triazoI-4-yl)propyl]- l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
- Example A Human indoleamine 2,3-dioxygenasae (IDO) enzyme assay
- IDO Human indoleamine 2,3-dioxygenasae with an ⁇ -terminal His tag was expressed in E.coli and purified to homogeneity. IDO catalyzes the oxidative cleavage of the pyrrole ring of the indole nucleus of tryptophan to yield iV-formylkynurenine.
- the assays were performed at room temperature as described in the literature using 95 nM EDO and 2 mM D-Trp in the presence of 20 mM ascorbate, 5 ⁇ M methylene blue and 0.2 mg/mL catalase in 50 mM potassium phosphate buffer (pH 6.5).
- Example B Determination of inhibitor activity in HeLa cell-based indoleamine 2,3-dioxygenase (IDO)/Kynurenine assay HeLa cells (#CCL-2) were obtained from the American Type Tissue Culture Collection
- IF ⁇ - ⁇ 50 ng/mL final concentration
- serial dilutions of compounds in total volume of 200 ⁇ L culture medium
- 140 ⁇ L of the supernatant per well was transferred to a new 96 well plate.
- 10 ⁇ L of 6.1 ⁇ trichloroacetic acid (#T0699, Sigma) was mixed into each well and incubated at 50 0 C for 30 min to hydrolyze N- formylkynurenine produced by indoleamine 2,3-dioxygenase to kynurenine.
- the reaction mixture was then centrifuged for 10 min at 2500 rpm to remove sediments.
- Example C Determination of effect of IDO inhibitors on T cell proliferation that is suppressed by EDO-expressing dendritic cells
- Monocytes were collected from human peripheral mononuclear cells by leukophoresis.
- Monocytes were then seeded at a density of 1 x 10 6 cells/well in a 96 well plate, using RPMI 1640 medium supplemented with 10 % fetal bovine serum and 2 mM L-glutamine (all from Invitrogen). Adherent cells were retained on the plate after overnight culture at 37 0 C.
- Adherent monocytes were then stimulated for 5-7 days with 100 ng/ml GM-CSF (# 300-03, PeproTech) and 250 ng/ml EL-4 (#200-04, PeproTech), followed by activation with 5 ⁇ g/mL LPS from Salmonella typhimu ⁇ um (#437650, Sigma) and 50 ng/mL IFN- ⁇ (# 285-IF, R&D Systems) for additional 2 days to induce dendritic cell maturation.
- T cell proliferation was measured by BrdU incorporation assay, using a colorimetric Cell Proliferation ELISA kit per manufacturer's instruction (#1647229, Roche Molecular Biochemicals). Cells were continuously cultured for 16-18 hrs in presence of 10 ⁇ M BrdU labeling solution.
- Example D In vivo testing of IDO inhibitors for antitumor activity
- In vivo anti-tumor efficacy can be tested using modified tumor allograft/xenograft protocols. For instance, it has been described in the literature that EDO inhibition can syngerize with cytotoxic chemotherapy in immune-competent mice (Muller, AJ., et al). This synergy was shown to be dependent on T-cells by comparison of the synergistic effects of an investigational EDO inhibitor in murine tumor xenograft models (e.g. Bl 6 and related variants, CT-26, LLC) grown in immune competent syngenic mice to that observed in syngenic mice treated with neutralizing anti-CD4 antibodies, or the same tumors grown in immune-compromised mice (e.g. nu/nu).
- murine tumor xenograft models e.g. Bl 6 and related variants, CT-26, LLC
- a third avenue for assessing the efficacy of IDO inhibitors in vivo employs 'pre- immunization' murine tumor allograft/xenograft models, hi these models, immune-competent mice are sensitized to a specific tumor antigen or antigens to mimic a therapeutic anti-tumor vaccination. This primes the mice for an anti-tumor response mediated by the immune system when mice are subsequently challenged with murine tumor cell lines (possessing similar tumor antigens to those used for immunization) in xenograft experiments. Expression of IDO has been shown to blunt the antitumor response and allow xenografts to grow more rapidly.
- therapeutic immunization may be used to evaluate the impact of IDO inhibitors in vivo.
- IDO inhibitors in vivo.
- TRP-2 immunogenic peptide
- immune system modifiers such as anti-CTL-4 antibody, can improve responses to such therapeutic immunizations.
- the impact of EDO inhibitors may be evaluated in a similar manner - tumor peptide immunization with or without IDO inhibitor. Efficacy is assess by animal survival (time to morbidity) or by the measurement of tumor metastases to the lungs and/or other organs at defined timepoints.
- any/all of the above mentioned models it may also be possible to directly and/or indirectly measure the number and/or activity of tumor reactive immune cells.
- Methods for measuring the number and/or activity of tumor reactive immune cells are well established and can be performed using techniques familiar to those schooled in the art (Current Protocols in Immunology, vol 4, Coligan, J.E., et al; Immunotherapy of Cancer, Human Press, 2006, Disis, MX. and references therein).
- a reduction in the immune suppressive effects of BDO may result in increased numbers or reactivity of tumor specific immune cells.
- IDO inhibition may further increase the number or reactivity of tumor reactive immune cells when combined with other therapeutics, for example chemotherapeutics and/or immune modulators (e.g. anti-CTLA4 antibody).
- All allograft/xenograft experiments can be performed using standard tumor techniques (reviewed by Corbett, et al).
- the cloning and introduction of genes (e.g. IDO, GM-CSF) into tumor cell lines can be performed using techniques familiar to those schooled in the art (reviewed in Sambrook, J, et at). See: Corbett, T., Polin, L., et al. In vivo methods for screening and preclinical testing. Cancer Drug Discovery and Development: Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, 2 nd Ed. Teicher, B.A.
- Example E In vivo testing of EDO inhibitors in human immunodeficiency virus-1 (HIV-I) encephalitis model
- Monocytes and PBL can be obtained by countercurrent centrifugal elutriation of leukopheresis packs from HIV-1 , 2 and hepatitis B seronegative donors.
- Monocytes are cultivated in suspension culture using Teflon flasks in Dulbecco's Modified Eagle's Medium (DMEM, Sigma- Aldrich) supplemented with 10 % heat-inactivated pooled human serum, 1 % glutamine, 50 ⁇ g/mL gentamicin, 10 ⁇ g/mL ciprofloxacin (Sigma), and 1000 LVmL highly purified recombinant human macrophage colony stimulating factor. After seven days in culture, MDM are infected with HTV- 1 ADA at multiplicity of infection of 0.01.
- DMEM Dulbecco's Modified Eagle's Medium
- mice Four-wk old male NOD/C.B-17 SCID mice can be purchased (Jackson Laboratory). Animals are maintained in sterile microisolator cages under pathogen-free conditions. All animals are injected intraperitoneally with rat anti-CD 122 (0.25 mg/mouse) three days before PBL transplantation and twice with rabbit asialo-GMl antibodies (0.2 mg/mouse) (Wako) one day before and three days after PBL injection (20 x 10 6 cells/mouse). HIV-I ADA -infected MDM (3 x 10 s cells in 10 ⁇ L) are injected intracranially (i.e.) eight days following PBL reconstitution generating hu-PBL-NOD/SCID HIVE mice.
- mice are subcutaneously (s.c) implanted with control (vehicle) or compound pellets (14 or 28 day slow release, Innovative Research).
- Initial experiments are designed to confirm the induction of virus- specific CTL in the hu PBL-NOD/SCID HIVE animals treated with EDO compounds. This is confirmed by tetramer staining and neuropathologic analyses of MDM elimination from the brain tissue. Then, the experiment is designed to analyze human lymphocyte reconstitution, humoral immune responses, and neuropathological alterations. In these experiments, animals are bled on day 7 and sacrificed at 14 and 21 days after i.e. injection of human MDM.
- HIV-I -specific antibodies are detected by Western blot tests according to the manufacturer instructions (Cambridge Biotech HIV-I Western blot kit, Calypte Biomedical). Similar amount of virus-specific antibodies are detected in control and compound-treated animals. A total of three independent experiments can be performed using three different human leukocyte donors. 3. FACScan of peripheral blood and spleen in hu PBL-NOD/SCID HIVE mice
- Two-color FACS analysis can be performed on peripheral blood at wk 1 -3 and splenocytes at wk 2 and 3 after i.e. injection of human MDM.
- Cells are incubated with fluorochrome-conjugated monoclonal Abs (mAbs) to human CD4, CD8, CD56, CD3, IFN- ⁇ (eBioscience) for 30 min at 4 0 C.
- mAbs monoclonal Abs
- eBioscience IFN- ⁇ intracellular staining is performed in combination with anti-human CD8 and FITC-conjugated anti-mouse CD45 to exclude murine cells.
- Brain tissue is collected at days 14 and 21 after i.e. injection of MDM, fixed in 4 % phosphate-buffered paraformaldehyde and embedded in paraffin or frozen at -80 0 C for later use. Coronal sections from the embedded blocks are cut in order to identify the injection site. For each mouse, 30-100 (5- ⁇ m-thick) serial sections are cut from the human MDM injection site and 3-7 slides (10 sections apart) are analyzed. Brain sections are deparaff ⁇ nized with xylene and hydrated in gradient alcohols. Immunohistochemical staining follows a basic indirect protocol, using antigen retrieval by heating to 95 0 C in 0.01 mol/L citrate buffer for 30 min for antigen retrieval.
- inAb to vimentin (1 :50, clone 3B4, Dako Corporation), which identifies all human leukocytes is used.
- Human MDM and CD8 + lymphocytes are detected with CD68 (1:50 dilution, clone KP 1) and CD8 (1 :50 dilution, clone 144B) antibodies, respectively.
- Virus-infected cells are labeled with mAb to HIV-I p24 (1 :10, clone KaI-I, all from Dako).
- Reactive murine microglial cells are detected with Iba-1 antibody (1:500, Wako).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions thereof and methods of use thereof relating to the treatment of cancer and other diseases.
Description
N-HYDROXYAMTOINOHETEROCYCLES AS MODULATORS OF ΓNDOLEAMINE 2,3-DIOXYGENASE
FIELD OF THE INVENTION
The present invention is directed to modulators of indoleamine 2,3-dioxygenase (EDO), as well as compositions and pharmaceutical methods thereof.
BACKGROUND OF THE INVENTION
Tryptophan (Tip) is an essential amino acid required for the biosynthesis of proteins, niacin and the neurotransmitter 5-hydroxytryptamine (serotonin). The enzyme indoleamine 2,3-dioxygenase (also known as INDO or IDO) catalyzes the first and rate limiting step in the degradation of L- tryptophan to N-formyl-kynurenine. In human cells, a depletion of Trp resulting from IDO activity is a prominent gamma interferon (IFN-7) —inducible antimicrobial effector mechanism. EFN-7 stimulation induces activation of EDO, which leads to a depletion of Trp, thereby arresting the growth of Trp-dependent intracellular pathogens such as Toxoplasma gondii and Chlamydia trachomatis. EDO activity also has an antiproliferative effect on many tumor cells, and EDO induction has been observed in vivo during rejection of allogeneic tumors, indicating a possible role for this enzyme in the tumor rejection process (Daubener, et al, 1999, Adv. Exp. Med. Biol., 467: 517-24; Taylor, et at., 1991, FASEB J., 5: 2516-22).
It has been observed that HeLa cells co-cultured with peripheral blood lymphocytes (PBLs) acquire an immuno-inhibitory phenotype through up-regulation of EDO activity. A reduction in PBL proliferation upon treatment with interleukin-2 (IL2) was believed to result from EDO released by the tumor cells in response to IFNG secretion by the PBLs. This effect was reversed by treatment with 1 - methyl -tryptophan (IMT), a specific EDO inhibitor. It was proposed that EDO activity in tumor cells may serve to impair antitumor responses (Logan, et al., 2002, Immunology, 105: 478-87).
Recently, an immunoregulatory role of Tip depletion has received much attention. Several lines of evidence suggest that IDO is involved in induction of immune tolerance. Studies of mammalian pregnancy, tumor resistance, chronic infections and autoimmune diseases have shown that cells expressing EDO can suppress T-cell responses and promote tolerance. Accelerated Trp catabolism has been observed in diseases and disorders associated with cellular immune activation, such as infection, malignancy, autoimmune diseases and AEDS, as well as during pregnancy. For example, increased levels of EFNs and elevated levels of urinary Trp metabolites have been observed in autoimmune diseases; it has been postulated that systemic or local depletion of Trp occurring in autoimmune diseases may relate to the degeneration and wasting symptoms of these diseases. In
support of this hypothesis, high levels of IDO were observed in cells isolated from the synovia of arthritic joints. IFNs are also elevated in human immunodeficiency virus (HIV) patients and increasing EFN levels are associated with a worsening prognosis. Thus, it was proposed that IDO is induced chronically by HIV infection, and is further increased by opportunistic infections, and that the chronic loss of Trp initiates mechanisms responsible for cachexia, dementia and diarrhea and possibly immunosuppression of AIDS patients (Brown, et al., 1991, Adv. Exp. Med. Biol., 294: 425-35). To this end, it has recently been shown that EDO inhibition can enhance the levels of virus-specific T cells and, concomitantly, reduce the number of virally-infected macrophages in a mouse model of HIV (Portula et al, 2005, Blood, 106:2382-90). IDO is believed to play a role in the immunosuppressive processes that prevent fetal rejection in utero. More than 40 years ago, it was observed that, during pregnancy, the genetically disparate mammalian conceptus survives in spite of what would be predicted by tissue transplantation immunology (Medawar, 1953, Symp. Soc. Exp. Biol. 7: 320-38). Anatomic separation of mother and fetus and antigenic immaturity of the fetus cannot fully explain fetal allograft survival. Recent attention has focused on immunologic tolerance of the mother. Because EDO is expressed by human syncytiotrophoblast cells and systemic tryptophan concentration falls during normal pregnancy, it was hypothesized that EDO expression at the maternal-fetal interface is necessary to prevent immunologic rejection of the fetal allografts. To test this hypothesis, pregnant mice (carrying syngeneic or allogeneic fetuses) were exposed to IMT, and a rapid, T cell-induced rejection of all allogeneic concepti was observed. Thus, by catabolizing tryptophan, the mammalian conceptus appears to suppresses T-cell activity and defends itself against rejection, and blocking tryptophan catabolism during murine pregnancy allows maternal T cells to provoke fetal allograft rejection (Munn, et al., 1998, Science 281 : 1191-3).
Further evidence for a tumoral immune resistance mechanism based on tryptophan degradation by EDO comes from the observation that most human tumors constitutively express EDO, and that expression of EDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice. This effect is accompanied by a lack of accumulation of specific T cells at the tumor site and can be partly reverted by systemic treatment of mice with an inhibitor of EDO, in the absence of noticeable toxicity. Thus, it was suggested that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor (Uyttenhove et al, 2003, Nature Med., 9: 1269-74). It has also been shown that the EDO inhibitor, 1-MT, can synergize with chemotherapeutic agents to reduce tumor growth in mice, suggesting that EDO inhibition may also enhance the anti-tumor activity of conventional cytotoxic therapies (Muller et al, 2005, Nature Med., 11:312-9). One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs. A subset of human EDO-expressing antigen- presenting cells (APCs) that coexpressed CDl 23 (EL3RA) and CCR6 and inhibited T-cell
proliferation have also been described. Both mature and immature CD123-positive dendritic cells suppressed T-cell activity, and this DDO suppressive activity was blocked by IMT (Muim, et al., 2002, Science 297: 1867-70). It has also been demonstrated that mouse tumor-draining lymph nodes (TDLNs) contain a subset of plasmacytoid dendritic cells (pDCs) that constitutively express immunosuppressive levels of IDO. Despite comprising only 0.5% of lymph node cells, in vitro, these pDCs potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs. Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD 19. Thus, it was hypothesized that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses (Munn, et al., 2004, J. Clin. Invest., 114(2): 280-90).
EDO degrades the indole moiety of tryptophan, serotonin and melatonin, and initiates the production of neuroactive and immunoregulatory metabolites, collectively known as kynurenines. By locally depleting tryptophan and increasing proapoptotic kynurenines, IDO expressed by dendritic cells (DCs) can greatly affect T-cell proliferation and survival. IDO induction in DCs could be a common mechanism of deletional tolerance driven by regulatory T cells. Because such tolerogenic responses can be expected to operate in a variety of physiopathological conditions, tryptophan metabolism and kynurenine production might represent a crucial interface between the immune and nervous systems (Grohmarra, et al., 2003, Trends Immunol., 24: 242-8). In states of persistent immune activation, availability of free serum Trp is diminished and, as a consequence of reduced serotonin production, serotonergic functions may also be affected (Wirleitner, et al., 2003, Curr. Med. Chem., 10: 1581-91).
Interestingly, administration of interferon-α has been observed to induce neuropsychiatric side effects, such as depressive symptoms and changes in cognitive function. Direct influence on serotonergic neurotransmission may contribute to these side effects. In addition, because IDO activation leads to reduced levels of tryptophan, the precursor of serotonin (5-HT), IDO may play a role in these neuropsychiatric side effects by reducing central 5-HT synthesis. Furthermore, kynurenine metabolites such as 3-hydroxy-kynurenine (3 -OH-KYN) and quinolinic acid (QUIN) have toxic effects on brain function. 3-OH-KYN is able to produce oxidative stress by increasing the production of reactive oxygen species (ROS), and QUIN may produce overstimulation of hippocampal N-methyl-D-aspartate (NMDA) receptors, which leads to apoptosis and hippocampal atrophy. Both ROS overproduction and hippocampal atrophy caused by NMDA overstimulation have been associated with depression (Wichers and Maes, 2004, J. Psychiatry Neurosci., 29: 11—17). Thus, IDO activity may play a role in depression.
Small molecule inhibitors of EDO are being developed to treat or prevent IDO-related diseases such as those described above. For example, PCT Publication WO 99/29310 reports methods for
altering T cell-mediated immunity comprising altering local extracellular concentrations of tryptophan and tryptophan metabolites, using an inhibitor of IDO such as 1 -methyl-DL-tryptophan, p-(3- benzofuranyl)-DL- alanine, p-[3 -benzo(b)thienyl] -DL-alanine, and 6-nitro-L-tryptophan) (Munn, 1999). Reported in WO 03/087347, also published as European Patent 1501918, are methods of making antigen-presenting cells for enhancing or reducing T cell tolerance (Munn, 2003). Compounds having indoleamine-2,3-dioxygenase (IDO) inhibitory activity are further reported in WO 2004/094409; and U.S. Patent Application Publication No. 2004/0234623 is directed to methods of treating a subject with a cancer or an infection by the administration of an inhibitor of indoleamine- 2,3-dioxygenase in combination with other therapeutic modalities. In light of the experimental data indicating a role for IDO in immunosuppression, tumor resistance and/or rejection, chronic infections, HTV-infection, AIDS (including its manifestations such as cachexia, dementia and diarrhea), autoimmune diseases or disorders (such as rheumatoid arthritis), and immunologic tolerance and prevention of fetal rejection in utero, therapeutic agents aimed at suppression of tryptophan degradation by inhibiting IDO activity are desirable. Inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HTV. Inhibition of IDO may also be an important treatment strategy for patients with neurological or neuropsychiatric diseases or disorders such as depression. The compounds, compositions and methods herein help meet the current need for EDO modulators.
SUMMARY OF THE INVENTION
The present invention provides, inter alia, compounds of Formula Ia:
Ia or pharmaceutically acceptable salts or prodrugs thereof, wherein constituent members are provided herein.
The present invention further provides compositions comprising a compound of Formula Ia, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
The present invention further provides methods of modulating enzyme activity of IDO comprising contacting a compound of Formula Ia, or pharmaceutically acceptable salt thereof, with IDO.
The present invention further provides methods of treating EDO-associated diseases, including cancer, viral infection and depression, comprising administering to a patient a therapeutically effective amount of a compound of Formula Ia, or pharmaceutically acceptable salt thereof.
The present invention further provides methods of altering extracellular tryptophan levels in a mammal comprising administering to the mammal an effective amount of a compound of Formula Ia, or pharmaceutically acceptable salt thereof.
The present invention further provides methods of inhibiting immunosuppression, such as EDO-mediated immunosuppression, in a patient comprising administering to the patient an effective amount of a compound of Formula Ia, or pharmaceutically acceptable salt thereof. The present invention further provides the compounds of Formula Ia for use in therapy.
The present invention further provides the compounds of Formula Ia for use in the preparation of a medicament for use in therapy.
DETAILED DESCRIPTION The present invention provides compounds which are modulators of DDO having Formula Ia:
Ia or pharmaceutically acceptable salts or prodrugs thereof, wherein:
U is N, O, S, CR , or NR"; V, and W are each, independently, N, O, S, CR2, or NR3, wherein the five-membered ring containing U, V, and W is an aromatic heterocycle;
A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C].6 haloalkyl, C1-6 hydroxyalkyl, Ci-6 cyanoalkyl> halosulfanyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NR°C(O)NRcRd, NRcC(O)ORa, CC=NR^NR0R0, NRcC(=NRi)NRcRd, P(Rf)2> P(ORe)2, P(O)RcRf, P(O)ORORf, S(O)Rb, S(O)NRcRd, S(O)2R", NR0S(O)2R6, and S(0)2NRcRd, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl is optionally substituted with 1, 2, or 3 substitutents independently selected from Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NR0R", C(O)OR3, OC(O)Rb, OC(O)NRcRd, NR°Rd, NRcC(O)Rb, NR°C(O)NRcRd, NR0C(O)OR", C(=NRi)NR°Rd, NR°C(=NRi)NRcRd, P(Rf)2, P(ORe)2j P(O)RcRf, P(O)ORORf, S(O)Rb, S(O)NRcRd, S(O)2Rb s NRcS(O)2Rb, and S(O)2NRcRd; R is H, C(O)R5, C(O)OR6, or C(O)NR6aR6b;
RΛ and RB are independently selected from H, F, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, halosulfanyl, CN, NO2, ORal, SRal, C(O)Rbl, C(0)NRclRdl, C(O)ORal, OC(O)Rbl, OC(O)NR01R"1, NRclRd\ NRclC(O)Rbl, NRoIC(O)NRclRdl, NRclC(O)ORal, C(=NR?)NRclRdI, NRclC(=NRi)NRcIRdl, P(Rπ)2, P(ORcl)2, P(O)RelRfl, P(O)ORelORn, S(O)Rbl, S(O)NRCIRdl, S(O)2Rbl, NRclS(O)2Rbl, and S(0)2NRclRdl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Cμ alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci.4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, halosulfanyl, CN, NO2, ORal, SRal, C(O)Rb\ C(O)NRclRdl, C(O)OR"', OC(O)Rbl, OC(O)NRcIRdl, NRclRdl, NRcIC(O)Rbl, NRclC(O)NRclRdl, NRclC(O)ORal, C(=NRi)NRclRdl, NRβIC(=NRl)NRclRdl, P(Rπ)2, P(OReI)2, P(O)RelRn, P(O)ORelORn, S(O)Rbl, S(O)NRCIRdl, S(O)2Rbl, NRclS(O)2Rbl, and S(O)2NRCIRdl; or RΛ and RB together with the carbon atom to which they are attached form a 3-, A-, 5-, 6-, or 7- membered cycloalkyl group or 3-, 4-, 5-, 6-, or 7- membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, halosulfanyl, CN, NO2, ORa1, SRal, C(O)Rbl, C(O)NRclRdl, C(O)OR3', OC(O)Rbl, OC(O)NRclRd\ NRclRdl, NRc'C(O)Rbl, NRCIC(O)NRCIRdl, NRclC(O)ORal, Q=NR^NR01R"1, NRclC(=NRi)NRclRdl, P(Rπ)2, P(ORel)2, P(O)RelRπ, P(O)OR61OR", S(O)Rbl, S(O)NRclRdl, S(O)2R", NRclS(O)2RbI, and SCO)2NRclRdl; or RA and RB, together with the carbon atom to which they are attached, form a C=CH2 group; Q is ORQ, OCCO)R0, OC(O)NR4R0, NR4RQ, NR4C(O)R0, NR4C(O)NR4R0, NR4C(O)OR0, NR4S(O)R0, NR4S(O)2R0, NR4C(=NRi)NR4RQ, SR0, S(O)R0, S(O)NR4R0, S(O)2R0, S(O)2NR4R0, C(O)R0, C(O)OR0, C(O)NR4R0, halo, cyano, azido, or nitro; or Q is H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, C,-6 haloalkyl, C1-6 hydroxyalkyl, Ci-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, halosulfanyl, CN, NO2, ORa2, -(C1-4 alkyl)-ORa2, SRa2, -(C1-4 alkyl)-SRa2, C(O)Rb2, -(C1-4 alkyl)- C(O)Rb2, C(O)NR02R112, -(C43HCyI)-C(O)NR02R"2, C(O)OR32, -(C1-4 alkyl)-C(O)ORa2, OC(O)Rb2, - (C1-4311CyI)-OC(O)R132, OC(O)NRc2Rd2, -(C1-43HCyI)-OC(O)NR02R"12, NR02R"2, -(C4 alkyl)-NRo2Rd2, NRc2C(O)Rb2, -(C1-4 alkyl)-NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, -(C1-48^yI)-NR02C(O)NR02R"2, NRc2C(O)ORa\ -(Ci-4 alkyl)-NR02C(O)OR°2, C(=NRi)NRo2Rd2, NRo2C(=NRi)NRc2Rd2, P(RG)2, P(ORe2)2) P(O)Rc2Rβ, P(O)ORe2ORβ, S(O)Rb2, -(CM alkyl)-S(O)Rb2, S(O)NR02R"2, -(C4alkyl)- S(O)NRc2Rd2, S(O)2R"2, -(Ci-4 alkyl)-S(O)2Rb2, NR02S(O)2R"2, -(C1-4 alkyl)-NRc2S(O)2Rb2, S(O)2NR02R"2 , and -(C1-4 alkyl)-S(O)2NRc2Rd2;
R0 is H, Ci-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, Ci-6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said
Ci.6 alkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Ci-6 hydroxyalkyl, C1-6 cyanoalkyl, halosulfanyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NR02R"2, C(O)OR"2, OC(O)Rb2, OC(O)NR02R"2, NR02R"2, NR02C(O)Rb2, NR02C(O)NR02R"2, NR02C(O)OR32, C(=NRi)NRo2Rd2, NRc2C(=NRi)NRc2Rd2, P(R^)2, P(ORe2)2) P(O)Re2RE, P(O)ORe2ORG, S(O)Rb2, S(O)NR02R"2, S(O)2R"2, NR02S(O)2R"2, and S(O)2NR02R"2; or R4 and RQ together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group or 5-20 membered heteroaryl group, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C]-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cj-6 haloalkyl, C1-6 hydroxyalkyl, Ci-6 cyanoalkyl, halosulfanyl, Cy, -(Ci.4alkyl)-Cy, CN, NO2, ORa2, -(C1- 4alkyl)-OR02, SRa2, -(CM alkyl)-SRa2, C(O)Rb2, -(Ci-4 alkyl)-C(O)Rb\ C(O)NRc2Rd2, -(Ci-4 alkyl)- C(O)NR02R"2, C(O)OR"2, -(C1-4 3IlCyI)-C(O)OR22, OC(O)Rb2, -(Ci-4 alkyl)-OC(O)Rb2, OC(O)NR02R"2, -(C1-43^I)-OC(O)NR02R"2, NR02R"2, -(C1-4 alkyFj-NR^R"2, NR°2C(O)Rb2, -(C-4 alkyl)-NR°2C(O)Rb2, NR02C(O)NR02R"2, -(C,.48UCyI)-NR02C(O)NR02R"2, NR02C(O)OR"2, -(Ci-4 alkyl)-NRc2C(O)ORa2,
C(=NRi)NRc2Rd2, NRc2C(=NRi)NRc2R"2, P(RC)2, P(ORe2)2, P(O)Re2RQ, P(O)ORe2ORG, S(O)R°2, -(C1-4 alkyl)-S(O)Rb2, S(O)NR02R"2, -(CMalkyl)-S(O)NRc2Rd2, S(O)2Rb2, -(Ci-4alkyl)-S(O)2Rb2, NR02S(O)2R"2, -(Ci.4alkyl)-NRc2S(O)2Rb2, S(O)2NR02R"2 , and -(C ,.4 alkyl)-S(O)2NRc2Rd2; Cy, Cy1, and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1 , 2, 3, 4 or 5 substituents independently selected from halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, CN, NO2, OR"3, SRa\ C(O)RW, C(O)NR03R"3, C(O)OR33, OC(O)Rb\ OC(O)NR0V3, NRc3Rd3, NRo3C(0)Rb3, NR03C(O)OR33, C(=NRi)NRc3Rd3, NRc3C(=NRi)NRc3Rd3, P(R°)2, P(ORe3)2, P(O)Re3R°, P(O)OR63OR13, S(O)R"3, S(O)NR03R"3, S(O)2RM, and S(O)2NR03R"3; R1 is H or C1-4 alkyl;
R2 is H, halo, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, CN, NO2, OH, C1-4 alkoxy, amino, C1-4 alkylamino, or C2-8 dialkylamino;
R3 is H, C1^ alkyl, C2-4 alkenyl, or C2-4 alkynyl;
R4 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C(O)-R4a, SO2-R4", aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, Ci-6 cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halosulfanyl, CN, NO2, ORa4, SRa\ C(O)R"4, C(O)NR04R"4, C(O)OR34, OC(O)RM, OC(O)NR04R"4, NR0V, NRc4C(O)Rb4, NR04C(O)NR04R"4, NRc4C(O)OR°4, C(=NRi)NRc4Rd4, NRc4C(=NRi)NRc4Rd4, P(Rf4)2, P(ORe4)2, P(O)R0V4,
S(O)R*4, S(O)NR0V4, S(O)2RM, NR04S(O)2R154, and S(O)2NR0V4;
R4a is H, C, .4 alkyl, C2-4 alkenyl, C2-4 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl;
R5 and R6 are independently selected from H, Cj-8 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, each optionally substituted by one or more substituents independently selected from halo, CN, NO2, OH, C]-4haloalkoxy, amino, CL4 alkylamino, C2-8 dialkylamino, Ci-6 alkyl, C2-6 alkenyl, and C2-
6 alkynyl;
R6a and R6b are independently selected from H, Ci-8 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, each optionally substituted by one or more substituents independently selected from halo, CN, NO2, OH,
C].4 alkoxy, Ci-4haloalkoxy, amino, Ci-4 alkylamino, C2-8 dialkylamino, Ci-6 alkyl, C2-6 alkenyl, and C2.
6 alkynyl;
Ra, RaI, Ra3, Ra4, and Ra5 are independently selected from H, Ci-6 alkyl, C,.6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-6 alkyl, C]-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl;
Rb, Rbl, R", RM, and Rbs are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-6 alkyl, Cj-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci_6 alkyl, C]-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; Ra2 is H, C1-6 alkyl, C,-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cy2, or Cy2KCi-6 alkyl)-, wherein said C].6 alkyl, C)-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl, is optionally substituted with 1, 2, 3, 4, or
5 substituents independently selected from halo, C]-6 alkyl, C2.6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl,
Ci.6 hydroxyalkyl, C1-6 cyanoalkyl, halosulfanyl, Cy2, CN, NO2, ORa5, SRa5, C(O)RbS, C(O)NRc5Rd5,
C(O)ORaS, OC(O)R"5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(=NRi)NRc5Rds, NRc5C(=NRi)NRc5Rd5, P(Rβ)2, P(ORe5)2, P(O)Re5Re, P(O)ORe5ORβ, S(O)Rb5,
S(O)NRcSRd5, Rb2, S(O)2Rb5, NRc5S(O)2Rb5, and S(O)2NR05Rd5;
Rb2 is H, Cj-6 alkyl, Cj-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, Cy2, or
wherein said CL6 alkyl, C)-6 haloalkyl, C2-6 alkenyl, C2.6 alkynyl, or aryl is optionally substituted with
1, 2, 3, 4, or 5 substituents independently selected from halo, Ci.6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C1-6 hydroxyalkyl, C-6 cyanoalkyl, halosulfanyl, Cy2, CN, NO2, ORaS, SRa5, C(O)RbS,
C(O)NRc5Rd5 3 C(O)OR85, OC(O)Rbs, OC(O)NRcSRdS, NRc5RdS, NRc5C(O)Rbs, NR05C(O)NR05R"5,
NRc5C(O)ORa5, C(=NRi)NRoSRd5 5 NRc5C(=NRi)NRc5RdS, P(Rβ)2, P(OReS)2, P(O)R65R15, P(O)OR05OR13, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5S(O)2Rb5, and S(O)2NRc5Rd5;
Rc and Rd are independently selected from H, Ci-I0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-I0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, C ]-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
Rcl and Rdl are independently selected from H, Ci-I0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said CM0 alkyl, CL6 haloalkyl, C2.6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, C ]-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or Rcl and Rdl together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
Rc2 and R*12 are independently selected from H, Ci,)0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cy2 and Cy^(C]-6 alkyl)-, wherein said CMo alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, is optionally substituted with 1, 2, or 3, substitutents independently selected from halo, Cj-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NR03R"3, C(O)OR33, OC(O)R"3, OC(O)NR03R"3, NR03R"3, NRc3C(O)Rb3, NR03C(O)OR33, C(=NRi)NRc3Rd3, NRc3C(=NRi)NRo3Rd3, P(Rβ)2, P(ORe3)2, P(O)Re3R°, P(O)OR63OR13, S(O)Rb3, S(O)NR03R113, S(O)2Rb3, and S(O)2NR03R113; or Rc2 and K02 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3, substitutents independently selected from Cy2, Cy2 -(Ci-6 alkyl)-, halo, Cj-4 alkyl, C2-4 alkenyl, C2.4 alkynyl, Ci-4 haloalkyl, halosulfanyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NR03R113, C(O)OR33, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NR03C(O)R", NR03C(O)OR"3, C(=NRi)NRo3Rd3, NRc3C(=NRi)NRc3Rd3, P(R°)2, P(ORe3)2, P(O)R63R13, P(O)OR63OR13, S(O)Rb3, S(O)NR°3Rd3, S(O)2Rb3, and S(O)2NR03R113;
R°3 and Rd3 are independently selected from H, Ci-I0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-I0 alkyl, CL6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, Ci-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl;
or R03 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
Rc4 and Rd4 are independently selected from H, Ci-I0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-I0 alkyl, CL6 haloalkyl, C2-S alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C]-6 alkyl, Ci-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or Re4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
Rc5 and Rd5 are independently selected from H, Ci-I0 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-I0 alkyl, C]-6 haloalkyl, C2.6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocyclo- alkylalkyl is optionally substituted with OH, amino, halo, Ci.6alkyi, C ]-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or RoS and Rd5 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
Re, Rel, Re2, Re3, Re4, and Re5 are independently selected from H, C1-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, (Ci-6 alkoxy)-Ci-6 alkyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocycloalkylalkyl;
Rf, Rπ,RG, R°, Rf4, and Rβ are independently selected from H, C,-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl;
R1 is H, CN, C(O)NH2, or NO2; R' is H, halo, C1-10 alkyl, C2-6 alkenyl, C2.6 alkynyl, Cy, Cy-(C1-6 alkyl)-, CN, NO2, ORa\ SRa3,
C(O)Rb3, C(O)NR03R"3, C(O)OR83, OC(O)Rb3, OC(O)NRc3Rd3, NR03R113, NRc3C(O)Rb\ NRc3C(O)ORa\ S(O)R53, S(O)NR03R113,
or S(O)2NRc3Rd3; wherein said C,.,o alkyl, C2-6 alkenyl, or C2-6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from CN, NO2, Cy, Cy-(C1-6 alkyl)-, ORa3, SR"3, C(O)Rb3, C(O)NR03R113, C(O)OR33, OC(O)Rb3, OC(O)NR03R113, NRo3Rd3, NRc3C(O)Rb3, NR03C(O)OR"3, C(=NRi)NRc3Rd3,
NRc3C(=NRi)NRc3Rd3, P(RD)2, P(ORo3)2, P(O)R03R0, P(O)OR03OR0, S(O)Rb3, S(O)NR03R113, S(O)2Rb3, and S(O)2NRc3Rd3;
R" is H, C,.]0 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, Cy-(C1-6 alkyl)-, C(0)Rb3, C(O)NRc3Rd3, C(O)OR"3, S(O)Rb3, S(O)NR03R113, S(O)2Rb3, or S(O)2NRc3Rd3; wherein said C1-10 alkyl, C2-6 alkenyl, or C2.6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from CN, NO2, Cy, -(C-6 alkyl)-Cy, ORa3, SR"3, C(O)Rb3, C(O)NRc3Rd3, C(O)OR33, OC(O)Rb3, OC(O)NR03Rd3, NR03R"13, NRe3C(O)Rb3, NRc3C(O)ORa3, C(=NRi)NRo3Rd3, NRo3C(=NRi)NRo3Rd3,
P(Rβ)2) P(ORe3)2, P(O)Re3RD, P(O)ORe3ORβ, S(O)R"3, S(O)NR°3Rd3, S(O)2Rb3, and S(O)2NR03R43; and p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
In some embodiments, V is O.
In some embodiments, U is N. In some embodiments, W is N. In some embodiments, U and W are both N. In some embodiments, U and W are both N and V is O. In some embodiments, at least one of U, V and W is N.
In some embodiments, at least one of U, V and W is N and another of U, V, and W is O or S. In some embodiments, A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C,.6 hydroxyalkyl, C1-6 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NRi)NRcRd, NR0Cf=NR)NR0R", P(Rf)2, P(ORe)2, P(O)ReRf, P(O)ORORf, S(O)Rb, S(O)NRcRd, S(O)2R", NRcS(O)2Rb, and S(O)2NRcRd, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl is optionally substituted with 1 , 2, or 3 substitutents independently selected from Cy1, CN, NO2, ORa, SR", C(O)Rb, C(O)NR°Rd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NR0C(O)OR3, C(=NRi)NRcRd, NR°C(=NRi)NRcRd, P(R5J2, P(ORe)2, P(O)R0R', P(O)ORORf, S(O)Rb, S(O)NRcRd, S(O)2R", NR0S(O)2R", and S(O)2NRcRd.
In some embodiments, A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy1, CN, NO2, ORa, SR3, C(O)R", C(O)NR°Rd, C(O)OR3, OC(O)Rb, OC(O)NR°Rd, NR°Rd, NRcC(O)Rb, NRcC(O)NRcRd, NR0C(O)OR0, S(O)Rb, S(O)NRcRd, S(O)2R", NR0S(O)2R", and S(O)2NR0R".
In some embodiments, A is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, Cj.β haloalkyl, Ci.g hydroxyalkyl, C1-6 cyanoalkyl, Cy1, CN, NO2, OR3, SRa, C(O)R", C(O)NR°Rd, C(O)OR3, OC(O)R", OC(O)NR0R", NR°Rd, NR0C(O)R", NR°C(O)NRcRd, NR0C(O)OR8, C(=NRi)NR°Rd,
NRcC(=NRi)NRcRd, P(Rf)2, P(ORe)2, P(O)ReRf, P(O)OROR*", S(O)R", S(O)NR0R", S(O)2R", NR0S(O)2R", and S(O)2NR0R", wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl is optionally substituted with 1, 2, or 3 substitutents independently selected from Cy1, CN, NO2, OR", SR", C(O)R", C(O)NR°Rd, C(O)OR8, OC(O)R", OC(O)NR0R", NRcRd, NR0C(O)R", NRcC(O)NRcRd, NR0C(O)OR3, C(=NRi)NR°Rd, NRcC(=NRi)NR°Rd, P(Rf)2, P(OR°)2, P(O)ReRf, P(O)OReORf, S(O)R", S(O)NR°Rd, S(O)2Rb, NR0S(O)2R6, and S(O)2NR0R".
In some embodiments, A is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 cyanoalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NR'C^NR^, NR0C(O)OR3, S(O)Rb, S(O)NRcRd, S(O)2Rb, NR0S(O)2R15, and S(O)2NRcRd.
In some embodiments, A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, C-6 cyanoalkyl, Cy1, CN, NO2, ORa, SR3, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NR°Rd, NR°C(O)Rb, NRcC(O)NR°Rd, NR0C(O)OR3, C(=NRi)NRcRd, NRcC(=NRi)NRcRd, P(Rf)2, P(ORe)2, P(O)RcRr, P(O)OReORf, S(O)Rb, S(O)NR°Rd, S(O)2Rb,
NRcS(O)2Rb, and S(O)2NRcRd, wherein said C,-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl is optionally substituted with 1, 2, or 3 substitutents independently selected from Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NR0R", C(O)OR3, OC(O)R", OC(O)NR°Rd, NR°Rd, NRcC(O)Rb, NR°C(O)NRcRd, NR0C(O)OR3, C(=NRi)NRcRd, NR°C(=NRi)NR0Rd, P(Rf)2, P(ORe)2, P(O)R6R', P(O)0ReORf, S(O)Rb, S(O)NR0R", S(O)2R", NR°S(O)2Rb, and S(O)2NRcRd.
In some embodiments, A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C]-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 cyanoalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NR°Rd, C(O)OR3, OC(O)Rb, OC(O)NR°Rd, NR0R", NRcC(O)Rb, NR0C(O)NR0R", NR0C(O)OR8, S(O)Rb, S(O)NRcRd, S(O)2Rb, NR°S(O)2Rb, and S(O)2NR0R".
In some embodiments, A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C]-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 cyanoalkyl, CN, NO2, ORa, SR3, C(O)R", C(O)NR0R", C(O)OR2, OC(O)Rb, OC(O)NRcRd, NR°Rd, NR0C(O)R", NR°C(O)NRcRd, NR0C(O)OR3, S(O)R", S(0)NRcRd, S(O)2R", NR0S(O)2R", and S(O)2NR°Rd. In some embodiments, A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, and Cj-6 haloalkyl.
In some embodiments, Q is OR0, OC(O)R0, OC(O)NR4R0, NR4R0, NR4C(O)R0, NR4C(O)NR4R0, NR4C(O)OR0, NR4S(O)R0, NR4S(O)2R0, SR0, S(O)R0, S(O)NR4R0, S(O)2R0 S(O)2NR4R0, C(O)R0, C(O)OR0, C(O)NR4R0, halo, cyano, azido, or nitro; In some embodiments, Q is H, CN, OR0, OC(O)NR4R0, C(O)OR0, NR4R0 NR4C(O)R0,
NR4C(O)NR4R0, NR4C(O)OR0, NR4S(O)2R0, SR0, S(O)2R0, or OC(O)NR4R0.
In some embodiments, Q is H, CN, OR0, OC(O)NR4R0, C(O)OR0, NR4R0, NR4C(O)R0, NR4C(O)NR4R0, NR4C(O)OR0, NR4S(O)2R0, or OC(O)NR4R0.
In some embodiments, Q is OR0, OC(O)NR4R0, Or NR4R0. In some embodiments, Q is OR0.
In some embodiments, Q is SR0.
In some embodiments, Q is S(O)2R0.
In some embodiments, Q is NR4RQ.
In some embodiments, Q is NR4RQ , and R4 and RQ together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group or 5-20 membered heteroaryl group, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, Cj-6 cyanoalkyl, Cy, -(Ci-4 alkyl)-Cy, CN, NO2, ORa2, -(C1-4 alkyl)-ORa2, SRa2, -(C1-4 alkyl)-SRa2, C(O)Rb2, -(C1-4 alkyl)-C(O)Rb2, C(O)NR02R"2, -(C1-4 alkyl)-C(O)NRc2Rd2 > C(O)OR82, -(C1-4 alkyl)-C(O)ORa2 5 OC(O)Rb2, -(C1-4 alkyl)-OC(O)Rb2, OC(O)NR02R"2, -(C1-4 alkyl)-OC(O)NRc2Rd2, NR=2R"2, -(CMalkyl)-NRc2Rd2, NRc2C(O)Rb2, -(C1-4 alkyl)-NRc2C(O)Rb2, NR02C(O)NR02R"2, -(C1^ aIkYl)-NR02C(O)NR02R"2, NR02C(O)ORa2, -(C1-4 alkyl)- NR02C(O)OR22, Ct=NR^NR02R"2, NRc2C(=NRi)NRo2Rd2 ;, P(RG)2, P(ORc2)2, P(O)R02R0,
P(O)0Re20Rβ, S(O)Rb2, -(C1-4 alkyl)-S(O)Rb2 3 S(O)NR02R"2, -(C1-4 HlICyI)-S(O)NR02R"2, S(O)2Rb2, -(C1-4 alkyl)-S(O)2Rb2, NRc2S(O)2Rb2, -(C1-4 BIkYl)-NR02S(O)2R"2, S(O)2NR02R"2 , and -(C,.4alkyl)- S(O)2NR02R"2.
In some embodiments, Q is NR4RQ and R4 and RQ together with the N atom to which they are attached form a 5-20 membered heteroaryl group, optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C,.6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, OR02, -(C1-4 alkyl)-ORa2, SRa2, -(C1-4 alkyl)-SRa2, C(O)R"2, -(C1-4 alkyl)-C(O)R"2, C(O)NR02R"2, -(C1-4 alkyl)-C(O)NRc2Rd2, C(O)OR32, -(C1-4 alkyl)- C(O)OR32, OC(O)Rb2, -(C1-4 alkyl)-OC(O)R"2, OC(O)NR02R"2, -(C1-43IlCyI)-OC(O)NR02R"2, NR02R"2, -(C1 -4 alkyO-NR^R"2, NRc2C(O)Rb2, -(C4 alkyl)-NRc2C(O)Rb2, NR02C(O)NR02R"2, -(C1-4 alkyl)- NR02C(O)NR02R42, NR02C(O)OR"2, -(C1^ aIlCyI)-NR02C(O)OR32, C(=NRi)NRo2Rd2, NRo2C(=NRi)NRc2Rd2 ) P(RG)2, P(ORe2)2, P(O)Re2Rc, P(O)ORe2ORG, S(O)Rb2, -(C1-4 alkyl)-S(O)Rb2, S(O)NR02R112, -(C1-4 alkyl)-S(O)NRc2R"2, S(O)2R"2, -(C1-4 alkyl)-S(O)2Rb2, NR02S(O)2R"2, -(C1-4 alkyl)- NR02S(O)2R"2, S(O)2NR02R"2 , and -(C1-43IkYl)-S(O)2NR02R"2. In some embodiments, Q is NR4RQ and R4 and RQ together with the N atom to which they are attached form a tetrazole group which is optionally substituted with halo, C1-6 alkyl, Ci.6 haloalkyl, or NR02R"2.
In some embodiments, Q is NR4RQ and R4 and RQ together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, -(C1-4 alkyl)-ORa2, SRa2, -(CM alkyl)-SR"2, C(O)Rb2, -(Cj-4 alkyl)-C(O)Rb2, C(O)NR02R112, -(C1-4 alkyl)-C(O)NRc2Rd2, C(O)OR32, -(C1. 4 alkyl)-C(O)ORa2, OC(O)R"2, -(C1-4 alkyl)-OC(O)Rb2, OC(O)NR02R"2, -(C1-4 alkyl)-OC(O)NRc2Rd2, NR02R"2, -(C1-4 alkyO-NR^R"2, NR02C(O)Rb2, -(CM alkyl)-NR02C(O)Rb2, NR02C(O)NR02R112, -(C1-4 3IkYl)-NR02C(O)NR02R"2, NR02C(O)OR02, -(C1-4 alkyl)-NRc2C(O)OR"2, C(=NRi)NRo2Rd2,
NRc2C(=NRi)NRc2Rd2, P(RC)2, P(ORc2)2, P(O)Rc2RG, P(O)ORc2ORβ, S(O)Rb2, -(C1-4 alkyl)-S(O)Rb2,
S(O)NR02R"2,
S(O)2Rb2, -(C1-4 alkyl)-S(O)2Rb2, NRc2S(O)2Rb2 ) -(C1-4 alkyl)- NR02S(O)2R"2, S(O)2NR62R"2 , and -(C1-4311CyI)-S(O)2NR02R"2.
In some embodiments, Q is NR4R0 and R4 and RQ together with the N atom to which they are attached form piperidinyl, morpholino, piperazinyl, 2,3-dihydro-lH-isoindolyl, or 1,2,3,4-tetrahydro- isoquinoline, each optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2.6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 cyanoalkyl, Cy, -(C,.4 alkyl)-Cy, CN, NO2, ORa2, -(C4 alkyl)-ORa2, SRa2, -(C1-4 alkyl)-SRa2, C(O)Rb2, -(C1-4 alkyl)- C(O)R"2, C(O)NRc2Rd2, -(C,.4alkyl)-C(O)NRc2Rd2, C(O)ORa2, -(C,.4 alkyl)-C(O)ORa2 3 OC(O)Rb2, -(C,.4alkyl)-OC(O)Rb2, OC(O)NRc2Rd2 5 -(C,.4alkyl)-OC(O)NRc2Rd2, NR02R112, -(C1-4 alkyl)-NRc2Rd2, NRc2C(O)Rb2, -(C1-4 alkyl)-NRc2C(O)Rb2, NR02C(O)NR02R"2, -(C1-4811CyI)-NR02C(O)NR02R"2, NR02C(O)OR32,
P(RE)2, P(ORe2)2, P(O)Re2Rβ, P(O)OR62OR12, S(O)Rb2, -(C1-4 alkyl)-S(O)Rb2, S(O)NR02R"2, -(CM alkyl)- S(O)NR02R"2, S(O)2R"2, -(C1-4 alkyl)-S(O)2R"2, NR02S(O)2R"2, -(CM alkyl)-NRc2S(O)2Rb2, S(O)2NR02R"2 , and -(C,.4alkyl)-S(O)2NRc2Rd2. In some embodiments, Q is NR4RQ and R4 and RQ together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(Ci-4 alkyl)-Cy, CN5 NO2, 0Ra2, SR32, C(O)R"2, C(O)NR02R"2, C(O)OR32, OC(O)R"2, OC(O)NR02R"2, NR02R"2, NR02C(O)R"2, NR02C(O)NR02R"2, NR02C(O)OR"2, S(O)R"2, S(O)NR02R"2, S(O)2Rb2, NR°2S(O)2Rb2, and S(O)2NR02R"2.
In some embodiments, Q is NR4RQ and R4 and RQ together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C]-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(CM alkyl)-Cy, CN, NO2, ORa2, SRa2, C(O)R"2, C(O)NRc2Rd2, C(O)OR32, OC(O)R"2, OC(O)NR02R"2, NR02R"2, NRo2C(0)Rb2, NR02C(O)NR02R"2, NR02C(OJOR"2, S(O)R"2, S(O)NR02R"2, S(O)2R"2, NR02S(O)2R"2, and S(O)2NR02R"2.
In some embodiments, Q is NR4RQ and R4 and RQ together with the N atom to which they are attached form piperidinyl, morpholino, piperazinyl, 2,3-dihydro-lH-isoindolyl, or 1,2,3,4-tetrahydro- isoquinoline, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C|.6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Cj-6 hydroxyalkyl, C7-6 cyanoalkyl, Cy,
-(C1-4 alkyl)-Cy, CN, NO2, OR"2, SR02, C(O)R"2, C(O)NR02R"2, C(O)OR32, OC(O)R"2, OC(O)NR02R"2, NR02R"2, NR02C(O)R"2, NR02C(O)NR02R"2, NR02C(O)OR"2, S(O)Rb2, S(O)NR02R"2, S(O)2R"2, NRc2S(O)2Rb2, and S(O)2NR02R"2.
In some embodiments, or Q is H, C1-6 alkyl, C2.6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CJ-6 hydroxyalkyl, Ci-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, -(C1-4 alkyl)-ORa2, SRa2, -(C1-4 alkyl)-SRa2, C(O)R"2,
-(C,.4alkyl)-C(O)Rb2, C(O)NRc2Rd2, -(C1-4 alkyiyC^NR^R"2, C(O)OR32, -(C1-4 alkyl)-C(O)ORa2, OC(O)Rb2, -(Ci-4 alkyl)-OC(O)Rb2, OC(O)NR02R112, -(C1-43IlCyI)-OC(O)NR02R112, NR02R112, -(C,.4 alkyl)-NRc2Rd2, NRc2C(O)Rb2, -(C1-4 alkyl)-NRc2C(O)Rb2, NR°2C(O)NRc2Rd2, -(C1-4 alkyl)- NR02C(O)NR02R112, NR02C(O)ORa2, -(C1-4 alkyl)-NRc2C(O)ORa2, C(=NRi)NRc2Rd2,
5 NRc2C(=NRi)NRc2Rd2, P(R^)2, P(ORe2)2, P(O)R62R12, P(O)ORe2ORβ, S(O)Rb2, -(Cj-4 alkyl)-S(O)Rb2, S(O)NR02R112, -(C1-4 alkyl)-S(O)NR02Rd2, S(O)2Rb2, -(C1-4 alkyl)-S(O)2Rb2, NRc2S(O)2Rb2, -(C1-4 alkyl)- NRc2S(O)2Rb2, S(O)2NR02R"2 , and -(CM aIlCyI)-S(O)2NR02R112.
In some embodiments, R^ is H, Cj.6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1.6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or
10 heterocycloalkylalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Cj-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, Ci-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, SRa2, C(O)R"2, C(O)NR02R"2, C(O)OR32, OC(O)Rb2, OC(O)NR02R"2, NR02R"2, NRo2C(0)Rb2,
15 NR02C(O)NR02R112, NR02C(O)OR"2, C(=NRi)NRc2Rd2, NRc2C(=NRi)NRo2Rd2, P(Rβ)2, P(ORe2)2, P(O)Re2R°, P(O)OR62OR*2, S(O)R"2, S(O)NR02R"2, S(O)2Rb2, NR02S(O)2R"2, and S(O)2NR02R*12. In some embodiments, RQ is H, Ci-6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci-6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclo-
20 alkylalkyl is optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, SR32, C(O)Rb2, C(O)NR02R"2, C(O)OR32, OC(O)Rb2, OC(O)NR02R112, NR02R"2, NR02C(O)R"2, NR02C(O)NR02R112, NR02C(O)ORa2, C(=NR!)NRo2Rd2 3 NRc2C(=NRi)NRo2Rd2, P(RG)2, P(ORe2)2, P(O)R62R*2, P(O)OR02OR*2, S(O)Rb2, S(O)NR02R112, S(O)2R"2, NR02S(O)2R1"2, and
25 S(O)2NR02R"2. hi some embodiments, RQ is H, C]-6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said CL6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo,
30 Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NR02R112, C(O)OR32, OC(O)Rb2, OC(O)NR02R"2, NR02R02, NR02C(O)R"2, NR02C(O)NR02R112, NR02C(O)OR32, S(O)Rb2, S(O)NR02R"2, S(O)2R"2, NR02S(O)2R"2, and S(O)2NR02R"2. hi some embodiments, RQ is C1-6 alkyl optionally substituted by 1, 2, 3, 4, or 5 substituents
35. independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, CiI6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, OR32, SR"2, C(O)Rb2, C(O)NR02R"2, C(O)OR32, OC(O)R"2, OC(O)NR02R"2, NR02R112, NR02C(O)R"2, NR02C(O)NR02R"2, NR02C(O)OR32,
C(=NRi)NRc2Rd2, NR02CC=NR^NR=2R"2, P(RQ)2, P(ORe2)2> P(O)Re2Rc, P(O)ORe2ORβ, S(O)Rb2, S(O)NRc2Rd2, S(O)2R"2, NRc2S(O)2Rb2, and S(O)2NR02R112.
In some embodiments, RQ is C1-6 alkyl optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6 haloalkyl, Ci-6 hydroxy- alkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NR52R112, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2 5 NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, S(O)Rb2, S(O)NR02R112, S(O)2R"2, NRc2S(O)2Rb2, and S(O)2NR02R112.
In some embodiments, RQ is aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Ci-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(Ci-4 alkyl)-Cy, CN, NO2, ORa2, SRa2, C(O)R"2, C(O)NRc2Rd2, C(O)OR"2, OC(O)Rb2, OC(O)NR02R112, NR02R412, NRc2C(O)Rb2, NRc2C(O)NRe2Rd2, NR02C(O)OR32, C(=NRi)NRo2Rd2, NRo2C(=NRi)NRo2Rd2, P(Rβ)2, P(ORe2)2, P(O)Re2Rβ, P(O)OR62OR12, S(O)Rb2, S(O)NR02R112, S(O)2R"2, NR02S(O)2R"2, and S(O)2NR02R112.
In some embodiments, R4 and RQ together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group or 5-20 membered heteroaryl group, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Cj-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, OR82, - (C1-4 alkyl)-ORa2, SRa2, -(C1-4 alkyl) -SRa2, C(O)R"2, -(C1-4 alkyl)-C(O)Rb2, C(O)NRc2Rd2, -(C1-4 alkyl)- C(O)NRc2Rd2, C(O)OR82, -(Ci-4 alkyl)-C(O)ORa2, OC(O)Rb2, -(C1-4 alkyl)-OC(O)Rb2, OC(O)NR=2R112, -(C1-4311CyI)-OC(O)NR02R112, NR02R*2, -(C1-4 alkyO-NR^R"2, NRc2C(O)Rb2, -(C1-4 alkyl)-NRc2C(O)Rb2, NRc2C(O)NR02Rd2, -(C1-4 alkyl)-NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, -(C1-4 alkyl)-NRc2C(O)OR"2, C(=NRϊ)NRo2Rd2, NRc2C(=NR!)NRc2Rd2, P(RC)2, P(ORe2)2, P(O)Re2Rβ, P(O)ORe2ORG, S(O)R"2, -(C1-4 alkyl)-S(O)Rb2, S(O)NR02R"2, -(C,.4alkyl)-S(O)NRc2Rd2, S(O)2R"2, -(C1-4 alkyl)-S(O)2Rb2, NR02S(O)2R"2, -(C1-4 alkyl)-NR°2S(O)2R"2, S(O)2NR02R*12 , and -(C43HCyI)-S(O)2NR02R112. In some embodiments, R4 and RQ together with the N atom to which they are attached form a
4-20 membered heterocycloalkyl group optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Ci-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, 0Ra2, SRa2, C(O)R"2, C(O)NR02R"2, C(O)OR32, OC(O)R"2, OC(O)NR62R*12, NR02R"2, NR02C(O)R"2, NR02C(O)NR02R"2, NR02C(O)OR"2, S(O)R"2, S(O)NR02R"2, S(O)2Rb2, NR02S(O)2R"2, and S(O)2NRc2Rd2.
In some embodiments, R4 is H, C4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C(O)-R48, SO2-R4\ aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, CL6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, CN, NO2, OR04, SR"4, C(O)RM, C(O)NRe4Rd4, C(O)OR"4, OC(O)R"4,
OCCO)NR0V4, NR0V4, NRe4C(O)RM, NR04CCO)NR0V4, NR04C(O)OR84, CC=NR^NR0V4,
PCRf4)2, P(ORc4)2, PCO)Rc4Rf4, PCO)ORe4ORf4, S(O)RM, SCO)NR0V4, SCO)2R"4, NR04SCO)2R"4, and SCO)2NRc4Rd4.
In some embodiments, R4 is H, Ci-4 alkyl, C(O)-R4a, SO2-R43, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci-4 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci.6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, CN, NO2, ORa4, SRa4, CCO)R"4, C(O)NR0V4, CCO)OR34, OCCO)R"4, OCCO)NR0V4, NRC V4, NR04CCO)R"4, NR04CCO)NR0V4, NR04CCO)OR34, CC=NR^NR0V4, NR04CC=NR^NR0V4, PCRf4)2> P(ORe4)2, PCO)R6V4, PCO)ORe4ORf4, SCO)RM, S(O)NR04R114, SCO)2RM, NR04SCO)2R"4, and SCO)2NRo4Rd4. In some embodiments, R4 is H. In some embodiments, RΛ and RB are independently selected from H, F, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, CN, NO2, ORal, SRal, CCO)Rbl, CCO)NR0V1, CCO)OR3', OC(O)Rbl, OCCO)NR0V1, NRcIRdl, NRolCCO)Rbl, NRolC(O)NRc)Rdl, NRclCCO)ORal, CC=NR)NR0 'Rdl, NRclC(=NRi)NRclRdl, PCRn)2, P(ORel)2, PCO)RelRπ, PCO)ORelORπ, S(O)Rbl, S(O)NRclRdl, SCO)2Rbl, NR01SCO)2R1", and SCO)2NRolRdl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci.4 alkyl, C2-4 alkenyl, C2.4 alkynyl, C]-4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, CN, NO2, ORal, SRal, C(O)RbI, CCO)NR01R"1, CCO)ORal, OC(O)Rbl, OCCO)NR0V1, NRclRdl, NR01CCO)R"1, NR0lCCO)NR0lRdl, NR01CCO)OR31, C(=NRi)NRclRdl, NR0lC(=NRi)NR0)Rdl, P(Rn)2, PCORel)2, PCO)R61R", PCO)ORelORfl, SCO)Rbl, SCO)NR0V1, SCO)2R1", NR0lSCO)2Rbl, and SCO)2NRolRdl.
In some embodiments, RA and RB are independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocycloalkylalkyl, wherein said Ci-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, Cj-4 hydroxyalkyl, C].4 cyanoalkyl, CN, NO2, ORal, SRal, CCO)R"1, CCO)NR0V1, CCO)ORal, OCCO)Rbl, OCCO)NR0V1, NRCIRdI, NRclC(O)Rbl, NRolCCO)NR0lRdl, NRclCCO)ORal, SCO)R"1, SCO)NR0V1, SCO)2Rbl, NRclSCO)2Rbl, and SCO)2NR0V.
In some embodiments, RA and RB are independently selected from H, F, and Ci.6 alkyl. In some embodiments, RA and RB are, independently, H or Cj-6 alkyl.
In some embodiments, RA and RB are both H.
In some embodiments, RA and RB together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7- membered cycloalkyl group or 3-, 4-, 5-, 6-, or 7- membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci_4 alkyl, C2-4 alkenyl, C2.4 alkynyl, C|.4 haloalkyl, C1.4 hydroxyalkyl, CM cyanoalkyl, CN, NO2, ORal, SRal, C(O)Rbl, C(O)NRclRdI, C(O)OR1", OC(O)Rbl, OC(O)NRclRdl, NRclRdl, NRclC{O)Rbl, NRclC(O)NRclRdl, NRC 1C(O)OR1", C(=NRi)NRclRdl, NRolC(=NRi)NRclRdl, P(Rπ)2, P(ORel)2, P(O)ReIRn, P(O)ORelORn, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(O)2RbI, and S(O)2NRclRdl. In some embodiments, R1 is H, CN, or NO2.
In some embodiments, Ra2 is H,
alkyl, Cj.6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cy2, or Cy^(C1-6 alkyl)-, wherein said Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl, is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C,.6 haloalkyl, C,.6 hydroxyalkyl, Ci-6 cyanoalkyl, Cy2, CN, NO2, OR"5, SRa5, C(O)Rbs, C(O)NRc5Rd5, C(O)OR"5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5RdS, NRc5C(O)Rb5, NRc5C(O)NRq5Rd5, NRc5C(O)ORa5, C(=NRi)NRc5RdS, NRcSC(=NRi)NRc5Rd5, P(Rβ)2, P(ORe5)2, P(O)Re5Rβ, P(O)OReSORβ, S(O)Rb5, S(O)NR05R115, Rb2, S(O)2Rb5, NRcSS(O)2Rb5, and S(O)2NRc5Rds.
In some embodiments, Rb2 is H, Ci-6 alkyl, C]-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, Cy2, or
said Ci-6 alkyl, Cj-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, or aryl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C]-6 alkyl, C2- 6 alkenyl, C2.6 alkynyl, C1-6 haloalkyl, Cj-6 hydroxyalkyl, Ci-6 cyanoalkyl, Cy2, CN, NO2, OR"5, SRa5, C(O)R"5, C(O)NRc5RdS, C(O)OR35, OC(O)Rbs, OC(O)NRc5Rds, NRcSRd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(=NRi)NRc5Rd5, NRcSC(=NRi)NRc5Rd5, P(Rβ)2, P(ORe5)2, P(O)Re5Rβ, P(O)ORe5ORβ, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5S(O)2Rb5, and S(O)2NRc5Rd5. In some embodiments, R° and Rd are independently selected from H, CMO alkyl, C]-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said CMO alkyl, Ci.6 haloalkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, Ci. 6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl.
In some embodiments, Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group.
In some embodiments, Cy, Cy1, and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, CM alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, CN, NO2, OR"3, SRa3, C(O)Rb3, C(O)NR03R413, C(O)OR03, OC(O)Rb3, OC(O)NR03Rd3, NRc3Rd3, NRc3C(O)Rb3,
NRc3C(O)ORa3, C^NR^NR^R113, NRc3C(=NRi)NRc3Rd3, P(RD)2, P(ORc3)2, P(O)Re3R°, P(O)ORe3ORβ, S(O)R"3, S(O)NR03R113, S(O)2R"3, and S(O)2NRc3Rd3.
In some embodiments, Cy is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NR03R113, NR03R113, NRc3C(O)Rb3, NRc3C(O)ORa3, S(O)Rb3, S(O)NRc3Rd3, S(O)2R"3, and S(O)2NRc3Rd3.
In some embodiments, R1 is H.
In some embodiments, R is H. In some embodiments, R2 is H.
In some embodiments, R3 is H.
In some embodiments, p is 1, 2, 3, 4 or 5.
In some embodiments, p is 1 or 2.
In some embodiments, p is 1. In some embodiments, the compounds of the invention have Formula I:
In some embodiments, the compounds of the invention have Formula Ila:
In some embodiments, the compounds of the invention have Formula II:
In some embodiments, the present invention provides compounds of Formula I:
I or pharmaceutically acceptable salts or prodrugs thereof, wherein:
U, V, and W are independently selected from N, O, S, CR2, and NR3, wherein the frve- membered ring containing U, V, and W is an aromatic heterocycle; A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Cue alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-S halo- alkyl, Cj.β hydroxyalkyl, Ci.6 cyanoalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR0, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NR0R*1; In some embodiments, RΛ and RB are independently selected from H, C1-6 alkyl, C2-6 alkenyl,
C2-6 alkynyl, C1-6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocycloalkylalkyl, wherein said Ci.β alkyl, C2.β alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Cj-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C]-4 hydroxyalkyl, Ci-4 cyanoalkyl, CN, NO2, ORal, SRal, C(O)Rbl, C(O)NRclRd\ C(O)OR3', OC(O)RbI, OC(O)NRclRd\ NRCIRdI, NR01C(O)R51, NR0lC(O)NRolRdI, NRcIC(O)ORal, S(O)Rbl, S(O)NRcIRdl, S(O)2Rbl, NRclS(O)2Rb\ and S(O)2NRclRdl. or RA and RB together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7- membered cycloalkyl group or 3-, 4-, 5-, 6-, or 7- membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, CN, NO2, ORal, SRal,
C(O)Rbl, C(O)NRclRdl, C(O)OR"1, OC(O)Rbl, OC(O)NRclRdl, NRclRdl, NRcIC(O)Rbl, NR0lC(O)NR0lRdl, NR0lC(O)ORal, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(O)2Rbl, and S(O)2NRclRdl;
Q is OR0, OC(O)RQ, OC(O)NR4RQ, NR4RQ, NR4C(O)RQ, NR4C(O)NR4R0, SRQ, S(O)RQ, S(O)NR4R0, S(O)2R0, or S(O)2NR4R0;
R° is H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2.6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C]-6 hydroxyalkyl, C]-6 cyanoalkyl, Cy, -(CMalkyl)-Cy, CN, NO2, OR"2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)OR82, OC(O)R"2, OC(O)NRc2Rd2, NR02R"2, NRc2C(O)Rb2, NR02C(O)NR02R"2, NRc2C(O)ORa2, S(O)R"2, S(O)NR02R"2, S(O)2R"2, NR02S(O)2R"2, and S(O)2NR02R"2; or R4 and RQ together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C]-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NR02R"2, C(O)OR=2, OC(O)Rb2, OC(O)NR02R"2, NR02R"2, NR02C(O)R"2, NR02C(O)NR02R"2, NRc2C(O)ORa2, S(O)R"2, S(O)NR02R"2, S(O)2Rb2, NR02S(O)2R"2, and S(O)2NR02R"2; Cy is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C1.4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Cj-4 haloalkyl, CN, NO2, ORa3, SRa3, C(O)R"3, C(O)NR03R"3, C(O)OR83, OC(O)R"3, OC(O)NR03R"3, NR03R"3, NR03C(O)R"3, NR03C(O)OR33, S(O)R"3, S(O)NR03R43, S(O)2R"3, and S(O)2NR03R"3;
R1 is H or C1-4 alkyl; R2 is H, halo, C]-4 alkyl, C-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, CN, NO2, OH, C,-4 alkoxy, amino, CM alkylamino, or C2-S dialkylamino;
R3 is H, Ci-4 alkyl, C2.4 alkenyl, or C2-4 alkynyl; R4 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, or C(O)-(C1-4 alkyl);
Ra, Ral, Ra2, and Ra3 are independently selected from H, C1-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said CL6 alkyl, Ci.6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C]-6 alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; R", RbI, R"2, and R"3 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl,
aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or hetero- cycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, Ci-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl;
R° and Rd are independently selected from H, Ci-I0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Ci-I0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C1-6 alkyl, Ci-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
Rcl and RdI are independently selected from H, Ci.io alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said Cj-10 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, hetero- aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, Ci-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or RcI and RdI together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; Rc2 and Rd2 are independently selected from H, Ci-I0 alkyl, Cj-6 haloalkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said Ci-I0 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, CL6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or R02 and R"12 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; and
Rc3 and Rd3 are independently selected from H, CM0 alkyl, C]-6 haloalkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said Ci-]0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl • is optionally substituted with OH, amino, halo, CJ-6 alkyl, C i.6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group.
At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term "C 1.6 alkyl" is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.
It is further intended that the compounds of the invention are stable. As used herein "stable" refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent.
It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
As used herein, the term "alkyl" is meant to refer to a saturated hydrocarbon group which is straight-chained or branched. Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n- propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like. An alkyl group can contain from 1 to about 20, from 2 to about 20, from 1 to about 10, from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms.
As used herein, "alkenyl" refers to an alkyl group having one or more double carbon-carbon bonds. Example alkenyl groups include ethenyl, propenyl, and the like. As used herein, "alkynyl" refers to an alkyl group having one or more triple carbon-carbon bonds. Example alkynyl groups include ethynyl, propynyl, and the like.
As used herein, "haloalkyl" refers to an alkyl group having one or more halogen substituents. Example haloalkyl groups include CF3, C2F5, CHF2, CCl3, CHCl2, C2Cl5, and the like.
As used herein, "halosulfanyl" refers to a sulfur group having one or more halogen substituents. Example halosulfanyl groups include pentahalosulfanyl groups such as SF5.
As used herein, "aryl" refers to monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, aryl groups have from 6 to about 20 carbon atoms.
As used herein, "cycloalkyl" refers to non-aromatic carbocycles including cyclized alkyl, alkenyl, and alkynyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems, including spirocycles. In some embodiments, cycloalkyl groups can have from 3 to about 20 carbon atoms, 3 to about 14 carbon atoms, 3 to about 10 carbon atoms, or 3 to 7 carbon atoms. Cycloalkyl groups can further have 0, 1, 2, or 3 double bonds and/or 0, 1, or 2 triple bonds. Cycloalkyl groups can further be substituted by one or more oxo groups. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclopentene, cyclohexane, and the like. A cycloalkyl group having one or more fused aromatic rings can be
attached though either the aromatic or non-aromatic portion. One or more ring-forming carbon atoms of a cycloalkyl group can be oxidized, for example, having an oxo or sulfido substituent. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like.
As used herein, a "heteroaryl" group refers to an aromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Any ring-forming N atom in a heteroaryl group can also be oxidized to form an N-oxo moiety. Examples of heteroaryl groups include without limitation, pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,3-thiadiazolyl, 1,2,4- thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, xanthene, and the like. In some embodiments, the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms.
As used herein, "heterocycloalkyl" refers to a non-aromatic heterocycle where one or more of the ring-forming atoms is a heteroatom such as an O, N, or S atom. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems as well as spirocycles. Any ring-forming C, N or S atom in a heterocycloalkyl group can be substituted by 1 or 2 oxo groups to form a carbonyl, N-oxo, sulfinyl, or sulfonyl moiety. Example "heterocycloalkyl" groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3- dihydrobenzofuryl, 1,3-benzodioxole, benzo-l,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles such as indolene, isoindolene, tetrahydroquinoline, and tetrahydroisoquinoline groups. A heterocycloalkyl group having one or more fused aromatic rings can be attached though either the aromatic or non-aromatic portion. Ih some embodiments, the heterocycloalkyl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heterocycloalkyl group contains 3 to about 20, 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 triple bonds.
As used herein, "halo" or "halogen" includes fluoro, chloro, bromo, and iodo.
As used herein, "hydroxyalkyl" refers to an alkyl group substituted with a hydroxyl group.
As used herein, "cyanoalkyl" refers to an alkyl group substituted with a cyano group.
As used herein, "alkoxy" refers to an -O-alkyl group. Example alkoxy groups include methoxy, ethoxy, propoxy {e.g., n-propoxy and isopropoxy), t-butoxy, and the like. As used herein, "arylalkyl" refers to alkyl substituted by aryl and "cycloalkylalkyl" refers to alkyl substituted by cycloalkyl. An example arylalkyl group is benzyl.
As used herein, "heteroarylalkyl" refers to alkyl substituted by heteroaryl and "heterocycloalkylalkyl" refers to alkyl substituted by heterocycloalkyl.
As used herein, "amino" refers to NH2. As used herein, "alkylamino" refers to an amino group substituted by an alkyl group.
As used herein, "dialkylamino" refers to an amino group substituted by two alkyl groups.
The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. A bond , in a structure diagram represented by a wavy line " WA/W/^ » js intended to indicate that the structure represents the cis or the trans isomer, or a mixture of the cis and trans isomers in any proportion.
Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam — lactim pairs, amide - imidic acid pairs, enamine — imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, IH- and 3H-imidazole, IH-, 2H- and 4H- 1 ,2,4-triazole, IH- and 2H- isoindole, and IH- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, the compounds of the invention, and salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment, in which is was formed or detected. Partial separation can include,
for example, a composition enriched in the compound of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compound of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or ACN are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The present invention also includes prodrugs of the compounds described herein. As used herein, "prodrugs" refer to any covalently bonded carriers which release the active parent drug when administered to a mammalian subject. Prodrugs can be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, sulfhydryl, or carboxyl group respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the invention. Preparation and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward
B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety.
Synthesis The novel compounds of the present invention can be prepared in a variety of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods as hereinafter described below, together with synthetic methods known in the art of synthetic organic chemistry or variations thereon as appreciated by those skilled in the art.
The compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C) infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography. Preparation of compounds can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene, et al., Protective Groups in Organic Synthesis, 2d. Ed., Wiley & Sons, 1991, which is incorporated herein by reference in its entirety. The reactions of the processes described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, i.e., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.
Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallization using a "chiral resolving acid" which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric •acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Resolution of racemic mixtures can also be carried out by
elution on a column packed with an optically active resolving agent {e.g., dinitrobenzoyl- phenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
Compounds of the invention can be synthesized according to routine methods by those skilled in the art and as shown in the below Schemes. According to Scheme 1, intermediates 1-5 (such as 6H-furo[3,4-c][l,2,5]oxadiazol-4-one) can be prepared starting with cleavage of bicyclic compounds 1-1 with a primary amine to yield hydroxymethyl derivatives 1-2. The hydroxyl group can be protected in any suitable manner such as by alklysilylchloride, ester, ether or other suitable protecting group (see, e.g., Greene, et al., Protective Groups in Organic Synthesis, supra) to yield protected compounds 1-3. The protected compounds 1- 3 can be converted to the corresponding N-hydroxyamidines 1-4 by thionation with an appropriate reagent such as CS2 or Lawesson's reagent followed by S-alkylation {e.g., S-methylation) with an appropriate reagent such as methyl iodide or methyltriflate followed by treatment with NH2OH. The N-hydroxyamidine group can be protected using, for example, phosgene, triphosgene, carbonyldiimidazole, etc., and the protected hydroxymethyl group can then be deprotected (such as by treatment with acid for alkylsilyl ethers) for further modification if desired.
Scheme 1
According to Scheme 2, compounds of the invention can be prepared starting with the intermediate 2-1 (which can be prepared according to Scheme 1) which can be oxidized at the hydroxymethyl group according to standard procedures for conversion of an alcohol to an aldehyde to yield intermediates 2-2. The aldehydes (2-2) can be further reacted with appropriate nucleophiles to yield hydroxyl (2-5) or amino (2-4) intermediates with optional substitution (RA) on the methylene.
These intermediates can be further modified by reaction of the hydroxyl groups with suitable electrophiles (e.g., alkylation, acylate, arylation) optionally in the presence of catalytic amounts of base or acid followed by deprotection to yield compounds of the invention 2-7 and 2-11. Additionally,
intermediate 2-5 can be oxidized to afford ketone 2-3 which can be further reacted with appropriate nucleophiles to yield hydroxyl (2-9) or amino (2-8) intermediates with optional substitution (RA and RB) on the methylene. Similarly, amines 2-4 and 2-8 can be directly deprotected to yield further compounds of the invention 2-6 and 2-10.
Scheme 2
Various compounds of the invention can be prepared according to the method shown in Scheme 3 where protected N-hydroxyamidines 3-1 are modified by Mitsonubu reaction with various aryl or heteroaryl alcohols (e.g., phenol or substituted phenol) followed by treatment with a base such as hydroxide to give aryloxy and heteroaryloxy derivatives 3-2. Additionally, protected N- hydroxyamidines 3-1 can be reacted with suitable reagents R4R0NC(O)X (where X is halo) or isocyanates RQ-N=C=O followed by treatment with base such as hydroxide to give compounds of the invention 3-3. In the case of reaction with the isocyanates, R4 of 3-3 would typically be H.
Scheme 3
3-3
Amino methyl compounds of the invention can be prepared according to the methods of
Scheme 4 where the hydroxymethyl group of a protected N-hydroxyamidine intermediate 4-1 is treated with mesylchloride or other suitable reagent to produce a good leaving group such as mesylate as exemplified in intermediate 4-2. The intermediate 4-2 is then reacted with amine NHR4R0 followed by treatment with base (such as hydroxide) to yield amino methyl compounds 4-3. The amino methyl compounds can be further derivatized to make various amides, ureas, sulfonamides, carbamates and the like by reaction of the amino moiety with RQC(O)-X, RQS(O)2-X, RQOC(O)-X and the like (X is a leaving group).
Scheme 4
4-3 4-4
Additional amino methyl compounds of the invention can be prepared according to the methods of Scheme 5 where the intermediate 4-2 is reacted with sodium azide followed by reduction (such as hydrogen over palladium or triphenylphosphine) to yield amino methyl compounds 4-6. The amino methyl compounds 4-6 can be further derivatized to make various compounds 4-7, such as amides, ureas, sulfonamides, carbamates and the like, by reaction of the amino moiety with R0C(O)- X, RQS(O)2-X, R0OC(O)-X and the like (X is a leaving group).
Scheme 5
Alkoxy compounds 6-2 can be prepared, for example, according the route shown in Scheme 6. Here, hydroxyalkyl or related compounds 6-1 are reacted with various electrophiles such as alkyl halides ("alkyl-X," where X is halo) followed by reaction with base such as hydroxide to form alkylated and similar compounds of formula 6-2. The alkyl halides can be optionally substituted with other various functional groups.
Scheme 6
6-1 6-2
An alternative method for the synthesis of N-hydroxyamidines (e.g., Example 33) is shown in Scheme 7 where an amide 7-1 is chlorinated with suitable chlorination reagent (such as PCIs, POCI3, SO2Cl2, or alike) followed by addition of NH2OH to the crude reaction mixture to afford the desired products 7-2.
Methods of Use Compounds of the invention can modulate activity of the enzyme indoIeamine-2,3- dioxygenase (IDO). The term "modulate" is meant to refer to an ability to increase or decrease activity of an enzyme or receptor. Accordingly, compounds of the invention can be used in methods of modulating IDO by contacting the enzyme with any one or more of the compounds or compositions described herein. In some embodiments, compounds of the present invention can act as inhibitors of IDO. In further embodiments, the compounds of the invention can be used to modulate
activity of EDO in cell or in an individual in need of modulation of the enzyme by administering a modulating (e.g., inhibiting) amount of a compound of the invention.
The present invention further provides methods of inhibiting the degradation of tryptophan in a system containing cells expressing IDO such as a tissue, living organism, or cell culture. In some embodiments, the present invention provides methods of altering (e.g., increasing) extracellular tryptophan levels in a mammal by administering an effective amount of a compound of composition provided herein. Methods of measuring tryptophan levels and tryptophan degradation are routine in the art.
The present invention further provides methods of inhibiting immunosuppression such as IDO-mediated immunosuppression in a patient by administering to the patient an effective amount of a compound or composition recited herein. IDO-mediated immunosuppression has been associated with, for example, cancers, tumor growth, metastasis, viral infection, viral replication, etc.
The present invention further provides methods of treating diseases associated with activity or expression, including abnormal activity and/or overexpression, of DDO in an individual (e.g., patient) by administering to the individual in need of such treatment a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof. Example diseases can include any disease, disorder or condition that is directly or indirectly linked to expression or activity of the IDO enzyme, such as over expression or abnormal activity. An EDO-associated disease can also include any disease, disorder or condition that can be prevented, ameliorated, or cured by modulating enzyme activity. Examples of EDO-associated diseases include cancer, viral infection such as HIV infection, depression, neurodegenerative disorders such as Alzheimer's disease and Huntington's disease, trauma, age-related cataracts, organ transplantation (e.g., organ transplant rejection), and autoimmune diseases including asthma, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and systemic lupus erythematosusor. Example cancers treatable by the methods herein include cancer of the colon, pancreas, breast, prostate, lung, brain, ovary, cervix, testes, renal, head and neck, lymphoma, leukemia, melanoma, and the like.
As used herein, the term "cell" is meant to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal.
As used herein, the term "contacting" refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, "contacting" the EDO enzyme with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having EDO, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the IDO enzyme.
As used herein, the term "individual" or "patient," used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following:
(1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease;
(2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder; and
(3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
Combination Therapy One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., JL2, GM- CSF, etc.), and/or tyrosine kinase inhibitors can be used in combination with the compounds of the present invention for treatment of EDO-associated diseases, disorders or conditions. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
Suitable antiviral agents contemplated for use in combination with the compounds of the present invention can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.
Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L-FD4 (also called beta-L-D4C and named beta-L-2', 3'-dicleoxy-5-fiuoro-cytidene); DAPD, ((-)-beta-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1- (ethoxy-methyl)-5-(l-methylethyl)-6-(phenylmethyl)-(2,4(lH,3H)-ρyrimidinedione); and (+)-
calanolide A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31- 8959); ritonavir (ABT-538); indinavir (MK-639); nelfiiavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-I 549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.l 1607. Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents
(including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (Cytoxan M), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethio- phosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide. In the treatment of melanoma, suitable agents for use in combination with the compounds of the present invention include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen," which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide. Compounds according to the invention may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in the treatment of melanoma.
Compounds of the invention may also be used in combination with vaccine therapy in the treatment of melanoma. Antimelanoma vaccines are, in some ways, similar to the anti-virus vaccines which are used to prevent diseases caused by viruses such as polio, measles, and mumps. Weakened melanoma cells or parts of melanoma cells called antigens may be injected into a patient to stimulate the body's immune system to destroy melanoma cells.
Melanomas that are confined to the arms or legs may also be treated with a combination of agents including one or more compounds of the invention, using a hyperthermic isolated limb perfusion technique. This treatment protocol temporarily separates the circulation of the involved limb from the rest of the body and injects high doses of chemotherapy into the artery feeding the limb, thus providing high doses to the area of the tumor without exposing internal organs to these doses that might otherwise cause severe side effects. Usually the fluid is warmed to 102° to 104° F. Melphalan is the drug most often used in this chemotherapy procedure. This can be given with another agent called tumor necrosis factor (TNF) (see section on cytokines). Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites
(including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6- mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.
Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactino- mycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (TAXOL™), mithramycin,
deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide.
Other cytotoxic agents include navelbene, CPT-I l, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine. Also suitable are cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis- platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.
Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4- IBB and PD-I, or antibodies to cytokines (IL-10, TGF-β, etc.).
Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.
Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.
Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.
Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the
"Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if set forth in its entirety.
Pharmaceutical Formulations and Dosage Forms When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions which is a combination of a compound of the invention and a pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or
may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of the invention above in combination with one or more pharmaceutically acceptable carriers. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual
compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.
The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending
upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts. The therapeutic dosage of the compounds of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
The compounds of the invention can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like.
Labeled Compounds and Assay Methods
Another aspect of the present invention relates to fluorescent dye, spin label, heavy metal or radio-labeled compounds of the invention that would be useful not only in imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the EDO enzyme in tissue samples, including human, and for identifying IDO enzyme ligands by inhibition binding of a labeled compound.
Accordingly, the present invention includes IDO enzyme assays that contain such labeled compounds.
The present invention further includes isotopically-labeled compounds of Formula I. An "isotopically" or "radio-labeled" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable
radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2H (also written as D for deuterium), 3H (also written as T for tritium), 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 18F, 35S, 36Cl, 82Br3 75Br, 76Br, 77Br, 123I, 124I, 125I and 131I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro EDO enzyme labeling and competition assays, compounds that incorporate 3H, 14C, 82Br, 12SI , 1311, 35S or will generally be most useful. For radio- imaging applications 11C, 18F, 125I, 123I, 1241, 1311, 75Br, 76Br or 77Br will generally be most useful.
It is understood that a "radio-labeled " or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3H, 14C, 1251 , 35S and 82Br.
Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art.
A radio-labeled compound of the invention can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the radio-labeled compound of the invention to the IDO enzyme. Accordingly, the ability of a test compound to compete with the radiolabeled compound for binding to the IDO enzyme directly correlates to its binding affinity.
Kits The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of IDO-associated diseases or disorders, obesity, diabetes and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of IDO according to one or more of the assays provided herein. In some instances where the compounds of the examples were isolated by preparative HPLC in the presence of trifluoroacetic acid (TFA) or other acid, the compound may have been obtained as the corresponding salt.
EXAMPLES
Example 1 : iV-CS-Chloro^-fluoro-phenyO-iV'-hydroxy^-hydroxymethyl-furazan-S- carboxamidine
4H,6H-Furo[3,4-c][l,2,5]oxadiazol-4-one was synthesized according to literature procedures (Pollet, et al, Synthesis Communications, 1979, 977-979.) To a stirred solution of (3Z,4Z)-furan- 2,3,4(5H)-trione 3,4-dioxime (3.0 g, 0.021 mol) in 1,4-dioxane (21 mL) under nitrogen, thionyl chloride (2.1 mL, 0.029 mol) was added dropwise. The resulting yellow solution was stirred overnight and then concentrated in vacuo. The resultant crystalline material was recrystallized once from a minimum amount of ethanol (EtOH) to give the desired compound as an off-white powder. The filtrate was concentrated down and recrystallized again. Combined solids yielded the desired product (2.0 g, 76%). 1H NMR (400 MHz, DMSO-J6) δ: 5.67 (s, 2H). MF = C4H2N2O3; LCMS calculated for C4H3N2O3 (M+H)+: m/z = 127.014.
Step B. N-(3-Chloro-4-βuorophenyl)-4-(hydroxymethyl)-l,2, 5-oxadiazoleS-carboxamide
4H)6H-Furo[3,4-c][l,2,5]oxadiazol-4-one (2.00 g, 0.0159 mol) was dissolved in EtOH (80 mL) and iV.N-dimethylacetamide (10 mL) and then 3-chloro-4-fluoroaniline (2.5 g, 0.017 mol) was added as a solid. The reaction was heated at 80 0C overnight. The crude reaction mixture was concentrated in vacuo. The oil was extracted twice with EtOAc and washed with water. The organic was dried over Na2SO4 and concentrated. The crude residue was purified by flash column chromatography eluting with EtOAc:Hexane (1 : 1) to yield the desired product (3.2 g, 74%). 1H NMR (400 MHz, DMSO-J6) δ: 1 1.30 (s, IH), 8.30 (dd, J= 7.0, 2.7 Hz, IH), 7.69 (ddd, J = 9.1, 4.4, 2.6
Hz, IH) 7.45 (dd, J = 9.1, 9.1 Hz, IH), 4.86 (d = 5.8 Hz, 2H), 5.78 (t, 5.8 Hz, IH); MF =
C10H7ClFN3O3; LCMS calculated for Ci0H8ClFN3O3(M+H)+: m/z = 272.024.
Step C: N-(3-Chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-l,2, 5-oxadiazole-3- carboxamide
To a stirred solution of N-(3-chloro-4-fluorophenyl)-4-(hydroxymethyl)-l,2,5-oxadiazole-3- carboxamide (3.2 g, 0.012 mol) in dichloromethane (DCM) (23 mL) at 0 0C was added 2,6-lutidine (3.4 mL, 0.029 mol) followed by triisopropylsilyl triflate (4.1 mL). The solution was stirred at 0 0C for 30 min and then the reaction was warmed to it overnight. The reaction was concentrated and chromatographed on a silica column eluting with 15% ethyl acetate/hexane to yield a colorless oil (4.59 g, 91%). 1H ΝMR (400 MHz, DMSO-^6) δ: 11.03 (s, IH), 8.01 (dd, /= 6.7, 2.6 Hz, IH), 7.67 (ddd, J = 9.1, 4.3, 2.6 Hz, IH)3 7.44 (dd, J = 9.1, 9.1 Hz, IH), 5.2 (s, 2H), 1.09 (m, 3H), 0.99 (d, J = 7.1 Hz, 18H) ; MF = Ci9H27ClFN3O3Si; LCMS calculated for C19H28ClFN3O3Si(M^-H)+: m/z = 428.157.
Step D: N-(3-Chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-l, 2, 5-oxadiazole-3- carboth io amide
Into a round bottom flask was placed a solution of N-(3-chloro-4-fluorophenyl)-4- [(triisopropylsilyl)oxy]methyl-l,2,5-oxadiazole-3-carboxamide (4.1 g, 9.5 mmol) in anhydrous toluene (79 mL) under N2. 2,4-Bis(4-methoxyphenyl)-2,4-dithioxo-l,3,2,4-dithiadiphosphetane (7.7 g, 19 mmol) was added while stirring at ambient temperature. After addition, the resulting suspension was stirred and heated at 100 0C for 20 hrs. A considerable amount of solid precipitate was filtered off while the reaction was still hot, which was residual Lawesson's reagent. The liquid was then concentrated to give a yellow oil which was dissolved in chloroform and loaded onto a 330 g silica column eluting with 25 % ethyl acetate/hexane to yield the desired product (3.31 g, 78%). 1H NMR (400 MHz, DMSO-^6) δ: 12.87 (s, IH), 7.8 (ddd, J= 8.9, 4.3, 2.7 Hz, IH), 8.21 (dd, J= 6.8, 2.7 Hz3 IH) 7.55 (dd, J= 9.0 , 9.0 Hz, IH), 5.14 (s, 2H), 1.07 (m, 3H), 0.97 (d, J= 7.0, 18H); (M+H)+: m/z = 444.134.
Step E: Methyl N-β-chloro^-fluorophenyO^-fCtriisopropylsilyQoxyJmethyl-l^.δ-oxadiazole-S-
carbimidoth ioate
To a solution of N-(3-chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-l,2,5- oxadiazole-3-carbothioamide (3.3 g, 7.4 mmol) in anhydrous DCM (148 mL) under N2 was added N,N-diisopropylethylamine (DEPEA) (1.4 mL). Methyl trifluoromethanesulfonate (900 μL, 8.2 mmol) was then added dropwise and stirred for 2 hrs. The reaction was stripped to dryness and purified on a 330 g silica ISCO cartridge, eluting with 25% EtOAc/hexane to yield the desired product as a yellow oil that solidified upon standing. (2.97 g, 87%). 1H ΝMR (400 MHz, DMSO-^6) δ: 11.32
(s, IH), 8.01 (dd, J =7.1, 2.7 Hz, IH), 7.45 (dd, J = 9.5 , 9.5 Hz, IH), 7.67 (m, IH), 4.4 (s = 3H), 5.13 (s, 2H), 1.1 (m, 3H); 0.99 (m, 18H); MF = C20H29ClFN3O2SSi; LCMS calculated for
C20H30ClFN3O2SSi(TMrI-H)+: m/z = 458.150. .
Step F: N-fS-Chloro^-fluorophenyty-N'-hydroxy-^fftriisopropylsilylJoxyJmethyl-l^.S-oxadiazole-S- carboximidamide
Methyl N-(3-chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-l,2,5-oxadiazole-3- carbimidothioate (3.0 g, 6.5 mmol) was dissolved in EtOH followed by addition of 4 mL hydroxylamine (99.9% in water solution) . The reaction was stirred at 75 0C for 6 hrs and monitored by HPLC. The reaction was concentrated in vacuo to a yellow oil which was dissolved in chloroform and chromatographed on 120 g of silica gel eluting with (1: 4), EtOAc/hexane. The product was concentrated to give the desired product as a white solid (2.57 g, 89%); MF = Ci9H28ClFN4O3Si; LCMS calculated for C19H29ClFN4O3Si(MH-H)+: m/z = 443.168.
Step G: 4-(3-Chloro-4-βuorophenyl)-3-(4-[(triisopropylsilyl)oxy] methyl-1 ,2,5-oxadiazol-3-yl)-l ,2,4- oxadiazol-5(4H)-one
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(triisopropylsilyl)oxy]methyl-l,2,5-oxadiazole-3- carboximidamide (2.2 g, 5.0 mmol) was dissolved in anhydrous tetrahydrofuran (THF) (31 mL) followed by addition of iV.N-carbonyldiimidazole (980 mg, 6 mmol). The reaction was heated to 70
0C and monitored by LCMS. Another 0.5 eq of iV,N-carbonyldiimidazole was added and the reaction was stirred overnight at 70 0C. The reaction was cooled and concentrated in vacuo. The crude oil was dissolved in chloroform and loaded onto a 120 g ISCO cartridge, ehited with 25% EtOAc/Hexane.
The combined fractions were stripped to dryness to give the desired product as a white solid (1.74 g,
73%). 1H ΝMR (400 MHz, DMSCW6) δ: 7.95 (m, IH), 7.65 (m , IH), 7.64 (m, IH), 5.12 (s, 2H),
1.14 (m, 3H), 1.04 (d, J = 7.0 Hz, 18H); MF = C20H26ClFN4O4Si; LCMS calculated for C20H27ClFN4O4Si(M+H)+: m/z = 469.147.
Step H: 4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-l, 2, 5-oxadiazol-3-yl]-l, 2, 4-oxadiazol- 5(4H)-one
4-(3-Chloro-4-fluorophenyl)-3-(4-[(triisopropylsilyl)oxy]methyl- 1 ,2,5-oxadiazol-3-yl)-l ,2,4- oxadiazol-5(4H)-one (1.7 g, 3.7 mmol) was dissolved in anhydrous MeOH (MeOH) (110 mL) followed by addition of 2 M of hydrogen chloride in MeOH (9.2 mL). Reaction was stirred at 70 0C for 4 hrs. After concentration in vacuo the sample was loaded onto 12O g ISCO cartridge eluting with EtOAc/hexane. Fractions were combined and evaporated to yield desired product as an off-white powder. (1.12 g, 97%). 1H NMR (400 MHz, DMSO-^6) δ: 7.96 (dd, J= 6.8 , 2.3 Hz, IH), 7.66 (m, IH), 7.64 (m, IH), 5.95 (s, IH), 4.85 (s, 2H); MF = C11H6ClFN4O4; LCMS calculated for C,,H7C1FN4O4(M+H)+: m/z = 313.014.
Step J: N-(3-Chloro-4-βuoro-phenyl)-N'-hydroxy-4-hydroxymethyl-furazan-3-carboxamidine 4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-l,2,5-oxadiazol-3-yl]-l,2,4-oxadiazol-
5(4H)-one (20 mg, 0.064 mmol) was dissolved in anhydrous EtOH (0.6 mL) followed by addition of 2 M of sodium hydroxide in water (60 μL). Reaction was stirred at 50 0C for 4 hrs. Consumption of starting material was monitored by TLC. The sample was quenched with acetic acid, diluted with MeOH and purified by preparative LCMS. The reaction was diluted with water and extracted with ethyl acetate three times, dried with sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by flash silica column chromatography to yield the desired product (16 mg, 87%). 1H NMR (400 MHz, DMSO-^6) δ: 11.49 (s, IH), 9.02 (s, IH), 7.18 (dd, J= 9.1, 9.1 Hz, IH),
6.97 (dd, J = 6.6, 2.7 Hz, IH), 6.69 (m, IH), 5.68 (t, J= 6.2 Hz, IH) 4.72 (d, J= 5.8 Hz, 2H); MF = C10H8ClFN4O3; LCMS calculated for C10H9ClFN4O3 (M+H)+: m/z = 287.035.
Example 2: Λr-(3-Chloro-4-fluorophenyl)-JV'-hydroxy-4-(phenoxymethyl)-l,2,5-oxadiazole-3- carboximidam ide
Step A: 4-(3-Chloro-4-fluorophenyl)-3-[4-(phenoxymethyl)-l ,2,5-oxadiazol-3-yl] -1 ,2,4-oxadiazol- 5(4H)-one
5(4H)-one (15 mg, 0.0480 mmol), phenol (14 mg, 0.14 mmol) and triphenylphosphine (16 mg, 0.062 mmol) were dissolved in anhydrous THF (500 μL) then cooled to 0 0C, followed by a dropwise addition of diethyl azodicarboxylate (9.8 μL, 0.062 mmol) in a solution of THF. Reaction was allowed to warm to rt then stirred 4 hrs. After concentration in vacuo, the sample was purified by reverse phase HPLC to yield a white powder (9 mg, 48%). MF = C17H10CIFN4O4; LCMS calculated for Ci7H11ClFN4O4 (M+H)+: m/z = 389.045
Step C: N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(phenoxymethyl)-l,2,5-oxadiazole-3- carboximidamide Into a vial was added 4-(3-chloro-4-fluorophenyl)-3-[4-(phenoxymethyl)-l,2,5-oxadiazol-3- yl]-l ,2,4-oxadiazol-5(4H)-one (9 mg, 23 mmol), EtOH (0.5 mL), and 2.0 M of sodium hydroxide in water (35 μL). Reaction was stirred for 2 hrs at rt. The reaction mixture was neutralized with acetic acid and then purified by preparative HPLC to yield the desired compound (7.6 mg , 90%). 1H NMR (400 MHz, DMSO-^6) δ: 11.58 (s, IH)5 9.05 (s, IH), 7.32 (t, 7 = 7.8 Hz, 2H) 7.19 (dd, J= 9.1, 9.1 Hz, IH), 7.0 (m, IH), 6.97 (m, 2 H) 6.96 (m, 1 H), 6.72 (ddd, J= 8.8, 4.0, 2.8 Hz, IH), 5.43 (s, 2 H); MF = C16H12ClFN4O3; LCMS calculated for C16H,3C1FN4O3(M+H)+: m/z = 363.066.
Example 3: 4-[(E/Z)-[(3-Chloro-4-fluorophenyl)aminoJ(hydroxyimino)inethyI]-l,2,5-oxadiazol- 3-ylmethyI phenylcarbamate
4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-l,2,5-oxadiazol-3-yl]-l,2,4-oxadiazol- 5(4H)-one (20 mg, 0.064 mmol), was dissolved in anhydrous DCM (400 μL). 4-Dimethylamino- pyridine (DMAP) (4 mg, 0.03 mmol) was added followed by addition of phenyl isocyanate (7.6 μL, 0.07 mmol). Reaction was stirred at rt for 24 hrs and then concentrated in vacuo. The crude was purified by HPLC to yield a white powder. The intermediate was redissolved in EtOH (0.7 mL) and 2 M of sodium hydroxide in water (60 μL) was added. Reaction was stirred for 2 hr at rt. Reaction was quenched with acetic acid and diluted with MeOH and then purified by preparative LCMS to yield the desired compound as a white powder (16 mg, 62%). 1H NMR (400 MHz, DMSO-^6) δ: 11.68 (s, IH), 10,00 (s, 1 H), 9.04 (s, IH), 7.47 (d, J= 8.1 Hz, 2 H), 7.00 (m, IH), 7.28 (dd, J= 7.5, 8.0 Hz, 2 H) , 7.19 (dd, J = 9.1, 9.1 Hz, IH), 7.0 (m, IH), 6.79 (m, 1 H) 5.49 (s, 2H). ; MF = C16H12ClFN4O3; LCMS calculated for C16H,3C1FN4O3(M+H)+: m/z = 363.066.
Example 4 : 4-[(Benzylamino)methyl] -7V-(3-chloro-4-fluorophenyl)-iV-hydroxy-l,2,S-oxadiazole- 3-carboximidamide
Step A: 4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylmethyl methanesulfonate
4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-l,2,5-oxadiazol-3-yl]-l,2,4-oxadiazol- 5(4H)-one (250 mg, 0.7996 mmol) was dissolved in anhydrous DCM (8 mL) followed by addition of triethylamine (TEA) (134 μL, 0.96 mmol). Reaction was cooled to 0 0C and methanesulfonyl chloride (68 μL, 0.88 mmol) was added dropwise. The reaction was diluted with water and extracted with ethyl acetate three times, dried with sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by flash column chromatography eluting with 25%-70% EtOAc to yield
the desired product (259 mg, 83%). MF = C12H8ClFN4O6S; LCMS calculated for C12H9ClFN4O6S (M+H)+: m/z = 390.992.
4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylmethyl methanesulfonate (0.020 g, 0.051 mmol) was dissolved in anhydrous acetoήitrile (ACN) (500 μL) followed by addition of DIPEA (44 μL, 0.26 mmol) and benzylamine (8.4 μL, 0.077 mmol). The reaction was stirred and heated at 60 °C for 1 hr. The reaction was stripped to dryness, redissolved in EtOH (500 μL) and 2 M sodium hydroxide in water (0.1 mL) was added. The reaction was stirred and heated at 60 0C for 2 hrs, quenched with acetic acid, diluted with MeOH and purified by preparative LCMS to yield desired product as a pure white powder (15 mg, 78%). MF = C17H15ClFN5O2; LCMS calculated for CπHi6ClFN5O2(M+H)+: m/z = 376.098.
Additional example compounds of the invention are provided below. Table 1 below (and Tables 2 and 3, infra) provide example compounds of the invention that show activity as IDO modulators according to one or more of the assays provided herein. The compounds were prepared according to synthetic procedure of the Example compound specified in the column marked "Prep. Ex." and were purified by the method in the column marked "Pur. Meth." In the "Pur. Meth." column, "A" refers to purification by LCMS (HPLC, pH = 2, trifluoroacetic acid (TFA)); "B" refers to purification by LCMS (HPLC, pH = 10, NH4OH); "C" refers to silica gel chromatography (typically hexanes/ethyl acetate); "D" refers to routine crystallization or precipitation methods; and "E" refers to the purification method as provided in the synthetic procedure for preparing that compound. Certain compounds of the Tables were isolated in the free base form or as a salt (typically as a result of the purification procedure) as indicated in the column marked "Salt". The salt stoichiometry indicated in the below tables and preparation descriptions is typically based on theory and one skilled in the art would understand that the actual product might contain more or less acid. Actual stoichiometry can be determined by routine methods such as elemental analysis. ACN refers to acetonitrile. DCM refers to dichloromethane. DMF refers to dimethylformamide. TFA refers to trifluoroacetic acid. TEA refers to tetraethylamine. DMAP refers to dimethylaminopyridine. DIPEA refers to N,N- diethylisopropylamine.
Table 1
Ex. Pur.
Structure MS Prep.
No. (M+l) Ex. Meth Salt Name
N-(3-chloro-4- fluorophenyl)-4-
[(2-chloro-
Example 31 : 3-(4-[(2-Morpholin-4-ylethyl)amino]methyl-l,2,5-oxadiazol-3-yl)-4-[3-
(trifluoromethyI)phenylJ-l,2,4-oxadiazoI-5(4H)-one
Step A: 4-(3-(Triβuoromethyl)phenyl)-3-(4-[(2-morpholin-4-ylethyl)amino]methyl-l,2,5-oxadiazol-3- y I)-1, 2, 4-oxadiazol-5(4H)-one
4-5-Oxo-4-[3-(trifluoromethyl)phenyl]-4J5-dihydro-l,2,4-oxadiazol-3-yl-l,2,5-oxadiazol-3- yl)methyl methanesulfonate (0.01 g, 0.025 mmol) was dissolved in anhydrous ACN (20 μL) followed. by addition of DIPEA(Il μL, 0.12 mmol) and N-(2-aminoethyl)morpholine (0.05 mmol). The reaction was stirred at 40 0C for 2 hrs. The reaction was diluted with MeOH and purified by preparative LCMS to afford the desired product. MF = Ci8Hi9F3N6O4; LCMS calculated for
Step B: 3-(4-[(2-Morpholin-4-ylethyl)amino]methyl-l,2,5-oxadiazol-3-yl)-4-[3-(trifluoromethyl)- phenyl] -1,2, 4-oxadiazol-5(4H)-one The purified intermediate was evaporated to dryness and then redissolved in EtOH (200 μL) and 2 M of sodium hydroxide in water (60 μL) was added. The reaction was stirred at rt for 2 hrs, quenched with acetic acid, diluted with MeOH and purified by preparative LCMS to afford the desired product (3 mg) MF = CnH2IF3N6O3; LCMS calculated for CπH22F3N6O3(M+H)+: m/z =
415.2.
Example 32: Λ^(3-Chloro-4-fluorophenyI)-Λr'-hydroxy-4-[(methylsulfonyI)(2-morpholin-4-yl- ethyl)amino]methyI-l,2,5-oxadiazole-3-carboximidamide
Step A: 4-(3-Chloro-4-fluorophenyl)-3-(4-[(2-morpholin-4-ylethyl)amino]methyl-l,2,5-oxadiazol-3-
yl)-l,2, 4-oxadiazol-5(4H)-one
Step B: N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-[(methylsulfonyl)(2-morpholin-4- ylethyl)amino]methyl-l,2,5-oxadiazole-3-carboximidamide
4-(3-Chloro-4-fluorophenyl)-3-(4-[(2-moφholin-4-ylethyl)amino]methyl-l,2,5-oxadiazol-3- yl)-l,2,4-oxadiazol-5(4H)-one (20 mg, 0.047 mmol) was dissolved in anhydrous ACN (200 μL) followed by addition of DIPEA (40 μL, 0.2 mmol) and methanesulfonyl chloride (4.0 μL, 0.052 mmol). The reaction was stirred at 40 0C for 2 hrs. The reactions was then diluted with MeOH and purified by HPLC. The purified fractions were concentrated to dryness, redissolved in EtOH (1 mL) and 2 M of sodium hydroxide in water (0.26 mL) was added. The reaction was stirred at rt for 2 hrs, quenched with acetic acid, diluted with MeOH and purified by preparative LCMS to afford the desired product (1.4 mg). MF = Ci7H22ClFN6O5S; LCMS calculated for C17H23C1FN6OSS(M+H)+: m/z = 477.1.
Example 33: iV-{4-[iV-(3-Chloro-4-fluoro-phenyl)-iVt-hydroxy-carbamimidoyl]-furazaii-3-yl- methyl}-benza inide
Step A: 3-[4-(azidomethyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-βuorophenyl)-l,2,4-oxadiazol-5(4H)- one
4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylmethyl methanesulfonate (400 mg, 1.02 mmol) was dissolved in anhydrous DMF (10 mL) followed by addition of sodium azide (133 mg, 2.04 mmol). Reaction was stirred for 3 hrs. Consumption of
starting material was monitored by TLC and HPLC. The reaction mixture was added to a mixture of (400 μL) bromine/ water and stirred for 10 min. DCM was added and the layers were separated. The combined organics were dried with sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by flash column chromatography to yield the desired product (225 mg, 65%). MF = C1 ,H5ClFN7O3; LCMS calculated for CπH6ClFN7O3(M+H)+: m/z = 338.020.
Step B: ^-^-(Aminomethyiyi.l^-oxadiazol-i-ylJ^-β-chloro^-fluorophenyfyAάΛ-oxadiazol- 5(4H)-one
5(4H)-one (225 mg, 0.66 mmol) was dissolved in anhydrous THF (5.6 mL) and water (5.6 mL). The reaction was cooled to 0 0C followed by addition of triphenylphosphine (192 mg, 0.73 mmol). The reaction was allowed to warm to rt and was stirred overnight. The reaction was stripped to dryness, azeotroped with toluene and redissolved in MeOH. The crude residue was purified by preparative LCMS to yield the desired product (200 mg, 96%). MF = C11H7ClFN5O3; LCMS calculated for CπH8ClFN5O3(M+H)+: m/z = 312.030.
Step C: 4-[(Benzylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2, 5-oxadiazole-3- carboximidamide Benzoic acid (4.3 mg, 0.035 mmol) and 3-[4-(aminomethyl)-l,2,5-oxadiazol-3-yl]-4-(3- chloro-4-fluorophenyl)-l,2,4-oxadiazol-5(4H)-one (10 mg, 0.032 mmol) was dissolved in ACN (0.2 mL) and DCM (0.2 mL). To the mixture was added DMAP (2.4 mg, 0.02 mmol) and DIPEA(Il μL, 0.096 mmol). After the mixture became a clear solution, bromotris(pyrrolydino)phophonium hexa- fluorophosphate (16 mg, 0.035 mmol) was added, followed by additional DIPEA(M μL, 0.0962 mmol). The reaction mixture was stirred at rt for 6 hrs. LCMS indicated ~70% ratio of product to starting amine. The reaction was then diluted with MeOH and crude residue was purified by preparative LCMS. The intermediate was stripped to dryness, redissolved in EtOH (1 mL) and 1 M of sodium hydroxide in water (0.06 mL). The reaction was stirred for 1 hr at rt. The reaction was quenched with acetic acid and then diluted with MeOH and crude residue was purified by preparative LCMS to afford the desired product (1.1 mg). MF = C17H13ClFN5O3; LCMS calculated for C17H14C1FN5O3(M+H)+: m/z = 390.077.
Example 34: iV-(3-Chloro-4-fluoro-phenyl)-iV'-hydroxy-4-[(3-phenyl-ureido)-methyl]-furazan-
3-carboxamidine
3-[4-(Aminomethyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4-oxadiazol- 5(4H)-one (10 rag, 0.003 mmol) was dissolved in ACN (0.2 mL) and DCM (0.2 mL). Phenyl isocyanate (7.6 mg, 0.064 mmol) DIPEA(0.0\2 mg, 0.096 mmol) and DMAP (0.4 mg, 0.03 mmol) were added and stirred at rt for 6 hrs. The reaction was then diluted with MeOH and purified by preparative LCMS. The intermediate was stripped to dryness, redissolved in EtOH (1 mL) and 1 M of sodium hydroxide in water (0.06 mL) was added. The reaction was stirred at rt for 1 hour, quenched with acetic acid and diluted with MeOH. The crude was purified by preparative LCMS to afford the desired product (2.0 mg). MF = Ci7H14ClFN6O3; LCMS calculated for CπHi5ClFN6O3(M+H)+: m/z = 405.1.
Example 35: 4-(Benzenesulfonylamino-methyI)-iV-(3-chIoro-4-fluoro-phenyl)-iV-hydroxy- furazan-3-carboxamidine
3-[4-(Aminomethyl)-l,2J5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4-oxadiazol- 5(4H)-one (10 mg, 0.003 mmol) was dissolved in ACN (0.2 mL) and DCM (0.2 mL). Benzenesulfonyl chloride (11 mg, 0.064 mmol) DIPEA (12 mg, 0.096 mmol) and DMAP (0.4 mg, 0.003 mmol) were dissolved in DMF (1 mL). The reaction was stirred at rt for 6 hrs. The reaction was then diluted with MeOH and purified by preparative LCMS. The intermediate was stripped to dryness, redissolved in EtOH (1 mL) and 1 M of sodium hydroxide in water (0.06 mL) was added. The reaction was stirred at rt for 1 hr, quenched with acetic acid, diluted with MeOH and the crude residue was purified by preparative LCMS to afford the desired product (2.4 mg). MF = Ci6H13ClFN5O4S; LCMS calculated for C6H14ClFN5O4S (M+H)+: m/z = 426.0.
Example 36: Benzyl ({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5- oxadiazol-3-yl}methyl)carbamate
S-^-CAminomethylJ-l^.S-oxadiazol-S-y^^-CS-chloro^-fluoropheny^-l^^-oxadiazol- 5(4H)-one (10.0 mg, 0.032 mmol) was dissolved in ACN (0.2 mL) and DCM (0.3 mL). Benzyl chloroformate (4.6 μL, 0.03 mmol) and DIPEA (5.6 μL, 0.032 mmol) was added and stirred overnight at rt. The reaction was concentrated, redissolved in MeOH, then purified on the preparative HPLC to give the desired intermediate. The intermediate was dissolved in EtOH (1.0 mL) and 1.0 M of sodium hydroxide in water (0.1 mL) and stirred for 1 hr. The reaction was quenched with acetic acid, MeOH (ImL) was added and the solution purified by preparative HPLC to afford the desired product (2.5 mg). MF = C18H15ClFN5O4; LCMS calculated for Ci8Hi6ClFN5O4 (M+H)+: m/z = 419.9.
Example 37: ^-(S-CyanophenyO-iV'-hydroxy^-methyl-l^jS-oxadiazole-S-carboxiinidamide
Step A: N-(3-Cyanophenyl)-4-methyl-l,2, 5-oxadiazole-3-carboxamide
4-Methyl-l,2,5-oxadiazole-3-carboxylic acid (200 mg, 1.6 mmol) and bromotris- (pyrrolydino)phophonium hexafluorophosphate was dissolved in a 1/1 mixture of DMF/DCM . To the mixture was added DMAP (120 mg, 0.95 mmol) and 3-amino-benzonitrile (184 mg, 1.6 mol) followed by ΛζN-diisopropylethylamine. The reaction mixture was stirred at rt overnight. The volatiles were removed in vacuo and the residue dissolved with chloroform and loaded onto a 40 g Silica ISCO cartridge eluting with 25%- 50% EtOAc/ Hexane to afford a white powder (25 mg). MF = CnH8N4O2; LCMS calculated for C] , H9N4O2(TvB-H)+: m/z = 229.1.
Step B: N-(3-Cyanophenyl)-N'-hydroxy-4-methyl-l ,2,5-oxadiazole-3-carboximidamide
N-(3-Cyanophenyl)-4-methyl-l,2,5-oxadiazole-3-carboxamide (25 mg, 0.11 mmol) was suspended in benzene (2 mL) under an atmosphere of nitrogen. Phosphorus pentachloride (25 mg, 0.12 mmol) was added and the solution was heated at reflux for 2.5 hrs. The reaction was then
evaporated to dryness. The crude was dissolved in EtOH (1.6 mL) and hydroxylamine (200 μL, 3 mmol, 50% solution in water) was added to the reaction. The crude was purified by preparative LCMS to afford the desired product (2.9 mg). MF = C11H9N5O2; LCMS calculated for C, 1Hi0N5O2 (M+H)+: m/z = 244.1.
Example 38 : iV-(3-Chloro-4-fluorophenyl)-Λr'-hydroxy-4-methyl-l ,2,3-thiadiazole-5-carbox- imidamide
Step A: 4-Methyl-[l,2,3]thiadiazole-5-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide
4-Methyl-l,2,3-thiadiazole-5-carboxylic acid (39.6 mg, 0.275 mmol) was suspended in DCM (2.0 mL). Bromotris(ρyrrolydino)phophonium hexafluorophosphate (128 mg, 0.27 mmol) and DIPEA (96 μL, 0.55 mmol) were added and premixed for 5 minutes. 3-Chloro-4-fluoroaniline (40 mg, 0.27 mmol) was added. The solution was stirred for 3 hrs, then purified by silica gel chromatography, (Hex/EA) - eluting at ~60% EA in hexane to afford the desired product (44 mg). MF = C10H7ClFN3OS; LCMS calculated for C10H8ClFN3OS (M+H)+: m/z = 272.0.
Step B: N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-methyl-l,2, 3-thiadiazole-5-carboximidamide
4-Methyl-[l,2,3]thiadiazole-5-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide (44 mg, 0.164 mmol) was dissolved in toluene (1 mL). Phosphorus pentachloride (41 mg, 0.20 mmol) was added and the vial was sealed and heated in an oil bath at 120 0C for 2 hrs. The solvent was removed in vacuo and the crude material was redissolved in EtOH (1.0 mL). 15.1 M of hydroxylamine in water (108 μL) was added and the solution was mixed for 0.5 hr. The compound was purified by preparative LCMS to afford the desired product (18 mg). MF = CioH8ClFN4OS; LCMS calculated for C10H9ClFN4OS (M+H)+: m/z = 287.0.
Examples 39 and 40: 4-[(5-Amino-lH-tetrazoH-yl)methyl]-iV-(3-chIoro-4-fluorophenyl)-iV- hydroxy-l,2,5-oxadiazole-3-carboximidamide (39), and 4-[(5-Amino-2H-tetrazol-2-yl)methyl]- -/V-(3-chloro-4-fluorophenyl)-Λ^-hydroxy-l,2,5-oxadiazole-3-carboximidamide (40)
4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylmethyl methanesulfonate (45 mg, 0.012 mmol) was dissolved in anhydrous ACN (100 μL) followed by addition of DIPEA (100 μL, 0.6 mmol) and lH-tetrazol-5-amine (15 mg, 0.017 mmol). The reaction was stirred and heated at 40 0C for 4 hr. The reaction was diluted with MeOH and purified by preparative LCMS to yield hydroxyamidine protected form of isomers A and B. The separated isomers were each stripped to dryness and redissolved in EtOH (500 μL) and 2 M sodium hydroxide in water (0.1 mL). The reactions were stirred at rt for 2 hrs. The reactions were quenched with acetic acid, diluted with MeOH and each purified by preparative LCMS to afford the desired products A and B as pure white powders (A, 18 mg, 44%; MF = CnH9ClFN9O2; LCMS calculated for CnH9ClFN9O2(M+H)+: m/z = 354.2; 1H NMR (400 MHz, DMSO-^6) δ: 1 1.70 (s, IH), 8.98 (s, IH), 7.22 (dd,lH), 7.04 (dd,- IH), 6.89 (bs, 2H), 6.82 (dd, IH), 5.71 (s, 2H); B, 25 mg, 61%, MF = CnH9ClFN9O2; LCMS calculated for C11H9ClFN9O2(M+!!)*:!!!^ = 354.2; 1H NMR (500 MHz, DMSO-^6) δ: 11.61 (s, IH), 8.98 (s, IH), 7.21 (dd,IH), 6.98 (dd, IH), 6.65 (dd, IH), 6.1 (bs, 2H), 6.07 (s, 2H)).
Example 41 : Λr-(3-Chloro-4-fluorophenyl)-Λ'r'-hydroxy-4-[(l H-tetrazoI-5-yIaππno)methyI]-l,2,5- oxadiazole-3-carboximidamide
Step A: Η-(3-Chloro-4-fluorophenyl)-4-[(lH-tetrazol-5-ylamino)methyl]-l,2,5-oxadiazole-3- carboxamide
To a solution of γV-(3-chloro-4-fluorophenyl)-4-formyl-l,2,5-oxadiazole-3-carboxamide (4.5
g, 17 mmol) in THF (75 mL) was added 5-aminotetrazole (4.26 g, 50.1 mmol), sodium sulfate (1.0 g, 8.0 mmol) and acetic acid (50 μL, 0.80 mmol). The resulting mixture was stirred at 40 0C for 36 h, and then an additional 20 mL THF was added followed by sodium tetrahydroborate (947 mg, 25 mmol). After stirring for 3 h, lithium tetrahydroborate (545 mg, 25.0 mol) was added to the reaction solution and stirred overnight. The reaction solution was diluted with 1 N NaOH solution. The aqueous layer was separated and acidified with 6 N HCl to pH 1. A white solid precipitated out of solution and was filtered to afford the desired product (4.82 g, 85%). LCMS for C11H9ClFN8O2(MH-H)+: m/z = 339.0.
Step B; N-β-Chloro-^fluorophenyfy-^lfl-ft-βrimethylsilytyethoxyJmethyl-lH-tetrazol-S-yQamino]- methyl-l,2,5-oxadiazole-3-carboxamide, and N-(3-Chloro-4-fluorophenyl)-4-[(2-[2-(trimethyl- silyl)ethoxy]methyl-2H-tetrazol-5-yl)amino]methyl-l,2,5-oxadiazole-3-carboxamide
To a solution of N-(3-chloro-4-fluoroρhenyl)-4-t(lH-tetrazol-5-ylamino)methyl]-l,2,5-oxa- diazole-3-carboxamide (130 mg, 0.38 mmol) in DCM (4.0 mL) was added TEA (134 μL, 0.96 mmol) and [/3-(trimethylsilyl)ethoxy]methyl chloride (143 μL, 0.806 mmol). The resulting mixture was stirred for 1 h. The reaction was concentrated and then purified by silica chromatography (20% ethyl acetate/hexanes) to afford the desired products as colorless oils (100 mg, 55%) and (70 mg, 39%). LCMS for C17H23ClFN8O3Si(M+H)+: m/z = 469.1.
Step C: N-β-chloro^-fluorophenylJ-N'-hydroxy-^ttl-ft-ftrimethylsilytyethoxyJmethyl-lH-tetrazol- 5-yl)amino]methyl-l,2,5-oxadiazole-3-carboximidamide
N-(3-Chloro-4-fluorophenyl)-4-[(l-[2-(trimethylsilyl)ethoxy]methyl-lH-tetrazol-5-yl)amino]- methyl-l,2,5-oxadiazole-3-carboxamide (96 mg, 0.20 mmol) was suspended in benzene (1.0 mL) and pyridine (0.5 mL) under an atmosphere of nitrogen. Phosphorus pentachloride (46.9 mg, 0.225 mmol) was added and the solution was heated at reflux for 2 hrs. The reaction was then stripped to dryness in vacuo. The reaction was dissolved in EtOH (2.6 mL) and hydroxylamine (300 μL, 5 mmol, 50% solution in water) was added to the reaction. After stirring for 1 h, the reaction solution was diluted with MeOH and purified by preparative LCMS to afford the desired product as a white solid (32 mg, 32%). LCMS C17H24ClFN9O3Si(M+H)+: m/z = 484.144.
Step D: N-fi-chloro^-fluorophenylJ-N'-hydroxy^-ftlH-tetrazol-S-ylaminoJmethylJ-l^.S-oxadiazole- 3-carboximidamide
To a solution of N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(l-[2-(trimethylsilyl)ethoxy]- methyl-lH-tetrazol-5-yl)-amino]-methyl-l,2,5-oxadiazole-3-carboximidamide (10.2 mg, 0.021 mmol) in DCM (0.5 mL) was added TFA (0.5 mL). The reaction solution was stirred at rt for 2 hrs. The reaction solution was concentrated in vacuo, and purified with LCMS to afford the desired product as a white powder (5.2 mg, 70%). LCMS for CπH10ClFΝ9O2(M+H)+: m/z = 354.1.
Further example compounds of the invention are provided in Table 2.
Table 2
Example 139: Ethyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-l,2,5- oxadiazol-3-yl)propanoate
A solution of N-^-chloro^-fluorophenyl^-φydroxymethyO-l^S-oxadiazole-θ-carbox- amide (8.50 g, 31.3 mmol) and Dess-Martin periodinane (14.6 g, 34.4 mmol) in DCM (400 mL) was stirred at 25 °C for 3 h. The reaction was diluted with saturated sodium bicarbonate solution and extracted with ethyl acetate three times, dried with sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by flash column chromatography to yield the desired product (7.50 g, 89%). LCMS for C1OH6ClFN3O3(TVB-H)+: m/z = 270.0.
Step 2: Ethyl (2E)-3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-I,2,5-oxadiazol-3-yl)acrylate
To a solution of (carbethoxymethyl)triphenylphosphonium bromide (3.14 g, 7.32 mmol) in toluene (37 mL) was added sodium tertf-butoxide (723 mg, 7.52 mmol) at rt under a nitrogen atmosphere. After stirring for 30 min, a solution of N-(3-chloro-4-fluorophenyl)-4-formyl-l,2,5- oxadiazole-3-carboxamide (811 mg, 3.01 mmol) in THF (10 mL) was cannulated into reaction flask. The resulting solution was heated at 80 0C for 3 h, then cooled to rt overnight. The reaction was quenched with a 1 Ν HCl solution, the aqueous solution was then extracted with ethyl acetate. The combined organic solutions were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified with flash chromatography (30% ethyl acetate/ hexane) to give the desired product as a white solid. 1H NMR (400 MHz, CD3OD): δ 7.92 (m, 2 H),
7.65 (m, 1 H), 7.26 (m, IH), 7.01 (m, 1 H)5 4.27 (m, 2 H), 1.33 (m, 3 H); LCMS for C14Hi2ClFN3O4(MH-H)+: m/z = 340.
Step 3: Ethyl 3-(4-[(3-chloro-4-βuorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)propanoate
To a solution of ethyl (2E)-3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3- yl)acrylate (0.86 g, 0.0025 mol) in ethyl acetate (10 mL, 0.1 mol) was added palladium (600 rag, 0.006 mol). The mixture was stirred at rt under an atmosphere of hydrogen for 2 h. The reaction solution was filtered through a pad of celite. The filtrate was concentrated and purified by flash chromatography (40% ethyl acetate/hexane) to give the desired product as a white solid (609 mg, 70%). LCMS for C,4H14C1FN3O4(M+H)+: m/z = 342.1.
Step 4: Ethyl 3-4-[(Z)-[(3-chloro-4~fluorophenyl)amino] (hydroxyimino)methyl] -1 ,2,5-oxadiazol~3- ylpropanoate Ethyl 3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)-propanoate (27 mg, 0.079 mmol) was suspended in benzene (1 mL) under a nitrogen atmosphere, and phosphorus pentachloride (18.0 mg, 0.086 mmol) was added and the solution was heated to reflux for 2.5 h. The solvent was removed in vacuo. The residue was dissolved in EtOH (1.0 mL) and hydroxylamine (100 μL, 2 mmol) (50% solution in water) was added to the reaction. After stirring Ih5 the solution was diluted with MeOH and purified with preparative LCMS to give the desired product (8.5 mg, 30%). 1H NMR (400 MHz, CD3OD): δ 7.03 (t, J = 8.9 Hz, 1 H), 6.95 (dd, J = 6.4, 2.7 Hz, 1 H), 6.71 (m, 1 H), 4.12 (q, /= 7.2 Hz, 2 H), 3.11 (t, J= 7.2 Hz, 2 H), 2.80 (t, /= 7.2 Hz, 2 H), 1.23 (t, J= 7.2 Hz, 3 H)LLCMS for CUH15C1FN4O4(M+H)+: m/z = 357.1.
Example 140: Λ'-(3-ChIoro-4-fluorophenyl)-Λ'r-hydroxy-4-(3-morpholin-4-ylpropyl)-l^,5- oxadiazoIe-3-carboxiniidamide
To a solution of ethyl 3-(4-[(3-chloro^-fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3- yl)propanoate (97.5 mg, 0.285 mmol) in TKDF (1.2 mL) was added lithium tetrahydroborate (14.3 mg, 0.656 mmol) at 0 0C under an atmosphere of nitrogen. The reaction solution was allowed to warm to rt for 2 h. The reaction was quenched with MeOH and concentrated. The residue was purified by flash chromatography (60% ethyl acetate/hexane) to give product. LCMS for Ci2Hi2ClFN3O3(MH-H)+: m/z = 300.1.
Step 2: 3-(4-[(3-Chloro-4-fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)propyl methanesulfonate
N-(3-Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-l ,2,5-oxadiazole-3-carboxamide (60 mg, 0.20 mmol) was dissolved in anhydrous DCM (2 mL), followed by addition of TEA (57 μL, 0.41 mmol). The reaction was stirred and cooled to 0 0C, and then methanesulfonyl chloride (29 μL, 0.37 mmol) was added dropwise. The reaction was quenched with water and diluted with DCM. The organic solution was separated, dried over Na2SO4, filtered, concentrated and purified by silica gel chromatography (25%-70% EtOAc/hexane) to give the desired product (19 mg). LCMS for C13HI4CIFN3OSS(MH-H)+: m/z = 378.
Step 3: N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyt)-l,2,5-oxadia∑ole-3-carboxamide
3-(4-[(3-Chloro-4-fluorophenyl)amino]carbonyl-l32,5-oxadiazol-3-yl)propylmethanesulfonate (19 mg, 0.051 mmol) was dissolved in anhydrous ACN (100 μL,) followed by addition of DIPEA (44
μL, 0.26 mmol) and morpholine (6.7 μL, 76.8 μmol). The reaction was stirred and heated at 70 0C for 3 h. The reaction was concentrated and purified with silica gel chromatography (60-100% ethyl acetate/hex) to give the desired product (10 mg, 54%). LCMS for C16Hi9ClFN4O3(JVB-H)+: m/z = 369.1.
Step 4: N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(3-morpholin-4-ylpropyl)-l,2,5-oxadiazole-3- carboximidamide
N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyl)-l,2,5-oxadiazole-3-carboxamide (10.0 mg, 27.1 μmol) was suspended in benzene (0.4 mL) under a nitrogen atmosphere and phosphorus pentachloride (6.2 mg, 29.8 μmol) was added and the solution was heated at reflux for 2.5 h. The reaction was then stripped to dryness in vacuo. The reaction was dissolved in EtOH (0.3 mL) and hydroxylamine (40 μL, 0.7 mmol) (50% solution in water) was added to the reaction. After stirring for 1 h, the reaction solution was diluted with MeOH and purified with preparative LCMS to give product (5.2 mg, 50%). LCMS for C16H20ClFN5O3(M-I-H)+: m/z = 384.1.
Example 141 : 5-[(5-Amino-lH-tetrazol-l-yl)methyl]-iV-(3-chIoro-4-fluorophenyI)-iV'-hydroxy- l,2,3-thiadiazole-4-carboxiniidamide
Step A: Methyl 2-diazo-4-methoxy-3-oxobutanoate
Methyl 4-methoxy-3-oxobutanoate (4.28 g, 0.029 mol) was dissolved in ether (20 mL). The solution was cooled in an ice bath. To the solution was added p-toluenesulfonyl azide (5.78 g, 0.029 mol) followed by N-ethylethanamine (2.0 mL, 0.019 mol). The solution was stirred at 0 °C for 15 minutes, then at rt for 30 minutes. Upon evaporation, the tosyl amide bi-product solidified. This was filtered off and the filtrate was purified by flash chromatography to give the desired product (4.5 g, 89%) as a light oil. 1H ΝMR (400 MHz, CDCl3): δ 4.55 (s, 2H), 3.83 (s, 3H), 3.45 (s, 3H). MF = C6H8N2O4. LCMS calculated for C6H9N2O4 (M+H)+: m/z = 173.0.
Step B: Methyl 5-(τnethoxymethyl)-l,2,3-thiadiazole-4-carboxylate
Methyl 2-diazo-4-methoxy-3-oxobutanoate (4.5 g, 0.026 mol) was cooled in an ice bath and ammonium sulfide (8.0 g, 0.12 mol) (40 - 48%) was added drop-wise over 2 minutes. White precipitate formed. The slurry was stirred for 30 minutes, and then purified by flash chromatography to give the desired product (4.2 g, 85%) as a light oil, that crystallized readily upon standing. 1H NMR (400 MHz, CD3OD): δ 5.02 (s, 2H), 3.98 (s, 3H)3 3.57 (s, 3H). MF = C6H8N2O3S; LCMS calculated for C6H9N2O3S (M+H)+: m/z = 189.0.
Step C: Methyl 5-formyl-l,2,3-thiadiazole-4-carboxylate
Methyl 5-(methoxymethyl)-l,2,3-thiadiazole-4-carboxylate (4.18 g, 0.022 mol) was dissolved in carbon tetrachloride (60 mL). To the solution was added bromine (4.18 g, 0.026 mol) and the solution was refluxed upon irradiation with long wavelength UV light (100 watts) for 3 h. The volatiles were evaporated in vacuo and the crude material purified by flash chromatography to give the desired product (2.70 g, 71 %) as a viscous oil. 1H NMR (400 MHz, CDCl3): β 10.67 (s, IH), 4.15 (s, 3H). MF = C5H4N2O3S; LCMS calculated for C5H5N2O3S (M+H)+: m/z = 173.0.
Step D: Methyl 5-(hydroxymethyl)-l,2,3-thiadiazole-4-carboxylate
Methyl 5-formyl-l,2,3-thiadiazole-4-carboxylate (460.0 mg, 0.0026 mol) was dissolved in ethanol (40 mL) and sodium tetrahydroborate (50 mg, 0.0013 mol) was added at 0 0C. The orange solution was allowed to warm to room temp and was stirred for 30 minutes. The reaction was quenched with acetic acid and then purified by preparative LCMS to give the desired product (340 mg, 73 %). MF = C5H6N2O3S; LCMS calculated for C5H7N2O3S (M+H)+: m/z = 175.1.
Step E: Methyl 5-[(triisopropylsilyl)oxy]methyl-l,2,3-thiadiazole-4-carboxylate
To a solution of methyl 5-(hydroxymethyl)-l,2,3-thiadiazole-4-carboxylate (1.22 g, 0.007 mol) in DCM (20 mL) at 0 0C was added 2,6-lutidine (2.0 mL, 0.018 mol) followed by triisopropylsilyl triflate (2.4 mL, 0.0091 mol). The solution was stirred at 0 0C for 5 minutes. The reaction was then concentrated and purified by flash chromatography to give the desired product (2.0 g, 87%). 1H NMR (400 MHz, CDCl3): δ; MF = C14H26N2O3SSi; LCMS calculated for C14H27N2O3SSi (M+H)+: m/z = 331.1.
Step F: N- (3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-l, 2, S-thiadiazole-4- carboxamide
To a cooled solution (0 0C) of methyl 5-[(triisopropylsilyl)oxy]methyl-l,2,3-thiadiazole-4- carboxylate (2.2 g, 0.0066 mol) and 3-chloro-4-fluoroaniline (1.5 g, 0.010 mol) in DCM (20 mL, 0.4 mol) was added 2.0 M of trimethylaluminum in hexane (12 mL) under nitrogen and stirred for 15 minutes. The volatiles were removed in vacuo and the crude was purified by flash chromatography to give the desired product (2.3 g, 78%). MF = Ci9H27ClFN3O2SSi; LCMS calculated for Ci9H28ClFN3O2SSi (M+H)+: m/z = 444.1.
Step G: N-(3-chloro-4-βuorophenyl)-5-[(triisopropyϊsilyl)oxy]methyl-l,2,3-thiadiazole-4- ca rboth ioam ide
A solution of ^/-(3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-l ,2,3-thiadiazole- 4-carboxamide (2.3 g, 0.0052 mol) in anhydrous THF (10 mL) was distributed equally into 2 microwave vials. 2,4-bis(4-methoxyphenyl)-2,4-dithioxo-l,3,2,4-dithiadiphosphetane (4.2 g, 0.010 mol) (Lawesson's reagent) was added to each vial. The reactions were each heated at 160 °C in a microwave for 15 minutes. The solutions were combined, concentrated and purified by flash chromatography to give the desired product (1.80 g, 76%). MF = Ci9H27ClFN3OS2Si; LCMS calculated for C19H28ClFN3OS2Si (M+H)+: m/z = 460.1.
Step H: Methyl N-(3-chloro-4-fluorophenyl)-5-[(triisoρropylsilyl)oxy]methyl-l, 2, 3-thiadiazole-4- carbimidothioate
To a solution of iV-(3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-l,2,3-thia- diazole-4-carbothioamide (0.18 g, 0.00039 mol) in anhydrous DCM (3 mL, 0.04 mol) under N2 was added DIPEA (82 μL, 0.00047 mol) followed by methyl trifiuoromethanesulfonate (47 μL, 0.00043 mol) . The reaction was stirred for 5 minutes and then concentrated in vacuo. The crude material was used in the next step. The product amount was estimated (185 mg, 100%). MF = C20H29ClFN3OS2Si; LCMS calculated for C20H30ClFN3OS2Si (M+H)+: m/z = 474.1.
Step I: N-(3-ckloro-4-fluorophenyl)-N'-hydroxy-5-[(triisopropylsilyl)oxy] 'methyl-1 ,2,3-thiadiazole-4- carboximidamide
Methyl N^-chloro^-fluorophenyO-S-tζtriisopropylsily^oxyjmethyl-l^jS-thiadiazole^- carbimidothioate (90 mg, 0.0002 mol) was dissolved in EtOH (2 mL) followed by addition of hydroxylamine (116 μL, 0.00190 mol) (50% by wt, 99.9% in water solution) . The reaction was stirred at 60 0C for 4 h and overnight at room temperature. The reaction was evaporated and purified by flash chromatography to give the desired product (85 mg, 98%). 1H NMR (400 MHz, CDCl3): δ 7.32 (s, IH), 7.25 (s, IH), 6.90 (m, 2H), 6.62 (m, 2H), 5.17 (s, 2H)5 1.05 (m, 21H). MF =
C19H28ClFN4O2SSi; LCMS calculated for Ci9H29ClFN4O2SSi (M+H)+: m/z = 459.2.
Step J: 4-(3-Chloro-4-fluorophenyl)-3-(5-[(triisopropylsilyl)oxy]methyl-l,2,3-thiadiazol-4-yl)-l,2,4- oxadiazol-5(4H)-one
Into a roimd bottom flask was added N-(3-chloro-4-fluorophenyl)-N'-hydroxy-5-[(triiso- propylsilyl)oxy]methyl-l,2,3-thiadiazole-4-carboximidamide (85.0 mg, 0.185 mmol), anhydrous THF (1.1 mL), and N,N-carbonyldiimidazole (55 mg, 0.34 mmol). The reaction was heated to 70 0C for 2.5 h. The reaction was concentrated in vacuo and the crude purified by flash chromatography to give the desired product (89 mg, 99%). MF = C20H26ClFN4O3SSi; LCMS calculated for C20H27ClFN4O3SSi (M+H)+: m/z = 485.2.
Step K: 4-(3-Chloro-4-fluorophenyl)-3-[5-(hydroxymethyl)-l ,2,3-thiadiazoϊ-4-yl] -1 ,2,4-oxadiazol- 5(4H)-one
into a round bottom flask was added 4-(3-chloro-4-fiuorophenyl)-3-(5-[(triisopropylsilyl)- oxy]methyI-l,2,3-thiadiazol-4-yl)-l ,2,4-oxadiazol-5(4H)-one (89 mg, 0.18 mmol), anhydrous MeOH (1.5 mL) , and hydrogen chloride in 1,4-dioxane (1.5 mL, 4.0 M) . The reaction was heated to 70 0C for 2.5 h. The reaction was concentrated in vacuo and the crude purified by flash chromatography to give the desired product (52 mg, 86%). MF = Ci1H6ClFN4O3S; LCMS calculated for CnH7ClFN4O3S (M+H)+: m/z = 329.0.
Step L: 4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,3-thiadiazol-5- ylmeihyl methanesulfonate
4-(3-Chloro-4-fluorophenyl)-3-[5-(hydroxymethyl)-l,2,3-thiadiazol-4-yl]-l,2,4-oxadiazol- 5(4H)-one was dissolved in anhydrous DCM (2 mL) followed by addition of TEA (26 μL, 0.19 mmol). The reaction was stirred at 0 0C for 15 minutes. Methanesulfonyl chloride (13 μL, 0.17 mmol) was added drop-wise and stirred for 15 minutes at 0 0C. The reaction was concentrated in vacuo and the crude purified by flash chromatography to give the desired product (42 mg, 65%). 1H NMR (400 MHz, CDCl3): δ 7.50 (m, IH), 7.25 (m, 2H)1 5.83 (s, 2H), 3.20 (s, 3H). MF = C12H8ClFN4O5S2; LCMS calculated for C12H9ClFN4O5S2 (M+H)+: m/z = 406.9.
Step M: 3-5-[(5-Amino-lH-tetrazol-l-yl)methyl]-l,2, 3-thiadiazol-4-yl-4-(3-chloro~4-fluorophenyl)- 1,2, 4-oxadiazol-5(4H)-one trifluoroacetate
4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,3-thiadiazol-5- ylmethyl methanesulfonate (42 mg, 0.10 mmol) was dissolved in anhydrous ACN (100 μL) followed by addition of DIPEA (90 μL, 0.52 mmol) and lH-tetrazol-5-amine (13 mg, 0.15 mmol). The reaction was stirred and heated at 40 0C for 2 hrs. The reaction was diluted with MeOH and purified by preparative HPLC to yield 2 isomers, the desired product is peak 1 (15 mg, 37%). 1H NMR (400
MHz, ^J-DMSO): δ 8.0 (m, IH), 7.67 (m, 2H), 6.98 (s, 2H), 5.80 (s, 2H). MF = Ci2H7ClFN9O2S;
LCMS calculated for C12H8ClFN9O2S (M+H)+: m/z = 396.0.
Step N: 5-[(5-Amino-lH-tetrazol-l-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2,3- th iadiazole-4-carboximidamide trifluoroacetate
To a solution of 3-5-[(5-ammo-lH-tetrazol-l-yl)methyl]-l,2,3-thiadiazol-4-yl-4-(3-chloro-4- fluorophenyl)-l,2,4-oxadiazol-5(4H)-one in EtOH (400 μL, 0.006 mol) was added a solution of sodium hydroxide in water (76 μL, 2.0 M). After stirring for 2 h, the reaction was quenched with acetic acid and diluted with MeOH and purified by preparative LCMS to give the desired product as white powder, (9.9 mg, 71%). 1H NMR (400 MHz, ^6-DMSO): S 11.29 (s, lH), 9.18 (s, IH), 7.09 (m, 3H), 6.86 (m, IH), 6.60 (m, IH), 5.92 (s, IH). MF = Ci1H9ClFN9OS; LCMS calculated for C11H10ClFN9OS (M+H)+: m/z = 370.0.
Example 142: iV-(3-Chloro-4-fluorophenyl)-iV'-hydroxy-5-(hydroxymethyl)-l,2,3-thiadiazole-4- carboximidamide
^(S-Chloro^-fluorophenyO-N'-hydroxy-S-t^riisopropylsilylJoxyJmethyl-l^jS-thiadiazole- 4-carboximidamide (10.0 mg, 0.0218 mmol) was stirred in MeOH (500 μL) and hydrogen chloride in 1,4-dioxane (500 μL, 4.0 M) was added. The mixture was stirred for 30 min at rt. Purification by preparative LCMS gave the desired product (2.8 mg, 42%). 1H ΝMR (400 MHz, J6-DMSO): δ 11.00 (s, IH), 8.99 (s, IH), 7.09 (m, IH), 6.82 (m, IH), 6.53 (m, IH), 5.92 (s, IH), 4.95 (s, IH). MF = C10H8ClFN4O2S; LCMS calculated for Ci0H9ClFN4O2S (M+H)+: m/z = 303.0.
Example 143: 4-[(Aminosulfonyl)amino]methyl-Λ''-(3-chloro-4-fluorophenyl)-Λr-hydroxy-l,2,5- oxadiazole-3-carboximidamide trifluoroacetate
S-^^Aminomethy^-ljZ.S-oxadiazol-S-ylj^-CS-chloro-^-fluoropheny^-l^^-oxadiazol- 5(4H)-one trifluoroacetate (30 mg, 0.07 mmol) and sulfamide (20 mg, 0.2 mmol) was dissolved in pyridine (1.0 mL) and heated at 120 °C for 3 min in a microwave. A solution of sodium hydroxide in water (0.5 mL, 1 N) was added and the solution was stirred for 30 minutes. Acidification with acetic acid and purification by preparative LCMS gave the desired product (17 mg, 50%). MF = C10H,oClFN604S; LCMS calculated for C10H1IClFN6O4S (M+H)+: m/z = 364.9. 1H NMR (400 MHz, CD3OD): δ 7.02 (m, 2H), 6.76 (m, IH), 4.50 (s, 2H).
Example 144: Λ^-(3-Chloro-4-fluorophenyI)-4-([(E/Z)-(cyanoimino)(methylainino)methyl]- aniinomethyl)-7V'-hydroxy-l,2,5-oxadiazole-3-carboximidamide
3-[4-(Aminomethyl)-l ,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l ,2,4-oxadiazol- 5(4H)-one trifluoroacetate (50 mg, 0.1 mmol) was dissolved in THF (3.0 mL). Diphenyl cyanocarbonimidate (33.6 mg, 0.141 mmol) and TEA (49 μL, 0.35 mmol) were added. The reaction was stirred at room temperature for 2 h. A solution of methylamine in THF (0.6 mL, 2.0 M) was then added and the mixture stirred for 2 h at rt. 1.0 M of sodium hydroxide in water (1.7 mL) was added and the mixture stirred for 1 h at rt. Acidification with acetic acid and purification by preparative LCMS at pH 10 gave the desired product as a white powder, (27 mg, 63%). MF = C13H12ClFN8O2; LCMS calculated for C13Hi3ClFN8O2 (M+H)+: m/z = 367.0. 1H NMR (400 MHz, CD3OD): δ 7.01 (m, 2H), 6.75 (m, IH), 4.66 (s, 2H), 2.83 (s, 3H).
Example 145: iV-(3-Chloro-4-fluorophenyl)-iV'-hy droxy-4-( [(methyla mino)sulf onyl] amino- methyl)-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
Sulfamide (32 mg, 0.33 mmol) and methylamine (15 μL, 0.33 mmol) were dissolved in pyridine (1.0 mL). The solution was heated to 120 0C for 5 minutes in a microwave. 3-[4-
(aminomethyl)- 1,2,5 -oxadiazol-3 -yl] -4-(3 -chloro-4-fluorophenyl)-l ,2,4-oxadiazol-5(4H)-one trifluoroacetate (32 mg, 0.075 mmol) was than added and the solution was heated to 120 0C for 3 minutes. A solution of sodium hydroxide in water (1 mL, 1 N) was added and the solution stirred at room temperature for 30 minutes. Acidification with acetic acid and purification by preparative LCMS gave the desired product (2.3 mg, 7%). MF = CI 1HI2CIFN6O4S; LCMS calculated for C11H13ClFN6O4S (M+H)+: m/z = 378.9.
Example 146: 4-[(Aminocarbonyl)amino]methyI-N-(3-chloro-4-fluorophenyI)-iV'-hydroxy-l,2,5- oxadiazoIe-3-carboxiniidamide trifluoroacetate
4-([(tert-Butylamino)carbonyl]aminomethyl)-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2,5- oxadiazole-3-carboximidamide trifluoroacetate (10 mg, 0.02 mmol) was stirred in TFA (2.0 mL) for 2 hrs. The reaction was warmed gently with heat gun. Evaporation and purification by preparative LCMS gave the desired product (8 mg, 70%). MF = C11Hi0ClFN6O3; LCMS calculated for C11H11ClFN6O3 (MH-H)+: m/z = 329.0. 1H NMR (400 MHz, CD3OD): δ 7.01 (m, 2H), 6.85 (m, IH), 4.59 (s, 2H).
Example 147: 4-([(Tert-butyIamino)carbonyl] aminomethyl)-iV-(3-chloro-4-fluorophenyl)-iV'- hydroxy-l,2,5-oxadiazoIe-3-carboximidamide trifluoroacetate
3-[4-(Aminomethyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4-oxadiazol-
5(4H)-one trifluoroacetate (15 mg, 0.035 mmol) and TEA (15 μL, 0.10 mmol) were dissolved in
DCM (0.5 mL) and then 2-isocyanato-2-methylpropane (24 μL, 0.21 mmol) was added. The reaction was stirred for 16 h at room temperature. A solution of sodium hydroxide in water (0.50 mL, 1.0 N) was added and the mixture stirred at room temperature for 2 h. Acidification with acetic acid
and purification by preparative LCMS gave the desired product (12 mg, 68%). MF = Ci5HiSClFNeO3,- LCMS calculated for Ci5H]9ClFN6O3 (M+H)+: m/z = 385.0.
Example 148: ^-(S-Chloro^-fluorophenyl^Λ^'-hydroxy^-CfCS-morpholin^-ylpropy^sulfonyl]- aminomethyl)-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
Step A: 3-Chloro-N-({4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl) '-1,2,5- oxadiaz ol-3-yl}methyl)propane-l -sulfonamide
To a solution of 3-[4-(aminomethyl)-l ,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4- oxadiazol-5(4H)-one (100 mg, 0.32 mol) in DCM (2 mL) under an atmosphere of nitrogen was added DIPEA (168 μL, 0.96 mmol), and 3-chloroproρane-l-sulfonyl chloride (117 μL, 0.66 mmol). The reaction was stirred at 25 0C for 5 min. The reaction was quenched with MeOH and purified by preparative HPLC to yield the desired product (38 mg, 20%). 1H NMR (400 MHz, CDCl3): β 7.5 (m, IH), 7.3 (m, 2H), 4.8 (d, 2H), 3.7 (t, 2H), 3.25 (t, 2H), 2.3 (m, 2H). MF = C14H12Cl2FN5OsS; LCMS calculated for C14Hi3Cl2FN5O5S (M+H)+: m/z = 452.2
Step B: N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-([(3-morpholin-4-ylpropyl)sulfonyl]aminomethyl)- 1,2, 5-oxadiazole-3-carboximidamide trifluoroacetate A solution of 3-chloro-N-(4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-
3-yl]-l,2,5-oxadiazol-3-ylmethyl)propane-l -sulfonamide (8.20 mg, 0.018 mmol) and morpholine (500 μL, 5.7 mmol) was stirred at 25 0C overnight. The reaction mixture was purified on preparative LCMS using pH 2 buffer. The solvents were evaporated in vacuo and the product was treated with a solution of sodium hydroxide in water (500 μL, 1 N) and ethanol (500 μL) at 25 0C for 20 min. The reaction was neutralized with acetic acid and purified on preparative LCMS using pH 2 buffer to give
the desired product (2 mg, 23.1%). MF = C17H22ClFN6O5S; LCMS calculated for Ci7H23ClFN6O5S (M+H)+: m/z = 477.1
Example 149: iV-(3-Chloro-4-fluorophenyl)--V'-hydroxy-4-[(piperidin-4-ylsuIfonyl)ainino]- niethy]-l,2,5-oxadiazoIe-3-carboximidaniide trifluoroacetate
Step A: N-(4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-J,2,4-oxadiazol-3-ylJ-l,2,5-oxadiazol- 3-ylme thyl)piperidine-4-sulfonamide trifluoroacetate
A solution of 3-[4-(aminomethyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l ,2,4- oxadiazol-5(4h)-one (100 mg, 0.32 mmol), DIPEA (170 μL, 0.96 mmol), benzyl 4-(chloro- sulfonyl)piperidine-l-carboxylate (310 mg, 0.96 mmol) in DCM (2 mL) was stirred at 25 0C for 15 min. The crude was quenched with MeOH and purified by preparative LCMS using pH 2 buffer. The pure Cbz protected product was treated with a solution of hydrogen bromide in acetic acid (2.0 mL, 4 N) for 20 minutes. The reaction was quenched with MeOH and purified on LCMS using pH 2 buffer to yield the desired product (38 mg, 20%). MF = C16H16ClFN6O5S; LCMS calculated for C16H17ClFN6O5S (M+H)+: m/z = 459.0.
Step B: N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-[(piperidin-4-ylsulfonyl)amino]methyl-l ,2,5- oxadiazole-3-carboximidamide trifluoroacetate:
To a solution of N-(4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]- l,2,5-oxadiazol-3-ylmethyl)piperidine-4-sulfonamide (7 mg, 0.015 mmol) in EtOH (500 μL), a solution of sodium hydroxide in water (500 μL, 1 N) was added and was stirred at 25 0C for 20 min.
The reaction was neutralized with acetic acid and diluted with MeOH and purified on preparative LCMS using pH 2 buffer to yield the desired product (2.8 mg, 42%). MF = C15H19ClFN6O4S; LCMS calculated for C]5H19ClFN6O4S (M+H)+: m/z = 433.1.
Example 150: 4-[(Il-(AminosuIfonyI)piperidin-4-yl]sulfonylamino)methyI]-iV-(3-chloro-4-
fluorophenyl)-iV-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
A solution of N-(4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]- l,2s5-oxadiazol-3-ylmethyl)piperidine-4-sulfonamide (15 mg, 0.033 mmol) and sυlfamide (9.4 mg, 0.098 mmol) in pyridine (1 mL) was heated at 130 0C for 3 min in a microwave. A solution of sodium hydroxide in water (0.5 mL, 1 Ν) was added and stirred for 20 minutes. The reaction mixture was acidified with acetic acid and purified by preparative LCMS to yield the desired product (8.2 mg, 49%). MF = Ci5H19ClFN7O6S2; LCMS calculated for C15H20ClFN7O6S2 (M+H)+: m/z= 512.1
Example 151: 4-([(l-Acetylpiperidin-4-yl)suIfonyl]aminomethyl)-Λ'-(3-chloro-4-fluorophenyI)- JV'-hydroxy-l,2,5-oxadiazoIe-3-carboximidainide trifluoroacetate
A solution of N-(4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]- 1 ,2,5-oxadiazol-3-ylmethyl)piperidine-4-sulfonamide (23 mg, 0.050 mmol) and acetic anhydride (500 μL, 5.30 mmol) in pyridine (1 mL) was stirred at 25 0C for 30 min. A solution of sodium hydroxide in water (0.5 mL, 1 N) was added and stirred for another 30 min. Acidification with acetic acid and purification by preparative LCMS gave the desired product (23 mg, 96%). MF = Ci7H2OClFN6O5S; LCMS calculated for C17H21ClFN6O5S (M+H)+: m/z = 475.1
Example 152: A^3-ChIoro-4-fluorophenyl)rNr-hydroxy-4-[5-(morpholin-4-ylmethyI)-2H- tetrazol-2-yl]methyI-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
Example 153: 7V-(3-ChIoro-4-fluorophenyl)--V'-hydroxy-4-[5-(morpholin-4-ylmethyl)-lH-
tetrazol-l-yl]methyI-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
Step A: 4-(lH-tetra∑ol-5-ylmethyl)morpholine:
A solution of 5-(chloromethyl)-lH-tetrazole (260 mg, 2.2 mmol) in morpholine (1.5 mL, 17.2 mmol) was stirred at 25 0C for 20 minutes. The crude reaction mixture was purified by preparative LCMS using pH 2 buffer to yield the desired product (300 mg, 82%). MF = C6HnN5O; LCMS calculated for C6H12N5O (M+H)+: m/z = 170.1.
Step B: N-(3-chloro-4-βuorophenyl)-N'-hydroxy-4-[5-(morpholin-4-ylmethyl)-2H-tetrazol-2-yl]- methyl- 1, 2, 5-oxadiazole-3-carboximidamide trifluoroacetate and
Η-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-[5-(morpholin-4-ylmethyl)-lH-tetrazol-l-yl]methyl'l,2,5- oxadiazole-3-carboximidamide trifluoroacetate
4-[4-(3 -ChI oro-4-fluorophenyI)-5 -oxo-4, 5 -dihydro- 1 ,2,4-oxadiazol-3 -yl] - 1 ,2,5 -oxadiazol-3 - ylmethyl methanesulfonate (81 mg, 0.21 mmol) was dissolved in anhydrous ACN (500 μL) followed by addition of DIPEA (0.18 mL, 1.0 mmol) and 4-(lH-tetrazol-5-ylmethyl)morpholine (110 mg, 0.62 mmol). The reaction mixture was stirred and heated at 45 0C for 1 hour. The reaction was then diluted with MeOH and purified by preparative LCMS to yield two isomers. The purified isomers were concentrated to dryness, redissolved in EtOH (1.0 mL) and a solution of sodium hydroxide in water (0.5 mL, 1 N) was added. The reactions were stirred for 20 minutes. Reactions were quenched with acetic acid, diluted with MeOH and purified by preparative LCMS to yield the two isomers (2.2 mg, 2.4%) and (3.2 mg, 3.5%).
Example 152: 1H NMR (400 MHz, DMSO-rftf): δ 11.5 (s, IH), 9.0 (s, IH), 7.2 (t, IH), 7.0 (d, IH), 6.75 (d, IH), 6.4 (s, 2H), 3.6 (bs, 8H). MF = C16HnClFN9O3,- LCMS calculated for C16H18ClFN9O3 (M+H)4": m/z = 438.1
Example 153: 1H NMR (400 MHz, DMSO-rf*): $ 1 1.5 (IH, s), 9.0 (IH, s), 7.2 (IH, t), 7.0 (lH,d), 6.8 (IH, d), 6.15 (2H, s), 3.6 (8H, bs). MF = Ci6H17ClFN9O3; LCMS calculated for C16H18ClFN9O3 (M+H)+: m/z = 438.1
Example 154: 4-[(5-Amino-l ,3,4-thiadiazol-2-yl)thio] methyl-iV-(3-chIoro-4-fluorophenyI)-Λ^'- hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylmethyl methanesulfonate (23 mg, 0.059 mmol) was dissolved in anhydrous ACN (1.0 mL) followed by addition of DIPEA (51 μL, 0.29 mmol) and 5-amino-l,3,4-thiadiazole-2-thiol (24 mg, 0.18 mmol). The reaction was stirred and heated at 45 0C for 16 h. The reaction mixture was diluted with MeOH and purified by preparative LCMS. The purified product was evaporated to dryness, redissolved in EtOH (0.5 mL) and a solution of sodium hydroxide in water (0.5 mL, 1 N) was added. The reaction was stirred for 20 minutes and quenched with acetic acid, diluted with MeOH and purified by preparative LCMS using pH 2 buffer to yield the desired product (7.1 mg, 23%). 1H NMR (400 MHz, DMSO-ak): δ 1 1.7 (s, IH)5 9.1 (s, IH), 7.2 (t, IH), 7.0 (IH, d), 6.75 (IH, m), 4.6 (s, 2H). MF = C12H9ClFN7O2S2; LCMS calculated for C12H10ClFN7O2S2 (M+H)+: m/z = 402.1
Example 155: 4-[(5-Amino-4H-l,2,4-triazol-3-yl)thio]methyl-Λr-(3-chIoro-4-fluorophenyI)-iV'- hydroxy-l,2,5-oxadiazoIe-3-carboximidamide trifluoroacetate
4~[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro- 1 ,2,4-oxadiazol-3-yl]-l ,2,5-oxadiazol-3- ylmethyl methanesulfonate (23 mg, 0.059 mmol) was dissolved in anhydrous ACN (1.0 mL) followed by addition of DIPEA (51 μL, 0.29 mmol) and 5-amino-4H-l,2,4-triazole-3-thiol (21 mg, 0.18 mmol). The reaction mixture was stirred and heated at 45 0C for 16 h. The reaction was diluted with MeOH and purified by preparative LCMS. The purified product was evaporated to dryness,
redissolved in EtOH(I niL) and a solution of sodium hydroxide in water (0.5 mL, 1 N) was added and stirred for 20 minutes. The reaction was quenched with acetic acid, diluted with MeOH and purified by preparative LCMS using pH 2 buffer to yield the desired product (15 mg, 52%). 1H NMR (400 MHz, rfβ-DMSO): β 1 1.7 (s, IH), 9.1 (s, IH), 7.2 (t, IH)1 7.0 (d, IH), 6.75 (m, IH), 4.6 (s, 2H). MF = C12H9ClFN8O2S; LCMS calculated for C12H10ClFN8O2S (M+H)+: m/z = 385.1.
Example 156: 4-[(5-Amino-4H-l,2,4-triazol-3-yl)sulfonyl]methyI-iV-(3-chloro-4-fluorophenyl)- Λ^-hydroxy-l^jS-oxadiazole-S-carboximidamide trifluoroacetate
A solution of 4-[(5-amino-4h-l,2,4-triazol-3-yl)thio]methyl-N-(3-chloro-4-fluorophenyl)-N'- hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate (11 mg, 0.023 mmol), m-chloroper- benzoic acid (10 mg, 0.046 mmol) and 1,4-dioxane (0.5 mL) was stirred at 25 0C for 1 hr. The reaction was diluted with MeOH and purified on preparative LCMS using pH 2 buffer to yield the desired product (5.8 mg, 48%). MF = C12H9ClFN8O4S; LCMS calculated for C12Hi0ClFN8O4S (M+H)+: m/z = 417.1
Example 157: iV-(3-Chloro-4-fluorophenyl)-4-[((E/Z)-(cyanoimino)[(4-methoxybenzyl)amino]- methylamino)methyl]-7V'-hydroxy-l,2,5-oxadiazole-3-carboximidamidc trifluoroacetate
Into the reaction was dissolved 3-[4-(aminomethy_)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4- fluoroρhenyl)-l,2,4-oxadiazol-5(4H)-one trifluoroacetate (30 mg, 0.07 mmol) in THF (0.74 mL). Diphenyl cyanocarbonimidate (20 mg, 0.08 mmol) and TEA (29 μL, 0.21 mmol) were added and the reaction was stirred at room temperature for 2 hr. A solution of sodium hydroxide in water (0.5 mL, 1 N) was added and the mixture was stirred at room temperature for 30 minutes. Acidification with
acetic acid and purification by preparative LCMS gave the desired product (40 mg, 97%). MF = C22H19ClF4N8Os; LCMS calculated for C22H20ClF4N8O5 (M+H)+: m/z = 473.1. 1H NMR (400 MHz5 CD3OD): δ 7.2 (m, 2H), 7.03 (m, IH), 6.95 (m, IH), 6.8 (m, 2H), 6.74 (m, IH)5 4.68 (s, 2H)5 4.38 (s, 2H)5 3.75 (s, 3H).
Example 158: 4-|({(E/Z)-[(Aminocarbonyl)iniiαo] [(4-methoxybenzyl)amino]ruethyl}amino)- methyl]-iV-(3-chloro-4-fluorophenyl)-iV'-hydroxy-l,2,5-oxadiazole-3-carboxiinidamide trifluoroacetate
N-(3-Chloro-4-fluorophenyl)-4-[((E/Z)-(cyanoimino)[(4-methoxybenzyl)amino]methyl- amino)methyl]-N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate (20 mg, 0.04 mmol) was dissolved in TFA (1.0 mL) and stirred for 1 hour at rt. Purification by preparative LCMS gave the' desired product (12 mg, 50%).
MF = C22H2IClF4N8O6; LCMS calculated for C22H22ClF4N8O6 (M+H)+: m/z = 491.0. 1H NMR (400 MHz, CD3OD): δ 7.24 (m, 2H), 7.03 (m, IH), 7.00 (m, IH)5 6.95 (m, 2H), 6.80 (m, IH), 4.93 (s5 2H),
4.52 (s, 2H), 3.79 (s, 3H).
Example 159: 4-({[(l£/Z)-Amino(iiitroiinino)methyl]ainino}methyl)-7V-(3-chloro-4-fluoro- phenyl)-N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
Example 160: 4-({f Amino(imino)methyl]amino}methyl)-7Y-(3-chloro-4-fluorophenyl)-N'- hydroxy-l,2,5-oxadiazole-3-carboximidamide
3-[4-(Aminomethyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4-oxadiazol- 5(4H)-one trifluoroacetate (30 mg, 0.07 mmol) and nitroguanidine (50 mg, 0.5 mmol) were dissolved in pyridine (1.0 mL). The reaction mixture was heated in a microwave at 170 0C for 30 minutes. The pyridine was evaporated and a solution of sodium hydroxide in water (0.5 mL, 1 N) was added. The mixture was stirred at room temperature for 30 minutes. Acidification with acetic acid and purification by preparative LCMS gave the desired nitroguanyl product (3.2 mg, 9%) and the guanyl product (4.7 mg, contaminated with pyridine). The guanyl material was treated with saturated aqueous sodium bicarbonate solution (1.0 mL) and extracted with ethyl acetate (3 x 3 mL). The combined extracts were dried with sodium sulfate, filtered and concentrated to give the desired guanyl free base (2.3 mg, 10%). MF = C11HiOClFNgO4; LCMS calculated for Ci1HnClFN8O4 (M-HH)+: m/z = 373.0. 1H NMR (400 MHz, CD3OD): δ 7.03 (m, 2H)5 6.80 (m, IH), 4.77 (s, 2H). MF = CnHnClFN7O2; LCMS calculated for CnHi2ClFN7O2 (M+H)+: m/z = 328.0. 1H NMR (400 MHz, CD3OD): δ 7.04 (m, IH), 7.00 (m, IH), 6.80 (m, IH), 4.77 (s, 2H).
Example 161 : Λr-(3-Chloro-4-fluorophenyl)-iV'-hydroxy-4-(4H-l,2,4-triazoI-4-ylmethyl)-l,2,5- oxadiazole-3-carboximidamide trifluoroacetate
A solution of 3-[4-(aminomethyl)-l,2,5-oxadiazol-3-yI]-4-(3-chloro-4-fluorophenyl)-l,2,4- oxadiazol-5(4h)-one trifluoroacetate (14.0 mg, 32.0 mmol), N'-[(le)-(dimethylamino)methylene]-N,N- dimethylhydrazonoformamide (6.80 mg, 48.0 mmol), and p-toluenesulfonic acid (550 mg, 3.2 mmol) in DMF (1 mL) was heated at 170 0C for 15 min in the microwave. A solution of sodium hydroxide in water (0.5 mL, 1 Ν) was added and the mixture was stirred for 30 minutes at room temperature.
Acidification with acetic acid and purification by preparative LCMS gave the desired product (1.3 mg, 9%). MF = C12H9ClFN7O2; LCMS calculated for Ci2HioClFN702 (M+H)+: m/z = 337.9.
Example 162: 4-[2-(5-Amino-lH-tetrazoI-l-yl)ethyl]-iV-(3-chloro-4-fluorophenyl)-Λ^'-hydroxy- l,2,5-oxadiazole-3-carboxinaidamide
Step A: N-(3-Chloro-4-fluorophenyl)-4-[(E)-2-methoxyvinyl]-l, 2, 5-oxadiazole-3-carboxamide N-(3-chloro-4-βuorophenyl)-4~[(Z)-2-methoxyvinyl]-l,2,5-oxadiazole-3-carboxamide
To a solution of (methoxymethyl)(triphenyl)phosphonium chloride (23.0 g, 66.0 mmol) in toluene (183 mL) was added sodium tert-butoxide (6.60 g, 0.066 mol) at rt under an atmosphere of nitrogen. After stirring for 30 min, a solution of N-(3-chloro-4-fluorophenyl)-4-formyl-l,2,5- oxadiazole-3-carboxamide (7.6 g, 28 mmol) in THF (18 mL) was cannulated into reaction flask. The resulting solution was stirred at rt for 1 h. The reaction was quenched with 1 Ν HCl and diluted with ethyl acetate and the aqueous layer was extracted with ethyl acetate once. The combined organic solutions were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified with silica gel chromatography (20% ethyl acetate/Hex) to give product (2.O g 24%, E isomer, 2.6 g, 31%, Z isomer) as white solids. Z isomer: 1H NMR (400 MHz, CDCl3): β 8.54 (s, 1 H) 7.87 (dd, J= 6.4, 2.7 Hz, 1 H), 7.42 (m, 1 H), 7.16 (t, J= 8.5 Hz, 1 H), 6.66 (d, J= 6.6 Hz, 1 H), 6.03 (d, J = 6.6 Hz, 1 H), 3.97 (s, 3 H). MF = C12H9ClFN3O3; LCMS for C12Hi0ClFN3O3 (M+H)+: m/z = 298.0.
Step B: N-(3-Chloro~4-fluorophenyl)-4-(2-methoxyethyl)-l,2,5-oxadiazole-3-carboxamide
^(S-Chloro^-fluoropheny^^-f^ZJ^-methoxyvinylj-l^.S-oxadiazole-S-carboxamide (4.6 g, 15 mmol) was dissolved in and ethyl acetate (77 mL) and 10% palladium on carbon (0.8 g) was added to reaction flask. The mixture was reacted under a 55 psi hydrogen atmosphere for 4 h. The solution was filtered through a pad of celite. The filtrate was concentrated and purified by silica gel
chromatography (20% ethyl acetate/hex) to give the desired product as a white solid (2.5 g, 54%). MF = C12H11ClFN3O3; LCMS calculated for C12H12ClFN3O3 (M+H)+: m/z = 300.1.
Step C: N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(2-methoxyethyl)-l, 2, 5-oxadiazole-3- carboximidamide
N-(3-Chloro-4-fluorophenyl)-4-(2-methoxyethyl)-l,2,5-oxadiazole-3-carboxamide (2.5 g, 8.3 mmol) was suspended in benzene (40 mL), pyridine (2.7 rtiL) and phosphorus pentachloride (3.5 g, 17 mmol) was added to the solution. The mixture was heated at 60 0C for 2.5 h. The reaction was then concentrated to dryness in vacuo. The crude was dissolved in EtOH (50 mL) and cooled to 0 0C and 50% hydroxylamine in water (10 mL) was added to the reaction flask until the pH reached 8. The reaction solution was concentrated, diluted with ethyl acetate and the aqueous layer was extracted with ethyl acetate once. The combined organic solutions were concentrated in vacuo and purified by silica gel chromatography (20%-50% ethyl acetate/hex) to give the desired product (2.5 g, 95%) as a yellow solid. MF - C12H12ClFN4O3; LCMS calculated for C12H13ClFN4O3 (M+H)+: m/z = 315.1.
Step D: 4-(3-Chloro-4-fluorophenyl)-3-[4-(2-methoxyethyl)-l,2, 5-oxadiazol-3-yl]-l ,2, 4-oxadiazol- 5(4H)-one
N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(2-methoxyethyl)-l,2,5-oxadiazole-3-carboximid- amide (2.5 g, 7.9 mmol) was dissolved in THF (44 mL) followed by addition of iV^V-carbonyl- diimidazole (1.5 g, 9.5 mmol). The reaction was heated to 70 0C for 1.5 h. The reaction solution was concentrated and purified by silica gel chromatography (20% ethyl acetate/hexane) to give the desired product (2.7 g, 99%). MF = C13H10ClFN4O4; LCMS calculated for C13HnClFN4O4 (M+H)+: m/z = 341.0.
Step E: 4-(3-Chloro-4-fluorophenyl)-3-[4-(2-hydroxyethyl)-l,2,5-oxadiazol-3-yl]-l,2,4-oxadiazol- 5(4H)-one
To a solution of 4-(3-chloro-4-fluorophenyl)-3-[4-(2-methoxyethyl)-l,2,5-oxadiazol-3-yl]- l,2,4-oxadiazol-5(4H)-one (2.55 g, 0.00748 mol) in DCM (24 mL) was added 1.0 M of boron tribromide in DCM (22.4 mL) under an atmosphere of nitrogen at -78 0C. The reaction solution was allowed to warm to rt over 2.5 h. The reaction was quenched with saturated NaHCU3 at 0 0C and diluted with ethyl acetate. The aqueous layer was extracted with ethyl acetate once, the combined organic solutions were dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel chromatography (60% ethyl acetate/hexane) to give the desired product as an off white solid (2.3 g, 96%). MF = Ci2H8ClFN4O4; LCMS calculated for C12H9ClFN4O4 (M+H)+: m/z = 327.0.
Step F: 2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylethyl methanesulfonate
To a solution of 4-(3-chloro-4-fluorophenyl)-3-[4-(2-hydroxyethyl)-l,2,5-oxadiazol-3-yl]- l,2,4-oxadiazol-5(4H)-one (2.50 g, 7.65 mmol) in DCM (34 mL) was added TEA (2.1 mL, 15 mmol) and methanesulfonyl chloride (0.83 mL, 10.7 mmol) at rt. After stirring for 30 min, the reaction was quenched with a 0.1 N HCl solution and diluted with ethyl acetate. The organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by silica gel column (20-70% ethyl acetate/hexane) to give the desired product as a white solid (2.74 g, 88%); MF = Ci3Hi0ClFN4O6S; LCMS calculated for Ci3H11ClFN4O6S(MH-H)+: m/z = 405.0.
Step G: 4-[2-(5-Amino-lH-tetra∑ol-l-yl)ethyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2, 5- oxadiazole-3-carboximidamide 2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylethyl methanesulfonate (16.0 mg, 0.039 mmol) was dissolved in anhydrous ACN (0.6 mL), followed by addition of DIPEA (27.5 μL, 0.158 mmol) and 1 H-tetrazol-5 -amine (4.0 mg, 0.047 mmol). The mixture was heated at 50 0C for 4 h. The reaction solution was then diluted with MeOH and purified by preparative HPLC to yield two isomers. The first eluting peak (isomer 1) was
dissolved in MeOH (0.5 mL) and 2.0 N of sodium hydroxide in water (0.079 mL) was added. After stirring for 0.5 h, reaction solution was diluted with MeOH and few drops of acetic acid and purified by preparative LCMS to give the desired product as a white powder (2.1 mg, 14%). MF = C12H11ClFN9O2; LCMS calculated for C12H12ClFN9O2 (M+H)+: m/z = 368.1. 1H NMR (400 MHz, DMSO- d6y. δ 11.60 (s, 1 H), 8.99 (s, 1 H), 7.17 (t, J = 9.0 Hz, 1 H), 7.00 (dd, J= 6.4, 2.7 Hz, 1 H), 6.79 (s, 2 H), 6.72 (m 1 H), 4.55 (t, J= 7.0 Hz, 2 H), 3.41 (t, J= 7.0 Hz, 2 H);
Example 163: 4-[2-(5-Amino-2H-tetrazol-2-yl)ethyI]-iV-(3-chloro-4-fluorophenyl)-iV'-hydroxy- l,2,5-oxadiazole-3-carboximidamide
2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylethyl methanesulfonate (16.0 mg, 0.039 mmol) was dissolved in anhydrous ACN (0.6 mL), followed by addition of DIPEA (27.5 μL, 0.158 mmol) and lH-tetrazol-5-amine (4.0 mg, 0.047 mmol). The solution was heated at 50 0C for 4 h. The reaction solution was then diluted with MeOH and purified by preparative HPLC to yield two isomers. The first eluting peak (isomer 1) was dissolved in MeOH (0.5 mL) and 2.0 N of sodium hydroxide in water (0.079 mL) was added. After stirring for 0.5 h, reaction solution was diluted with MeOH and few drops of acetic acid and purified by preparative LCMS to give the desired product as a white powder (3.8 mg, 26%). MF = C12HnClFN9O2; LCMS calculated for C12Hi2ClFN9O2 (MH-H)+: m/z = 368.1.
Example 164: Λ^-(3-Chloro-4-fluorophenyl)-iV-hydroxy-4-[2-(lH-imidazol-l-yl)ethyI]-l,2,5- oxa diazole-3-carboximidamide
2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-lJ2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylethyl methanesulfonate (9.0 mg, 0.022 mmol) was dissolved in anhydrous ACN (0.5 mL), followed by addition of DIPEA (15.5 μL, 0.0889 mmol) , and imidazole (3.0 mg, 0.044 mmol). The reaction solution was heated at 60 0C for 12 h. The reaction solution was then treated with 2.0 M of
sodium hydroxide in water (0.20 mL). After stirring for 0.5 b, to the solution was added a few drops of acetic acid and diluted with MeOH and purified by preparative LCMS to give the desired product (3.5 mg, 45%). MF = C14Hi2ClFN6O2; LCMS for C14H13ClFN6O2 (M+H)+: m/z = 351.1.
Example 165: iV-(3-Chloro-4-fluorophenyl)-iV-hydroxy-4-(2-morpholin-4-ylethyl)-l,2,5- oxadiazole-3-carboximidamide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methanesulfonate and morpholine as the starting materials. MF = Ci5H17ClFNsO3; LCMS for
C15H18ClFN5O3 (M+H)+: m/z = 370.1.
Example 166: Λr-(3-ChIoro-4-fluorophenyl)-Λ'1-hydroxy-4-[2-(4-methy]piperazin-l-yl)ethyl]- l,2,5-oxadiazoIe-3-carboximidamide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methanesulfonate and 1-methylpiperazine as the starting materials. MF = Ci6H20ClFN6O2; LCMS for
C16H21ClFN6O2 (M+H)+: m/z = 383.1.
Example 167: 7V-(3-Chloro-4-fluorophenyl)-iV'-hydroxy-4-[2-(4H-l,2,4-triazol-4-yl)ethylJ-l,2,5- oxadiazole-3-carboximidaniide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methane- sulfonate and lH-l,2,4-triazole as the starting materials. MF = Ci3Hi1ClFN7O2; LCMS for C13HnClFN7O2 (M+H)+: m/z = 352.1. 1H NMR (400 MHz, DMSO- d6): δ 1 1.60 (s, 1 H), 10.53 (s, 0.1 H), 9.14 (s, 0.1 H), 8.99 (s, 1 H), 8.58 (s, 2H), 8.52 (s, 0.2 H), 7.98 (m, 0.1 H), 7.35 (m, 0.2 H), 7.10 (t, J= 9.0 Hz, 1 H), 6.98 (dd, J= 6.5, 2.8 Hz, 1 H), 6.68 (m, 1 H), 4.49 (t, J= 7.1 Hz, 2 H), 3.41 (t, J= 7.1 Hz, 2 H) 3.34 (t, J= 6.8 Hz, 0.4 H);
Example 168: ^-(S-Chloro^-fluorophenyO-iV-hydroxy-^ll-ClH-l^^-triazol-l-yOethyll-l^jS- oxadiazole-3-carboximidamide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methane- sulfonate and lH-l,2,4-triazole as the starting materials. MF = Ci3HnClFN7O2; LCMS for
C13H12ClFN7O2 (MH-H)+: m/z = 352.1.
Example 169: Λr-(3-Chloro-4-fluorophenyl)-Λrr-hydroxy-4-[2-(lH-tetrazoI-l-yl)ethyIJ-l,2,5-oxa- diazole-3-carboximidamide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methane- sulfonate and lH-tetrazole as the starting materials. MF = C12Hi0ClFNsO2; LCMS for Ci2Hi1ClFN8O2
(M+H)+: m/z = 353.1. 1H NMR (400 MHz, DMSO- d6): d 11.61 (s, 1 H), 9.43 (s, 1 H), 9.39 (s, 0.1 H), 9.11 (s, 0.1 H), 8.99 (s, 1 H), 7.34 (m, 0.2 H), 7.17 (t, J = 9.0 Hz, 1 H), 7.00 (dd, J= 6.4 Hz, 2.7 Hz, 1 H), 6.72 (m, 1 H), 4.93 (t, J= 6.8 Hz, 2 H), 3.56 (t, J= 6.8 Hz, 2 H);
Example 170: iV-(3-ChIoro-4-fluorophenyl)-iV-hydroxy-4-[2-(2H-tetrazol-2-yl)ethyll-l,2,5- oxadiazole-3-carboxiniidaniide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methane- sulfonate and lH-tetrazole as the starting materials. MF = C12Hi0ClFN8O2; LCMS for C12Hi 1ClFN8O2 (M+H)+: m/ z = 353.1.
Example 171 : iV-(3-ChIoro-4-fluorophenyl)-7V -hydroxy^-vinyl-l^S-oxadiazoIe-S-carbox- imidamide ,
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l ,2,5-oxadiazol-3-ylethyl methane- sulfonate and DEPEA as the starting materials. MF = CuHsClFN4O2; LCMS for CnH9ClFN4O2
(M+H)+: m/ z = 283.0.
Example 172: iV-(3-ChIoro-4-fluorophenyI)-4-[2-(dimethylamino)ethyl]-iV-liydroxy-l,2,5-oxa- diazoIe-3-carboximidamide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l ,2,4-oxadiazol-3-yl]-l ,2,5-oxadiazol-3-ylethyl methane- sulfonate and dimethylamine as the starting materials. MF = C]3Hi5ClFN5O2; LCMS for
C13H16ClFN5O2 (M+H)+: m/ z = 328.1.
Example 173: iV-(3-Chloro-4-fluorophenyl)--V-hydroxy-4-(2-thiomorpholin-4-ylethyl)-l,2,S- oxadiazole-3-carboximidamide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l ,2,4-oxadiazol-3~yl]-l ,2,5-oxadiazol-3-ylethyl methane- sulfonate and thiomorpholine as the starting materials. MF = C15Hi7ClFN5O2S; LCMS for
C15H18ClFN5O2S (M+H)+: mJ z = 386.1.
Example 174: iV-(3-Chloro-4-fluorophenyl)-A^-hydroxy-4-(2-pyrro lidin-l-ylethyl)-l,2,5-o xadiazole-3-carboximidamide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methane- sulfonate and pyrrolidine as the starting materials. MF = Ci5Hi7ClFN5O2; LCMS for ClsHiSClFN5O2 (M+H)+: m/ z = 354.1.
Example 175: Λr-(3-Chloro-4-fluorophenyl)-iV-liydroxy-4-{2-[isopropyI(methyl)amino]ethyl}- l,2,5-oxadiazoIe-3-carboximidamide
This compound was prepared according to the procedure of Example 164, using 2-4-[4-(3- chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3-ylethyl methane- sulfonate and N-methyl-2-propanamine as the starting materials. MF = C15Hi9ClFN5Oa; LCMS for CI5H20CIFN5O2 (MH-H)+: m/ z = 356.1.
Example 176: iV-(3-ChIoro-4-fluorophenyl)-iV-hydroxy-4-2-[(methylsuIfonyl)amino]ethyl-l,2,5- oxadiazole-3-carboximidamide
Step A: 3-[4-(2-azidoethyl)-lr2,5-oxadiazol-3-yl]-4-(3-chloro-4-βuorophenyl)-l,2,4-oxadiazol-5(4H)- one
2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l ,2,4-oxadiazol-3-yl]-l 32,5-oxadiazol-3- ylethyl methanesulfonate (370 mg, 0.91 mmol) was dissolved in DMF (5 mL) followed by addition of sodium azide (120 mg, 1.80 mmol). The reaction mixture was heated at 60 0C for 2 h. The reaction solution was then cooled to rt and diluted with water and ethyl acetate and the aqueous layer was extracted with ethyl acetate once. The combined organic solutions were dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography (30% ethyl acetate/hex) to give the desired product as a white solid (231 mg, 72%). MF = Ci2H7ClFN7O3; LCMS calculated for C2H8ClFN7O3 (M+H)+: m/z - 352.0.
Step B: 3-[4-(2-aminoethyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4-oxadiazol- 5(4H)-one trifluoroacetate
3-[4-(2-Azidoethyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4-oxadiazol- 5(4H)-one (230 mg, 0.65 mmol) was dissolved in THF (4.0 mL) and water (4.0 rtiL). The reaction solution was cooled to 0 0C, followed by addition triphenylphosphine (0.34 g, 1.3 mmol). After stirring at 0 0C for 30 min, solvent was removed in vacuo and the residue was dissolved in MeOH. The compound was purified by preparative LCMS to give the desired product as a white solid (121 mg, 56.8%). MF = C12H9ClFN5O3; LCMS calculated for C12H10ClFN5O3 (M+H)+: m/z = 326.0.
Step C: Η-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-2-[(πιethylsulfonyl)amino]ethyl-l,2,5-oxadiazole- 3-carboximidamide
To a solution of 3-[4-(2-aminoemyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)- 1 ,2,4-oxadiazol-5(4H)-one trifluoroacetate (16.0 mg, 0.037 mmol) in DCM (1.0 mL) was added TEA (15 μL, 0.11 mmol) and methanesulfonyl chloride (4.2 μL, 0.055 mmol). The resulting mixture was stirred at rt for 1 h and then the solvent was removed under reduced pressure. The residue was dissolve in MeOH (1 mL) and 2.0 M sodium hydroxide in water (0.10 mL) was added. After stirring for 4 h, the reaction solution was diluted with MeOH and a few drop of acetic acid and then purified by preparative LCMS to give the desired product as a white solid (14.1 mg, 78.3%). MF = C12H13ClFN5O4S; LCMS calculated C12H14ClFN5O4S (M+H)+: m/z = 377.0.
Example 177: N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-4-(2-(sulfamoylamino)ethyI)-l,2,5- oxadiazole-3-carboximidamide
A solution of 3-[4-(2-aminoethyl)-l,255-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4- oxadiazol-5(4h)-one trifluoroacetate (23.0 mg, 53.0 mmol), sulfamide (15.0 mg, 160 mmol) and pyridine (1.0 mL) was heated at 120 °C for 3 min in a microwave. To the reaction solution was added 0.5 mL 1 N NaOH and stirred for 30 min. The reaction solution was then acidified with acetic acid and purified by preparative LCMS to give the desired product (12 mg, 46%). MF = CnHi2ClFN6O4S; LCMS calculated for C11Hi3ClFN6O4S (M+H)+: m/z = 379.0. 1H NMR (400 MHz, DMSO- ds): d
11.52 (s, 1 H), 10.45 (s, 0.1 H), 9.05 (s, 0.1 H), 8.98 (s, 1 H), 7.95 (m, 0.1 H), 7.32 (m, 0.2 H), 7.15 (t, J= 9.0 Hz, 1 H), 7.00 (dd, J= 6.5 Hz, 2.7 Hz, 1 H), 6.76 (t, J= 5.9 Hz, 1 H), 6.65 (m, 1 H), 6.59 (s, 2 H), 3.29 (m, 2 H), 3.07 (t, J= 7.2 Hz, 2 H);
Example 178: Ethyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-l,2,5- oxadiazol-3-yl)propanoate
A solution of N-(3-chloro-4-fluorophenyl)-4-(hydroxjαnethyl)-l,2,5-oxadiazole-3-carbox- amide (8.50 g, 31.3 mmol), Dess-Martin periodinane (14.6 g, 34.4 mmol) and DCM (400 mL) was stirred at 25 0C for 3 h. The reaction was diluted with a saturated sodium bicarbonate solution and extracted with ethyl acetate three times, dried with sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by flash column chromatography to yield the desired product (7.50 g, 89%). LCMS for C]0H6ClFΝ3O3(M+H)+: m/z = 270.0.
Step 2: Ethyl (2E)-3-(4-[(3-chloro-4~fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)acrylate
To a solution of (carbethoxymethyl)triphenylphosphonium bromide (3.14 g, 7.32 mmol) in toluene (37 mL) was added sodium terf-butoxide (723 mg, 7.52 mmol) at rt under a nitrogen atmosphere. After stirring for 30 min, a solution of AΛ(3-chloro-4-fluorophenyl)-4-formyl-l,2,5- oxadiazole-3-carboxamide (811 mg, 3.01 mmol) in THF (10 mL) was cannulated into reaction flask.
The resulting solution was heated at 80 0C for 3 h, then cooled to rt overnight. The reaction was quenched with a 1 N HCl solution, the aqueous solution was extracted with ethyl acetate. The combined organic solutions were washed with brine, dried over Na2SO4, filtered and concentrate
under reduced pressure. The residue was purified with flash chromatography (30% ethyl acetate/ hexane) to give the desired product as a white solid (0.91 g, 89%). 1H NMR (400 MHz, CD3OD): δ 7.92 (m, 2 H), 7.65 (m, 1 H), 7.26 (m, IH), 7.01 (m, 1 H), 4.27 (m, 2 H), 1.33 (m, 3 H); LCMS for C14H12ClFN3O4 (M+H)+: m/z = 340.
Step 3: Ethyl 3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)propanoate
To a solution of ethyl (2E)-3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-l,2,5-oxadiazol-3- yl)acrylate (0.86 g, 0.0025 mol) in ethyl acetate (10 mL, 0.1 mol) was added palladium (600 mg, 0.006 mol). The mixture was stirred at room temperature under an atmosphere of hydrogen for 2 h. The reaction solution was filtered through a pad of celite. The filtrate was concentrated and purified by flash chromatography (40% ethyl acetate/hexane) to give the desired product as a white solid (609 mg, 70%). LCMS for C14H14ClFN3O4 (M+H)+: m/z = 342.1.
Step 4: Ethyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N'-h.ydroxycarbamimidoyl)-l,2,5-oxadia∑ol-3- yl)propanoate
Ethyl 3-(4-[(3 -chloro-4-fiuorophenyl)amino]carbonyl-l ,2,5-oxadiazol-3-yl)propanoate (27 mg, 0.079 mmol) was suspended in benzene (1 mL) under an atmosphere of nitrogen and phosphorus pentachloride (18.0 mg, 0.086 mmol) was added. The solution was heated to reflux for 2.5 h. The solvent was removed in vacuo. The residue was dissolved in EtOH (1.0 mL) and hydroxylamine (100 μL, 2 mmol) (50% solution in water) was added to the reaction. After stirring Ih, the solution was diluted with MeOH and purified by preparative LCMS to give the desired product (8.5 mg, 30%). 1H NMR (400 MHz, CD3OD): δ 7.03 (t, /= 8.9 Hz, 1 H), 6.95 (dd, J= 6.4, 2.7 Hz, 1 H), 6.71 (m, 1 H), 4.12 (q, J= 7.2 Hz, 2 H), 3.11 (t, J= 7.2 Hz, 2 H), 2.80 (t, J= 7.2 Hz, 2 H), 1.23 (t, J= 7.2 Hz5 3 H); LCMS for C14H15ClFN4O4 (M+H)+: m/z = 357.1.
Example 179: yV-(3-ChIoro-4-fluorophenyI)-Λr'-hydroxy-4-(3-morphoIin-4-ylpropyI)-l,2,5- oxadiazole-3-carboximidamide
Step 1: N~(3-Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-l, 2, 5-oxadiazole-3-carboxamide
To a solution of ethyl 3-(4-[(3-chloro-4-fluorophenyl)araino]carbonyl-l,2,5-oxadiazol-3- yl)propanoate (97.5 mg, 0.285 mmol) in THF (1.2 mL) was added lithium tetrahydroborate (14.3 mg, 0.656 mmol) at 0 0C under an atmosphere of nitrogen. The reaction solution was allowed to warm to rt for 2 h. The reaction was quenched with MeOH and concentrated. The residue was purified by flash chromatography (60% ethyl acetate/hexane) to give the desired product (70 mg, 80%). LCMS for C12H12ClFN3O3 (M+H)+: m/z = 300.1.
Step 2: 3-(4-[(3-Chloro-4-βuorophenyl)amino]carbonyl-l,2,5-oxadiazol-3-yl)propyl methane- sulfonate
N-(3 -Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-l ,2,5-oxadiazole-3 -carboxamide (60 mg, 0.20 mmol) was dissolved in anhydrous DCM (2 mL), followed by addition of TEA (57 μL, 0.41 mmol). The reaction was stirred and cooled to 0 0C, and methanesulfonyl chloride (29 μL, 0.37 mmol) was added drop-wise. The reaction was quenched with water and diluted with DCM. The organic layer was separated, dried over Na2SO4, filtered, concentrated and purified by silica gel chromatography (25%-75% EtOAc/hexane) to give the desired product (60 mg, 80%). LCMS for C13H14ClFN3O5S (M+H)+: m/z = 378.
3-(4-[(3-Chloro-4-fluorophenyl)amino]carbonyl- 1 ,2,5-oxadiazol-3-yl)propyl methane- sulfonate (19 mg, 0.051 mmol) was dissolved in anhydrous ACN (100 μL,) followed by the addition of DIPEA (44 μL, 0.26 mmol) and morpholine (6.7 μL, 76.8 μmol). The reaction were stirred and heated at 70 0C for 3 h. The reaction was concentrated and purified by silica gel chromatography (60- 100% ethyl acetate/hexanes) to give the desired product (10.2 mg, 54%). LCMS for C]6Hi9ClFN4O3 (M+H)+: m/z = 369.1.
Step 4: N-(3-Chloro-4-βuorophenyl)-N'-hydroxy-4-(3-morpholin-4-ylpropyl)-l,2, 5-oxadiazole-S- carboximidamide
N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyl)-l,2,5-oxadiazole-3-carboxamide (10.0 mg, 27 μmol) was suspended in benzene (0.4 mL) under an atmosphere of nitrogen and phosphorus pentachloride (6.2 mg, 29.8 μmol) was added. The solution was heated at reflux for 2.5 h. The volatiles were evaporated in vacuo. The reaction was dissolved in EtOH (0.3 mL) and hydroxylamine (40 μL, 0.7 mmol) (50% solution in water) was added to the reaction. After stirring for 1 h, the reaction solution was diluted with MeOH and purified by preparative LCMS to give the desired product (5.2 mg, 50%). LCMS for CI6H20CIFN5O3 (M+H)+: m/z = 384.1.
Example 180: 4-{3-[(Aminosulfonyl)amino]propyI}-JV"-(3-chloro-4-fluorophenyl)-Λ'τ-hydroxy- l,2,5-oxadiazole-3-carboximidamide
3-[4-(3 -Aminopropyl)- 1 ,2, 5-oxadiazol-3 -yl] -4-(3 -chloro-4-fluorophenyl)- 1 ,2,4-oxadiazol- 5(4H)-one trifluoroacetate (7.8 mg, 0.017 mmol) and sulfamide (9.4 mg, 0.98 mol) was dissolved in pyridine (1.0 mL). The solution was heated at 120 0C for 3 minutes in a microwave. A solution of sodium hydroxide in water (0.5 mL, 1.0 N) was added and the mixture stirred at room temperature for 16 hrs. Acidification with acetic acid and purification by preparative LCMS gave the desired product (5.7 mg, 84%). 1H NMR (400 MHz, CD3OD): δ 7.02 (t, IH), 6.95 (m, IH), 6.7 (m, IH), 3.1 (m, 2H),
2.9 (m, 2H)3 2.0 (m, 2H). MF = C12H14ClFN6O4S. LCMS calculated for CI2H15CIFN6O4S (M+H)+: m/z = 393.0.
Stepl: S-fe-ø-Azidopropyty-l.Σ.S-oxadiazolS-ylJ^-β-chloro^-fluorophenyty-l^^-oxadiazol- 5(4H)-one
3-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl]-l,2,5-oxadiazol-3- ylpropyl methanesulfonate (0.25 g, 0.60 mmol) was dissolved in anhydrous DMF (3.0 mL). Sodium azide (97 mg, 1.5 mmol) was added and the reaction was stirred at 65 0C for 1 h. The reaction mixture was quenched with water and extracted with EtOAc. EtOAc extracts were washed with water and brine, dried over Na2SO4, filtered and volatiles evaporated. Crude material was used in the next step without further purification (200 mg, 92%). MF = Ci3H9ClFN7O3; LCMS calculated for C13H10ClFN7O3 (M+H)+: m/z = 366.0.
Step 2: S-ft-β-AminopropylJ-l^^-oxadiazolS-ylJ-^β-chloro-J-fluorophenyfy-I^^-oxadiazol- 5(4H)-one triβuoro acetate
3-[4-(3-Azidopropyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-l,2,4-oxadiazol- 5(4H)-one (200 mg, 0.5 mmol) was dissolved in anhydrous THF (3 mL) and water (3 mL). The reaction was cooled to 0 0C followed by addition of triphenylphosphine (430 mg, 1.6 mmol). The reaction was stirred at 0 0C for 30 minutes and then the volatiles evaporated in vacuo. The residue was azeotroped with toluene, dissolved in MeOH and purified by preparative LCMS using pH 2 buffer to give the desired product (45.3 mg, 20%). MF = C13Hi0ClFNsθ3; LCMS calculated for C13H11ClFN5O3 (M+H)+: m/z = 340.0.
Example 181: iV-(3-Chloro-4-fluorophenyl)-4-(3-{ [(E/Z)-(cyanoimino)(methyI- amino)methyllamino}propyl)-iV-hydroxy-l,2,5-oxadiazole-3-carboxiiiιidamide trifIuoroacetate
3-[4-(3-Aminopropyl)-l ,2,5-oxadiazol-3-yl]-4-(3 -chloro-4-fluorophenyl)-l ,2,4-oxadiazol- 5(4H)-one trifluoroacetate (11.0 mg, 0.0251 mmol) was dissolved in THF (0.32 mL). Diphenyl cyanocarbonimidate (8.73 mg, 0.0366 mmol) and TEA (13 μL, 0.092 mmol) were added and the reaction stirred at room temperature for two hrs. A solution of methylamine in THF (46 μL, 2.0 N) was added and the reaction was stirred at room temperature for two hrs. A solution of sodium hydroxide in water (0.5 mL, 1.0 N) was added and the mixture stirred at room temperature for 16 hrs. Acidification with acetic acid and purification by preparative LCMS gave the desired product (5.6 mg, 44%). MF = C15H15ClFN8O2; LCMS calculated for C15H16ClFN8O2 (M+H)+: m/z = 395.0.
Example 182: iV-(3-Chloro-4-fluorophenyI)-Λ^'-hydroxy-4-[3-(4H-l,2,4-triazoI-4-yl)propyl]- l,2,5-oxadiazole-3-carboximidamide trifluoroacetate
To a microwave tube was added 3-[4-(3-aminopropyl)-l,2,5-oxadiazol-3-yl]-4-(3-chloro-4- fluorophenyl)-l,2,4-oxadiazol-5(4H)-one trifluoroacetate (26.3 mg, 0.0580 mmol), N'-[(1E)- (dimethylamino)methylene]-N,N-dimethylhydrazonoformamide (9.1 mg, 0.064 mmol), p-toluene- sulfonic acid monohydrate (1 mg, 0.006 mmol) and toluene (0.5 mL). The reaction was heated in a microwave at 170 0C for 30 minutes. Solvent was removed in vacuo and the residue was purified by preparative LCMS. A solution of sodium hydroxide in water (0.5 mL, 1.0 Ν) was added and the mixture stirred at room temperature for 16 hrs. Acidification with acetic acid and purification by preparative LCMS gave the desired product give product (13 g, 48%). 1H ΝMR (400 MHz, CD3OD): δ 9.0 (s, 2H), 7.02 (m, IH), 6.9 (m, IH), 6.7 (m, IH), 4.3 (m, 2H), 2.95 (m, 2H), 2.4 (m, 2H). MF = C14H12ClFN7O2; LCMS calculated for C14H13ClFN7O2 (M+H)+: m/z = 366.0.
Data for additional example compounds of the invention are provided in Table 3, below.
Table 3
Example A: Human indoleamine 2,3-dioxygenasae (IDO) enzyme assay
Human indoleamine 2,3-dioxygenasae (IDO) with an Ν-terminal His tag was expressed in E.coli and purified to homogeneity. IDO catalyzes the oxidative cleavage of the pyrrole ring of the indole nucleus of tryptophan to yield iV-formylkynurenine. The assays were performed at room temperature as described in the literature using 95 nM EDO and 2 mM D-Trp in the presence of 20 mM ascorbate, 5 μM methylene blue and 0.2 mg/mL catalase in 50 mM potassium phosphate buffer (pH 6.5). The initial reaction rates were recorded by continuously following the absorbance increase at 321 nm due to the formation of JV-formlylkynurenine. See: Sono, M., Taniguchi, T., Watanabe, Y., and Hayaishi, O. (1980) /. Biol. Chem. 255, 1339-1345 Compounds of the invention having an IC50 less than about 100 μM were considered active.
Example B: Determination of inhibitor activity in HeLa cell-based indoleamine 2,3-dioxygenase (IDO)/Kynurenine assay HeLa cells (#CCL-2) were obtained from the American Type Tissue Culture Collection
(ATCC, Manassas, VA) and routinely maintained in minimum essential medium (eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 10 % fetal bovine serum (all from Invitrogen). Cells were kept at 37 0C in a humidified incubator supplied with 5 % CO2. The assay was performed as follows: HeLa cells were seeded in a 96 well culture plate at a density of 5 x 103 per well and grown overnight. On the next day, IFΝ-γ (50 ng/mL final concentration) and serial dilutions of compounds (in total volume of 200 μL culture medium) were added into cells. After 48 hours of incubation, 140 μL of the supernatant per well was transferred to a new 96 well plate. 10 μL of 6.1 Ν trichloroacetic acid (#T0699, Sigma) was mixed into each well and incubated at 50 0C for 30 min to hydrolyze N- formylkynurenine produced by indoleamine 2,3-dioxygenase to kynurenine. The reaction mixture was then centrifuged for 10 min at 2500 rpm to remove sediments. 100 μL of the supernatant per well was transferred to another 96 well plate and mixed with 100 μl of 2% (w/v) jo-dimethyl-
aminobenzaldehyde (#15647-7, Sigma-Aldrich) in acetic acid. The yellow color derived from Kynurenine was measured at 480 nm using a SPECTRAmax 250 microplate reader (Molecular Devices). L-kynurenine (#K8625, Sigma) was used as standard. The standards (240, 120, 60, 30, 15, 7.5, 3.75, 1.87 μM) were prepared in 100 μL culture media and mixed with equal volume of 2 % (w/v) /7-dimethylaminobenzaldehyde. The percent inhibition at individual concentrations was determined and the average values of duplicates were obtained. The data was analyzed by using nonlinear regression to generate IC50 values (Prism Graphpad). See: Takikawa O, et al. (1988). Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 263(4):2041-8. Compounds of the invention having an IC5O less than about 100 μM were considered active.
Example C: Determination of effect of IDO inhibitors on T cell proliferation that is suppressed by EDO-expressing dendritic cells Monocytes were collected from human peripheral mononuclear cells by leukophoresis.
Monocytes were then seeded at a density of 1 x 106 cells/well in a 96 well plate, using RPMI 1640 medium supplemented with 10 % fetal bovine serum and 2 mM L-glutamine (all from Invitrogen). Adherent cells were retained on the plate after overnight culture at 37 0C. Adherent monocytes were then stimulated for 5-7 days with 100 ng/ml GM-CSF (# 300-03, PeproTech) and 250 ng/ml EL-4 (#200-04, PeproTech), followed by activation with 5 μg/mL LPS from Salmonella typhimuήum (#437650, Sigma) and 50 ng/mL IFN-γ (# 285-IF, R&D Systems) for additional 2 days to induce dendritic cell maturation.
After dendritic cell activation, the medium was replaced with completed RPMI 1640 supplemented with 100-200 U/mL IL-2 (#CYT-209, ProSpec-Tany TechnoGene) and 100 ng/mL anti-CD3 antibody (#555336, PharMingen), T cells (2-3 X 105 cells/well), and serial dilutions of IDO compounds. After incubation for 2 more days, T cell proliferation was measured by BrdU incorporation assay, using a colorimetric Cell Proliferation ELISA kit per manufacturer's instruction (#1647229, Roche Molecular Biochemicals). Cells were continuously cultured for 16-18 hrs in presence of 10 μM BrdU labeling solution. Then, the labeling medium was removed, and 200 μL FixDenat per well was added to the cells and incubated for 30 minutes at room temperature. The FixDenat solution was removed and 100 μL/well anti-BrdU-POD antibody conjugate working solution was added. The reaction was carried out for 90 minutes at room temperature. The antibody conjugate was then removed, and cells were rinsed three times with 200 μL/well washing solution. Finally, 100 μL/well of substrate solution was added and the results were obtained using a microplate reader (Spectra Max PLUS, Molecular Devices) during color development. Multiple readings at various time points were obtained to ensure the data was within the linear range. The data was
routinely obtained from replicated experiments, and appropriate controls were included. See: Terness P, et al. (2002). Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase- expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196(4):447-57; and Hwu P, et al. (2000). Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164(7):3596-9. Compounds of the invention having an IC5O less than about 100 μM were considered active.
Example D: In vivo testing of IDO inhibitors for antitumor activity
In vivo anti-tumor efficacy can be tested using modified tumor allograft/xenograft protocols. For instance, it has been described in the literature that EDO inhibition can syngerize with cytotoxic chemotherapy in immune-competent mice (Muller, AJ., et al). This synergy was shown to be dependent on T-cells by comparison of the synergistic effects of an investigational EDO inhibitor in murine tumor xenograft models (e.g. Bl 6 and related variants, CT-26, LLC) grown in immune competent syngenic mice to that observed in syngenic mice treated with neutralizing anti-CD4 antibodies, or the same tumors grown in immune-compromised mice (e.g. nu/nu).
The concept of differential anti-tumor effects in immune-competent versus immune- compromised mice may also permit testing of investigational DDO inhibitors as single agents. For instance, LLC tumors grow well in their syngenic host strain, C57B1/6. However, if these mice are treated with the IDO inhibitor 1-MT (versus placebo) the formation of tumors is markedly delayed, implying that DDO inhibition was growth inhibitory (Friberg, M., et al). Following this logic, one can examine the efficacy of DDO inhibition in the LLC xenograft tumor model grown in C57B1/6 immune competent mice and compare that to the effects of DDO inhibitors on LLC tumor growth in nude or SCDD mice (or C57B1/6 mice treated with antibodies that neutralize T-cell activity). As the effects of relieving the tumor-mediated immune suppressive activity of DDO will likely differ depending on the immunogenic potential of different tumor models, genetic modifications can be made to the tumor cells to increase their immunogenic potential. For instance, expression of GM-CSF in B16.F10 cells increases their immunogenic potential (Dranoff, G., et al). As such, in some tumor models (e.g. B16.F10) one can generate [poly]clones that express immune stimulatory proteins such as GM-CSF and test the growth inhibitory effects of EDO inhibitors against tumors established from these tumor cells in both immune-competent and -compromised mice.
A third avenue for assessing the efficacy of IDO inhibitors in vivo employs 'pre- immunization' murine tumor allograft/xenograft models, hi these models, immune-competent mice are sensitized to a specific tumor antigen or antigens to mimic a therapeutic anti-tumor vaccination. This primes the mice for an anti-tumor response mediated by the immune system when mice are subsequently challenged with murine tumor cell lines (possessing similar tumor antigens to those used for immunization) in xenograft experiments. Expression of IDO has been shown to blunt the antitumor response and allow xenografts to grow more rapidly. Importantly, the growth of tumors in this
model is inhibited by the DDO inhibitor 1-MT (Uyttenhove, C, et at). This model is particularly attractive as IDO activity is permissive for P815 tumor growth and specific inhibition of IDO should therefore growth inhibitory.
Lastly, therapeutic immunization may be used to evaluate the impact of IDO inhibitors in vivo. For example, it has been demonstrated using B16-BL6 cells that one can challenge Blk/6 mice with an intravenous injection of tumor cells followed by treatment with a well characterized immunogenic peptide (e.g. TRP-2) expressed by the tumor cells (Ji, et al., J. Immunol, 2005, 175:1456-63). Importantly, immune system modifiers, such as anti-CTL-4 antibody, can improve responses to such therapeutic immunizations. The impact of EDO inhibitors may be evaluated in a similar manner - tumor peptide immunization with or without IDO inhibitor. Efficacy is assess by animal survival (time to morbidity) or by the measurement of tumor metastases to the lungs and/or other organs at defined timepoints.
In any/all of the above mentioned models, it may also be possible to directly and/or indirectly measure the number and/or activity of tumor reactive immune cells. Methods for measuring the number and/or activity of tumor reactive immune cells are well established and can be performed using techniques familiar to those schooled in the art (Current Protocols in Immunology, vol 4, Coligan, J.E., et al; Immunotherapy of Cancer, Human Press, 2006, Disis, MX. and references therein). Conceptually, a reduction in the immune suppressive effects of BDO may result in increased numbers or reactivity of tumor specific immune cells. Further, IDO inhibition may further increase the number or reactivity of tumor reactive immune cells when combined with other therapeutics, for example chemotherapeutics and/or immune modulators (e.g. anti-CTLA4 antibody).
All allograft/xenograft experiments can be performed using standard tumor techniques (reviewed by Corbett, et al). The cloning and introduction of genes (e.g. IDO, GM-CSF) into tumor cell lines, can be performed using techniques familiar to those schooled in the art (reviewed in Sambrook, J, et at). See: Corbett, T., Polin, L., et al. In vivo methods for screening and preclinical testing. Cancer Drug Discovery and Development: Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, 2nd Ed. Teicher, B.A. and Andrews, P.A., Gumana Press Inc., Totowa, NJ, 2004; Dranoff, G., Jaffee, E., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci, USA. 90:3539-3543, 1993; Friberg, M., Jennings, R., et al. Indoleamine 2,3-dioxygenase contributes to rumor cell evasion of T cell-mediated rejection. Int. J. Cancer: 101 :151-155, 2002; Muller, A. J., DuHadaway, J.B., et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Binl, potentiates cancer chemotherapy. Nat. Med. 11:312-319, 2005; Sambrook, J, Russel, D. Molecular Cloning: A laboratory Manual (3rd edition). Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY, USA. 2001; and Uyttenhove, C, Pilotte, L., et al. Evidence for a tumoral
immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9:1269-1274, 2003.
Example E: In vivo testing of EDO inhibitors in human immunodeficiency virus-1 (HIV-I) encephalitis model
1. Cell isolation and viral infection
Monocytes and PBL can be obtained by countercurrent centrifugal elutriation of leukopheresis packs from HIV-1 , 2 and hepatitis B seronegative donors. Monocytes are cultivated in suspension culture using Teflon flasks in Dulbecco's Modified Eagle's Medium (DMEM, Sigma- Aldrich) supplemented with 10 % heat-inactivated pooled human serum, 1 % glutamine, 50 μg/mL gentamicin, 10 μg/mL ciprofloxacin (Sigma), and 1000 LVmL highly purified recombinant human macrophage colony stimulating factor. After seven days in culture, MDM are infected with HTV- 1ADA at multiplicity of infection of 0.01.
2. Hu-PBL-NOD/SCID HIVE mice
Four-wk old male NOD/C.B-17 SCID mice can be purchased (Jackson Laboratory). Animals are maintained in sterile microisolator cages under pathogen-free conditions. All animals are injected intraperitoneally with rat anti-CD 122 (0.25 mg/mouse) three days before PBL transplantation and twice with rabbit asialo-GMl antibodies (0.2 mg/mouse) (Wako) one day before and three days after PBL injection (20 x 106 cells/mouse). HIV-I ADA-infected MDM (3 x 10s cells in 10 μL) are injected intracranially (i.e.) eight days following PBL reconstitution generating hu-PBL-NOD/SCID HIVE mice. Immediately following i.e. injection of HIV-I infected MDM the hu-PBL-NOD/SCID HIVE mice are subcutaneously (s.c) implanted with control (vehicle) or compound pellets (14 or 28 day slow release, Innovative Research). Initial experiments are designed to confirm the induction of virus- specific CTL in the hu PBL-NOD/SCID HIVE animals treated with EDO compounds. This is confirmed by tetramer staining and neuropathologic analyses of MDM elimination from the brain tissue. Then, the experiment is designed to analyze human lymphocyte reconstitution, humoral immune responses, and neuropathological alterations. In these experiments, animals are bled on day 7 and sacrificed at 14 and 21 days after i.e. injection of human MDM. Blood collected in EDTA- containing tubes is used for flow cytometry and plasma is used for detection of HJV-I p24 using ELISA (Beckman Coulter™). HIV-I -specific antibodies are detected by Western blot tests according to the manufacturer instructions (Cambridge Biotech HIV-I Western blot kit, Calypte Biomedical). Similar amount of virus-specific antibodies are detected in control and compound-treated animals. A total of three independent experiments can be performed using three different human leukocyte donors.
3. FACScan of peripheral blood and spleen in hu PBL-NOD/SCID HIVE mice
Two-color FACS analysis can be performed on peripheral blood at wk 1 -3 and splenocytes at wk 2 and 3 after i.e. injection of human MDM. Cells are incubated with fluorochrome-conjugated monoclonal Abs (mAbs) to human CD4, CD8, CD56, CD3, IFN-γ (eBioscience) for 30 min at 4 0C. To evaluate the cellular immune response, DFN-γ intracellular staining is performed in combination with anti-human CD8 and FITC-conjugated anti-mouse CD45 to exclude murine cells. To determine the Ag-specific CTL, allophycocyanin-conjugated tetramer staining for HIV-I838 (pl7 (aa77-85) SLYNTVATL, SL-9) and HIV-lpo1 [(aa476-485) ILKEPVHGV, IL-9] is performed on phytohemaglutinin/interleukin-2 (PHA/IL-2)- stimulated splenocytes. Cells are stained following the recommendation of the NIH/National Institute of Allergy and Infections Disease, National Tetramer Core Facilities. Data were analyzed with a FACS Calibur™ using CellQuest software (Becton Dickinson Immunocytometry System).
4. Histopathology and image analyses Brain tissue is collected at days 14 and 21 after i.e. injection of MDM, fixed in 4 % phosphate-buffered paraformaldehyde and embedded in paraffin or frozen at -80 0C for later use. Coronal sections from the embedded blocks are cut in order to identify the injection site. For each mouse, 30-100 (5-μm-thick) serial sections are cut from the human MDM injection site and 3-7 slides (10 sections apart) are analyzed. Brain sections are deparaffϊnized with xylene and hydrated in gradient alcohols. Immunohistochemical staining follows a basic indirect protocol, using antigen retrieval by heating to 95 0C in 0.01 mol/L citrate buffer for 30 min for antigen retrieval. To identify human cells in mouse brains, inAb to vimentin (1 :50, clone 3B4, Dako Corporation), which identifies all human leukocytes is used. Human MDM and CD8+ lymphocytes are detected with CD68 (1:50 dilution, clone KP 1) and CD8 (1 :50 dilution, clone 144B) antibodies, respectively. Virus-infected cells are labeled with mAb to HIV-I p24 (1 :10, clone KaI-I, all from Dako). Reactive murine microglial cells are detected with Iba-1 antibody (1:500, Wako). Expression of human IDO (huEDO) is visualized with Abs obtained from the Department of Cell Pharmacology, Central Research Institute, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Primary antibodies are detected with the appropriate biotinylated secondary antibodies and visualized with avidin-biotin complexes (Vectastain Elite ABC kit, Vector Laboratories) and horseradish peroxidase (HRP) coupled dextran polymer (EnVision, Dako Corporation). Immunostained sections are counterstained with Mayer's hematoxylin. Sections from which primary antibody is deleted or irrelevant IgG isotype is incorporated served as controls. Two independent observers in a blinded fashion count the numbers of CD8+ lymphocytes, CD68+ MDM and HIV-I p24+ cells in each section from each mouse. Light microscopic examination is performed with a Nikon Eclipse 800 microscope (Nikon Instruments Inc).
Semi-quantitative analysis for Ibal (percentage of area occupied by immunostaining) is carried out by computer-assisted image analysis (Image-Pro®Plus, Media Cybernetics) as previously described.
J. Statistic analysis Data can be analyzed using Prism (Graph Pad) with Student Mest for comparisons and
ANOVA. P- values < 0.05 were considered significant.
6. Reference
Poluektova LY, Munn DH, Persidsky Y, and Gendelman HE (2002). Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-I encephalitis. J. Immunol. 168(8):3941-9.
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.
Claims
1. A compound of Formula Ia:
Ia or pharmaceutically acceptable salts or prodrugs thereof, wherein:
U is N, O, S, CR , or NR";
V, and W are each, independently, N, O, S, CR2, or NR3, wherein the five-membered ring containing U, V, and W is an aromatic heterocycle;
A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, C)-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C|_6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, halosulfanyl, Cy1, CN, NO2, OR", SRa, C(O)Rb, C(O)NRcRd, C(O)OR8, OC(O)R", OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NRi)NRcRd, NR°C(=NRi)NRcRd, P(R^2, P(ORe)2) P(O)R6R', P(O)OReORf, S(O)Rb, S(O)NR°Rd, S(O)2R", NRcS(O)2Rb, and S(O)2NRcRd, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl is optionally substituted with 1, 2, or 3 substitutents independently selected from Cy1, CN, NO2, OR", SR3, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(=NR')NRcRd, NRcC(=NRi)NRcRd > P(Rf)2, P(ORe)2, P(O)ReRf, P(O)OReORf, S(O)Rb, S(O)NRcRd, S(O)2R", NR0S(O)2R", and S(O)2NR0R";
R is H, C(O)R5, C(O)OR6, or C(O)NR6aR6b;
RA and RB are independently selected from H, F, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C)-6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, halosulfanyl, CN, NO2, ORaI, SRal, C(O)Rbl, C(O)NRclRdl, C(O)OR3', OC(O)Rbl, OC(O)NRclRdl, NRclRdl, NRclC(O)Rbl, NRclC(O)NRclRdl, NR0' C(O)OR" ', C(=NR')NRclRdl, NR°'C(=NRi)NRclRdl, P(Rπ)2, P(ORel)2, P(O)RelRn, P(O)ORelORπ, S(O)Rbl, S(O)NR0lRdl, S(O)2R1", NRcIS(O)2Rbl, and S(O)2NRclRdI; wherein said C1-6 alkyl, C2.6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, C1-4 hydroxyalkyl, Ci-4 cyanoalkyl, halosulfanyl, CN, NO2, ORal, SRal, C(O)Rbl, C(O)NR0lRdI, C(O)OR"1, OC(O)Rbl, NRc)Rdl, NRclC(O)Rbl, NRclC(O)NRclRdl, NR01C(O)OR"1, C(=NRi)NRclRdl, NRclC(=NRi)NRoIRdl, P(Rn)2, P(ORel)2, P(O)ReIRn, P(O)ORclORn, S(O)Rbl, S(O)NRclRdl, S(O)2Rbl, NRclS(O)2Rbl, and S(O)2NRclRdl; or RA and RB together with the carbon atom to which they are attached form a 3-, A-, 5-, 6-, or 7- membered cycloalkyl group or 3-, 4-, 5-, 6-, or 7- membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C 1.4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1.4 haloalkyl, C1.4 hydroxyalkyl, Ci-4 cyanoalkyl, halosulfanyl, CN, NO2, ORal, SRal, C(O)Rbl, C(O)NR0lRdl, C(O)OR"1, OC(O)Rbl, OC(O)NRclRdl, NRclRdl, NRclC(O)Rbl, NR0lC(O)NRCIRdl, NRclC(O)ORal, Cf=NRONR01R"1, NR01CC=NRONR01R111, P(RΠ)2, P(ORel)2, P(O)RelRπ, P(O)OR61OR", S(O)RbI, S(O)NRclRdI, S(O)2Rbl, NRclS(O)2Rbl, and S(O)2NRcIRdl; or RA and RB, together with the carbon atom to which they are attached, form a C=CH2 group;
Q is ORQ, OC(O)R0, OC(O)NR4R0, NR4R0, NR4C(O)R0, NR4C(O)NR4R0, NR4C(O)OR0, NR4S(O)R0, NR4S(O)2R0, NR4Ct=NRONR4R0, SR0, S(O)R0, S(O)NR4R0, S(O)2R0, S(O)2NR4R0, C(O)R0, C(O)OR0, C(O)NR4R0, halo, cyano, azido, or nitro; or Q is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, each optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, Ci-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, C]-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, halosulfanyl, CN, NO2, ORa2, -(C]-4 alkyl)-ORa2, SRa2, -(Ci-4 alkyl)-SRa2, C(O)Rb2, -(C1-4 alkyl)- C(O)Rb2, C(O)NRc2Rd2, -(C,.4alkyl)-C(O)NRc2Rd2 ) C(O)OR82, -(C1-4 alkyl)-C(O)ORa2, OC(O)Rb2, - (C1-4 alkyl)-OC(O)Rb2, OC(O)NR02R"2, NR02R"2, -(C,-4alkyl)-NRc2Rd2, NRc2C(O)Rb2, -(C1-4 alkyl)-NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, -(C1-4 alkyl)-NRc2C(O)NRc2Rd2, NR02C(O)OR32, -(C1-4 alkyl)-NRc2C(O)ORa2, C(=NRi)NRc2Rd2, NRc2C(=NRi)NRc2Rd2, P(Rβ)2, P(ORe2)2, P(O)R02R12, P(O)OR02OR*2, S(O)Rb2, -(C1-4 alkyi)-S(O)Rb2, S(O)NRc2Rd2, -(CMalkyl)- S(O)NR02R"2, S(O)2Rb2, -(C,.4alkyl)-S(O)2Rb2 5 NRc2S(O)2Rb2, -(C1-4 alkyl)-NRc2S(O)2Rb2, S(O)2NR02R"2 , and -(C,.4 alkyl)-S(O)2NRc2Rd2;
R0 is H, C]-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, halosulfanyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NR02R"2, C(O)OR32, OC(O)R"2, OC(O)NR02R"2, NR02R"2, NRc2C(O)Rb2, NR02C(O)NR02R"2, NR02C(O)OR"2, C(=NRi)NRc2R<12, NR02CC=NRONR02R"2, PCRβ)2, PCORe2)2, PCO)Re2RG, PCO)ORe2ORΩ, S(O)R"2, S(O)NR=2R"2, S(O)2Rb2, NRc2SCO)2Rb2, and S(O)2NR02R"2; or R4 and R° together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group or 5-20 membered heteroaryl group, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, halosulfanyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, OR32, -CC1. 4 alkyl)-ORn2, SRa2, -(C1-4 alkyl)'-SR°2, C(O)R62, -(C1-4 alkyl)-C(O)Rb2, C(O)NRc2Rd2, -(Cj-4 alkyl)- C(O)NR02R"12, C(O)OR32, -(CM alkyl)-C(O)ORa2, OC(O)Rb2, -(Cj-4 alkyl)-OC(O)Rb2, OC(O)NRc2Rd2, -(C1-43HCyI)-OC(O)NR02R"2, NR02R"2, -(C1-4 alkyφ-NR^R"2, NRc2C(O)Rb2, -(C1-4 alkyl)-NRc2C(O)Rb2, NR02C(O)NR=2R"2, -(C-43HCyI)-NR02C(O)NR02R"2, NRc2C(O)ORa2, -(C1-4 alkyl)-NR02C(O)ORa2, C(=NRi)NRc2Rd2, NRc2C(=NRi)NRc2R"2, P(Rβ)2, P(ORe2)2) P(O)Re2RG, P(O)OR62OR12, S(O)Rb2, -(C1-4 alkyl)-S(O)Rb2, S(O)NR02R"2, -(CM aIlCyI)-S(O)NR02R"2, S(O)2Rb2, -(Ci-4alkyl)-S(O)2Rb2, NR02S(O)2R"2, -(C1-4 alkyl)-NRc2S(O)2Rb2, S(O)2NR02R"2 , and
Cy, Cy1, and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocyclpalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, halosulfanyl, CN, NO2, ORaϊ, SR"3, C(O)Rb3, C(O)NRc3R"3, C(O)OR33, OC(O)Rb3, OC(O)NRc3Rd3, NRo3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, C(=NRi)NRc3R"3, NRo3C(=NRi)NRc3Rd3, P(Rβ)2, P(ORe3)2, P(O)Re3Rβ, P(O)ORe3OR°, S(O)Rb\ S(O)NR03R"3, S(O)2Rb3, and S(O)2NR03R"3;
R1 is H or C1-4 alkyl;
R2 is H5 halo, C]-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, CN, NO2, OH, C1-4 alkoxy, amino, C1-4 alkylamino, or C2.8 dialkylamino;
R3 is H, C)-4 alkyl, C2.4 alkenyl, or C2-4 alkynyl;
R4 is H, Cj-4 alkyl, C2.4 alkenyl, C2-4 alkynyl, C(O)-R4a, SO2-R4\ aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, Cj.6 haloalkyl, Cj-6 hydroxyalkyl, C1-6 cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halosulfanyl, CN, NO2, ORa\ SRa4, C(O)R"4, C(O)NR04R"4, C(O)OR"4, OC(O)RM, OC(O)NR04R"4, NRo4Rd4, NRe4C(6)Rb4, NR04C(O)NR0V, NR04C(O)OR34, C(=NR')NRC4R"4, NR04C(HNR1-)NR0V4, P(Rf4)2, P(ORe4)2, P(O)R6V4, P(O)ORe4ORf4, S(O)R54, S(O)NR04R"4, S(O)2RM, NR04S(O)2R64, and S(O)2NR04R"4;
R4a is H, Ci-4 alkyl, C2.4 alkenyl, C2-4 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl;
R5 and R6 are independently selected from H, Ci-8 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, each optionally substituted by one or more substituents independently selected from halo, CN, NO2, OH, Ci-4 alkoxy, C^haloalkoxy, amino, Ci-4 alkylamino, C2-8 dialkylamino, Ci.e alkyl, C2,6 alkenyl, and C2- 6 alkynyl;
R6a and R6b are independently selected from H, Ci-8 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, each optionally substituted by one or more substituents independently selected from halo, CN, NO2, OH, Ci-4 alkoxy, Ci.4haloalkoxy, amino, Ci-4 alkylamino, C2-8 dialkylamino, C2.β alkenyl, and C2. 6 alkynyl; R\ Ral, Ra3, Ra4, and Ra5 are independently selected from H, C]-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl;
Rb, RbI, Rb3, RM, and Rb5 are independently selected from H, C,.6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2.6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C]-6 alkyl, Ci.6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C]-6 alkyl, C1-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl;
Ra2 is H, C1-6 alkyl, Cj-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cy2, or Cy2^-(C1-6 alkyl)-, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl, is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C]-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C1-6 hydroxyalkyl, C,.6 cyanoalkyl, halosulfanyl, Cy2, CN, NO2, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)OR85, OC(O)Rb5, OC(O)NRc5Rd5, NR05R"5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(=NRi)NRc5Rd5, NRcSC(=NRi)NRc5Rd5, P(Rβ)2, P(ORe5)2, P(O)R65R15, P(O)ORe5ORβ, S(O)Rb5, S(O)NRc5Rd5, Rb2, S(O)2R"5, NRc5S(O)2Rb5, and S(O)2NR0V5;
Rb2 is H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, Cy2, or wherein said C]-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, or aryl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, halosulfanyl, Cy2, CN, NO2, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)OR"5, OC(O)R"5, OC(O)NRcSRd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(=NRi)NRc5Rds, NRc5C(=NRi)NRo5Rds, P(R^)2, P(ORe5)2l P(O)Re5Rβ, P(O)ORe5ORβ, S(O)Rb5, S(O)NRc5Rd5, S(O)2R"5, NRc5S(O)2Rb5, and S(O)2NRc5Rd5;
Rc and Rd are independently selected from H, C1-10 alkyl, Q-β haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C,_i0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C1-6 alkyl, Ci-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
Rcl and Rdl are independently selected from H, Ci-10 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C1-I0 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, C1-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or Rcl and Rdl together with the N atom to which they are attached form a A-, S-, 6- or 7- membered heterocycloalkyl group;
Rc2 and Rd2 are independently selected from H, Ci-I0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cy2 and C^-(CL6 alkyl)-, wherein said Ci-I0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, is optionally substituted with 1, 2, or 3, substitutents independently selected from halo, C1.4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NR03R"3, C(O)OR33, OC(O)R"3, OC(O)NR03R113, NR03R"3, NRc3C(O)Rb3, NRc3C(O)ORa3, C(=NRi)NRc3Rd3, NRc3C(=NRi)NRo3Rd3, P(R0)2, P(ORe3)2, P(O)Re3Rβ, P(O)ORe3OR°, S(O)Rb3, S(O)NR0V3, S(O)2R"3, and S(O)2NRc3Rd3; or R°2 and 1R!32 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group optionally substituted with 1, 2, or 3, substitutents independently selected from Cy2, Cy2 -(Ci-6 alkyl)-, halo, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, halosulfanyl, CN, NO2, OR"3, SRa3, C(O)Rb3, C(O)NR°3Rd3, C(O)OR"3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NR03C(O)R"3, NRc3C(O)ORa3, C(=NRi)NRo3Rd3, NRc3C(=NRi)NRc3Rd3, P(R°)2, P(ORc3)2, P(O)R63R*3, P(O)ORe3ORα, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NR03R113;
R°3 and R03 are independently selected from H, Ci-J0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said Ci-)0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C)-6 alkyl, Cj-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
R°4 and Rd4 are independently selected from H, CMO alkyl, Ci-6 haloalkyl, C2.6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said CM0 alkyl, C)-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci-6 alkyl, Cj-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or Rc4 and Rd4 together with the N atom to which they are attached form a 4-, S-, 6- or 7- membered heterocycloalkyl group;
Rc5 and Rds are independently selected from H, CMO alkyl, C].6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said CM0 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocyclo- alkylalkyl is optionally substituted with OH, amino, halo, Ci.6alkyl, Ci.6haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or RcS and RdS together with the N atom to which they are attached form a A-, 5-, 6- or 7- membered heterocycloalkyl group;
Re, Rel, Re2, Re3, Re4, and Re5 are independently selected from H, CU6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, (C1-6 alkoxy)-Ci-6 alkyl, C2.6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocycloalkylalkyl;
Rf, Rfl, R°, R°, RM, and Rβ are independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C2.6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl;
R' is H1 CN, C(O)NH2, or NO2;
R' is H, halo, C1-I0 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy3 Cy-(C1-6 alkyl)-, CN, NO2, ORa3, SRa3, C(O)R"3, C(O)NRc3Rd3, C(O)OR33, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd\ NRc3C(O)Rb3, NR03C(O)OR03, S(O)RM, S(O)NRc3Rd3, S(O)2Rb3, or S(O)2NR03R113; wherein said C1-10 alkyl, C2.6 alkenyl, or C2-6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from CN, NO2, Cy, Cy-(C1-6 alkyl)-, ORa3, SRa3, C(O)NR03R"3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NR03R*3, NRc3C(O)Rb3, NR03C(O)OR"3, C(=NRi)NRc3Rd3, NRc3C(=NRi)NRc3Rd3, P(R°)2, P(ORe3)2, P(0)Re3R°, P(O)ORe3ORD, S(O)Rb3, S(O)NR03R"3, S(O)2R"3, and S(O)2NR03R113;
R" is H, C1-10 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, Cy-(C6 alkyl)-, C(O)Rb3, C(O)NR03R113, C(O)OR83, S(O)R", S(O)NRc3Rd3, S(O)2Rb3, or S(O)2NRc3Rd3; wherein said C1-10 alkyl, C2-6 alkenyl, or C2-6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from CN, NO2, Cy, -(C1-6 alkyl)-Cy, ORa3, SRa3, C(O)R"3, C(O)NR03R113, C(O)OR33, OC(O)R"3, OC(O)NR03R113, NRo3Rd3, NR03C(O)R", NR03C(O)OR03, C(=NRi)NRe3Rd3, NRc3C(=NRi)NRc3Rd3, P(R°)2, P(ORe3)2, P(O)Rc3R°, P(O)OR63OR13, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NR03R113; and p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
2. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein V is O.
3. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein U is N.
4. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein W is N.
5. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein U and W are both N.
6. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein U and W are both N and V is O.
7. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein at least one of U, V and W is N.
8. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein at least one of U, V and W is N and another of U. V, and W is O or S.
9. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein A is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, C]-6 alkyl, C2. 6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, C]-6 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)R", C(O)NRcRd, C(O)OR0, OC(O)Rb, OC(O)NRcRd, NR°Rd, NRcC(O)Rb, NR°C(O)NR°Rd, NR0C(O)OR3, C(=NR')NRcRd, NRcC(=NRi)NRcRd, P(Rf)2, P(ORe)2, P(O)RT*/, P(O)ORORf, S(O)Rb, S(0)NRcRd, S(O)2Rb, NRcS(O)2Rb, and S(O)2NRcRd, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl is optionally substituted with 1, 2, or 3 substitutents selected from Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)OR3, OC(O)Rb, OC(O)NRcRd, NR°Rd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, Ct=NR^NR12R", NRcC(=NRi)NRcRd, P(Rf)2, P(ORe)2, P(O)ReRf, P(O)ORORf, S(O)Rb, S(O)NRcRd, S(O)2R", NR0S(O)2R", and S(O)2NRcRd.
10. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, Ci.6 alkyl, C2.6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy1, CN, NO2, OR\ SRa, C(O)Rb, C(O)NRcRd, C(O)OR", OC(O)Rb, OC(O)NRcRd, NRcRd, NR0C(O)R", NRcC(O)NRcRd, NRcC(O)ORa, C(=NR1')NR°Rd, NRcC(=NRi)NReRd, P(Rf)2, P(ORe)2, P(O)ReRf, P(O)ORORf, S(O)R", S(O)NRcRd, S(O)2R", NR0S(O)2R", and S(O)2NRcRd, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl is optionally substituted with 1, 2, or 3 substitutents selected from Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NR0R", C(O)OR", OC(O)R", OC(O)NR0R", NR°Rd, NR0C(O)R", NR°C(O)NRcRd, NR0C(O)OR3, C(=NRi)NR°Rd, NR0Ct=NR1-)NR0R", P(Rf)2, P(ORe)2, P(O)ReRf, P(O)OReORf, S(O)Rb, S(O)NR0R", S(O)2R", NR0S(O)2R", and S(O)2NR°Rd.
11. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, C1-6 cyanoalkyl, CN, NO2, OR0, SR", C(O)R", C(O)NR0R", C(O)OR", OC(O)R", OC(O)NR0R", NR°Rd, NR0C(O)R", NR0C(O)NR0Rd, NR0C(O)OR", S(O)R", S(O)NR°Rd, S(O)2R", NR0S(O)2R", and S(O)2NR°Rd.
12. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein A is phenyl optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, Ci-6 alkyl, and Ci-6 haloalkyl.
13. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Q is H, CN, ORQ, OC(O)NR4R0, C(O)OR0, NR4R0, NR4C(O)R0, NR4C(O)NR4R0, NR4C(O)OR0, NR4S(O)2R0, or OC(O)NR4R0.
14. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Q is OR0, OC(O)NR4R0, Or NR4R0.
15. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Q is OR0.
16. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Q is NR4R0.
17. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Q is NR4R0 and R4 and R° together with the N atom to which they are attached form a 4-20 membered heterocycloalkyl group or 5-20 membered heteroaryl group, each optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, Cj-6 haloalkyl, Ci-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, -(C1-4 alkyl)-ORa2, SRa2, -(C1-4 alkyl)-SRa2, C(O)Rb2, -(CM alkyl)-C(O)RbZ, C(O)NRc2Rd2, -(C1-4 alkyl)-C(O)NRc2Rd2, C(O)OR32, -(C1. 4 alkyl)-C(O)ORa2, OC(O)Rb2, -(C1-4 alkyl)-OC(O)Rb2, OC(O)NR02R"2, -(C1-4 alkyl)-OC(O)NRc2Rd2, NRc2Rd2, -(C1-4 alkyO-NR^R*2, NRc2C(O)Rb2, -(C1-4 alkyl)-NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, -(C1-4 alkyl)-NRc2C(O)NRc2Rd2, NR02C(O)OR"2, -(C1-4 alkyl)-NRc2C(O)ORa2, C(=NRi)NRc2Rd2, NRc2C(=NRi)NRc2Rd2, P(Rβ)2, P(ORc2)2, P(O)R62R*2, P(O)ORe2ORD, S(O)Rb2, -(C1-4 alkyl)-S(O)Rb2, S(O)NR02R112, -(C1-4 alkyl)-S(O)NRc2Rd2, S(O)2R52, -(C1-4 alkyl)-S(O)2Rb2, NRc2S(O)2Rb2, -(C1-4 alkyl)- NRc2S(O)2Rb2, S(O)2NR02R"2, and -(CMaIlCyI)-S(O)2NR02R112.
18. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Q is NR4R0 and R4 and R° together with the N atom to which they are attached form a 5-20 membered heteroaryl group, optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, CL6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C]-6 cyanoalkyl, Cy, -(C]-4alkyl)-Cy, CN, NO2, ORa2, - (C1-4 alkyl)-ORa2, SR"2, -(C1-4 alkyl)-SRa2, C(O)Rb2, -(C1-4 alkyl)-C(O)Rb2, C(O)NR02R"2, -(C1-4 alkyl)- C(O)NR02R112, C(O)OR32, -(C,.4 alkyl)-C(O)ORa2, OC(O)Rb2, -(C1-4 alkyl)-OC(O)Rb2, OC(O)NR02R112, -(C1-43UCyI)-OC(O)NR02R112, NRc2Rd2, -(CMalkyl)-NRc2Rd2, NRc2C(O)Rb2, -(C1-4 alkyl)-NR02C(O)R°2, NR02C(O)NR02R"2, -(C4 alkyl)-NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, -(C1-4 alkyl)-NRc2C(O)ORa2, C(=NRi)NRc2Rd2, NRo2C(=NRi)NRc2Rd2, P(Rβ)2, P(ORc2)2, P(O)R=2R12, P(O)OR02OR*2, S(O)Rb2, -(C1-4 alkyl)-S(O)Rb2, S(O)NRc2Rd2, -(C1-4 HHCyI)-S(O)NR02R"2, S(O)2R"2, -(C-4 alkyl)-S(O)2Rb2, NRc2S(O)2Rb2, -(C1-4 alkyl)-NRc2S(O)2Rb2, S(O)2NR02R"12 , and -(C1-43I-CyI)-S(O)2NR02R"2.
19. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Q is NR4RQ and R4 and RQ together with the N atom to which they are attached form a tetrazolyl, triazolyl, or iπiidazolyl group which is optionally with 1 or 2 halo, C]-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce haloalkyl, C1-6 hydroxyalkyl, C]-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, -(C1-4 alkyl)-ORa2, SRa2, -(C1-4 alkyl)-SRa2, C(O)Rb2, -(C1-4 alkyl)-C(O)Rb2, C(O)NR02R"2, -(C1-4 BHCyI)-C(O)NR02R"2, C(O)OR82, -(C1-4 alkyl)-C(O)ORa2, OC(O)Rb2, -(C1-4 alkyl)-OC(O)Rb2, OC(O)NR02R112, -(C4 alkyl)- OC(O)NR02R112, NR02R"2, -(CM alkyl^NR^R"2, NR02C(O)R02, -(CM alkyl)-NRc2C(O)Rb2, NR02C(O)NR02R"2, -(C1-4 alkyl)-Mt02C(O)NRc2Rd2, NR02C(O)OR32, -(C1-4 alkyl)-NR02C(O)ORa2, S(O)Rb2, -(C1-4 alkyl)-S(O)Rb2, S(O)NR02R"2, -(C-4 alkyl)-S(O)NRc2Rd2, S(O)2Rb2, -(C1-4 alkyl)- S(O)2Rb2, NRc2S(O)2Rb2, -(C1^ aIlCyI)-NR02S(O)2R"2, S(O)2NR02R"2 , and -(C1-4 3IkYl)-S(O)2NR02R112.
20. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Q is NR4RQ and R4 and RQ together with the N atom to which they are attached form a tetrazolyl group which is optionally substituted with 1, 2, or 3 substitutents selected from halo, C1-6 alkyl, C1-6 haloalkyl, and NR=2R"2.
21. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Q is NR4RQ and R4 and RQ together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, Cj-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, C6 cyanoalkyl, Cy, -(C1-4 alkyl)- Cy, CN, NO2, ORa2, -(C1-4 alkyl)-ORa2, SRa2, -(C1-4 alkyl)-SRa2, C(0)Rb2, -(C1-4 alkyl)-C(O)Rb2, C(O)NR02R"2, -(C1-43IkYl)-C(O)NR02R"2, C(O)OR32, -(C1-4 alkyl)-C(O)ORa2, OC(O)Rb2, -(C1-4 alkyl)- OC(O)Rb2, OC(O)NR02R"2, -(C4 8IlCyI)-OC(O)NR02R"2, NR02R"2, -(C1-43IlCyI)-NR02R"2, NR02C(O)R1*, -(C1-4 alkyl)-NRc2C(O)Rb2, NR02C(O)NR02R"2, -(C43IkYl)-NR02C(O)NR02R"2, NR02C(O)OR"2, -(C-4 alkyl)-NRc2C(O)ORa2, C(=NRi)NRc2Rd2, NRc2C(=NRi)NRo2Rd2, P(Rβ)2, P(ORe2)2, P(O)Re2Rβ, P(O)ORe2ORG, S(O)Rb2, -(C1-4 3HCyI)-S(O)R"2, S(O)NR02R"2, -(C1-43IkYl)-S(O)NR02R"2, S(O)2R"2, - (C1-4 alkyl)-S(O)2Rb2, NRc2S(O)2Rb2, -(C1-4 alkyl)-NRc2S(O)2Rb2, S(O)2NR02R"2 , and -(C1-4 alkyl)- S(O)2NR02R"2.
22. The compound of cl3im 1, or phsrmsceuticslly acceptable salt thereof, wherein Q is NR4RQ and R4 3nd RQ together with the N atom to which they are attached form piperidinyl, morpholino, piperazinyl, 2,3-dihydro-lH-isoindolyl, or 1,2,3,4-tetrahydro-isoquinoline, each optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, Ci-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, -(Cj-4 alkyl)-ORa2, SR"2, -(C1- 4 alkyl)-SRa2, C(O)Rb2, -(C1-4 alkyl)-C(O)Rb2, C(O)NR02R112, -(C1-43HCyI)-C(O)NR02R"2, C(O)OR"2, - (C1-4 alkyl)-C(O)ORa2, OC(O)Rb2, -(Ci-4alkyl)-OC(O)Rb2, OC(O)NR02R"12, -(C1-4 alkyl)- OC(O)NRc2Rd2, NR02R"2, -(CM aHCyI)-NR02R112, NRc2C(O)Rb2, -(C1-4 alkyl)-NRc2C(O)Rb2, NR02C(O)NR02R112, -(C1-4 alkyl)-NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, -(C1-4 alkyl)-NRc2C(O)ORa2, C(=NRi)NRc2Rd2, P(RD)2, P(ORe2)2, P(O)Re2Re, P(O)ORe2ORG, S(O)R"2, -(C1-4 alkyl)-S(O)Rb2, S(O)NR02R"2, -(C1-48HCyI)-S(O)NR02R112, S(O)2R"2, -(CMalkyl)-S(O)2Rb2, NR02S(O)2R"2, -(C,.4 alkyl)-NR02S(O)2Rb2, S(O)2NR02R"2 , and -(C1-4 BIlCyI)-S(O)2NR02R"2.
23. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R^ is H, C1-6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said C 1.6 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, C1-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, Ci-6 haloalkyl, Ci.6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NR02R"2, C(O)OR82, OC(O)Rb2, OC(O)NR02R"2, NR02R"2, NRc2C(O)Rb2, NR02C(O)NR02R"2, NR02C(O)OR"2, C(=NRi)NRo2Rd2 3 NRc2C(=NRi)NRo2R"2, P(RC)2, P(ORe2)2) P(O)Ro2RG, P(O)ORe2ORG, S(O)R"2, S(O)NR02R"2, S(O)2R"2, NR02S(O)2R"2, and S(O)2NR02R"2.
24. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein RQ is C1-6 alkyl optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, CL6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, OR"2, SRa2, C(O)R"2, C(O)NR02R"2, C(O)OR32, OC(O)R"2, OC(O)NR02R"2, NR02R"2, NR02C(O)R"2, NR02C(O)NR02R"2, NR02C(O)OR82, C(=NRi)NRc2Rd2, NRo2C(=NRi)NRo2Rd2, P(Rβ)2, P(ORe2)2, P(O)R62R12, P(O)ORe2ORβ, S(O)Rb2, S(O)NR02R"2, S(O)2R"2, NR02S(O)2R"2, and S(O)2NR02R"2.
25. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein RQ is aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, C1-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, Cj-6 haloalkyl, Ci-6 hydroxyalkyl, C1-6 cyanoalkyl, Cy, -(C1-4 alkyl)-Cy, CN, NO2, OR*2, SR"2, C(O)R"2, C(O)NR02R"2, C(O)OR02, OC(O)Rb2, OC(O)NR02R"2, NR02R"2, NRc2C(O)Rb2, NR02C(O)NR02R"2, NRc2C(O)ORa2, C(^NRONR02R"2, NRo2C(=NRi)NRo2R"2, P(R^)2, P(ORe2)2, P(O)R02R*2, P(O)ORc2ORβ, S(O)R"2, S(O)NR02R"2, S(O)2R"2, NR02S(O)2R"2, and S(O)2NR02R"2.
26. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R4 is H, Ci-4 alkyl, C(O)-R4", SO2-R4", aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein said Ci-4 alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5 substituents selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C1-6 hydroxyalkyl, Cμβ cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, CN, NO2, ORa4, SRa4, C(O)R"4, C(O)NRCV4, C(O)OR84, OC(O)R54, OC(O)NRc4Rd4, NRc4Rd4, NR04C(O)R"4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NR!)NRc4Rd4, NRc4C(=NRi)NRc4Rd4, P(Rf4)2, P(ORe4)2, P(O)Re4Rf4, P(O)ORe4ORf4, S(O)RM, S(O)NRc4Rd4, S(O)2RM, NR04S(O)2R1^, and S(O)2NRc4Rd4.
27. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R4 is H.
28. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein RA and RB are independently selected from H, F, and Ci.6 alkyl.
29. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein RA and RB are both H.
30. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R1 is H.
31. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R is H.
32. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R2 is H.
33. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R3 is H.
34. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein p is 1, 2, 3, 4 or 5.
35. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein p is 1 or 2.
36. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein p is 1.
37. The compound of claim 1 having Formula I:
38. The compound of claim 1 having Formula Ha:
39. The compound of claim 1 having Formula II:
40. The compound of claim 1 having Formula III:
41. The compound of claim 1 selected from:
N-(3-chloro-4-fluoro-phenyl)-Nl-hydroxy-4-hydroxymethyl-furazan-3-carboxamidine;
^-(S-chloro^-fluoropheny^-N'-hydroxy-^-^henoxymethy^-l^jS-oxadiazole-S-carbox- imidamide;
4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3-yl- methyl phenylcarbamate; 4-[(ben2ylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2,5-oxadiazole-3- carboximidamide;
7/-(3-chloro-4-fluorophenyl)-4-[(2-chlorophenoxy)methyl]-Nl-hydroxy-l,2,5-oxadiazole-3- carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-[(3-chlorophenoxy)methyl]-Nl-hydroxy-l,2,5-oxadiazole-3- carboximidamide;
Λ/-(3-chloro-4-fluorophenyl)-4-[(4-chlorophenoxy)methyl]-Ν'-hydroxy-l,2,5-oxadiazole-3- carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(2-methoxyphenoxy)methyl]-l,2,5-oxadiazole-3- carboximidamide;
Λ/-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(3-methoxyphenoxy)methyl]-l,2,5-oxadiazole-3- carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(4-methoxyphenoxy)methyl]-l,2,5-oxadiazole-3- carboximidamide;
Λ/-(3-chloro-4-fluorophenyl)-4-[(3-cyanophenoxy)methyl]-N'-hydroxy-l,2,5-oxadiazole-3- carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-[(4-chloro-2-methoxyphenoxy)methyl]-N'-hydroxy-l,2,5-oxa- diazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-[(3,4-dimethoxyphenoxy)methyl]-N'-hydroxy-l ,2,5-oxa- di azole-3 -carboximidamide;
{4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3-yl}- methyl phenylcarbamate;
{4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3-yl}- methyl isopropylcarbamate;
N-(3-chloro-4-fluorophenyl)-iV-hydroxy-4-(piperidin-l-ylmethyl)-l,2,5-oxadiazole-3- carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-[(dimethylamino)methyl]-NI-hydroxy-l,2,5-oxadiazole-3- carboximidamide;
N-(3-chloro-4-fluorophenyl)-iV-hydroxy-4-[(4-phenylpiperazin-l-yl)methyl]-l,2,5-oxa- diazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-Λ/'-hydroxy-4-[(isoxazol-3-ylamino)methyl]-l,2,5-oxadiazole-3- carboximidamide;
4- { [( 1 -benzylpiperidin-4-yl)amino]methyl } -N-(3-chloro-4-fluorophenyl)-Ν'-hydroxy-l ,2,5- oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-Λ/l-hydroxy-4-{[4-(2-methoxyphenyl)ρiperazin-l-yl]methyl}- l,2,5-oxadiazole-3-carboximidamide; N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4- {[(pyridin-2-ylmethyl)amino]methyl} -1 ,2,5-oxa- diazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-{[(2-phenylethyl)amino]methyl}-l,2,5-oxa- diazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-{[(3-phenylpropyl)amino]methyl}-l,2,5-oxa- diazole-3 -carboximidami de;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-({[(lR)-l-phenylethyl]amino}methyl)-l,2,5-oxa- diazole-3 -carboximidami de;
4-{[(2-chlorobenzyl)amino]methyl}-iV-(3-chloro-4-fluorophenyl)-Ν'-hydroxy-l,2,5-oxa- diazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-{[(4-phenylbutyl)amino]methyl}-l,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-(3,4-dihydroisoquinolin-2(lH)-ylmethyl)-N'-hydroxy-l,2,5- oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-(2,3-dihydro-lH-indol-l-ylmethyl)-Nl-hydroxy-l,235- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-(morpholin-4-ylmethyl)-l,2,5-oxadiazole-3- carboximidamide;
3-(4-[(2-morpholin-4-ylethyl)amino]methyl-l,2,5-oxadiazol-3-yl)-4-[3-(trifluoromethyl)- phenyl]-l,2,4-oxadiazol-5(4H)-one;
N-(3-chloro-4-fluoroρhenyl)-Nf-hydroxy-4-[(methylsulfonyl)(2-morpholin-4-ylethyl)amino]- methyl-l,2,5-oxadiazole-3-carboximidamide;
N-{4-[N-(3-chloro-4-fluoro-phenyl)-iV-hydroxy-carbamimidoyl]-rurazan-3-ylmethyl}- benzamide;
N-(3-chloro-4-fluoro-phenyl)-N'-hydroxy-4-[(3-phenyl-ureido)-methyl]-furazan-3-carbox- amidine;
4-(benzenesulfonylamino-methyl)-N-(3-chloro-4-fluoro-phenyl)-N'-hydroxy-furazan-3- carboxamidine; benzyl({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol- 3-yl}methyl)carbamate;
^-(S-cyanopheny^-N'-hydroxy^-methyl-l^.S-oxadiazole-S-carboximidamide;
N-CS-chloro^-fluoropheny^-N-hydroxy^-methyl-l^^-thiadiazole-S-carboximidamide;
4-[(5-amino-lH-tetrazol-l-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2,5-oxa- diazole-3-carboximidamide;
4-[(5-amino-2H-tetrazol-2-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l ,2,5-oxa- diazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(lH-tetrazol-5-ylamino)methyl]-l,2,5- oxadiazole-3 -carboximidamide;
N-(3 -chloro^-fluorophenyO-iV-hydroxy^-C {[3 -( 1 H-imidazol-1 -yl)propyl]amino} methyl)- l,2,5-oxadiazole-3-carboximidamide;
N-(3 -chloro^-fluorophenyty-N-hydroxy^- { [(2-moφholin-4-ylethyl)amino]methyl } - 1 ,2,5- oxadiazole-3 -carboximidamide;
{4-[({4-[(E/Z)-[(3-chloro-4-fluoroρhenyl)amino](hydroxyimino)metliyl]-l,2,5-oxadiazol-3- yl } methyl)araino]phenyl } acetic acid;
N-(3-chloro-4-fluorophenyl)-N-hydroxy-47[(4-hydroxypiperidin-l-yl)inethyl]-l,2,5-oxa- diazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N-hydroxy-4-{[4-(2-hydroxyethyl)piperazin-l-yl]methyl}- l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N-hydroxy-4-({[(lR)-2-hydroxy-l-phenylethyl]amino}methyl)- 1 ,2,5-oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-N-hydroxy-4-{[(2-hydroxyethyl)amino]methyl}-l,2,5- oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N-hydroxy-4-{[(2-pyridin-4-ylethyl)amino]methyl}-l,2,5- oxadiazole-3 -carboximidamide;
Ν-(3-chloro-4-fiuorophenyl)-N-hydroxy-4- { [(tetrahydrofuran-2-ylmethyl)amino]methyl} - l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-Ν'-hydroxy-4-{[(l,3-thiazol-2-ylmethyl)amino]methyl}-l,2,5- oxadiazole-3 -carboximidamide;
4-({[4-(aminosulfonyl)benzyl]amino}methyl)-N-(3-chloro-4-fluorophenyl)-N-hydroxy-l,2,5- oxadiazole-3-carboximidamide;
{4-[(E/Z)-[(3-chloro-4-fluoropheny])amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3-yl}- methyl dimethylcarbamate;
4- { [4-(aminosulfonyl)phenoxy]methyl } -N-(3 -chloro-4-fluorophenyl)-N'-hydroxy- 1,2,5- oxadiazole-3-carboximidamide;
N-(3 -chloro^-fluorophenyO-N-hydroxy^- { [4-(methylsulfonyl)phenoxy]methyl} -1 ,2,5- oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N-hydroxy-4-(lH-imidazol-l-ylmethyl)-l ,2,5-oxadiazole-3- carboximidamide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-(lH-l ,2,4-triazol-l -ylmethyl)-l ,2,5-oxadiazole-3- carboximidamide;
4-[({2-[4-(aminosulfonyl)phenyl]ethyl}amino)methyl]-N-(3-chloro-4-fluorophenyl)-N- hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-JV-hydroxy-4-(2H-tetrazol-2-ylmethyl)-l,2,5-oxadiazole-3- carboximidamide; N-CS-chloro^-fluoropheny^-N'-hydroxy^-ClH-tetrazol-l-ylmethyO-l^jS-oxadiazole-S- carboximidamide;
{4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3-yl}- methyl morpholine-4-carboxylate;
2-[4-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl} methoxy)phenyl]acetamide;
4-(aminomethyl)-N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-l,2,5-oxadiazole-3-carbox- imidamide;
4-[(5-amino-lH-tetrazol-l-yl)methyl]-N-[3-(trifluoromethyl)phenyl]- Nl-hydroxy-l,2,5- oxadiazole-3 -carboximidamide,"
4-[(5-benzyl-lH-tetrazol-l-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2,5- oxadiazole-3 -carboximidamide;
4-[(5-benzyl-2H-tetrazol-2-yl)methyl]-Ν-(3-chloro-4-fluorophenyl)-Nl-hydroxy-l,2,5- oxadiazole-3 -carboximidamide;
[2-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amiπo](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl}methyl)-2H-tetrazol-5-yl]acetic acid;
N-(3-chloro-4-fluorophenyl)-4-(cyanomethyl)-N'-hydroxy-l,2,5-oxadiazole-3-carboximid- amide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-[(2-oxo-l,3-oxazolidin-3-yl)methyl]-l ,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluoroρhenyl)-4-( { [2-(dimethylamino)ethyl]amino}methyl)-Nl-hydroxy-l ,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-iV-hydroxy-4-{[(3-morpholin-4-ylpropyl)amino]metriyl}-l,2>5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-iV-hydroxy-4-[(5-pyridin-4-yl-2H-tetrazol-2-yl)methyl]-l,2,5- oxadiazole-3 -carboximidamide;
4-( { [4-(aminosulfonyl)benzyl]amino} methyl)-N-[3-(trifluoromethyl)phenyl]-N'-hydroxy- l,2,5-oxadiazole-3-carboximidamide;
N-[3-(trifluoromethyl)phenyl]-.V-hydroxy-4-(l H-tetrazol-1 -ylmethyl)-l ,2,5-oxadiazole-3- carboximidamide;
N-[3-(trifluoromethyl)phenyl]-N'-hydroxy-4-(2H-tetrazol-2-ylmethyl)-l,2,5-oxadiazole-3- carboximidamide;
N-[3-(trifluoromethyl)phenyl]-N'-hydroxy-4-{[(2-moφholin-4-ylethyl)amino]methyl} -1,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-N1-hydroxy-4-{[(pyridin-3-ylmethyl)amino]methyl}-l,2)5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-iV-hydroxy-4-{[(2-pyrrolidin-l-ylethyl)amino]methyl}-l,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-NI-hydroxy-4-( { [2-( 1 H-imidazol-4-yl)ethyl]amino } methyl)- l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-({[2-(2-oxopyrrolidin-l-yl)ethyl]amino}methyl)- l ,2,5-oxadiazole-3-carboximidamide;
N-(3-choro-4-fluorophenyl)-iV-hydroxy-4-[(5-methyl-l H-tetrazol-1 -yl)methyl]-l ,2,5- oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(5-methyl-2H-tetrazol-2-yl)methyl]-l,2,5- oxadiazole-3-carboximidamide;
N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl}methyl)-Ν-(2-morpholin-4-ylethyl)acetamide;
N-(3-chloro-4-fluorophenyl)-NI-hydroxy-4- { [5-(methylthio)-2H-tetrazol-2-yl]methyl} -1 ,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-{[5-(methylthio)-lH-tetrazol-l-yl]methyl}-l,2,5- oxadiazole-3-carboximidamide;
N-CS-chloro^-fluorophenyO-iV-hydroxy^-KS-phenyl-lH-tetrazol-l-yOmethyll-l^.S- oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-iV-hydroxy-4-[(5-phenyl-2H-tetrazol-2-yl)methyl]-l,2,5- oxadiazole-3 -carboximi damide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-({5-[3-(trifluoromethoxy)phenyl]-2H-tetrazol-2- yl}methyl)-l ,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(5-pyridin-3-yl-2H-tetrazol-2-yl)methyl]-l,2,5- oxadiazole-3 -carboximidamide;
N-CS-chloro^-fluoropheny^-iV-hydroxy^-fCS-pyrrolidin-l-yl^H-tetrazol^-y^methyl]- l ,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-Ν'-hydroxy-4-({5-[3-(trifluoromethoxy)phenyl]-lH-tetrazol-l- yl}methyl)-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[(5-pyridin-2-yl-lH-tetrazol-l -yl)methyl]-l,2,5- oxadiazole-3 -carboximidamide ;
N-CS-chloro^-fluorophenyO-N'-hydroxy^-tCS-pyrrolidin-l-yl-lH-tetrazol-l-yOmethyl]- l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-{[5-(4-fluorophenyl)-lH-tetrazol-l-yl]methyl}-N'-hydroxy- l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-({5-[2-(dimethylamino)ethyl]-lH-tetrazol-l-yl}methyl)-N1- hydroxy-l,2,5-oxadiazole-3-carboximidamide
N-(3 -chloro-4-fluorophenyl)-4- { [5 -(4-fluorophenyl)-2H-tetrazol-2-yl]methyl } -N"-hydroxy- l ,2,5-oxadiazole-3-carboximidamide; N-(3-chloro-4-fluorophenyl)-4-({5-[2-(4-chlorophenoxy)ethyl]-2H-tetrazol-2-yl}methyl)-iV- hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-({5-[5-(trifluoromethyl)pyridin-2-yl]-2H-tetrazol- 2-yl}methyl)-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-({5-[2-(4-chlorophenoxy)ethyl]-lH-tetrazol-l-yl}methyl)-Nl- hydroxy-l ,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-[({2-[(2R,6S)-2,6-dimethylmorρholin-4-yl]ethyl}amino)- methylJ-iV-hydroxy-l ,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-({[2-(2-methylpiperidin-l-yl)ethyl]amino}- methyl)- 1 ,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-{[(l,l-dimethyl-2-inoφholin-4-ylethyl)aniino]methyl}-N'- hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-iV-hydroxy-4-{[(2-piperazin-l-ylethyl)amino3methyl}-l,2,5- oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-({[(l-ethylpyrrolidin-2-yl)methyl]amino}methyl)-N'-hydroxy- l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-({[2-(dimethylamino)propyl]amino}methyl)-N'-hydroxy- l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N-hydroxy-4-{[(2-methyl-2-morpholin-4-ylpropyl)amino]- methyl}-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-{[(2-methyl-2-piperidin-l-ylpropyl)amino]- methyl}-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-{[(piperidin-2-ylmethyl)amino]methyl}-l,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-({[2-(l,l-dioxidothiomorpholin-4-yl)ethyl]-amino}-methyl)- N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-[(piperidin-3-ylamino)methyl]-l,2,5-oxadiazole-3- carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-{[(pyrrolidin-3-ylmethyl)amino]methyl}-l,2,5- oxadiazole-3-carboximidamide;
N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl}methyl)-2-methylpropanamide; iV-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l ,2,5-oxadiazol-3- yl}methyl)-2,2-dimethylpropanamide;
Λ'r-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl } methyl)-2-phenylacetamide;-
^v-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl}methyl)-3-phenylpropanamide; iV-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl}methyl)-l,3-thiazole-5-carboxamide;
N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,235-oxadiazol-3- yl}methyl)cyclopentanecarboxamide;
N-(3-chloro-4-fluorophenyl)-iV-hydroxy-4- { [(methylsulfonyl)amino]methyl} -1 ,2,5- oxadiazole-3-carboximidamide;
4-({[(benzylamino)carbonyl]amino}methyl)-iV-(3-chloro-4-fluorophenyl)-Nl-hydroxy-l,2,5- oxadiazole-3-carboximidamide; iV-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[({[(2-phenylethyl)-amino]carbonyl}-amino)- methyl] -1 ,2,5 -oxadiειzole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-({[(isopropylamino)-carbonyl]amino}-methyl)- l,2,5-oxadiazole-3-carboxitnidamide;
N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl } methyl)morpholine-4-carboxamide; iV-(3-chloro-4-fluorophenyl)-4-({[(dimethylamino)carbonyl]amino}methyl)-N'-liydroxy- l,2,5-oxadiazole-3-carboximidamide;
N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl} methyl)acetamide; methyl ( {4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l ,2,5-oxadiazol- 3 -yl} methyl)carbamate; isobutyl ( {4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l ,2,5-oxa- diazol-3-yl} methyl)carbamate; benzyl ( {4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l ,2,5-oxadiazol- 3-yl} methyl)carbamate;
N-(3 -chloro-4-fluorophenyl)-4- { [(ethylsulfonyl)amino]methyl } -Ν-hydroxy- 1,2,5 -oxadiazole- 3-carboximidamide;
N-(5 - { [( {4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino] (hydroxyimino)methyl] - 1 ,2,5-oxadiazol- 3-yl}methyl)amino]sulfonyl}-4-methyl-l,3-thiazol-2-yl)acetamide; iV-(3-chloro-4-fluorophenyl)-JV-hydroxy-4-{[({5-[l-methyl-5-(trifluoromethyl)-lH-pyrazol- 3-yl]-2-thienyl}sulfonyl)amino]methyl}-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-({[(l-methyl-lH-imidazol-4-yl)sulfonyl]amino}- methyl)-l,2,5-oxadiazole-3-carboximidaniide;
N-(3 -chloro-4-fluorophenyl)-4-( { [(2,4-dimethyl- 1 , 3 -thiazol-5 -yl)sulfonyl] amino} methyl)-.V- hydroxy- 1 ,2,5-oxadiazole-3-carboximidaniide;
Λ^(3-chloro-4-fluorophenyl)^-({[(3,5-dimethylisoxazoM-yl)sulfonyl]amir-o}methyl)-iV'- hydroxy-l,2,5-oxadiazole-3-carboximidamide; N-(3 -chloro-4-fluorophenyl)-iV-hydroxy-4-( {[(1,3, 5-trimethyl- 1 H-pyrazol-4-yl)sulfonyl]- amino}methyl)-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-({[(l,2-dimethyl-lH-imidazol-4-yl)sulfonyl]amino}inethyl)- Nl-hydroxy-l,2,5-oxadiazole-3-carboximidaraide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-{[(propylsulfonyl)amino]methyl}-l,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-{[(cyclopropylsulfonyl)amino]methyl}-Nτ-hydroxy-l,2,5- oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-Ν'-hydroxy-4-{[(3-methylisothiazol-5-yl)amino]inethyl} -1,2,5- oxadiazole-3 -carboximidamide; ethyl 3-4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- ylpropanoate;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-(3-moφholin-4-ylpropyl)-l,2,5-oxadiazole-3- carboximidamide;
5-[(5-amino-lH-tetrazol-l-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2,3-thia- diazole-4-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-5-(hydroxymethyl)-l,2,3-thiadiazole-4-carboximid- amide;
4-[(aminosulfonyl)amino]methyl-Λ'r-(3-chloro-4-fluorophenyl)-N-hydroxy-l,2,5-oxadiazole- 3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-([(E/Z)-(cyanoimino)(methylamino)methyl]aminomethyl)-N- hydroxy- 1 ,2,5 -oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-([(methylamino)-sulfonyl]aminomethyl)-l ,2,5- oxadiazole-3 -carboximidamide;
4-[(aminocarbonyl)amino]methyl-N-(3-chloro-4-fluorophenyl)-iV'-hydroxy-l)2,5-oxadiazole- 3 -carboximidamide;
4-([(tert-butylamino)carbonyl] aminomethyl)-N-(3 -chloro-4-fluorophenyl)-N'-hydroxy- 1,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-([(3-morpholin-4-ylpropyl)sulfonyl]amino- methyl)-l ,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
N-CS-chloro^-fluorophenyO-N'-hydroxy-^-fCpiperidin^-ylsulfony^aminoJmethyl-l^^- oxadiazole-3 -carboximidamide trifluoroacetate;
4-[([l-(aminosulfonyl)piperidin-4-yl]sulfonylamino)methyl]-N-(3-chloro-4-fluorophenyl)-iV'- hydroxy- 1 ,2,5 -oxadiazole-3-carboximidamide;
4-([(l-acetylpiperidin-4-yl)sulfonyl]aminomethyl)-iV-(3-chloro-4-fluorophenyl)-N'-hydroxy- l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[5-(moφholin-4-ylmethyl)-2H-tetrazol-2-yl]- methyl-1 ,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
N-(3 -chloro^-fluoropheny^-N'-hydroxy-^-fS-Cmorpholin-^ylmethyl)- 1 H-tetrazol- 1 -yl] - methyl-1 ,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
4-[(5-amino-l,3,4-thiadiazol-2-yl)thio]methyl-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2,5- oxadiazole-3-carboximidamide;
4-[(5-amino-4H-l,2,4-triazol-3-yl)thio]meth.yl-N-(3-chloro-4-fluorophenyl)-N-hydroxy- l,2,5-oxadiazole-3-carboximidamide;
4-[(5-amino-4H-l,2,4-triazol-3-yl)sulfonyl]methyl-N-(3-chloro-4-fluorophenyl)-N'-hydroxy- l,2,5-oxadiazole-3-carboximidamide;
N-(3 -chloro-4-fluorophenyl)-4- [( { (E/Z)-(cyanoimino)[(4-methoxybenzyl)amino]methyl } - amino)methyl]-Nl-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
4-[({(E/Z)-[(aminocarbonyl)imino][(4-methoxybenzyl)amino]methyl}ainino)methyl]-N-(3- chloro^-fluorophenyO-ΛP-hydroxy-l^S-oxadiazole-S-carboximidamide;
4-({[(E/Z)-amino(nitroimino)methyl]amino}methyl)-N-(3-chloro-4-fluorophenyl)-Nl- hydroxy-1 ,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
4-({[amino(imino)methyl]amino}methyl)-N-(3-cliloro-4-fluorophenyl)-Λ/'-hydroxy-l,2,5- oxadiazole-3 -carboximidamide;
N-CS-chloro^-fluoropheny^-N'-hydroxy^^H-l^^-triazoM-ylmethy^-l^jS-oxadiazole-S- carboximidamide;
4-[2-(5-amino-lH-tetrazol-l-yl)ethyl]-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,255- oxadiazole-3-carboximidamide;
4-[2-(5-amino-2H-tetrazol-2-yl)ethyl]-N-(3-chloro-4-fluorophenyl)-NI-hydroxy-l,2,5- oxadiazole-3-carboximidamide;
N-Q -chloro-4-fluorophenyl)-N'-hydroxy-4-[2-(l H-imidazol- 1 -yl)ethyl]- 1 ,2 , 5-oxadiazole-3 - carboximidamide trifluoroacetate;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-(2-morpholin-4-ylethyl)-l,2,5-oxadiazole-3- carboximidamide trifluoroacetate; iV-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[2-(4-methylpiperazin-l-yl)ethyl]-l )2,5-oxa- diazole-3-carboximidamide bis(trifluoroacetate); iV-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[2-(4H-l ,2,4-triazol-4-yl)ethyl]-l,2,5-oxadiazole- 3-carboximidamide;
N-CS-chloro^-fluorophenyO-N'-hydroxy^-p-ClH-l^^-triazol-l-yOethyll-l^^-oxadiazole- 3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-N1-hydroxy-4-[2-(l H-tetrazol-1 -yl)ethyl]-l ,2,5-oxadiazole-3- carboximidamide; iV-CS-chloro^-fluorophenyO-N'-hydroxy^-P^H-tetrazol^-yOethyll-l^.S-oxadiazole-S- carboximidamide; N-CS-chloro^-fluoropheny^-N'-hydroxy^-vinyl-l^.S-oxadiazole-S-carboxiinidamide;
N-(3-chloro-4-fluorophenyl)-4-[2-(dimethylamino)ethyl]-N'-hydroxy-l,2J5-oxadiazole-3- carboxiraidamide trifluoroacetate;
N-(3 -chloro-4-fluoroph.enyl)-Nl-hydroxy-4-(2-thiomorpholin-4-ylethyl)- 1 ,2,5 -oxadiazole-3 - carboximidamide trifluoroacetate;
N-(3 -chloro-4-fluorophenyl)-Nl-hydroxy-4-(2-pyrrolidin- 1 -ylethyl)- 1 ,2,5-oxadiazole-3 - carboximidamide trifluoroacetate;
N-(3-chloro-4-fluorophenyl)--V-hydroxy-4-{2-[isopropyl(methyl)amino]ethyl}-l,2,5- oxadiazole-3-carboximidamide trifluoroacetate;
N-(3-chloro-4-fluorophenyl)-.V-hydroxy-4- {2-[(methylsulfonyl)amino]ethyl} -1 ,2,5- oxadiazole-3-carboximidamide;
4- {2-[(aminosulfonyl)amino]ethyl} -N-(3-chloro-4-fluorophenyl)-N'-hydroxy- 1 ,2,5- oxadiazole-3-carboximidamide;
4-{[(aminosulfonyl)amino]methyl}-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-l,2,5- oxadiazole-3-carboximidamide;
4-{[(aminosulfonyl)amino]methyl}-N'-hydroxy-N-[3-(trifluoromethyl)phenyl]-l,2,5- oxadiazole-3 -carboximidamide ;
N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl}methyl)-N'-cyanomoφholine-4-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-morpliolin-4-ylethyl)amino]- methyl}amino)methyl]-Nl-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
4-[({(E/Z)-[(aminocarbonyl)imino][(2-morpholin-4-ylethyl)amino]methyl}amino)methyl]-N- (3-chloro-4-fluorophenyl)-Nl-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-{[((E/Z)-(cyanoimino){[2-(dimethyIamino)ethyl]amino}- methyl)amino]methyl}-N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-{[((E/Z)-(cyanoimino){[2-(lH-imidazol-5-yI)ethyl]amino}- methyl)amino]methyl}-N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
4-{[((E/Z)-[(aminocarbonyl)imino]{[2-(lH-imidazol-5-yl)ethyl]amiπo}methyl)amino]- methyl}-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-hydroxy-l-methylethyl)amino]- methyl}amino)methyI]-NI-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(isopropylamino)methyl]amino}- methyl)-iV-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-methoxy-l-methylethyl)amino]- methyl} amino)methyl]-NI-hydroxy-l ,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-methoxyethyl)amino]methyl}- amino)methyl]-iV-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate; N-(3-chloro-4-jEluorophenyl)-4-({[(E/Z)-(cyanoimino)(tetrahydro-2H-pyran-4-ylamino)- methyl]amino}methyl)-Nl-hydroxy-i,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
N-(3-chloro-4-fluorophenyl)-4-{[((E/Z)-(cyanoimino){[(l-ethylpyrrolidin-2-yl)methyl]- amino}methyl)amino]methyl}-NI-hydroxy-l,2,5-oxadiazole-3-carboximidamide bis(trifluoroacetate);
4-({[(E/Z)-amino(cyanoimino)methyl]amino}methyl)-N-(3-chloro-4-fluorophenyl)-Nl- hydroxy-1 ,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-hydroxyethyl)amino]methyl}- amino)methyl]-ΛP-hydroxy-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
N-(3-chloro-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(dimethylamino)methyl3amino}- methyl)-iV-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro^-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(ethylarnino)methyl]ammo}rnethyl)-N'- hydroxy-1 ,2,5 -oxadiazole-3-carboximidamide;
N-(3-bromo-4-fluorophenyl)-4-( { [(E/Z)-(cyanoimino)(ethylamino)methyl]araino } methyl)-iV- hydroxy-l,2,5-oxadiazole-3-carboximidamide;
4-({[(E/Z)-(cyanoimino)(dimethylamino)methyl]amino}methyl)-N'-hydroxy-N-[3-(trifluoro- methyl)phenyl] -1,2,5 -oxadiazole-3 -carboximidamide;
4-({[(E/Z)-(cyanoimino)(ethylammo)methyl]amino}methyl)-N'-hydroxy-N-[3-(trifluoro- methyl)phenyl]-l,2,5-oxadiazole-3-carboximidamide;
Λf-(3-bromo-4-iluoroρhenyl)-4-({[(E/Z)-(cyanoimino)(dimethylainino)methyl]ainino}- methyl)-N'-hydroxy-l, 2,5 -oxadiazole-3-carboximidamide;
4-({[(E/Z)-(cyanoimino)(methylamino)methyl]amino}methyl)-N1-hydroxy-N-[3-(trifluoro- methyl)phenyl]-l,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
N-(3-bromo-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(methylamino)inethyl]ammo}methyl)- N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
4-({[(E/Z)-amino(cyanoimino)methyl]amino}methyl)-N-(3-bromo-4-fluorophenyl)-Nl- hydroxy-1 ,2,5-oxadiazole-3-carboximidamide;
4-({[(E/Z)-amino(cyanoimino)methyl]amino}methyl)-iV-hydroxy-N-[3-(trifluoromethyl)- phenyl]-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-({[(isopropylamino)sulfonyl]amino}methyl)- l,2,5-oxadiazole-3-carboximidamide;
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-( { [(methylamino)sulfonyl]amino}methyl)-l ,2,5- oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-( { [(ethylamino)sulfonyl]amino} methyl)-iV-hydroxy-l ,2,5- oxadiazole-3 -carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-({[(dimethylamino)sulfonyl]amino}methyl)-NI-hydroxy-l,2,5- oxadiazole-3-carboximidamide; N-[3-(difluoromethyl)phenyl]-N'-hydroxy-4-(lH-tetrazol-l-ylmethyl)-l ,2,5-oxadiazole-3- carboximidamide;
N-tS-Cdifluoromethy^phenylJ-N'-hydroxy^-CZH-tetrazol^-ylmethyO-l^.S-oxadiazole-S- carboximidamide;
N'-hydroxy-4-(4H-l,2,4-triazol-4-ylmethyl)-iV-[3-(trifluoromethyl)phenyl]-l,2,5-oxadiazole- 3-carboximidamide;
N-(3-bromo-4-fluorophenyl)-Nl-hydroxy-4-(4H- 1 ,2,4-triazol-4-ylmethyl)-l ,2,5-oxadiazole-3- carboximidamide;
4-[(5-amino-lH-tetrazol-l-yl)methyl]-N-(3-bromo-4-fluorophenyl)-N1-hydroxy-l,2,5- oxadiazole-3 -carboximidamide;
4-[(5-amino-2H-tetrazol-2-yl)methyl]-jV-(3-bromo-4-fluoroρhenyl)-N'-hydroxy-l,2,5- oxadiazole-3 -carboximidamide;
N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3-yl}- methyl)-l H-imidazole-2-carboxamide trifluoroacetate;
N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3-yl}- methyl)-l H-pyrazole-4-carboxamide trifluoroacetate;
N-( {4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l ,2,5-oxadiazol-3-yl} - methyl)-4-methyl-l,2,3-thiadiazole-5-carboxamide;
N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3-yl}- methyl)-lH-imidazole-4-carboxamide trifluoroacetate;
N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyτmino)methyl]-l ,2,5-oxadiazol-3-yl}- methyl)-l,2,3-thiadiazole-4-carboxamide;
5-amino-N-({4-t(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxa- diazol-3-yl } methyl)- 1 ,3 ,4-thiadiazole-2-carboxamide;
5-amino-N-( {4-[(Z)-[(3-chloro-4-fluorophenyl)amino] (hydroxyimino)methyl]-l ,2,5- oxadiazol-3-yl}methyl)-lH-pyrazole-4-carboxamide;
4-(aminomethyl)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-l,2,5-oxadiazole-3-carboximid- amide trifluoroacetate;
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-{[(methylsulfonyl)amino]methyl}-l,2,5-oxadia- zole-3-carboximidamide;
4-(aminomethyl)-NI-hydroxy-N-[3-(trifluoromethyl)phenyl]-l ,2,5-oxadiazole-3-carboximid- amide trifluoroacetate;
N"-hydroxy-4- { [(methylsulfonyl)amino]methyl} -N-[3 -(trifluoromethyl)phenyl]- 1 ,2,5-oxadia- zole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-iV-hydroxy-4-({[(2,2,2-trifluoroethyl)sulfonyl]ammo} methyl)- l,2,5-oxadiazole-3-carboximidamide; ^(S-bromo^-fluoropheny^-N'-hydroxy-^-ClH-tetrazol-l-ylmethy^-ljZ.S-oxadiazole-S- carboximidamide;
[l-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3-yl}- raethyl)-lH-tetrazol-5-yl]acetic acid;
N-(3-chloro-4-fluorophenyl)-4-({[(2,4-dioxo-l,2,3,4-tetrahydropyrimidin-5-yl)sulfonyl]- amino}methyl)-N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-( {[(1 ,3-dimethyl-2,4-dioxo-l ,2,3,4-tetrahydropyrimidin-5-yl)- sulfonyl]amino}methyl)-N'-hydroxy-l,2,5-oxadiazole-3-carboximidamide;
N-CS-chloro^-fluoropheny^-N'-hydroxy^-tS-ClH-tetrazol-l-y^propyy-l^.S-oxadiazole-S- carboximidamide;
N-(3-chloro-4-fluorophenyl)-N"-hydroxy-4-[3-(2H-tetrazol-2-yl)propyl]-l,2,5-oxadiazole-3- carboximidamide;
N-(3-chloro-4-fluorophenyl)-N'-hydroxy-4-[3-(4H-l,2,4-triazol-4-yl)propyl]-l,2,5- oxadiazole-3 -carboximidamide;
4-{3-[(aminosulfonyl)amino]propyl}-N-(3-chloro-4-fluorophenyl)-Nt-hydroxy-l,2,5-oxadia- zole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-4-(3-{[(E/Z)-(cyanoimino)(methylamino)methyl]amino}propyl)- iV-hydroxy-1 ,2,5-oxadiazole-3-carboximidamide trifluoroacetate;
4-[(3-amino-4H-l,2,4-triazol-4-yl)methyl]-N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-l,2,5- oxadiazole-3 -carboximidamide;
4-[(5 -amino- 1 H- 1 ,2,4-triazol- 1 -yl)methyl] -N-(3 -chloro-4-fluorophenyl)-iV-hydroxy- 1 ,2,5 - oxadiazole-3-carboximidamide;
N-(3-chloro-4-fluorophenyl)-Nl-hydroxy-4-[(l,3,4-thiadiazol-2-ylamino)methyl]-l,2,5- oxadiazole-3-carboximidamide trifluoroacetate;
N-[3-(difluoromethyl)phenyl]-Nl-hydroxy-4-({[(methylamino)sulfonyl]amino}methyl)-l,2,5- oxadiazole-3-carboximidamide;
4-[(5-amino-lH-tetrazol-l-yl)methyl]-N-[3-(difluoromethyl)phenyl]-Nl-hydroxy-l ,2,5- oxadiazole-3-carboximidamide;
4-[(5-amino-2H-tetrazol-2-yl)methyl]-N-(4-fluoro-3-methylphenyl)-N'-hydroxy-l,2,5- oxadiazole-3-carboximidamide;
N-[3-(difluoromethyl)phenyl]-Nl-hydroxy-4-(l H-tetrazol-1 -ylmethyl)-l ,2,5-oxadiazole-3- carboximidamide;
N-[3-(difluoromethyl)phenyl]-Nl-hydroxy-4-(2H-tetrazol-2-ylmethyl)-l,2,5-oxadiazole-3- carboximidamide;
N-[3-(difluoromethyl)phenyl]-NI-hydroxy-4-{[(methylsulfonyl)amino]methyl} -1 ,2,5- oxadiazole-3 -carboximidamide; 4-{[(aminosulfonyl)amino]methyl}-N-[3-(difluoromethyl)phenyl]-N'-hydroxy-l,2,5- oxadiazole-3 -carboximidamide;
N-P-Cdifluoromethy^phenyy-iV'-h.ydroxy^-CltOrifluoromethylJsulfonyyaminolmethyl)- l,2,5-oxadiazole-3-carboximidamide;
4-{[bis(methylsulfonyl)amino]methyl}-N-[3-(difluoromethyl)phenyl]-iV-hydroxy-l,2,5- oxadiazole-3 -carboximidamide;
4-[(5-amino-lH-tetrazol-l-yl)methyl]-N-(4-fluoro-3-methylphenyl)-iV-hydroxy-l,2,5- oxadiazole-3 -carboximidamide;
4- { [(6-aminohexyl)amino]methyl } -N-(3 -chloro-4-fluorophenyl)-N'-hydroxy- 1 ,2,5- oxadiazole-3 -carboximidamide;
5-[({6-[({4-[(Z)-[(3-chlorb-4-fluorophenyl)amino](hydroxyimino)methyl]-l,2,5-oxadiazol-3- yl } methyl)amino] hexyl } amino)carbonyl] -2-(7-hydroxy-3 -oxo-3H-xanthen-9-yl)benzoic acid;
N-(4-fluoro-3-methylphenyl)-Nτ-hydroxy-4- { [(methylsulfonyl)amino]methyl } -1 ,2,5- oxadiazole-3-carboximidamide;
4-[2-(5-amino-lH-tetrazol-l-yl)ethyl]-N-(3-bromo-4-fluoroρhenyl)-N'-hydroxy-l ,2,5- oxadiazole-3-carboximidamide;
N-(3-bromo-4-fluorophenyl)-N1-hydroxy-4- {2-[(methylsulfonyl)amino]ethyl} -1 ,2,5- oxadiazole-3-carboximidamide;
4-{2-[(aminosulfonyl)amino]ethyl}-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-l,2,5- oxadiazole-3-carboximidamide; and pharmaceutically acceptable salts thereof.
42. A composition comprising a compound of claim 1, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
43. A method of modulating activity of indoleamine 2,3-dioxygenase comprising contacting said indoleamine 2,3-dioxygenase with a compound of claim 1, or pharmaceutically acceptable salt thereof.
44. The method of claim 43 wherein said modulating is inhibiting.
45. A method of inhibiting immunosuppression in a patient comprising administering to said patient an effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.
46. A method of treating cancer, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disease in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or pharmaceutically acceptable salt thereof.
47. The method of claim 46 further comprising administering an anti-viral agent, a chemotherapeutic, an immunosuppressant, radiation, an anti-tumor vaccine, an anti-viral vaccine, cytokine therapy, or a tyrosine kinase inhibitor.
48. A method of treating melanoma in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.
49. The method of claim 48 further comprising administering a chemotherapeutic, radiation, an anti-tumor vaccine, or cytokine therapy.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008547407A JP5294874B2 (en) | 2005-12-20 | 2006-12-19 | N-hydroxyamidino heterocycle as modulator of indoleamine 2,3-dioxygenase |
ES06845740.7T ES2540561T3 (en) | 2005-12-20 | 2006-12-19 | N-hydroxyamidinoheterocycles as indolamine 2,3-dioxygenase modulators |
CA2634198A CA2634198C (en) | 2005-12-20 | 2006-12-19 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
EP06845740.7A EP1971583B1 (en) | 2005-12-20 | 2006-12-19 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75185405P | 2005-12-20 | 2005-12-20 | |
US60/751,854 | 2005-12-20 | ||
US80133706P | 2006-05-18 | 2006-05-18 | |
US60/801,337 | 2006-05-18 | ||
US85755806P | 2006-11-08 | 2006-11-08 | |
US60/857,558 | 2006-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007075598A2 true WO2007075598A2 (en) | 2007-07-05 |
WO2007075598A3 WO2007075598A3 (en) | 2007-11-01 |
Family
ID=38218518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/048290 WO2007075598A2 (en) | 2005-12-20 | 2006-12-19 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
Country Status (7)
Country | Link |
---|---|
US (2) | US8450351B2 (en) |
EP (1) | EP1971583B1 (en) |
JP (1) | JP5294874B2 (en) |
CA (1) | CA2634198C (en) |
ES (1) | ES2540561T3 (en) |
TW (1) | TWI382974B (en) |
WO (1) | WO2007075598A2 (en) |
Cited By (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008036652A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
WO2010005958A3 (en) * | 2008-07-08 | 2010-06-24 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
EP2242367A2 (en) * | 2008-01-08 | 2010-10-27 | The Trustees Of The University Of Pennsylvania | Rel inhibitors and methods of use thereof |
US8034953B2 (en) | 2005-05-10 | 2011-10-11 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US8377976B2 (en) | 2006-09-19 | 2013-02-19 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2013113791A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113863A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113715A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
US8507541B2 (en) | 2006-09-19 | 2013-08-13 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2013135672A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
WO2013135671A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
WO2014118099A1 (en) | 2013-01-30 | 2014-08-07 | Basf Se | Fungicidal naphthoquinones and derivatives |
WO2014150677A1 (en) * | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (ido) |
WO2015031295A1 (en) * | 2013-08-27 | 2015-03-05 | Bristol-Myers Squibb Company | Ido inhibitors |
WO2015100282A1 (en) | 2013-12-24 | 2015-07-02 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2016041489A1 (en) * | 2014-09-15 | 2016-03-24 | 中国科学院上海有机化学研究所 | Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor |
US9321755B2 (en) | 2013-11-08 | 2016-04-26 | Incyte Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
WO2016081748A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
WO2016106266A1 (en) | 2014-12-22 | 2016-06-30 | Bristol-Myers Squibb Company | TGFβ RECEPTOR ANTAGONISTS |
WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
WO2016140884A1 (en) | 2015-03-02 | 2016-09-09 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
WO2016161279A1 (en) | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
WO2016168149A1 (en) | 2015-04-13 | 2016-10-20 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
WO2016183118A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2016183115A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
WO2017004016A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
WO2017019757A1 (en) | 2015-07-28 | 2017-02-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
WO2017035118A1 (en) | 2015-08-25 | 2017-03-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
WO2017079117A1 (en) | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
WO2017087678A2 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2017091580A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
WO2017106291A1 (en) | 2015-12-15 | 2017-06-22 | Bristol-Myers Squibb Company | Cxcr4 receptor antagonists |
WO2017140835A1 (en) | 2016-02-19 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity |
WO2017152085A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
WO2017152857A1 (en) * | 2016-03-09 | 2017-09-14 | 中国科学院上海有机化学研究所 | Indoleamine-2,3-dioxygenase inhibitor containing nitrogen alkylated and arylated sulphoxide imines |
WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
WO2017181849A1 (en) * | 2016-04-20 | 2017-10-26 | 江苏豪森药业集团有限公司 | Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application |
WO2018013818A2 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
WO2018183097A1 (en) * | 2017-03-29 | 2018-10-04 | Merck Sharp & Dohme Corp. | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
WO2018183608A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
WO2018184392A1 (en) * | 2017-04-05 | 2018-10-11 | 南京华威医药科技集团有限公司 | Indoleamine 2,3-dioxygenase inhibitor containing hydrazino group |
WO2018187613A2 (en) | 2017-04-07 | 2018-10-11 | Bristol-Myers Squibb Company | Anti-icos agonist antibodies and uses thereof |
WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CN108966651A (en) * | 2016-04-20 | 2018-12-07 | 江苏豪森药业集团有限公司 | Indole amine 2,3-dioxygenase inhibitor and the preparation method and application thereof |
WO2019006283A1 (en) | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of ido inhibitors |
WO2019023459A1 (en) | 2017-07-28 | 2019-01-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046498A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046500A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046496A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074887A1 (en) | 2017-10-10 | 2019-04-18 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019079261A1 (en) | 2017-10-16 | 2019-04-25 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
WO2019089921A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
US10323004B2 (en) | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019133747A1 (en) | 2017-12-27 | 2019-07-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
CN110054622A (en) * | 2018-01-18 | 2019-07-26 | 四川科伦博泰生物医药股份有限公司 | Furodiazole derivative, preparation method and its application in medicine |
WO2019149255A1 (en) * | 2018-02-02 | 2019-08-08 | 成都海创药业有限公司 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof |
WO2019160884A1 (en) | 2018-02-13 | 2019-08-22 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019173587A1 (en) | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019183040A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
WO2019200256A1 (en) | 2018-04-12 | 2019-10-17 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
WO2019204257A1 (en) | 2018-04-16 | 2019-10-24 | Arrys Therapeutics, Inc. | Ep4 inhibitors and use thereof |
WO2019213340A1 (en) | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
WO2020006016A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as t cell activators |
WO2020014132A2 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
US10538497B2 (en) | 2015-12-15 | 2020-01-21 | Merck Sharp & Dohme Corp. | Compounds as indoleamine 2,3-dioxygenase inhibitors |
US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
US10633342B2 (en) | 2016-05-04 | 2020-04-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020102501A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
US10696650B2 (en) | 2017-08-17 | 2020-06-30 | Ikena Oncology, Inc. | AHR inhibitors and uses thereof |
US10696648B2 (en) | 2016-05-04 | 2020-06-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
US10899764B2 (en) | 2015-04-21 | 2021-01-26 | Jiangsu Hengrui Medicine Co., Ltd. | Imidazo isoindole derivative, preparation method therefor and medical use thereof |
WO2021026179A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2021041588A1 (en) | 2019-08-28 | 2021-03-04 | Bristol-Myers Squibb Company | Substituted pyridopyrimidinonyl compounds useful as t cell activators |
WO2021055698A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10987322B2 (en) | 2014-06-06 | 2021-04-27 | Flexus Biosciences, Inc. | Immunoregulatory agents |
WO2021101919A1 (en) | 2019-11-19 | 2021-05-27 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of helios protein |
WO2021108288A1 (en) | 2019-11-26 | 2021-06-03 | Bristol-Myers Squibb Company | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
WO2021108528A1 (en) | 2019-11-26 | 2021-06-03 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
US11046682B2 (en) | 2016-08-23 | 2021-06-29 | Beijing Innocare Pharma Tech Co., Ltd. | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof |
WO2021133748A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinolinonyl piperazine compounds useful as t cell activators |
WO2021133751A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as t cell activators |
WO2021133750A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted bicyclic piperidine derivatives useful as t cell activators |
WO2021133752A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted heteroaryl compounds useful as t cell activators |
WO2021133749A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted piperazine derivatives useful as t cell activators |
WO2021139682A1 (en) | 2020-01-07 | 2021-07-15 | Hifibio (Hk) Limited | Anti-galectin-9 antibody and uses thereof |
WO2021141907A1 (en) | 2020-01-06 | 2021-07-15 | Hifibio (Hong Kong) Limited | Anti-tnfr2 antibody and uses thereof |
US11066383B2 (en) | 2016-05-04 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2021146370A1 (en) | 2020-01-15 | 2021-07-22 | Blueprint Medicines Corporation | Map4k1 inhibitors |
WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
WO2021194914A1 (en) | 2020-03-23 | 2021-09-30 | Bristol-Myers Squibb Company | Substituted oxoisoindoline compounds for the treatment of cancer |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
US11173145B2 (en) | 2017-01-17 | 2021-11-16 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
WO2022033419A2 (en) | 2020-08-10 | 2022-02-17 | Shanghai Xbh Biotechnology Co., Ltd. | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2022081718A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
US11351164B2 (en) | 2016-08-26 | 2022-06-07 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2022133083A1 (en) | 2020-12-16 | 2022-06-23 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
WO2022169921A1 (en) | 2021-02-04 | 2022-08-11 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
WO2022171745A1 (en) | 2021-02-12 | 2022-08-18 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
CN114920710A (en) * | 2017-04-27 | 2022-08-19 | 鲁南制药集团股份有限公司 | Urea derivatives |
WO2022192145A1 (en) | 2021-03-08 | 2022-09-15 | Blueprint Medicines Corporation | Map4k1 inhibitors |
WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022216573A1 (en) | 2021-04-05 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
WO2022216644A1 (en) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
WO2023288264A1 (en) | 2021-07-15 | 2023-01-19 | Blueprint Medicines Corporation | Map4k1 inhibitors |
WO2023288254A1 (en) | 2021-07-14 | 2023-01-19 | Blueprint Medicines Corporation | Heterocyclic compounds as map4k1 inhibitors |
WO2023122778A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
WO2023122772A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
WO2023122777A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
WO2023150186A1 (en) | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
EP4249066A2 (en) | 2014-12-23 | 2023-09-27 | Bristol-Myers Squibb Company | Antibodies to tigit |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
WO2024036100A1 (en) | 2022-08-08 | 2024-02-15 | Bristol-Myers Squibb Company | Substituted tetrazolyl compounds useful as t cell activators |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60327737D1 (en) * | 2002-01-22 | 2009-07-09 | Biomatera Inc | PROCESS FOR DRYING BIODEGRADABLE POLYMERS |
ATE398616T1 (en) * | 2005-02-04 | 2008-07-15 | Ctg Pharma S R L | NEW 4-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIATIC AGENTS |
US20070203140A1 (en) * | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
US20080182882A1 (en) * | 2006-11-08 | 2008-07-31 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US20100261774A1 (en) * | 2009-02-13 | 2010-10-14 | Children's Hospital Medical Center | Methods for the modulation of Leishmania major infection in mammals |
NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
EP2911669B1 (en) | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
EP3019488B1 (en) * | 2013-07-11 | 2018-11-07 | Bristol-Myers Squibb Company | Ido inhibitors |
EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
WO2016100851A1 (en) | 2014-12-18 | 2016-06-23 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
CN106660974B (en) * | 2015-03-31 | 2019-08-30 | 江苏恒瑞医药股份有限公司 | 1,2,5- furodiazole derivative, preparation method containing sulfamoyl and its application in medicine |
NZ736709A (en) * | 2015-05-15 | 2019-05-31 | Gilead Sciences Inc | Benzimidazole and imidazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase |
MX2017016844A (en) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Compositions and methods for treating cancer. |
EP3954369A1 (en) | 2015-07-24 | 2022-02-16 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
CN106565696B (en) * | 2015-10-09 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | Oxadiazole derivative, preparation method and medical application thereof |
WO2017079669A1 (en) | 2015-11-04 | 2017-05-11 | Incyte Corporation | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor |
CN107033097B (en) * | 2016-02-04 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | Oxadiazole derivative, preparation method and medical application thereof |
US20190169140A1 (en) * | 2016-08-02 | 2019-06-06 | Shandong Luye Pharmaceutical Co., Ltd. | Ido1 inhibitor and preparation method and application thereof |
TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
US11672771B2 (en) | 2016-11-04 | 2023-06-13 | Aximmune, Inc. | Beta-alethine, immune modulators, and uses thereof |
CN106967005B (en) * | 2017-04-07 | 2019-07-16 | 上海肇钰医药科技有限公司 | A kind of compound that can inhibit IDO, Its Preparation Method And Use |
WO2019011170A1 (en) * | 2017-07-14 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | Oxadiazole derivative, preparation method therefor and medical application thereof |
KR20200052349A (en) | 2017-09-11 | 2020-05-14 | 아토사 테라퓨틱스, 인크. | How to manufacture and use endoxifen |
WO2019055786A1 (en) | 2017-09-14 | 2019-03-21 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of cancer |
WO2019074748A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
WO2019136157A2 (en) | 2018-01-05 | 2019-07-11 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and ido expression to potentiate immunotherapy |
CA3094336A1 (en) | 2018-03-20 | 2019-09-26 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
US20190314324A1 (en) | 2018-04-13 | 2019-10-17 | The University Of Chicago | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy |
CN110407765B (en) * | 2018-04-28 | 2022-12-06 | 上海挚盟医药科技有限公司 | 1,2,5-oxadiazole derivative, preparation method and medical application thereof |
GB201809050D0 (en) | 2018-06-01 | 2018-07-18 | E Therapeutics Plc | Modulators of tryptophan catabolism |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0536424A1 (en) | 1991-04-26 | 1993-04-14 | Japan Tobacco Inc. | Novel benzopyran derivative |
US5712294A (en) | 1994-05-27 | 1998-01-27 | Adir Et Compagnie | N-pyridyl carboxamides and derivatives |
WO2001051456A2 (en) | 2000-01-13 | 2001-07-19 | Tularik Inc. | Antibacterial agents |
WO2006122150A1 (en) | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2007068377A1 (en) | 2005-12-17 | 2007-06-21 | Bayer Cropscience Ag | Carboxamides for controlling micro-organisms in plant and material protection |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3236855A (en) | 1964-01-17 | 1966-02-22 | Merck & Co Inc | Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation |
US3354174A (en) | 1964-02-19 | 1967-11-21 | Sterling Drug Inc | 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines |
US3553328A (en) * | 1967-02-28 | 1971-01-05 | Chevron Res | Stable carbamate insecticide granules |
US3553228A (en) | 1967-09-26 | 1971-01-05 | Colgate Palmolive Co | 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles |
DE2040628A1 (en) | 1970-08-17 | 1972-02-24 | Fahlberg List Veb | Substd hydroxyguanidines prepn |
US3948928A (en) | 1972-03-17 | 1976-04-06 | Dainippon Pharmaceutical Co., Ltd. | 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof |
JPS5621033B2 (en) | 1973-09-05 | 1981-05-16 | ||
GB1501529A (en) | 1975-09-11 | 1978-02-15 | Philagro Sa | Derivatives of amidoximes |
FR2323683A1 (en) | 1975-09-11 | 1977-04-08 | Philagro Sa | Phytohormonal and herbicidal amidoxime derivs. - prepd. by treatment of an imino ether with an O-amino oxy-acetate |
US4323681A (en) | 1980-09-29 | 1982-04-06 | American Home Products Corporation | 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides |
JPS58208275A (en) | 1982-05-20 | 1983-12-03 | Lion Corp | 5-amino-pyrazole derivative and antitumor agent containing it |
ATE25250T1 (en) | 1983-07-22 | 1987-02-15 | Bayer Ag | SUBSTITUTED FURAZANES. |
JPS60193968A (en) | 1984-03-13 | 1985-10-02 | Toyo Jozo Co Ltd | Imidazoleamidoxime having cyclopentene ring and its preparation |
JPS6259283A (en) | 1985-09-10 | 1987-03-14 | Kaken Pharmaceut Co Ltd | Cephalosporin compound |
JP2696342B2 (en) | 1988-06-27 | 1998-01-14 | 日本曹達株式会社 | Amidine derivative, method for producing the same, acaricide and agricultural / horticultural fungicide |
EP0352832B1 (en) | 1988-07-05 | 1992-05-06 | Akzo N.V. | Compounds with bronchodilator activity |
JPH04297449A (en) | 1991-03-27 | 1992-10-21 | Hokko Chem Ind Co Ltd | N-hydroxybenzylguanidine derivative and germicide for agriculture and horticulture |
FR2677019B1 (en) | 1991-05-27 | 1994-11-25 | Pf Medicament | NOVEL PIPERIDINES DISUBSTITUEES-1,4, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
JP2709677B2 (en) | 1992-06-19 | 1998-02-04 | 株式会社大塚製薬工場 | Phosphonic acid diester derivatives |
US5731315A (en) | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
US5883102A (en) | 1995-10-17 | 1999-03-16 | Astra Pharmaceuticals Limited | Pharmaceutically active compounds |
AU1730497A (en) | 1996-02-17 | 1997-09-02 | Agrevo Uk Limited | Fungicidal 1,2,4-oxadiazoles and analogues |
US5955495A (en) | 1996-05-03 | 1999-09-21 | Hoffmann-La Roche Inc. | Method of treating diseases of the CNS |
JPH11171702A (en) | 1997-09-24 | 1999-06-29 | Takeda Chem Ind Ltd | Pest controlling method |
US6451840B1 (en) | 1997-12-05 | 2002-09-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
ES2213929T3 (en) | 1997-12-10 | 2004-09-01 | Dainippon Ink And Chemicals, Inc. | OXYMES DERIVATIVES AND CHEMICAL PRODUCTS FOR AGRICULTURAL USE THAT INCLUDE THE SAME |
EP1084121B1 (en) | 1998-06-02 | 2002-07-31 | Takeda Chemical Industries, Ltd. | Oxadiazoline derivatives and their use as insecticides |
FR2784678B1 (en) | 1998-09-23 | 2002-11-29 | Sod Conseils Rech Applic | NOVEL N- (IMINOMETHYL) AMINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
AU763030B2 (en) | 1999-03-03 | 2003-07-10 | Samjin Pharmaceutical Co., Ltd. | Piperazine derivatives and process for the preparation thereof |
NZ515026A (en) | 1999-04-09 | 2003-10-31 | Abbott Gmbh & Co | Heterocyclic amidine derivatives useful as prodrugs of thrombin inhibitors |
CN1164574C (en) | 1999-05-24 | 2004-09-01 | 三菱制药株式会社 | Phenoxypropylamine compounds |
JP2001158785A (en) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | Agrochemical composition |
JP2001158786A (en) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | Controller against mammalian ectoparasite |
JP2001233861A (en) * | 2000-02-22 | 2001-08-28 | Ube Ind Ltd | Pyrazole oxime compound, method for producing the same and use of the same |
CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
EP1444225B1 (en) | 2001-06-18 | 2012-10-10 | Merck Serono SA | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists. |
ES2281633T3 (en) | 2002-02-19 | 2007-10-01 | Pfizer Italia S.R.L. | TRICYCLE DERIVATIVES OF PIRAZOL, PROCEDURE FOR ITS PREPARATION AND ITS USE AS ANTITUMOR AGENTS. |
GB0208224D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
WO2003087347A1 (en) | 2002-04-12 | 2003-10-23 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
US7109354B2 (en) * | 2002-05-28 | 2006-09-19 | 3-Dimensional Pharmaceuticals, Inc. | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
WO2004093871A1 (en) | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer |
US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
ATE536353T1 (en) | 2003-08-20 | 2011-12-15 | Vertex Pharma | 2-(4-AMINO-1,2,5-OXADIAZOLE-4-YL)-IMIDAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS |
DE10348023A1 (en) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | New alanyl aminopeptidase inhibitors for the functional manipulation of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
DE10348022A1 (en) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
TW200619212A (en) | 2004-09-08 | 2006-06-16 | Mitsubishi Pharma Corp | Morpholine derivatives |
WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
WO2006133417A1 (en) | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
MX2007016268A (en) | 2005-06-30 | 2009-02-23 | Anthrogenesis Corp | Repair of tympanic membrane using placenta derived collagen biofabric. |
TWI382974B (en) | 2005-12-20 | 2013-01-21 | Incyte Corp | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US20070203140A1 (en) | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
JP4297449B2 (en) | 2006-05-12 | 2009-07-15 | 株式会社サクラクレパス | India ink |
US20080119491A1 (en) | 2006-09-19 | 2008-05-22 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036652A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US20080182882A1 (en) | 2006-11-08 | 2008-07-31 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
JP5399262B2 (en) | 2006-12-08 | 2014-01-29 | エグゼリクシス パテント カンパニー エルエルシー | LXR and FXR modulators |
CL2008000066A1 (en) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | COMPOUNDS DERIVED FROM (5-HYDROXY-3-OXO-2,3-DIHYDROPIRIDAZINE-4-CARBONYL) GLYCINE, HIFROXYLASE HYDROXYLASE HIF INHIBITORS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEM |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | Method for altering the lifespan of eukaryotic organisms |
CN104042611B (en) | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 1 of inhibitor as indoleamine 2,3-dioxygenase, 2,5- oxadiazoles |
-
2006
- 2006-12-19 TW TW095147648A patent/TWI382974B/en active
- 2006-12-19 WO PCT/US2006/048290 patent/WO2007075598A2/en active Application Filing
- 2006-12-19 CA CA2634198A patent/CA2634198C/en active Active
- 2006-12-19 ES ES06845740.7T patent/ES2540561T3/en active Active
- 2006-12-19 JP JP2008547407A patent/JP5294874B2/en active Active
- 2006-12-19 US US11/641,284 patent/US8450351B2/en active Active
- 2006-12-19 EP EP06845740.7A patent/EP1971583B1/en active Active
-
2013
- 2013-02-28 US US13/780,510 patent/US8951536B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0536424A1 (en) | 1991-04-26 | 1993-04-14 | Japan Tobacco Inc. | Novel benzopyran derivative |
US5712294A (en) | 1994-05-27 | 1998-01-27 | Adir Et Compagnie | N-pyridyl carboxamides and derivatives |
WO2001051456A2 (en) | 2000-01-13 | 2001-07-19 | Tularik Inc. | Antibacterial agents |
WO2006122150A1 (en) | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2007068377A1 (en) | 2005-12-17 | 2007-06-21 | Bayer Cropscience Ag | Carboxamides for controlling micro-organisms in plant and material protection |
Cited By (225)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8372870B2 (en) | 2005-05-10 | 2013-02-12 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same for treating cancer |
US8846726B2 (en) | 2005-05-10 | 2014-09-30 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US8034953B2 (en) | 2005-05-10 | 2011-10-11 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US11192868B2 (en) | 2005-05-10 | 2021-12-07 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US10208002B2 (en) | 2005-05-10 | 2019-02-19 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US8951536B2 (en) | 2005-12-20 | 2015-02-10 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US8377976B2 (en) | 2006-09-19 | 2013-02-19 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US8507541B2 (en) | 2006-09-19 | 2013-08-13 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008036652A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
WO2008036652A3 (en) * | 2006-09-19 | 2008-07-10 | Incyte Corp | Amidines as modulators of indoleamine 2,3-dioxygenase |
EP2242367A4 (en) * | 2008-01-08 | 2012-07-04 | Univ Pennsylvania | Rel inhibitors and methods of use thereof |
EP2242367A2 (en) * | 2008-01-08 | 2010-10-27 | The Trustees Of The University Of Pennsylvania | Rel inhibitors and methods of use thereof |
US8609730B2 (en) | 2008-01-08 | 2013-12-17 | The Trustees Of The University Of Pennsylvania | Rel inhibitors and methods of use thereof |
US8822511B2 (en) | 2008-07-08 | 2014-09-02 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US10369137B2 (en) | 2008-07-08 | 2019-08-06 | Incyte Corporation | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US9789094B2 (en) | 2008-07-08 | 2017-10-17 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US10653677B2 (en) | 2008-07-08 | 2020-05-19 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
KR101847107B1 (en) | 2008-07-08 | 2018-04-10 | 인사이트 홀딩스 코포레이션 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
EA029781B1 (en) * | 2008-07-08 | 2018-05-31 | Инсайт Корпорейшн | 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase |
US10034864B2 (en) | 2008-07-08 | 2018-07-31 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
JP2014114299A (en) * | 2008-07-08 | 2014-06-26 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US8796319B2 (en) | 2008-07-08 | 2014-08-05 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
EP3360873A1 (en) * | 2008-07-08 | 2018-08-15 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
WO2010005958A3 (en) * | 2008-07-08 | 2010-06-24 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US9320732B2 (en) | 2008-07-08 | 2016-04-26 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
JP2011527686A (en) * | 2008-07-08 | 2011-11-04 | インサイト・コーポレイション | 1,2,5-oxadiazole as an inhibitor of indoleamine 2,3-dioxygenase |
EP2824100A1 (en) * | 2008-07-08 | 2015-01-14 | Incyte Corporation | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US11207302B2 (en) | 2008-07-08 | 2021-12-28 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
EA022669B1 (en) * | 2008-07-08 | 2016-02-29 | Инсайт Холдингс Корпорейшн | 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase |
US8993605B2 (en) | 2008-07-08 | 2015-03-31 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US8088803B2 (en) | 2008-07-08 | 2012-01-03 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
WO2013113863A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113715A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113791A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013135672A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
WO2013135671A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
WO2014118099A1 (en) | 2013-01-30 | 2014-08-07 | Basf Se | Fungicidal naphthoquinones and derivatives |
EA031470B1 (en) * | 2013-03-15 | 2019-01-31 | Бристол-Майерс Сквибб Компани | Ido inhibitors |
US9675571B2 (en) | 2013-03-15 | 2017-06-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (IDO) |
AU2014235750B2 (en) * | 2013-03-15 | 2018-05-17 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (IDO) |
WO2014150677A1 (en) * | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (ido) |
CN105209443A (en) * | 2013-03-15 | 2015-12-30 | 百时美施贵宝公司 | Inhibitors of indoleamine 2,3-dioxygenase (IDO) |
EA029981B1 (en) * | 2013-08-27 | 2018-06-29 | Бристол-Майерс Сквибб Компани | Ido inhibitors |
WO2015031295A1 (en) * | 2013-08-27 | 2015-03-05 | Bristol-Myers Squibb Company | Ido inhibitors |
US9758492B2 (en) | 2013-08-27 | 2017-09-12 | Bristol-Myers Squibb Company | IDO inhibitors |
US9873688B2 (en) | 2013-11-08 | 2018-01-23 | Incyte Holdings Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
US9321755B2 (en) | 2013-11-08 | 2016-04-26 | Incyte Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
CN105899498A (en) * | 2013-11-08 | 2016-08-24 | 因赛特控股公司 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
CN109810104B (en) * | 2013-11-08 | 2022-05-03 | 因赛特控股公司 | Method for synthesizing indoleamine 2, 3-dioxygenase inhibitors |
CN109810104A (en) * | 2013-11-08 | 2019-05-28 | 因赛特控股公司 | Method for synthesis of indole amine 2,3- dioxygenase inhibitor |
US10280157B2 (en) | 2013-11-08 | 2019-05-07 | Incyte Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
WO2015100282A1 (en) | 2013-12-24 | 2015-07-02 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
EP3466949A1 (en) | 2013-12-24 | 2019-04-10 | Bristol-Myers Squibb Company | Tricyclic compound as anticancer agents |
EP3610924A1 (en) | 2014-06-06 | 2020-02-19 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
EP3998079A1 (en) | 2014-06-06 | 2022-05-18 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
US10987322B2 (en) | 2014-06-06 | 2021-04-27 | Flexus Biosciences, Inc. | Immunoregulatory agents |
CN106687450A (en) * | 2014-09-15 | 2017-05-17 | 中国科学院上海有机化学研究所 | Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor |
WO2016041489A1 (en) * | 2014-09-15 | 2016-03-24 | 中国科学院上海有机化学研究所 | Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor |
US11053207B2 (en) | 2014-09-15 | 2021-07-06 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor |
CN106687450B (en) * | 2014-09-15 | 2019-08-16 | 中国科学院上海有机化学研究所 | A kind of indoles amine -2,3- dioxygenase inhibitor and preparation method thereof |
WO2016081748A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
EP3725808A1 (en) | 2014-11-21 | 2020-10-21 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
WO2016106266A1 (en) | 2014-12-22 | 2016-06-30 | Bristol-Myers Squibb Company | TGFβ RECEPTOR ANTAGONISTS |
EP4249066A2 (en) | 2014-12-23 | 2023-09-27 | Bristol-Myers Squibb Company | Antibodies to tigit |
WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
WO2016140884A1 (en) | 2015-03-02 | 2016-09-09 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
US10399932B2 (en) | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
US9790169B2 (en) | 2015-04-03 | 2017-10-17 | Bristol-Myers Squibb Company | IDO inhibitors |
WO2016161269A1 (en) | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
WO2016161279A1 (en) | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
US10167254B2 (en) | 2015-04-03 | 2019-01-01 | Bristol-Myers Squibb Company | IDO inhibitors |
US10399933B2 (en) | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
EP3964527A2 (en) | 2015-04-13 | 2022-03-09 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
WO2016168149A1 (en) | 2015-04-13 | 2016-10-20 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
US10899764B2 (en) | 2015-04-21 | 2021-01-26 | Jiangsu Hengrui Medicine Co., Ltd. | Imidazo isoindole derivative, preparation method therefor and medical use thereof |
WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2016183115A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
WO2016183118A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
WO2017004016A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
WO2017019757A1 (en) | 2015-07-28 | 2017-02-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
WO2017035118A1 (en) | 2015-08-25 | 2017-03-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
WO2017079117A1 (en) | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
WO2017087678A2 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2017091577A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
WO2017091580A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
WO2017106291A1 (en) | 2015-12-15 | 2017-06-22 | Bristol-Myers Squibb Company | Cxcr4 receptor antagonists |
US10538497B2 (en) | 2015-12-15 | 2020-01-21 | Merck Sharp & Dohme Corp. | Compounds as indoleamine 2,3-dioxygenase inhibitors |
WO2017140835A1 (en) | 2016-02-19 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity |
WO2017152085A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
WO2017152857A1 (en) * | 2016-03-09 | 2017-09-14 | 中国科学院上海有机化学研究所 | Indoleamine-2,3-dioxygenase inhibitor containing nitrogen alkylated and arylated sulphoxide imines |
CN108699014A (en) * | 2016-03-09 | 2018-10-23 | 中国科学院上海有机化学研究所 | A kind of indoles amine -2,3- dioxygenase inhibitors containing N-alkylation and arylation sulphoxide imine |
CN107176933A (en) * | 2016-03-09 | 2017-09-19 | 中国科学院上海有机化学研究所 | A kind of indoles amine -2,3- dioxygenase inhibitors containing N-alkylation and arylation sulphoxide imine |
CN107176933B (en) * | 2016-03-09 | 2020-10-09 | 中国科学院上海有机化学研究所 | Indoleamine-2,3-dioxygenase inhibitor containing nitrogen alkylated and arylated sulfoximine |
WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
WO2017181849A1 (en) * | 2016-04-20 | 2017-10-26 | 江苏豪森药业集团有限公司 | Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application |
CN108966651A (en) * | 2016-04-20 | 2018-12-07 | 江苏豪森药业集团有限公司 | Indole amine 2,3-dioxygenase inhibitor and the preparation method and application thereof |
US10696648B2 (en) | 2016-05-04 | 2020-06-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10633342B2 (en) | 2016-05-04 | 2020-04-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10323004B2 (en) | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11066383B2 (en) | 2016-05-04 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11591392B2 (en) | 2016-07-14 | 2023-02-28 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
US10077306B2 (en) | 2016-07-14 | 2018-09-18 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
WO2018013818A2 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
US10533052B2 (en) | 2016-07-14 | 2020-01-14 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
US11046682B2 (en) | 2016-08-23 | 2021-06-29 | Beijing Innocare Pharma Tech Co., Ltd. | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof |
US11351164B2 (en) | 2016-08-26 | 2022-06-07 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
US11173145B2 (en) | 2017-01-17 | 2021-11-16 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
WO2018183097A1 (en) * | 2017-03-29 | 2018-10-04 | Merck Sharp & Dohme Corp. | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
US11034661B2 (en) | 2017-03-29 | 2021-06-15 | Merck Sharp & Dohme Corp. | Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors |
RU2765371C2 (en) * | 2017-03-29 | 2022-01-28 | Мерк Шарп энд Доум Корп. | New substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as inhibitors of indolamine-2,3-dioxygenase (ido) |
WO2018183608A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
WO2018184392A1 (en) * | 2017-04-05 | 2018-10-11 | 南京华威医药科技集团有限公司 | Indoleamine 2,3-dioxygenase inhibitor containing hydrazino group |
CN108689958A (en) * | 2017-04-05 | 2018-10-23 | 南京华威医药科技开发有限公司 | A kind of indoleamine 2 containing diazanyl, 3- is bis- to add oxidase inhibitor |
CN108689958B (en) * | 2017-04-05 | 2021-09-17 | 南京华威医药科技集团有限公司 | Indoleamine 2,3-dioxygenase inhibitor containing hydrazino |
WO2018187613A2 (en) | 2017-04-07 | 2018-10-11 | Bristol-Myers Squibb Company | Anti-icos agonist antibodies and uses thereof |
US10689388B1 (en) | 2017-04-21 | 2020-06-23 | Ikena Oncology, Inc. | Indole AHR inhibitors and uses thereof |
US10570138B2 (en) | 2017-04-21 | 2020-02-25 | Kyn Therapeutics | Indole AHR inhibitors and uses thereof |
WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
US11358969B2 (en) | 2017-04-21 | 2022-06-14 | Ikena Oncology, Inc. | Indole AHR inhibitors and uses thereof |
CN114920710A (en) * | 2017-04-27 | 2022-08-19 | 鲁南制药集团股份有限公司 | Urea derivatives |
WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
US11066392B2 (en) | 2017-05-12 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11236049B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of IDO inhibitors |
WO2019006283A1 (en) | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of ido inhibitors |
WO2019023459A1 (en) | 2017-07-28 | 2019-01-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
US11555026B2 (en) | 2017-08-17 | 2023-01-17 | Ikena Oncology, Inc. | AHR inhibitors and uses thereof |
US10696650B2 (en) | 2017-08-17 | 2020-06-30 | Ikena Oncology, Inc. | AHR inhibitors and uses thereof |
WO2019046500A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046498A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046496A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11649212B2 (en) | 2017-10-09 | 2023-05-16 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019074887A1 (en) | 2017-10-10 | 2019-04-18 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019079261A1 (en) | 2017-10-16 | 2019-04-25 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019089921A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
US11306149B2 (en) | 2017-12-27 | 2022-04-19 | Bristol-Myers Squibb Company | Anti-CD40 antibodies and uses thereof |
US11952427B2 (en) | 2017-12-27 | 2024-04-09 | Bristol-Myers Squibb Company | Anti-CD40 antibodies and uses thereof |
WO2019133747A1 (en) | 2017-12-27 | 2019-07-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
CN110054622B (en) * | 2018-01-18 | 2021-02-23 | 四川科伦博泰生物医药股份有限公司 | Oxadiazole derivative, preparation method and medical application thereof |
CN110054622A (en) * | 2018-01-18 | 2019-07-26 | 四川科伦博泰生物医药股份有限公司 | Furodiazole derivative, preparation method and its application in medicine |
WO2019149255A1 (en) * | 2018-02-02 | 2019-08-08 | 成都海创药业有限公司 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof |
US11591301B2 (en) | 2018-02-02 | 2023-02-28 | Hinova Pharmaceuticals Inc. | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof |
WO2019160884A1 (en) | 2018-02-13 | 2019-08-22 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019173587A1 (en) | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019183040A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
WO2019200256A1 (en) | 2018-04-12 | 2019-10-17 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
WO2019204257A1 (en) | 2018-04-16 | 2019-10-24 | Arrys Therapeutics, Inc. | Ep4 inhibitors and use thereof |
WO2019213340A1 (en) | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
WO2020006016A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as t cell activators |
US11401328B2 (en) | 2018-07-09 | 2022-08-02 | Five Prime Therapeutics, Inc. | Antibodies binding to ILT4 |
WO2020014132A2 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
WO2020102501A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2021026179A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2021041588A1 (en) | 2019-08-28 | 2021-03-04 | Bristol-Myers Squibb Company | Substituted pyridopyrimidinonyl compounds useful as t cell activators |
WO2021055698A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
WO2021101919A1 (en) | 2019-11-19 | 2021-05-27 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of helios protein |
WO2021108288A1 (en) | 2019-11-26 | 2021-06-03 | Bristol-Myers Squibb Company | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
WO2021108528A1 (en) | 2019-11-26 | 2021-06-03 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
US11591339B2 (en) | 2019-11-26 | 2023-02-28 | Ikena Oncology, Inc. | Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors |
WO2021133752A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted heteroaryl compounds useful as t cell activators |
WO2021133750A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted bicyclic piperidine derivatives useful as t cell activators |
WO2021133751A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as t cell activators |
WO2021133748A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinolinonyl piperazine compounds useful as t cell activators |
WO2021133749A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted piperazine derivatives useful as t cell activators |
WO2021141907A1 (en) | 2020-01-06 | 2021-07-15 | Hifibio (Hong Kong) Limited | Anti-tnfr2 antibody and uses thereof |
WO2021139682A1 (en) | 2020-01-07 | 2021-07-15 | Hifibio (Hk) Limited | Anti-galectin-9 antibody and uses thereof |
WO2021146370A1 (en) | 2020-01-15 | 2021-07-22 | Blueprint Medicines Corporation | Map4k1 inhibitors |
WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
WO2021194914A1 (en) | 2020-03-23 | 2021-09-30 | Bristol-Myers Squibb Company | Substituted oxoisoindoline compounds for the treatment of cancer |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
WO2022033419A2 (en) | 2020-08-10 | 2022-02-17 | Shanghai Xbh Biotechnology Co., Ltd. | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
WO2022081718A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
WO2022133083A1 (en) | 2020-12-16 | 2022-06-23 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
WO2022169921A1 (en) | 2021-02-04 | 2022-08-11 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
WO2022171745A1 (en) | 2021-02-12 | 2022-08-18 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
WO2022192145A1 (en) | 2021-03-08 | 2022-09-15 | Blueprint Medicines Corporation | Map4k1 inhibitors |
WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022216573A1 (en) | 2021-04-05 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
WO2022216644A1 (en) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
WO2023288254A1 (en) | 2021-07-14 | 2023-01-19 | Blueprint Medicines Corporation | Heterocyclic compounds as map4k1 inhibitors |
WO2023288264A1 (en) | 2021-07-15 | 2023-01-19 | Blueprint Medicines Corporation | Map4k1 inhibitors |
WO2023122777A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
WO2023122772A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
WO2023122778A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
WO2023150186A1 (en) | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
WO2024036100A1 (en) | 2022-08-08 | 2024-02-15 | Bristol-Myers Squibb Company | Substituted tetrazolyl compounds useful as t cell activators |
WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
Also Published As
Publication number | Publication date |
---|---|
US8951536B2 (en) | 2015-02-10 |
US20070185165A1 (en) | 2007-08-09 |
JP5294874B2 (en) | 2013-09-18 |
ES2540561T3 (en) | 2015-07-10 |
JP2009520817A (en) | 2009-05-28 |
TWI382974B (en) | 2013-01-21 |
US8450351B2 (en) | 2013-05-28 |
CA2634198C (en) | 2014-06-03 |
TW200730515A (en) | 2007-08-16 |
CA2634198A1 (en) | 2007-07-05 |
WO2007075598A3 (en) | 2007-11-01 |
EP1971583B1 (en) | 2015-03-25 |
US20130177590A1 (en) | 2013-07-11 |
EP1971583A2 (en) | 2008-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8951536B2 (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
EP2559690B1 (en) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
EP2064207B1 (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
EP2315756B1 (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
US20080119491A1 (en) | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
CA2929552A1 (en) | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | |
WO2008058178A1 (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
EP2064194A2 (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2634198 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006845740 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008547407 Country of ref document: JP |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06845740 Country of ref document: EP Kind code of ref document: A2 |